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ABSTRACT 
The controversial discipline of homeopathy is examined from three original 
perspectives. 
Conceptual background The structure and presentation of Hahnemann's 
research programme is contrasted with philosophical assumptions about 
medical science and emerging theoretical structures in German academic 
medicine circa 1800, and the subsequent rift between homeopathy and 
alfopathy is explained at this level. The sources of homeopathic theory and 
method are located in mainstream eighteenth-century experiment. Alleged 
relationships to alchemical medicine are discounted, with the exception of 
certain pharmacy techniques introduced after 1816. Divergent schools and 
approaches within homeopathy are traced to their sources, and mapped onto 
a unified therapeutic field. 
Historical importance A systematic review of prospective clinical 
evaluations of homeopathy, 1821-1953, contends that these played an 
important but neglected part in the evolution of the clinical trial. Placebo-
controlled trials by sceptics most probably originated in prior Hahnemannian 
use of within-patient placebo controls. Pragmatic trials of homeopathy versus 
allopathy in the mid nineteenth century show that judgements of 
homeopathic inefficacy made by influential nineteenth-century opponents, 
which have coloured debate ever since, were not evidence-based. Early 
twentieth-century clinical trials by homeopaths were methodologically in 
advance of biomedical trials in some respects. 
Clinical relevance A systematic review of 205 prospective controlled 
clinical trials published since 1940 found evidence of homeopathy's safety, 
and specific and global efficacy in trials of high internal validity. Implications 
for clinical research and practice are considered, founded on analysis of 
intrahomeopathic differences and trends. On the basis of trial evidence, the 
relative merits of placebo-controlled and pragmatic evaluations of 
homeopathy are discussed. Clinical relevance was found particularly in areas 
that pose problems for biomedicine, and proposals for pragmatic trials of 
homeopathy versus standard treatment are made in the following conditions: 
unexplained female infertility; postviral fatigue syndrome; influenza; atopy. 
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1 INTRODUCTION 
1. 1. Rationale 
Public demand for alternative and complementary medicine has never been 
greater, and homeopathy is high on the list of sought-after therapies 
(House of Lords 2000). Commissioners looking for evidence to justify funding 
naturally turn to published reports of clinical trials or reviews of those trials. 
At this point several problems emerge. 
Accessibility of information Because of homeopathy's isolation from 
mainstream medicine, most homeopathic trials have been published in grey 
literature, inaccessible through Medline, Embase or other standard databases. 
Representativeness of contemporary trials Many homeopaths claim theirs is a 
general therapy, applicable and successful in a wide range of conditions. 
Situated outside orthodox medicine, homeopathy has been starved of funds 
for research -Albrecht (1999) estimated spending no higher than $1.5 million 
annually worldwide for all types of homeopathy. As a consequence, there are 
few contemporary clinical trials overall (fewer than 300 were found in the 
comprehensive literature search conducted for this thesis). Of these trials, the 
majority have used standardized treatments, on the lines of a conventional 
drug trial, even though the majority of homeopaths practise a therapy where 
treatments are tailored to the individual, particularly in chronic disease. Some 
conditions, such as bronchial asthma, for which homeopaths claim their 
therapy works particularly well, are very underrepresented in the trial record. 
Homeopathy's controversiality Like some other complementary therapies, 
homeopathy is regarded as a placebo therapy by many scientists, regardless 
of evidence of efficacy from clinical trials (Vandenbroucke 1997). Unlike most 
other complementary therapies, however, homeopathy began as part of 
orthodox western medicine, at the beginning of the nineteenth century. Its 
controversiality and present fringe status stem from judgements made about 
it in the nineteenth century by powerful opponents in orthodox medicine (e.g. 
Academie de Medecine 1835a; Holmes 1842; House of Commons 1854-55). 
Whether or not those judgements were scientifically valid, they still inform 
current debate (Ernst 1995b; Crellin 1997). 
Relevance of existing reviews Traditional review articles in homeopathy, as is 
the case in most fields, have generally been unsystematic and written by 
opponents or proponents of the therapy as a whole (or even of one approach 
within it). Monographs and textbooks containing reviews, which might be 
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regarded as sources, are highly selective in their choice of examples (e.g. 
Aulas, Bordelay, Royer 1991; Meyer 1996). Well-conducted recent systematic 
reviews (with protocols) have used wide-ranging literature search strategies 
to answer the scientific question 'Is homeopathy any more than a placebo 
effect?' (e.g. Beissel, Cucherat, Haugh et al. 1996; Linde, Clausius, Ramirez et 
al. 1997). Because of the question posed, however, these reviews have tended 
to leave out study designs which might inform health services research and 
provision. 
Exclusion of historical evidence The widespread use of homeopathy in the 
nineteenth century has been acknowledged by medical historians (e.g. 
Kaufmann 1971; Nicholls 1988), but only rarely evaluated for evidence of 
effectiveness (e.g. Leary 1994). Since homeopathy tends to add to rather than 
replace its clinical treatments, and since the numbers involved in nineteenth-
century trials were many times greater than the sum of all contemporary trial 
participants, exclusion of the historical record may also misrepresent the 
therapy. 
For these reasons, a historical approach to the evaluation of homeopathy is 
proposed, one which connects the discipline to its past, and to that of 
orthodox medicine. In one sense this thesis contains two concise histories of 
important aspects of homeopathy: Part I accounts for the origins, 
characteristics and development of the content and methods of the therapy 
from before 1800 to the present day, while Part II examines evidence from 
clinical trials of homeopathy from the early nineteenth century up until the 
middle of the twentieth century. Part III is not historically oriented, but 
contains a systematic review of clinical trials from 1940 to the end of 1998, 
looking at issues of current concern including safety and clinical relevance. 
Questions concerning the nature of highly diluted homeopathic medicines 
and the manner in which they are biologically active fall outside the scope of 
this thesis. 
1.2. Overview 
1.2.1. Homeopathy's place in the history of therapeutics 
The historiography of homeopathy has tended to come from inside the 
profession. Where different evolutionary streams in homeopathy have been 
discussed, the treatment usually reflects the allegiances of the author, and 
tends to be antagonistic towards competing schools of thought (e.g. Coulter 
1977; Demarque 1981). More recently, following trends within the 'new' non-
medical academic historiography of medicine, the field has enlarged to 
include accounts and analysis from outside homeopathy: for example, studies 
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of specific historical moments, regional microhistories, sociological analysis of 
casebooks of well-known homeopaths, and accounts of political and economic 
conflict between homeopathy and orthodox medicine. But, as in social 
constructionism generally, little attention has been paid to the content or 
theoretical and practical adequacy of homeopathy (e.g. Berliner 1982). 
Therefore, Part I (Chs 2-4) explores the discipline by means of explanatory 
coverage of its historical origins, conceptual foundation, pharmacological 
techniques and internal development, without any attempt to impose norms 
based on what is currently acceptable within any one area of the discipline. 
Ch. 2 contrasts the structure of Hahnemann's research programme with 
emerging structures in German academic medicine around 1800, and is also 
innovative in attempting to account for Hahnemann's formal presentation of 
homeopathy by detailing his rhetorical use of academic conventions in his bid 
to overthrow them. Ch. 3 examines the generally assumed irrationality of 
homeopathic theory and method by a thorough exploration of Hahnemann's 
allegedly covert debt to alchemy. Ideas from alchemical medicine that are 
frequently presumed to survive in homeopathy - such as the doctrine of 
signatures (e.g. Flaherty 1995) - are shown to have been decisively rejected, 
yet an acknowledged but overlooked borrowing from Islamic alchemical 
pharmacy is shown to have transformed the preparation of homeopathic 
medicines after 1818. The probable origins of Hahnemann's avant-garde 
miasmatic and germ theory in a forgotten eighteenth-century treatise are also 
explored, again possibly for the first time. Ch. 4 recounts the post-
Hahnemannian development of the principal schools and approaches within 
homeopathy, and is innovative in showing that allegedly irreconcileable 
theoretical and practical differences can be mapped and understood as a 
unified therapeutic field - one which is systematically traversed by many 
therapists in the present day. 
1.2.2. Homeopathy and the development of clinical evaluation 
Part II (Chs 5-9) consists of a comprehensive and systematic review of 
prospective historical trials, 1821-1953. Ch. 5 presents the background against 
which such a review must take place, namely the neglect of the clinical trial in 
orthodox medical historiography, compounded by the even greater neglect of 
homeopathy's clinical record. 
The great majority of historical trials found in the literature search fall neatly 
into three methodological groups corresponding to three chronological 
phases in the evaluation of homeopathy (and perhaps medicine generally): 
open observation, pragmatic comparison, and explanatory trial. Ch. 6 reviews 
mainly prospective case series from the period 1821-35, and the significance of 
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the cut-off date will be apparent when it is remembered that 1835 was the 
year in which the Academie de Medecine issued its ostensibly evidence-based 
pronouncement against homeopathy, and the therapy's journey from centre 
to fringe began in earnest. Ch. 7 reviews mainly pragmatic comparisons with 
allopathy from the period 1844-86, some of which were clearly an 
embarrassment to the increasingly powerful medical establishment, as 
evidenced by attempts to prevent trials and comparisons from being carried 
out, or to suppress the results once completed. Ch. 9 looks at the increasing 
adoption of the orthodox explanatory research model in the years 1914-53, at 
a time when homeopathy had been almost entirely displaced by biomedicine. 
The evidence found in each chapter is reviewed along with the reception of 
the trials where found, and then synthesized in relation to the judgements 
made on homeopathy at the time. 
A fourth group of historical trials is reviewed in Ch. 8. These are trials in 
which placebo controls were used in the period 1829-1903. Such a disparate 
group - only 2 placebo-controlled therapeutic trials, plus 5 placebo-controlled 
pathogenetic drug tests and 3 trials of placebo alone regarded as the rhetorical 
equivalent of homeopathy - deserves separate treatment from the therapeutic 
trials in Chs 6 and 7. This is in view of the importance accorded to the 
introduction of masked evaluation, including placebo controls, in the history 
of clinical evaluation, and again the evidence is synthesized in relationship to 
nineteenth-century (and current) opinion. All the reviews in Part II are 
innovative, but Ch. 8 particularly so. It contains the first detailed account of 
within-patient placebo controls in everyday homeopathic practice as used 
throughout the nineteenth and twentieth centuries. Evidence that this internal 
usage was imitated in the first external placebo-controlled evaluations of 
homeopathy is presented, in complete contrast to the normative view that 
homeopaths adopted placebo controls in trials as early as they did because of 
external prompting. 
1.2.3. Is homeopathy clinically relevant? 
In view of the problems of accessibility mentioned in 1.1 above, the 
development of a comprehensive database of controlled trials was 
paramount. This has been based on a search for every prospective controlled 
homeopathic clinical trial published between 1940 and the end of 1998, with 
controls including orthodox treatment or no treatment as well as placebo, as 
in an earlier systematic review (Kleijnen, Knipschild, ter Riet 1991). Part III 
(Chs 10-13) constitutes a systematic review of the contemporary trials found, 
split into chapters for convenience: Ch. 10 Rationale, Ch. 11 Methods, Ch. 12 
Results, Ch. 13 Discussion. Exploratory rather than hypothesis-based, it is 
innovative in its inclusion of: 
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• more trials than any previous review; 
• analysis of intrahomeopathic differences and trends; 
• an evaluation of homeopathy's safety; 
• the evaluation of a generic methodological quality assessment tool 
designed to allow meaningful inclusion and comparative evaluation of 
prospective controlled trials other than randomized placebo-controlled 
ones - as well as allowing other nonexperimental designs to be evaluated 
and added to the database at a later time; 
• discussion of homeopathy's clinical relevance; 
• identification of areas that appear to hold most clinical relevance and 
warrant further research. 
1.2.4. Retrospect and prospect 
The conclusions drawn in the thesis as a whole are summarized and extended 
in Ch. 14. These relate to empirical evidence concerning the origins of 
homeopathy's epistemology, pharmacognosy and theories of disease 
transmission; and to empirical evidence of its efficacy drawn from nearly two 
centuries of clinical trials. 
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PART I: HOMEOPATHY'S PLACE IN THE HISTORY OF THERAPEUTICS 
2 Homeopathy and 'the progress of science' 
3 Origins of Hahnemann's pharmacognosy and miasmatic theory 
4 Homeopathy after Hahnemann 
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2 HOMEOPATHY AND 'THE PROGRESS OF SCIENCE' 
Material in this chapter appeared in: Dean M.E. (2001). Homeopathy and "the progress of 
science". History of Science. 39: 255-283. 
Background Eighteenth-century medical practice became increasingly 
irreconcilable with Enlightenment principles. The 1790s saw French attempts 
to reconstitute medicine based on observation, leading to better insight into 
the results of pathological processes. This coincided with German attempts to 
create a scientific medicine on deductive rational principles aimed at the 
hypothesized cause of disease. A different response, homeopathy, emerged at 
the same time. 
Questions How did the conceptual foundation of homeopathy differ from 
prevailing approaches to the creation of a new medical science? Can 
differences at this level explain its later exclusion from biomedicine? 
Argument Hahnemann shared the aspirations of those contemporaries who 
wished to create a medicine to match the real achievements of the sciences. 
He borrowed the rhetorical structures of German academic medicine, while 
advancing an approach to healing fundamentally opposed to rationalist 
assumptions. Further examination of the epistemological basis of homeopathy 
shows he adopted a procedure of global hypothesis formation and testing, 
which allowed him to believe homeopathy answered the call for a Kantian 
medical 'science'. Homeopathy's attention to the person diverged strongly 
from contemporary trends, and may have contributed in large part to its 
rejection by orthodoxy. 
2.1. Introduction 
In 1790, after he had turned his back on medicine and looked to translation to 
earn a living, a German doctor summarized the state of therapeutics in an 
annotation to the Treatise of Materia Medica of William Cullen (1710-90), the 
eminent Edinburgh physician (Cullen 1789; Cullen 1790): 
Blood-letting, fever remedies, tepid baths, lowering drinks, weakening 
diet, blood cleansing and everlasting aperients and clysters [enemas] 
form the circle in which the ordinary German physician turns round 
unceasingly. (cited in Haehl 1927 i: 35) 
Cullen's despairing translator and annotator was Friedrich Christian Samuel 
Hahnemann (1755-1843). Born in Meissen, he became a physician, chemist 
and linguist, studying medicine in Leipzig and Vienna, and finally graduating 
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from Erlangen in 1779. After 1790, for the remaining five decades of his long 
life, he mounted a sustained attack on blood-letting, purging, blistering, 
polypharmacy, massive doses and the abusive treatment of the mentally ill, 
that aligned him with Roger Bacon, Paracelsus, J.B. Van Helmont and G.E. 
Stahl, who had all addressed the same issues, frequently in the same terms. 
Before involving himself with therapeutic reform, he had achieved 
prominence and respect from his peers in each of his chosen professional 
fields. Christoph Hufeland (1762-1836) is often described as the greatest 
German clinician of the late eighteenth century (e.g. Habrich 1991), and he 
described Hahnemann as 'one of the most distinguished of German 
physicians ... a practical physician of matured experience and reflection' in 
his preface to Hahnemann (1801a). A quantitative survey of peer citations 
found in Lorenz Crell's Chemische Annalen in the years 1784-89 ranks 
Hahnemann in the first 15 German chemists (Hufbauer 1982: 91). Translations 
of scientific, medical, and literary works into German from English, French, 
Latin and Italian were highly regarded enough to earn him awards and many 
commissions for further translations and also original textbooks. His 
translation of the influential Wholesale Manufacture of Chemicals by J.P. 
Demachy (1784) was considered by the reviewer in Chemische Annalen, ii 
(1785), 77 (cited in Haehl 1927 i, 28) to be an improvement on the French 
original, because of Hahnemann's many critical annotations and 
amplifications. His own Apotheker Lexikon (Hahnemann 1793-99) treated 
every aspect of best practice in pharmacy so definitively and comprehensively 
that it constituted a major reform, superseding its competitors in the opinion 
of three reviewers also cited by Haehl (1927, i, 49). 
At the same time, he advocated positive public health measures as 
progressive as anything to be found in Rickmann (1771) or Frank (1779-1819), 
though without the latter's statist intentions: his programme encompassed 
improved diet and housing for the working people, reform of prisons, strict 
control of trades such as rag-picking and papermaking that harboured and 
spread contagious disease, and compulsory isolation of infectious patients 
(Hahnemann 1792 / 1795). Developing from this, in the two decades after 
1790, Hahnemann created a new pharinacotherapeutic system he believed to 
be more humane and effective than any known before that time, and which 
he eventually named homeopathy. In spite of a seemingly secure polymathic 
foundation, Hahnemann was vilified like his iconoclastic predecessors, and 
his proposed solution to the therapeutic anarchy of the day earned him even 
more notoriety than his critique. Typically, he was portrayed as a quack 
unable to earn a living from orthodox medicine (Holmes 1842), dishonest or 
insane (Guy 1860), and, in a dismissal extending to all who followed his 
precepts, as 'too weak mentally to practise medicine or even to take care of 
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himself' (Spooner 1882). 
Here I make no attempt to give more than the briefest mention of the 
philosophical and scientific basis of Hahnemann's attack on traditional 
therapeutics, or of the sources and precursors Hahnemann drew on in 
designing his system (for which see Ch. 3), or of his influence on nineteenth-
century therapeutics and pharmacology. I would like simply to examine some 
of the ways in which Hahnemann tried to position homeopathy in German 
medical life at the beginning of the nineteenth century, and some of the 
difficulties inherent in his rhetorical and practical engagement with a 
theoretical academic discourse which started with a fundamentally different 
assumption from his about the place of therapeutics in medicine, a discourse 
which at its most extreme led to the abandonment of therapeutics in the 
interests of science. I try to show that homeopathy's eventual exclusion from 
biomedicine may be more plausibly accounted for at this level, rather than by 
the notorious infinitesimal doses usually advanced as the self-evident 
explanation. 
2.2. Philosophy, medicine and the Aufklarung 
Hahnemann was not alone in his dissatisfaction with medicine's failure to 
fulfil the ideals of the German Enlightenment or Aufkliirung. During the 1790s 
many German physicians supported the call for a reconstituted medicine, 
based on the critical philosophy of Immanuel Kant (1724-1804), to match the 
certainties of the physical sciences. In 1784 a Berlin journal had asked several 
leading thinkers to contribute an answer to the question, What is 
Enlightenment? Kant's essay famously opens: 
Enlightenment is man's emergence from his self-incurred immaturity. (Kant 
1784, original emphases) 
And in 1798 the doctor Johann Karl Osterhausen paid direct homage to Kant 
in an essay 'On medical enlightenment', which he defined as: 
Man's emergence from his dependence in matters concerning his 
physical wellbeing. (quoted in Gay 1970: 17) 
The conceptual gulf separating the lowly craft of medicine from the 
established sciences was spelled out by Kant in a letter of 1799: doctors were 
currently fighting symptoms, whereas in Brown's system 'the disease was like 
an X equation' (quoted in Risse 1972). Kant was promoting his doctrine that 
scientific knowledge was necessarily quantitative by referring to the system of 
John Brown (1735-88), the Scottish student of Cullen who had reduced all 
disease to a single fundamental category: variation in 'excitement', or degree 
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of vitality (Brown 1780). The health of any organism consisted of maintaining 
a balance between its 'excitability', or predisposition to excitement, and 
internal and external 'stimuli' -food, drugs, emotions, for example - which 
constantly impinged on excitability: increase in excitement led to 'sthenic' 
disease, and decrease to 'asthenic' disease. Conventional disease labels, such 
as 'jaundice', 'dropsy' or 'fever', were assigned points between two extremes 
on a graduated scale similar to that of a thermometer, and treatment was 
correspondingly simple: 
The indication for the cure of sthenic diathesis is to diminish, that for 
the cure of asthenic diathesis is to encrease the excitement, and to 
continue to encrease it. (Brown 1791 cited in Conner 1966) 
In practice, debilitating treatments such as blood-letting or opium, and 
stimulants such as alcohol answered every clinical need. Brown's revival of 
early Greek Methodism is the best-known and most influential example of the 
rationalist trend in late eighteenth-century medicine. German interest in the 
Brunonian system, as it was called, was such that medical students and 
faculty fought in the streets of Gottingen in 1802 for several days to decide the 
truth of the doctrine, until the cavalry were sent in (Hegel 1970 iii, 379). In 
complete contrast to the better known French attempts to reconstitute 
medicine as an inductive science based on Linnaean nosological categories 
and the search for the lesion, the German task was to look for first principles 
which would underlie nosology and therapeutics, and so elevate rationalism 
to new heights. 
Andreas Roeschlaub (1768-1835), professor of medicine at Bamberg 
University, was one of the initiators of the German trend. As the leading 
German Brunonian, Roeschlaub had developed Brown's simple irritation 
'equation' by adding a vital principle with which irritation came into conflict. 
In touch with the latest developments in other fields, he also attempted to 
reconcile Brunonianism with Lavoisierian chemistry and accounted for the 
disease polarities in terms of oxidation and disoxidation (ibid.). His interest in 
chemical explanations of disease was paralleled elsewhere. For instance, J.-B.-
T. Baumes (1756-1828), professor at Montpellier, proposed a division of 
diseases based on deficiencies of hydrogen, azoth (nitrogen), caloric 
(Lavoisier's elastic fluid from which heat derived), phosphorus or oxygen 
(Baumes 1798; 1801-02). Roeschlaub's main ambition though was to provide 
the conceptual illumination for a formal deductive science of medicine, and in 
an important article of 1799 he constructed a hierarchical framework to 
support the practice and teaching of such a system (Roeschlaub 1799). 
The preliminary phase of the operation required the creation of a standard 
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terminology to allow unambiguous description of theory and practice. 
Among other things, this involved clarification of the terms Heilkunde and 
Heilkunst, about which it seems there had been some confusion. 
Etymologically, both are based on the root Heil - cure, heal. The suffix -kunde 
indicates knowledge and theory, and turns an entity or activity into a subject 
or discipline: Heilkunde is medicine in the same way that Erdkunde is 
geography. The noun Kunst means art or skill, and was added to many terms 
during the eighteenth century to indicate a craft or professional activity 
employing an organized body of knowledge or Wissenschaft. According to 
Roeschlaub, Medizin - medicine - contains two fundamental divisions: 
Heilkunde - theoretical, scientific - and Heilkunst - technical, practical. It is 
important to realize that Heilkunde is concerned solely with ridding patients of 
diseases. It does not include background fields such as chemistry, anatomy 
and physiology, nor does it encroach on the areas occupied by hygiene and 
health maintenance. Heilkunde is further subdivided into general and applied 
sections, dealing with the laws of health and disease, their manifestations in 
pathology and classified nosology, and pharmacology. Heilkunst meanwhile 
consists of what doctors do in practice to realize this theoretical knowledge, 
and includes diagnostics, prognostics and therapeutics. The word was in fact 
the eighteenth-century German equivalent of the Hippocratic techne iatrike 
(Latin ars medendi), and a down-to-earth definition from 1803 helps to clarify 
its essentially practical objective: Heilkunst could be 'implemented internally 
in various forms, or externally, as with salves' (cited in Grimm & Grimm 
1862). 
Roeschlaub was explicit that his variant of Brunonianism sat at the apex of the 
new Kantian medical science, and would provide the a priori guidelines for 
successful therapeutics. His ideas were highly influential, and stimulated the 
philosopher Friedrich Schelling (1775-1854)-whose medical degree from 
Landshut (1802) was purely honorary - to articulate an even more ambitious 
programme for the realization of a medical science that would transcend 
Brunonianism and embody the highest ideals of post-Kantian 
Naturphilosophie. Man was coincident with the universe, but had lost touch 
with this essential oneness. Not until he had learned to understand external 
nature, through contemplation of his own innermost reality, could he hope to 
formulate laws of existence. From this certain knowledge would come insight 
into health and disease, thus allowing a rational therapeutics to be deduced 
from metaphysical principles without the need for empirical testing (Schelling 
1797; 1799). 
Nevertheless, German attempts to create a deductive medico-philosophic 
science and the better-known French attempts to reformulate medicine on 
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inductive clinical lines were therapeutically unproductive, in the lifetime of 
their patients at least. By the end of the nineteenth century, in spite of 
enormous advances in descriptive pathology, normal and abnormal 
physiology, surgery, and public health, the internal medicine of the end of the 
eighteenth century had advanced scarcely at all: 
Blood-letting gradually lost favour, but ... the pharmacopoeia was a 
bag of blanks ... the few medicines that were effective included 
mercury for syphilis and ringworm, digitalis to strengthen the heart, 
amyl nitrite to dilate the arteries in angina, quinine for malaria, 
colchicum for gout- and little else ... (Porter 1997: 674) 
If safety had been a criterion of use as well as efficacy, the list would have 
been even shorter. 
2.3. Conceptual foundation of homeopathy 
Praktische Arzneykunde was another expression for Heilkunst, at a time when 
German technical terminology was in state of creative flux, and Christoph 
Hufeland's Journal of that name was programmatically opposed to the 
theoretical turn in academic medicine. It was there that Hahnemann (1796b; 
1852b) chose to announce his 'new principle for ascertaining the curative 
powers of drugs'. Treatment under the new system differed from current 
medical practice in consisting of single pure drugs that had been subject to 
thorough experimental testing on healthy volunteers (in moderately small 
doses) before being given in smaller, and hence safer, doses to the sick. These 
pathogenetic trials (Pru.Jungen, tests, anglicized as provings) indicated the 
therapeutic sphere of influence of each drug, according to the similia principle 
- similia similibus curentur, let likes be cured with likes. Hahnemann later 
published his first experiments with greatly attenuated therapeutic doses in 
1801 in Hufeland's Journal, and several important critical and homeopathic 
articles followed, which invariably appealed to clinically validated experience 
as the arbiter of therapeutic efficacy, not theory or tradition (Hahnemann 
1801a; 1801b; 1801c; 1801d; 1805c; 1806; 1807).1 
It is probably on this account that homeopathy has been dismissed as pure 
empiricism- that is, lacking any explanatory theory (e.g. House of Commons 
1854-55) - as often as it has been dismissed as a survival of eighteenth-century 
rationalism- that is, theory unconnected with experimental confirmation (e.g. 
1 All except the last two can be found in the collections Kleine mediciniscl1e Schriften 
(Hahnemann 1829) and The Lesser Writings (Hahnemann 1852b). 
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Shryock 1948: 138). It is often pointed out that since Hippocrates official 
medicine had tended to oscillate between empirical and rationalist poles 
(Faber 1921; Temkin 1963). It is also true that Hahnemann favoured the 
biographical natural-history-of-disease approach of the empirical school, 
exemplified by Hippocrates and Sydenham, over the ontological claim of 
rationalists such as Galen and Brown to know the essential nature of disease: 
We were never nearer the discovery of the science of medicine than in 
the time of Hippocrates. This attentive, unsophisticated observer 
sought nature in nature. He saw and described the diseases before him 
accurately, without addition, without speculation (Hahnemann 1805c; 
1852b). 
Because of this, recent historians have tended to see homeopathy as an 
empirical discipline, in conflict with Brunonianism (e.g. Schwanitz 1983), or 
even as empiricism's final answer to 1500 years of Galenic rationalism 
(Coulter 1977). Admittedly, Hahnemann (1801a) demolished Brown's 
Elements of Medicine, regardless of Roeschlaub's advocacy; and early in the 
history of Naturphilosophie, Hahnemann (1808c) was wondering whether 
satire or elegy would be the most appropriate vehicle to commemorate the 
self-spun 'gossamer' fabrications of Schelling and his emulators. Even 
chemical nosologies such as Roeschlaub's and Baumes's were new flasks for 
some very old ideas (Albury 1977), and Hahnemann (Hahnemann 1801c; 
1852b), the chemist, believed rudimentary chemistry was being used as a 
medical figleaf. However, recalling Bacon's (1620 i, §95) observation that 
empirical ants were no more effective than rationalist spiders, Hahnemann 
(1801c) also made searching criticisms of empirical treatments aimed at ill-
defined 'diseases' that were hardly more than a vague symptom or two -
such as 'rheumatism' and 'dropsy' - and not just the sorts of cause that 
rationalism claimed to know. He pointed out that the empiricists had known 
how to observe but not how to cure, hence their reliance on diet and the 
'healing power of nature' above all. In 'Examination of the sources of the 
ordinary materia medica' he also criticized the random nature of testing one 
substance after another in each disease: the tiny number of known specifics -
scarcely more than mercury for syphilis, cinchona bark for malaria and 
sulphur for skin eruptions in the 1500 years since Galen - had been 
discovered by the empiricists as if by chance, or appropriated from folk 
medicine (Hahnemann 1817; 1852b). And he was not alone in wondering how 
the specifics worked. As Kant's successor G.W.F. Hegel (1770-1831) pointed 
out contemporaneously in his review of biology and medicine: 
The materia medica has not yet uttered a single rational word on the 
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connection between a disease and its remedy; experience alone is 
supposed to decide the matter. Experience with chicken droppings is 
therefore as valuable as that with the various officinal plants, for 
human urine and the droppings of chickens and peacocks were 
formerly used medicinally, in order to produce nausea. (Hegel 1970 iii, 
206) 
Homeopathy's resistance to simple binary classification was addressed to 
some extent by Guttentag (1940), who developed the rational-empirical 
oscillation further in the time dimension by representing medical history 
since Hippocrates as a spiral. He located Hahnemann at a cusp point midway 
between the two poles of the spiral, along with other late eighteenth-century 
figures such as Withering and Jenner. Guttentag did not analyse further the 
scientific basis of homeopathy, except to say that it was an empirical clinical 
discipline, not an explanatory biological hypothesis. 
In fact, the technical term with the closest epistemological fit for 
Hahnemann's conceptual innovation is abduction (or retroduction), 
introduced at the end of the nineteenth century by the philosopher C.S. 
Peirce. This was his translation of apagoge, Aristotle's third form of inference -
along with induction and deduction - which had hitherto been translated as 
reduction (and is often referred to now as 'inference to best explanation'): 
The form of inference, therefore, is this: The surprising fact, C, is 
observed; But if A were true, C would be a matter of course. Hence, 
there is reason to suspect that A is true. Thus, A cannot be abductively 
inferred, or if you prefer the expression, cannot be abductively 
conjectured until its entire content is already present in the premiss, 'If 
A were true, C would follow as a matter of course.' (Peirce 1935 vi, 
522-528) 
According to Hanson (1958: 70ff), abduction is not synonymous with the 
better-known hypothetico-deductive model, associated with the theorists 
Whewell and Popper, although Hanson's main example of abduction-
Kepler's reconceptualization of the Copernican circular planetary orbits -has 
for some reason left many unconvinced that the two forms of inference can be 
distinguished. Hahnemann's 'surprising facts' were the inexplicable empirical 
specifics, long an embarrassment to rationalism, such as cinchona, mercury 
and sulphur. He had seen many cases of malarial fever while practising in 
Transylvania in 1777-79 (Cullen 1790 ii: 114).The mercurial disease was often 
confused with syphilis, sulphur workers produced itching rashes, so, 
suspecting a hitherto unnoticed relationship between the medicinal action 
and toxicological symptoms of cinchona, Hahnemann's footnote to Cullen 
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(ibid. ii: 108) describes how he took in 1790, 
by way of experiment, for several days 3 drachms of good bark twice a 
day. My feet, finger-ends, &c., first became cold, and I felt tired and 
sleepy, then my heart began to beat, and my pulse became hard and 
quick; I got an insufferable feeling of uneasiness, a trembling (but 
without rigor). A weariness in all my limbs; then a beating in my head, 
redness of the cheeks, thirst, - in short, all the old symptoms with 
which I was familiar in ague [malaria] appeared one after another, yet 
without any actual chill or rigor. In brief, even those particularly 
characteristic symptoms which I was wont to observe in agues -
obtuseness of the senses, a kind of rigidity in limbs, but especially that 
numb disagreeable feeling which seems to have its seat in the 
periosteum of all the bones of the body- all put in an appearance. This 
paroxysm lasted each time 2 or 3 hours, and came on afresh whenever 
I repeated the dose, but not otherwise. I left off, and was quite well. 
Hahnemann, it turns out, illustrates Hanson's distinction as well as Kepler. 
Aristotelian abduction originated as a logical description and justification of 
the process of inference from disparate biological species to the genera which 
contain them. In other words it seeks higher level ontological groupings 
which subsume lower level data - synthetic a priori insights, in Kantian 
terms. The specifics were doubly surprising, because they showed a 
paradoxical ability to produce the very symptoms they were reputed to cure. 
Hahnemann's explanatory hypothesis and conceptual definition was the 
similia principle, or homeopathicity, which subsumed known treatments of 
vastly different appearance and qualities for diseases that were themselves 
unrelated. 
And as Atran (1990: 89ff) points out, apagoge has not only this dual function 
for Aristotle - to provide an intuitive hypothesis and then a concept or 
definition which figures as the major premiss in syllogistic demonstration -
but most importantly is required to 'factor out ... the truly essential from the 
natural incidents of the common-sense type.' The similia hypothesis allowed 
Hahnemann to reject the plausible explanations of his contemporaries, such 
as Cullen's (1790 ii: 108) entirely orthodox claim that cinchona cured malaria 
because its bitter taste had a tonic effect on the stomach. Fulfilling Peirce's 
requirement that the abductive hypothesis be subject to experimental 
validation, Hahnemann's tests from 1790 onwards involved making careful 
records of what happened when he gave different drugs first to himself and 
then to other healthy volunteers, and what happened when he treated the sick 
with drugs capable of producing the same symptoms (Hahnemann 1805b). 
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2.4. The appearance of the Organon 
Hahnemann's textbook of homeopathy, first published in 1810, provides 
theoretical and practical instructions for the new approach to therapy he had 
created in the previous 20 years, and integrates his similia hypothesis with a 
Hippocratic natural-history approach to nosology, Stahl's homeostatic 
vitalism, Plenciz's germ theory, John Hunter's theory of medicinal counter-
irritants, placebo controls and many other disparate and previously unrelated 
influences (Hahnemann 1810; Hahnemann 1913; Hahnemann 2000). It went 
through five editions in his lifetime, and has been in print continuously since 
then in many languages. Before examining the internal structure of his 
programme as laid out in the book, it is worth trying to estimate the impact 
Hahnemann wished the book to have, judging by the way he presented it. 
Although the bones of the system had first been presented in Hufeland's 
Journal under the title Heilkunde der Erfahrung (The Medicine of Experience) in 
· 1805, the change of title to the more imposing Organon der rationellen Heilkunde 
indicates that Hahnemann believed that appeals to experience were unlikely 
to sway a medical establishment wedded to a priori theories of disease and 
how medical knowledge was to be structured. The term Organon, which can 
be a conceptual tool, systematic treatise or physical instrument, echoes the 
collective title traditionally given to Aristotle's treatises on logic, and Francis 
Bacon's Novum Organum of 1620. Apart from Aristotle's and Bacon's, there 
had been remarkably few Organons before Hahnemann, although the word 
had achieved some currency in Germany following the appearance of J.H. 
Lambert's (1764) Neues Organon. Hahnemann might conceivably have read 
this epistemological treatise - which contains the first use of the word 
phenomenology - by the most important German philosopher of the 
generation immediately before Kant. 
The meaning of the rest of Hahnemann's title has become obscure, because 
the implications of Heilkunde at this date- medical theory- are unfamiliar in 
modern German. Heilkunde now inclusively means medicine, or medical 
science in the broadest sense, in which theory and practice are held to be 
integrated, or therapeutics. And unsurprisingly, the Terminology Office of the 
European Commission in Luxembourg defines Heilkunst - ID Number 
3102196 in the Medicine Collection (RLM76)- as just 'another word for 
Heilkunde'. The rationell of the first edition is equally remote. Rationell, 
signifying 'technical', 'scientific', 'validated by empirical reason', had been 
introduced in 1798 by Goethe from French. It was distinct from the existing 
but rarely used rational, a term with traditional philosophical overtones, and 
filled an important gap left unoccupied by Wissenschaft. Hahnemann's 
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employment of the term in a medical context seems intended to occupy a 
rhetorical high ground similar to that enjoyed by 'evidence-based' in present-
day clinical discourse, while prefiguring Jakob Henle's (1846) later use of 
rationell in a book title to draw a line between his empirical research and the 
speculative physiology that Naturphilosophie was famous for. Once again, the 
word's original sense has faded, leaving an identifiable gap: Rudolf Carnap, 
Karl Popper and others complained that psychoanalysis and Marxism did not 
deserve their self-descriptions as scientific - wissenschaftlich. The 
disappearance of the original meaning of rationell might even have been a 
factor in the foregrounding of the demarcation problem by the Vienna Circle. 
Nowadays it simply means rational, although a secondary meaning of 
'economically efficient' was introduced in the 1930s (equivalent to one of the 
meanings of 'rationalized' in English) reconnecting the word to its 
'empirically-proven' origin. Nevertheless, the original title called attention to 
itself as constituting the architectonic 'science' the Kantians, Brunonians and 
Naturphilosophen aspired towards. 
The title page was adorned with C.F. Gellert's (1715-69) quintessentially 
Enlightenment verse: 
The truth we humans need 
Us blest to make and keep, 
A wise hand lightly covered o'er, 
But did not bury deep.2 
We may guess from this that the book will not advance any theory of the 
occult essence or origins of disease. This is confirmed by the preface which 
informs us that 'no occupation is more unanimously declared to be a 
conjectural art than medicine', but that the author's researches had led him 
'very far from the common highway of medical routine ... away from the old 
edifice, which, being built up of opinions, was only maintained by opinions.' 
Interestingly, the term homeopathy is absent from the title page. An 
unpaginated half title, between the Introduction and the main text, is a partial 
exception: Organon der rationellen Heilkunde nach homoopathischen Gesetzen is 
found in the first edition, but not in any of the five later editions Hahnemann 
prepared for the press. A legitimate translation would be: 'Treatise of 
scientific medical theory according to homeopathic laws'. Hahnemann had 
coined Homoopathie (Greek homoios, similar+ pathos, suffering) together with 
2 Die Wahr~eit, die wir ~Ile _nothig haben, I Die uns als Menschen gliicklich macht, I Ward 
von der we1sen Hand, die s1e uns zugedacht, I Nur Ieicht verdeckt, nicht tief vergraben. 
I have adjusted the translation in Hahnemann (1893: 155). 
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the pejorative Alloopathie to describe unsystematic treatment (alloios, other, 
dissimilar) in 1807 in a scholarly literature review that became the 
Introduction to the Organon (Hahnemann 1807; 1833a: 48-101). It contains 
nearly 250 examples of the mostly unconscious use of the similia principle by 
440 named physicians, past and present, as evidence for the method 
elaborated in the rest of the book. 
The main body of the Organon is laid out as 271 numbered sections containing 
propositions and arguments, grouped thematically, like the aphorisms of the 
Novum Organum, emphasizing the book's critical philosophical intent. They 
vary in length from single sentences to extensively footnoted paragraphs 
spanning several pages. The first two aphorisms set the tone: 
The physician has no higher aim than to make sick people well, to heal 
as it is known. 
The highest ideal of cure is the speedy, gentle and enduring restoration 
of health, or the removal and annihilation of disease in its entirety, by 
the quickest, most trustworthy, and least harmful way, according to 
principles that can be readily understood. 
2.5. The structure of the Organon 
To understand the structure of Hahnemann's medical programme as 
formalized for the first time, Roeschlaub makes a convenient point of 
reference. As noted, the Organon was ostensibly concerned with rationelle 
Heilkunde, which to a Roeschlaub implied a priori knowledge of the causes of 
disease. Hahnemann (e.g. 1801c; 1808c) believed history had shown this was 
an unprofitable line of inquiry, but a hierarchic presentation of his therapeutic 
posed difficulties because the similia principle ran counter to the causal 
model required by Western science. In the essay that was expanded to 
become the Organon, Hahnemann (1805c; 1852b) had written: 
Medicine is a science of experience; its object is to eradicate diseases by 
means of remedies. The knowledge of diseases, the knowledge of 
remedies, and the knowledge of their employment constitute medicine. 
This tripartite division lacks any overarching theory of disease causation, and, 
although Hahnemann was a contagionist, and the influence of Plenciz's (1762) 
germ theory can be found in his writings from 1801 onwards (see Ch. 3), he 
recognized that most diseases could not be so easily explained. The 
components of the homeopathic method differ radically from its rationalist 
(not to mention empiricist) counterparts, and Hahnemann was obliged to 
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create a theoretical justification to give the appearance that the rest of the 
book had been deduced a priori. Accordingly, the similia principle is placed 
at the apex of the system, and incorporated into the Roeschlaubian hierarchy 
as far as possible by dividing the Organon proper into four sections dealing 
successively with: 
1. disease as response to disturbance of homeostasis; theory of specific 
medicinal counter-forces, i.e. the similia principle; 
2. individual case-taking; 
3. conduct of collective pathogeneses; 
4. practicalities of medicine selection, case-management and pharmacy. 
Table 2.1 Correspondence of the internal structure of Hahnemann's Organon 
(1810) to Roeschlaub's (1799) deductive schema 
1. Hei/kunde or 
Theoretical medicine 
Roeschlaub 
General 
Applied 
Disease concept and 
causation 
Pathology 
Nosology 
Pharmacology 
Hahnemann 
Disease concept; theory of cure by similars 
(§§ 1-38) 
i. Case-taking(§§ 39-82) 
ii. Pathogeneses (§§ 83-125) 
2. Heilkunst or 
Technical medicine 
Diagnostics 
Prognostics 
Therapeutics 
iii. Medicine selection(§§ 126-99), dosage, case-
management (§§ 200-71) 
Hahnemann's original tripartite division corresponds to sections 2-4, and the 
way in which it can be superimposed (numbered i-iii, as in the Organon § 38) 
on Roeschlaub's categories is shown in Table 2.1. In complete contrast to the 
determinist chain of cause, classified nosologies, their attached treatments, 
and pigeon-holed patients, Hahnemann's system is essentially circular, 
despite the superficial resemblance in the way the material is ordered. Its 
justification - the similia principle - lies at its heart, not at its head. The 
impression of seamless continuity is reinforced by the absence of 
conventional section headings or chapters: the paragraphs run 
uninterruptedly, and sections i-iii are mentioned only in the text. 
In contrast to systems emerging to take the place of humoralism, such as the 
chemical nosologies of Roeschlaub and Baumes, or the diathesis construct 
(Ackerknecht 1982a), disease is not to be viewed as purely idiopathic or 
essential. Yet, although disease is occasioned by external causes, and there are 
even 'fixed' contagious diseases, these causes have no independent disease-
existence a part from their effects on the organism: 
The invisible disease-producing alteration in the inward man together 
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with the visible alteration in health (the sum of the symptoms) make 
up that which is called disease; both together actually constitute the 
disease. (Hahnemann 1913 § 6) 
Virus, miasms, poisons and drugs all have the ability to alter health, for better 
or worse, and the homeopathic principle demands that their pathogenetic 
capacity be correlated with the symptoms of the patient: 
a few berries of belladonna are just as much disease-producing forces 
as inoculated vaccine-matter, or a viper-bite, or a great shock, and 
every one of these influences, just because it has the power to produce 
disease, can become a remedy and a force to counteract disease, as 
soon as it is opposed to a similar disorder already existing in the body. 
(ibid.§ 32) 
Disease, nevertheless, must be viewed holistically, since 
the oneness of life forbids the idea that any bodily disease can remain 
completely and absolutely local so long as it is not confined to a part of 
the body entirely shut off from all the rest. The remainder of the 
system simultaneously suffers more or less, and betrays its suffering in 
this or that symptom. (ibid. § 43) 
Moreover, diagnosis does not involve matching patients to the static 
nosologies of Sydenham, Cullen and Pinel, which 
even if it could be accomplished with tolerable accuracy and 
completeness, would serve the physician only as a natural historian, in 
the way that the classification of other natural phenomena and natural 
objects is of value in general natural history. In other words, it would 
aid his historical perception by means of a tabulated and ordered 
survey. But for the physician as a practitioner of the art of medicine it 
would be of no value whatever, (ibid. § 45) 
because each disease, properly examined, has never been seen before. 
Pathology (subdivision i) therefore must be discovered in a process of 
unbiased phenomenological inquiry, in which the patient's experience is not 
merely a pointer to an explanatory or reductive diagnosis. The therapist notes 
the observable manifestations of illness and records the account of physical 
and psychological suffering related by the patient and his carers, 'using their 
exact expressions' without translation into transient medical codes, and 
paying particular attention to qualities, modalities and concomitants of 
symptoms, as well as general disturbances of function (ibid.§§ 62-69). The 
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extensive and detailed anamnesis does not provide a mere collection of 
symptoms, however, but must be integrated in the therapist's mind as a 
unified Symptomeninbegriff. This is a term of art for Hahnemann, who exploits 
Inbegriffs dual meanings of totality and epitome. The same procedure is 
adopted in collective diseases, such as epidemics: a symptom-complex is built 
up from the partial manifestations of the disease seen in each individual, 
allowing a valid collective remedy to be synthesized (ibid.§§ 79-81). 
A similar form of meticulous case-taking is used in the pathogenetic drug 
tests which constitute homeopathy's nosology (subdivision ii). This spans the 
Organon, where the detailed instructions for conducting provings are given, 
and the rnateria rnedica where the results of systematic drug tests are listed-
again using the provers' own expressions (Hahnemann 1805b; 1811-21; 
1822-27; 1828-30; 1833-37).3 The aim was the creation of a materia medica in 
which nothing was 'conjectured, asserted without proof, imagined, invented; 
but all is the pure reply of Nature to careful questioning', (Hahnemann 1913 § 
121). 
In the investigation of these drug-symptoms all suggestion must be as 
rigidly avoided as in the examination of the symptoms of disease. The 
greater part of what is recorded as the genuine result of experiment 
must be the voluntary statements of the prover; nothing must be 
conjectural, nothing guessed at, and as little as possible should consist 
of answers to formal questions; least of all should the record contain 
expressions relating to sensations with which the prover has 
previously been prompted, or the results of questions that suggest the 
answers 'Yes' or 'No'. (ibid.§ 115) 
In a footnote to § 122, Hahnemann called on others to carry forward his 
investigations of the previous 20 years: 
When thousands of exact and tireless observers, instead of one as 
hitherto, have laboured at the discovery of these first elements of a 
scientific Materia Medica, what will it not be possible to effect in the 
whole extent of the endless kingdom of disease! Then the art of 
medicine will no longer be mocked as an art of conjecture lacking all 
foundation. 
The practical details of prescription, case-management and pharmacy 
3 For tabulated analysis of the development and publication history of Hahnemann's materia 
medica, see Hughes (1893: 17-39). 
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(subdivision iii) correspond to Heilkunst, therapeutics, where many 
instructions are given for the selection of the remedy in individual cases. The 
defining aspect of homeopathic diagnosis-prescription is an individualization 
based on the unique, as opposed to common, aspects of the patient's 
symptoms: 
In this search for a specific homoeopathic remedy, that is, in this 
comparison of the totality of the symptoms of the natural disease with 
the symptom-lists of available medicines, the more striking and 
unusual of the characteristic symptoms of the disease should especially 
be kept in view; for it is precisely to these symptoms that analogues 
must be found among the disease-symptoms of the drug which is to be 
the most suitable remedy. On the other hand the general signs, like loss 
of appetite, weariness, discomfort, disturbed sleep, and so forth, are of 
little significance when unaccompanied by more precise indications, 
because they are found in the symptomatology of most drugs as of 
most diseases. (ibid. § 129) 
In other words, the subtle variations of symptoms experienced in relation to 
time, position, temperature, weather and so on - the so-called modalities - are 
of greater importance than the same undifferentiated symptoms or 
nosological category. It is also here, rather than under nosology, that the usual 
distinction made between mental and physical illness is declared to be purely 
conventional: 
Indeed, [mental diseases] are in no wise really an exceptional class of 
disease, though often sharply separated off from others in 
classification. For in every other kind of disease the condition of the 
mind and of the disposition is invariably altered in some way, and the 
disposition and mental characteristics of the patient form symptoms of 
prime importance in all cases which the physician has to treat. (ibid. § 
186) 
We shall, therefore, never learn to cure scientifically or 
homeopathically, unless we consider in every case of disease these 
alterations in mind and disposition, and choose as a counter-force the 
remedy which is capable of causing similar alterations. (ibid. § 189) 
In practical terms: 
Aconite will never bring about a speedy or lasting cure in a patient of 
quiet, equable disposition; Nux vomica is as little serviceable to gentle 
phlegmatic patients, Pulsatilla as little to the gay and happy, Ignatia as 
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little to those who are imperturbable and disinclined either to fear or to 
vexation, 
since each of those had shown itself capable of producing the opposite 
disturbances of mind in the healthy. 
The Organon does not contain worked examples of the method, but these 
were published soon after as 'Cases illustrative of homoeopathic practice' 
(Hahnemann 1817; 1852b). For instance, to illustrate the process of 
conceptualizing the symptoms and matching them with the materia medica, 
Hahnemann presents the simple case of Frau Sch-, a middle-aged laundress 
with a troublesome condition that had kept her from work for 3 weeks. The 
unique symptoms she presented with on 1 September 1815 were: 
(1) Any movement, especially on stepping, and worst on making a 
false step, leads to shooting pain in the epigastric region coming every 
time from the left side. (2) Complete relief on lying down, no pain 
anywhere, neither in the side nor in the epigastrium. (3) Sleepless after 
3 a.m. (4) Enjoys her food, but feels nauseous after eating only a little. 
(5) This leads to increased salivation which runs from her mouth, like 
water-brash. (6) Frequent empty eructations after each meal. (7) 
Passionate temper, disposed to anger. -Covered in perspiration when 
the pain is severe.-Menses normal two weeks earlier. 
Hahnemann details how each symptom of Frau Sch-'s ailment can be found 
in the pathogeneses contained in the materia medica, and distinguishes 
between several medicines for each symptom on the basis of the modalities. 
To give only his working out of the first symptom: 
Belladonna, China and Rhus toxicodendron cause shootings in the 
epigastrium, but none of them only on motion, as is the case here. 
Pulsatilla certainly causes shootings in the epigastrium on making a 
false step, but only as a rare alternating action, and has neither the 
same digestive derangements as occur here at (4) compared with (5) 
and (6), nor the same mental state. Bryonia alone has among its chief 
alternating actions, as the whole list of its symptoms demonstrates, 
pains from movement and especially shooting pains, as also stitches 
beneath the sternum (in the epigastrium) on raising the arm, and on 
making a false step it causes shooting in other parts. (ibid.) 
The other symptoms are dealt with in the same way, each being compared 
with medicines which produce the general symptom, then distinguished on 
the basis of the individualizing modalities. For instance, nausea after eating 
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was common to eight drug pathogeneses, but none so constantly or 
associated with such enjoyment of food as Bryonia. Frau Sch-'s psychological 
state was an important factor in differentiation, and again Bryonia was 
preeminent.4 
Hahnemann points out that the individualization of simple cases is carried 
out as a rapid mental operation once the materia medica is memorized or the 
practitioner knows where to find the symptoms, but giving all the reasons for 
and against each stage of the process in writing leads to 'tedious prolixity'. 
Since each disease is a unique process, not a fixed entity, case-taking merges 
with prescription and case-management: 
Now we can neither enumerate all possible aggregates of symptoms of 
all concrete cases of disease, nor indicate a priori the homeopathic 
medicines for these (a priori undefinable) possibilities. For every 
individual given case (and every case is an individuality, differing 
from all others) the homeopathist must himself find them. (ibid.) 
And because the treatment is a unique analogue of the patient's symptom-
complex, the distinction between theory and therapeutics is blurred and 
circles back to the similia principle, or general Heilkunde. 
2.6. Hahnemann and the academy 
Homeopathy might have been the product of a controversial iconoclast, but it 
was regarded as part of orthodox medicine at first, as Hegel's (1970 iii: 205) 
account of its pharmacological mechanism shows. Nevertheless, it was not 
aimed at hypothesized proximate or ultimate causes, as in rationalist or 
symptomatic medicine. Still less did its explicitly holistic individualization of 
disease states hand doctors a bagful of easy-to-remember empirical specifics, 
to which more or less plausible justifications could be attached; even the 
'fixed' contagious diseases seen in epidemics required different remedies to 
be calibrated at each outbreak (Hahnemann 1810 § 79). The Organon pointed 
in a different direction from its German and French contemporaries, yet it 
4 The follow-up to this case is interesting. Hahnemann prescribed a drop of (undiluted) 
Bryonia tincture in the customary single dose and asked Frau Sch- to see him in 48 hours, 
telling a colleague present at the time that she would be better the next day. She never 
returned, and when the colleague sought her out later from curiosity, she replied: 'What was 
the use of going back? The very next day I was quite well, and could start my washing again. 
I am extremely obliged to the doctor, but the likes of us have no time to leave off our work. 
For three weeks previously my illness prevented me from earning anything.' (ibid.) 
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appeared at a time when Hahnemann wished to acquire a secure academic 
base from which to promote homeopathy and transform therapeutics, and the 
detailed critique of existing practices, for which its author had become 
notorious, is notably absent. It would be surprising therefore if it were the 
sole example of his rhetorical deployment of terminology and structures 
corresponding to the mindset of German academic medicine. Two years after 
the appearance of the Organon, he presented his habilitation thesis at Leipzig 
University, where university regulations allowed anyone capable of 
successfully defending a thesis to lecture as an unsalaried Privatdozent 
(Hahnemann 1812; 1852b). His demonstration that the 'hellebore' used in 
Classical Greece, Rome and Islam was none other than the plant known to the 
moderns as Veratrum album, cites more than 500 sources from Greek, Roman, 
Arabic, English, French and Italian authors in the original languages, up to 
the year 1200. An idea of the aloofness of the work can be got from 
Hahnemann's disdainful prefatory note that he would 'leave it to others to 
give an account of the use of hellebore in modern times'. Medical and 
linguistic historiography that combined 'fearsome erudition and minute 
scholarship, quite divorced from any practical problems in medical practice' 
(King 1958: 173) was an unusual departure for Hahnemann, given his 
outspoken rejection of unvalidated historical authority and philosophical 
theorizing in medicine, and seems to call for explanation absent from the text. 
In a discussion of the pecking orders that scientific and scholarly communities 
create for different disciplines, Jardine (1991: lllff) points out that they are 
important when we want to find out which disciplines serve as models of 
procedure and presentation for others. For example, in Renaissance Italian 
medical training physicians nearly always gained doctorates in philosophy as 
well as medicine, as part of a process of professional legitimation aimed at 
raising the status of mere empirics. Jardine cites von Seemen (1926) who 
described a similar situation in German medical teaching in the first decades 
of the nineteenth century, and casts much light on Hahnemann's remarkable 
thesis. As the limitations of Brunonianism became more apparent, medical 
textbooks became increasingly obsessed with historical precedent, even to the 
exclusion of current theory and practice. This 'history craze' became as 
characteristic of the Romantic movement in German medicine as 
Naturphilosphie, and led its followers to worship the 'record of the 
manifestations of the original ideas which underlie all sound medical theory 
and practice.' 
A reinterpretation of his thesis in this light suggests that, in order to gain the 
right to lecture at Leipzig, Hahnemann abandoned the well-known practical 
urgency that enlivens the rest of his considerable output and instead 
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presented the authorities with an academic performance designed to flatter -
or flatten - their judgement at that moment in 1812. The strategy worked. His 
opponents had anticipated a field day demolishing a homeopathic thesis, but 
in the event Hahnemann was unopposed and obtained his platform. 
2. 7. The transformations of the Organ on 
This historiographical display had been anticipated in the Introduction to the 
1810 Organon, albeit grounded in the demands of day-to-day therapy. The 
German academic world was not won over on its own terms, however, and 
vitriolic attacks on Hahnemann by Hecker and others followed (see Haehl 
1927 i, 89ff). At the same time, the attractions of Naturphilosophie were 
beginning to prove irresistible for many. The professor of pathology at Jena, 
published a medical system (Kieser 1817-19) in which less than a fifth of the 
section on diagnosis mentioned practical observation, the bulk being devoted 
to speculation about the meaning of various symptoms in relation to 
Schelling's theories of male-female polarities and positive and negative 
electrical charges (cited in Schenk 1966: 180). In the same year Hahnemann 
reaffirmed his traditional practical stance in 'Nota bene for my reviewers', 
declaring that homeopathy stood or fell on the evidence of validly conducted 
clinical experiments (Hahnemann 1817; 1852b).5 
The difficulty of fitting a unified acausal methodology into deductive 
hierarchies such as Roeschlaub's and Kieser's no doubt explains another 
important change in the second and subsequent editions: a new title, Organon 
der Heilkunst, acknowledged that, in its essential form, homeopathy began 
and ended in therapeutics. Moreover, for Hahnemann, it was the only 
therapeutics worth the name. At the same time, Gellert's verse was replaced 
with a new motto: the Horatian challenge aude sapere, dare to know (Epodes I, 
2, 40). This could be seen as forming yet another connexion with Kant, whose 
essay 'What is Enlightenment?' continues: 
The motto of enlightenment is therefore: sapere aude! Have courage to 
use your own understanding! (Kant 1784, original emphasis) 
5 Perhaps it was a sign of the times, or just of his normal impatience, that he pushed the 
historical review to the end of the Organon's Introduction in the second edition, and preceded 
it with an equally lengthy recension of his medical critique. The history of homeopathy's 
precursors was later reduced to a handful of examples in the fifth edition of 1833. 
Hahnemann's extensive annotations and revisions to the 5th edition were not published until 
much later (Hahnemann 1921). 
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Yet Hahnemann was a child of the Enlightenment-literally, after his father 
had brought him up according to Rousseau's principles (which Hahnemann 
later translated: Rousseau 1796)- and scarcely needed lessons from Kant. 
Also in 1784, Hahnemann had written in one of his earliest publications that 
the true physician 
rejects nothing not investigated by himself, nor takes the word of 
another, and has the courage to think for himself and to treat 
accordingly. (Hahnemann 1784: 179) 
The Organon' s brief first aphorism acquired a lengthy footnote, burning any 
academic bridges that might have been under construction. It attacks 'learned 
reveries' about the essence of life and origin of disease, identification of 
disease with its cause, 'unintelligible and pompous expressions' designed to 
impress, and chairs of 'theoretical medicine', and ended with another call to 
arms: 
It is high time that all those who call themselves physicians should 
cease to deceive suffering humanity with words that have no meaning, 
and begin to act - that is to say, to afford relief, and cure the sick in 
reality. (Hahnemann 1819a; 1833a) 
However, in spite of Hahnemann's efforts to reform therapeutics, many 
conceptual, scientific, economic, sociological and psychological obstacles 
stood in his way. Fashions in medical jargon may also have played a small 
part in homeopathy's struggle for recognition. Heilkunst - the working-out at 
the individual level of medical theory- was being replaced as a term, even in 
the early 1800s, by praktische Heilkunde, and later by Therapie. By the mid 
nineteenth century, outside of internal homeopathic literature, Heilkunst had 
been pushed to the margins in terms such as Wasserheilkunst, hydrotherapy-
in other words, those fields rapidly being shed by the growing body of 
biomedicine.6 The Viennese 'therapeutic nihilist' Joseph Dietl complained 
(1845) that the physician had been for too long a mere Heilkilnstler - therapist 
- and should strive to become a Naturforscher- scientific researcher (cited in 
Lachmund 1998). Heilkunde itself began to be affected by the same process of 
semantic displacement and decline: Jutte (1998) points out that in the 1880s 
dissident therapies were dismissed as Naturheilkunde, nature-cure, by the 
6 I am grateful to an anonymous reviewer for History of Science who drew my attention to the 
historiographical survival of the term in Die Apologie der Heilkunst: eine grieclzische 
Sophistenrede des fiinften vorchristlichen Ja1zr1mnderts, transl., ed. and annotated by Theodor 
Gomperz (Leipzig, 1890). 
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practitioners of scientific Schulmedizin? Yet Hahnemann maintained he was 
advancing a scientific therapeutics till the end, as shown by the references to 
rationelle Heilkunst in the later editions of the Organon. Increasingly, the 
expression is used as an ironic reproach to the followers of different medical 
gods, either those who perpetuated the old abuses, or such as Dietl, whose 
calls for a new rationelle Therapie (cited by Lachmund 1998) unconsciously 
echoed Hahnemann's rhetorical claim of 30 years before. 
Readers of translations not based on historical German usage faced further 
problems. For instance, the only English translation of the first edition -
usefully clear in most respects- conflated the titles of the first and second 
editions, distorting the German terms at the same time: rationelle Heilkunde -
scientific medical theory- and Heilkunst- therapeutics- became 'rational 
healing art' (Hahnemann 1913). Since all doctors believe they act rationally 
and practise the 'healing art', they could be forgiven for asking what 
Hahnemann meant. 
2.8. The grounds for rejection 
The tendency of sceptical opponents of homeopathy to base their entire 
critique on the a priori impossibility of infinitesimal doses while ignoring 
more fundamental components of the therapy, such as drug tests, the similia 
principle and individualization of prescriptions, was noted by August Bier 
(1925), the influential Berlin surgeon who critically investigated the subject. 
Hahnemann is still excluded from accounts of early pharmacological 
investigation of the pure effects of drugs in humans, despite the priority and 
scale of his work (between 1805 and 1837, he published provings of 100 drugs 
that he had personally conducted or directed), and the sometimes explicit 
indebtedness of canonical pioneers such as Magendie, Orfila and Purkyne to 
his methods, because homeopathy is held to 'contradict the most elementary 
scientific knowledge' (Weatherall 1994). Nevertheless, infinitesimal doses 
were not part of the homeopathic hypothesis, were rarely used in drug tests, 
and were only gradually introduced into treatment as Hahnemann's 
experience with the method increased.8 They were a refinement and not a 
requirement of the system. Even though Hahnemann (1833b; 1852a) 
repeatedly claimed that chemistry was as inappropriate to the analysis of his 
triturated and succussed medicines as it was to detecting the difference 
7 Naturheilkunde survives as naturopathy; see Wiesenauer (1992) for evidence that it might 
even be rationell, in the modem sense of economically efficient. 
B See: Hughes (1893: 930-939) for a chronological review of Hahnemann's posology. 
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between plain and magnetized iron, the fact that infinitesimal doses have 
always been open to clinical testing, regardless of prior beliefs about their 
plausibility, suggests that explanations of homeopathy's comprehensive 
rejection by official medicine should be sought elsewhere. 
Philosophy and medicine were explicitly connected in German intellectual life 
in the period 1790-1840 in a manner not countenanced elsewhere. Later, 
Romantic medicine came to be seen as a blind alley in the onward march of 
medical progress, disavowed nowhere more strongly than in Germany, and 
the era's coincidence with Hahnemann's working life ensured he was tarred 
with the same brush. Shryock's (1948: 138) claim that homeopathy 
was established in Germany during the last days of the 
Naturphilosophie, and was characterized ... by a monistic pathology and 
therapeutics 
is typical of its period in its inaccuracies of date, intellectual relationships, 
nosology and treatments. Yet it remains true that the reorientation of medical 
and scientific historiography in the second half of the twentieth century away 
from intra-professional triumphalism and 'great men' towards socially-
oriented reflexivity has generally left homeopathy's content and methods on 
one side, in favour of regional studies of its clientele or its political and 
economic battles with allopathy.9 
Much therefore remains to be explored in the relationships of homeopathic 
science to the intellectual environment of its birthplace, and the parallel 
formation of biomedicine in the nineteenth century. Hahnemann came from a 
similar Pietist background to Kant, and the enactment of the categorical 
imperative in a medical context underlay his life's work, long after he had left 
Pietism behind. Nonetheless, he was not bound to accept Kant's confidence in 
Brunonian theory. He was just as critical of visionary hyper-Brunonianism 
such as Schelling's (Hahnemann 1808c), and maintained- rightly it would 
appear - that a fallacious association with Naturphilosophie and Romantic 
medicine had retarded the acceptance of homeopathy (Haehl 1927 ii: 287). 
Yet, ironically for a philosophy that seems to have had such an influence on 
Hahnemann's critical outlook, it was a Kantian pronouncement about the 
legitimate domains of scientific inquiry that hastened the marginalization of 
homeopathy, more subtly but possibly even more thoroughly than the 
'infinitesimal' doses that proclaimed a self-evident absurdity. 
9 For recent social historiography of homeopathy, see: Faure (1992b ), Jutte (1998). Notable 
content-based exceptions are: Schmidt (1990) and Dellmour (1997). 
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As noted, Hahnemann emphasized the individuality of each sick person, and 
the crucial importance of emotional and cognitive states in determining the 
simillimum - the most similar and thus most suitable medicine: 
It is not too much to say that the mental symptoms of a patient often 
form the determining factor in the choice of the medicinal counter-
force. They are the characteristics which the observant physician can 
least of all afford to overlook. (Hahnemann 1810; 1913 § 187) 
Kant had said that the contents of the mind could not be studied scientifically, 
on the interesting grounds that they exist in time but not in space, and are 
hence unamenable to mathematical description. This orientation helped to 
underwrite the tendency towards identification of disease processes with 
their lesional endstates that came to characterize 'hospital' and 'laboratory' 
definitions of illness, the assumption being that the classification and 
diagnosis of any disease should indicate essential organic and biochemical 
characteristics common to all patients who present with it, and that any 
symptomatic or causal treatment ought ideally to be valid at all times, in all 
places, for everybody (Foucault 1963; Ackerknecht 1967; Jewson 1976; Maulitz 
1987). The search for the single apodictic answer to each species of disease 
came to the fore in the milieux that proclaimed their devotion to empirical 
fact most loudly; but was linked, not just with the now-familiar 
disappearance of the patient narrative but, moreover, with an explicit and 
institutionalized disbelief in what the patient or experimental 'subject' might 
have to report (Lachmund 1998). Since that time, many trained in what 
became the dominant medical model, including the practical majority who 
were uninterested in nosology, have had difficulty comprehending a therapy 
that side-stepped causation and elevated the individual's 'claims' to 
subjective experience above her common mammalian reactions. For example, 
the idea of compiled personal reactivities clearly mystified an otherwise 
sympathetic commentator (Berkowitz 1994) on a recent successful 
randomized placebo-controlled trial of infinitesimal doses for childhood 
diarrhea Gacobs, Jimenez, Gloyd, et al. 1994). 
Another objection to homeopathy's acausal descriptive personalism was the 
unfalsifiability of its prescription-analogues.1° Hahnemann rejected the 
relevance of the Kantian a priori to the understanding of disease, but the 
quest for the simillimum invoked another kind of Kantian a priori, one that 
10 Popper's criterion was applied to homeopathy in falsificationism's heyday (Cioffi 1970; 
Carnpbell 1978; Schwanitz 1983: 177). 
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functions as an ideal exemplar or paradigm (in the traditional, Aristotelian 
sense of paradeigma, pattern). Kant (1787: 384) discusses this under the 
heading 'Of the regulative employment of the ideas of pure reason', using 
geometrical and physical illustrations such as the circle or vacuum: 
The most remarkable circumstance connected with these principles is, 
that they seem to be transcendental, and, although only containing 
ideas for the guidance of the empirical exercise of reason, and although 
this empirical employment stands in an asymptotic relation alone ... 
that is, continually approximate, without ever being able to attain 
them, they possess, notwithstanding, as a priori synthetical 
propositions, objective though undetermined validity, and are 
available as rules for possible experience. In the elaboration of our 
experience, they may also be employed with great advantage, as 
heuristic principles. 
Many drugs might produce similar symptoms to the patient's, but only the 
one offering the closest fit to the symptom-complex was chosen. It follows 
that the simillimum remains as an ideal of treatment that can only be 
approximated in any case of illness, albeit using a teachable heuristic 
involving an equation of analogous qualities, as in the case of Frau Sch-. 
Falsifying such an hypothesis poses considerable difficulties, given the 
astonishing number of variables at play in symptom collection and matching, 
not to mention evaluation of the clinical results. Are the difficulties therefore 
evidence of homeopathy's lack of scientific plausibility? Hahnemann believed 
not, but his warning that valid appraisals had to follow his method of 
individualizing were usually ignored. And even Hahnemann's care in case-
taking could also be held against him: it might have been 'in line with the best 
modern teaching and considerably in advance of the average practice' 
(original emphasis) of the next century even, but it was clear that the 
undeniable therapeutic benefits of homeopathy were a non-specific effect due 
to patient-practitioner interaction (Suttie 1936: 130ff). 
The theory's predictive power in the face of new diseases such as cholera or 
old ones such as pneumonia that defied orthodox treatment might reasonably 
have been considered a better test of its plausibility (see e.g. Tessier 1850; 
Eidherr 1862; Lasveaux 1988; Leary 1994), but even its clinical successes could 
be held against it, most notoriously in Britain, where the behaviour of the 
Medical Council, set up by the President of the Board of Health, Sir Benjamin 
Hall, to compare results of different treatments in the 1854 London cholera 
epidemic, exemplifies the difficulties that impartial clinical evaluation of 
competing therapies posed for the profession at this date. The historic 
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importance of this large-scale trial was apparent to its participants at the time, 
and has been emphasized more recently as a defining moment in the 
evolution of the clinical trial (Lilienfeld 1982). When asked by Hall to explain 
the suppression of the returns from the London Homoeopathic Hospital, 
Golden Square, Soho (at the epicentre of the epidemic), the Council tacitly 
acknowledged the dramatic superiority of the independently evaluated 
homeopathic results, but agreed unanimously that: 
by introducing the returns of homoeopathic practitioners, they would 
not only compromise the value and utility of their averages of cure, as 
deduced from the operation of known remedies, but they would give 
an unjustifiable sanction to an empirical practice alike opposed to the 
maintenance of truth and to the progress of science. 
(House of Commons 1854-55: 194) 
Rudolf Virchow believed the possibility of an explanation was not a scientific 
criterion (cited in Guttentag 1966), but it was probably more realistic to say 
that 
Western knowledge is a form of having ... If knowledge is a form of 
possession, it follows that one possesses only what one understands. 
For what is not understood cannot truly be called a possession. 
Pragmatism is a disinherited offshoot of the true idea of Western 
knowledge because it is satisfied with the fruition of what it does not 
possess by comprehension. (Haas 1956: 182) 
When that celebrated ironist Jean Paul (1826-28 ii: 292) exclaimed: 
Hahnemann, double-headed prodigy of philosophy and learning - whose 
system spelled the final ruin of the prescription-mongers, but was 
nevertheless little taken up by practitioners, and is more reviled than 
investigated, 
he may not have guessed his judgement would stand for nearly another two 
centuries before it could be gainsaid. 
44 
3 ORIGINS OF HAHNEMANN'S PHARMACOGNOSY AND MIASMATIC 
THEORY 
Material in this chapter appeared as: Dean M.E. (2000). Homeopathy and alchemy: (1) A 
pharmacological gold standard. The Homeopath (79): 22-27; Dean M.E. (2001). Homeopathy 
and alchemy: (2) Contagion from miasms. The Homeopath (80): 26-33. 
Background Critics traditionally object that homeopathy involves not natural 
phenomena and scientifically grounded method but manufactured or 
irrational techniques and ideas. Many homeopaths and occultists claim that 
Hahnemann was mainly inspired by alchemy, a debt which he concealed. 
Questions Were the essential elements of homeopathic theory and practice 
inventions of Hahnemann? What connexion if any do they have with pre-
scientific alchemical theory and practice? 
Argument The main elements of Hahnemannian theory and practice - such 
as the similia principle, drug tests, theory of infectious miasms, and even 
small doses - had emerged in orthodox medical debate in the decades 
immediately before he wrote. Serial dilution and potentization appear to be 
the only elements derived from medieval alchemical medicine, but 
Hahnemann only accepted them into homeopathy after empirical testing. He 
is best seen as an experimentalist and systematizer of much that was 
previously unexplained and uncoordinated. 
3.1. The main objections 
By 1805 the essential groundwork had been accomplished, and Hahnemann 
began to formalize his system. As noted in Ch. 2, homeopathy was initially 
regarded as part of orthodox medicine. However, Hahnemann's dilution of 
doses beyond the point where Avogadro's hypothesis (contemporaneously 
announced in 1810) stated that no molecule of the original substance could 
remain, proved to be the most visible single stumbling block to the therapy's 
acceptance, and prevented consideration of almost everything else. Then as 
now, virtually all critique of homeopathy ignored its clinical method and the 
evaluation of its efficacy. Rejection came on a priori grounds: homeopathic 
medicines are sometimes diluted beyond the Avogadro number NA, so any 
effects of homeopathy must be placebo effects. Despite the fact that 
attenuation is a secondary development of and subordinate to the similia 
principle, and even though many homeopathic medicines are not diluted 
beyond NA, critics have continually based their rejection of homeopathy 
solely on its so-called 'infinitesimal' doses. The criticism has been expressed 
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in much the same terms during two centuries: 
The waters of the whole world would require the addition only of 
1.32603 grains to make the dilution such that each drop should contain 
but the quadrillionth of a grain; ... The belief, therefore, that anything 
so small could have any effect on disease is too ridiculous to require 
comment. (Routh 1852: 8) 
The laws of physics and chemistry are the same in Bangkok, Bristol 
and Buenos Aires, and homeopathy is just as much nonsense in one 
part of the world as in another. (Fisken 1996) 
Even when formal clinical evaluation is involved, the situation is little 
different. A recent meta-analysis of 89 randomized placebo-controlled trials of 
homeopathy included 51 trials in which at least one group received medicines 
not diluted beyond NA (Linde, Clausius, Ramirez et al. 1997). Yet one of the 
two hostile editorials commissioned to accompany the publication of the 
meta-analysis rejected its largely positive findings on the basis of 
homeopathy's 'infinitesimal doses' (Vandenbroucke 1997). 
In contrast, the criticism of homeopathy made by the epidemiologist P.C.A. 
Louis at a meeting of the Academie de Medecine in 1835 is more thoughtful: 
he said that 'Homeopathy shows many signs of being invented rather than 
discovered' (Academie de Medecine 1835a). His implication was that there 
was no scientific research tradition leading up to homeopathy, and that the 
similia principle, serial dilution and potentization were arbitrary inventions 
not grounded in empirical observation of nature. In keeping with the 
prevailing therapeutic nihilism of the French school, Louis was pessimistic 
about the value of any treatments available at that time, orthodox or 
dissident, and his criticism of homeopathy is less vitiated by self-interest or 
chauvinism than was the norm (see Ch. 6). The well-known American doctor 
O.W. Holmes (1809-94) took up Louis's strain in his polemic Homeopathy [sic] 
and its Kindred Delusions (1842), an essay still revered today as a humiliating 
demolition of Hahnemann (King 1958: 157; Ernst 1995b; Crellin 1997). As if it 
were not incredible that Hahnemann had discovered something of such 
importance as the similia principle, was it not completely implausible that he 
had discovered the potentization of medicines, not to mention the miasma tic 
origin of disease? One major discovery can be allowed to any scientist, but 
three undermine his credibility. Holmes's sarcasm was obvious: Hahnemann 
was not a scientist, and he had not 'discovered' anything, but simply made it 
all up. 
It should be clear from the account in Ch. 2 that Hahnemann did not conjure 
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the similia principle, but formed and tested a hypothesis to unify the 
'surprising facts' of empirical specifics known to him, and supported it with 
hundreds of examples of paradoxical cures found in the literature. 
Nevertheless, Louis and Holmes aimed at the techniques of homeopathy as 
much as the epistemological foundation. The issue is complicated by the fact 
that Hahnemann also received criticism in the early positivist period for 
allegedly deriving his entire method from alchemy, more specifically from the 
great Swiss dissident alchemist-physician Paracelsus (c.1491-1541) (Schultz 
1831). Academic historians still claim today that Hahnemann proposed a 
'modified form of Paracelsianism' (Brock 1992: 38), and based his therapy on 
the doctrine of signatures (Flaherty 1995). The therapy was not merely 
invented, but was a relic of the superstition and witchcraft that preceded the 
scientific revolution, completely undermining Hahnemann's claims to 
scientificity and rationality. This charge is even more grave than Louis's, and 
merits investigation. 
3.2. Hahnemann and alchemy 
It has to be acknowledged that the question of direct alchemical influence on 
Hahnemann's development of homeopathy remains open, in spite of his 
denials of any connexion with Paracelsus. Proponents of the theory of 
personal esoteric involvement point out, for instance, that Hahnemann's 
father painted plates in the Meissen factory set up after the alchemist Johann 
Bottger (1682-1719) had stumbled on the secret of Chinese porcelain while 
trying (unsuccessfully) to manufacture gold (Fernando 1998). Moreover, 
during his period in Vienna Hahnemann was introduced by his mentor and 
tutor, the Freemason Joseph von Quarin (1733-1814), to an influential fellow 
Mason, Baron Samuel von Brukenthal, who invited Hahnemann to his estate 
in Hermannstadt (now named Sibiu, in Romania). Hahnemann was admitted 
to the craft almost immediately on arrival in Hermannstadt in 1777, and spent 
two happy years practising medicine in the locality, as well as cataloguing 
von Brukenthal's collections of coins and early medical and alchemical texts 
(Haehl 1927). Since many of the Viennese lodges, in the higher degrees, 
adhered to a synthetic ritual that contained Masonic, alchemical and 
Rosicrucian elements (Palou 1966) the origins of homeopathy can surely be 
found in the heady atmosphere of late eighteenth-century Austrian 
Freemasonry, so the argument goes. Moreover, Burnett studied the 
information that was available in the late Victorian period and concluded that 
Hahnemann had failed to give Paracelsus his due (Clarke 1923), and 
Oosterhuis (1937) later published an impressive catalogue of parallels 
between the two reformers - which tends to suggest that Hahnemann might 
indeed have had something to hide. 
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On the sceptical side, within homeopathy, an interpretation has emerged 
which seeks to minimize alchemical connexions, while promoting 
Hahnemann's undoubted empiricist and scientific credentials (e.g. Coulter 
1977; Demarque 1981). After all, Hahnemann was one of the 15 most cited 
chemists in Lorenz Crell's Chemische Annalen in the years 1784-89, a journal 
which above all others laid the foundations for the German chemical 
community's preeminence in the coming century (Hufbauer 1982: 91). Why 
should such a prominent experimentalist have had recourse to discredited 
superstitions like the doctrine of signatures? Hahnemann claimed in 1825 to 
be unaware of the similarities between his and Paracelsus' medical systems, 
and when Schultz (1831) published what he regarded as evidence of direct 
influence, Hahnemann then dismissed the Paracelsan writings as 
incomprehensible (Haehl 1927, ii: 274). This is hardly surprising in view of the 
fact that it has taken lifetimes of scholarship to unravel the contradictory 
opinions, obscure jargon, proto-science and occultism found in the Paracelsan 
corpus (e.g. Pagel 1982b)-lifetimes that were unavailable to Hahnemann, 
who was busy with his own task. 
Attempts to absolve Hahnemann of alchemical sympathies are as 
understandable as the interest in his possible esotericism. How then should 
such conflicting claims be evaluated? Hahnemann's vitalist ideas, which 
appeared comparatively late in his career, can be plausibly traced to 
Paracelsan and ultimately Oriental theories, but they were often held by other 
eighteenth-century European medical thinkers. For instance, Georg Ernst 
Stahl (1660-1734) opposed the advance of Cartesian dualism, which was 
rapidly leading to the relegation of mind to the bottom of the medical 
hierarchy of systems, and reintroduced the idea of an anima, or 'biomedical 
soul', arguing essentially that 
medicine is the science of life ... and physicians repudiate medicine 
when they refuse to ask what life is ... many diseases are remedied by 
the spontaneous 'autocracy' of some sort of vital guide or direction. We 
must study the mode of action of this guide, and base our therapeutic 
method on seconding its operations. (Hall 1975. i: 352) 
Stahl's influence was noticeable in German medicine throughout the 
eighteenth century, and his term autocratie is used by Hahnemann - who had 
previously rejected the idea in 'The value of the speculative systems of 
medicine' (Hahnemann 1808c; 1852b)- as a synonym for Lebenskraft and 
dynamis in the 1833 Organon. Similar observations can be made about holistic 
features of Hahnemann's system, such as the protective nature of symptoms: 
recent research has shown that the threat of metastasis was commonly used 
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by eighteenth-century physicians as a means of ensuring loyalty and 
compliance with instructions among their patients (Nicolson 1988). 
Because aspects of vitalism and holism were still reasonably widespread at 
the beginning of the nineteenth century, especially in Germany, the 
characteristics of homeopathy which it seems most fruitful to investigate for 
evidence of a unique debt to alchemy are its research methods and 
pharmacological techniques. In other words, the similia principle, drug tests, 
pharmacopeia, dilutions, trituration and potentization. Hahnemann's theories 
of infectious disease causation - the acute and chronic miasm concepts - also 
deserve a closer look in this context, since they went against most current 
trends. 
By way of definition, 'alchemy' is broadly treated here as the complex of 
magical and metallurgical lore, herbal and mineral therapies, spiritual 
practices and metaphysics which: surfaced in tum in China, Hellenistic Egypt 
and under Islam; took an increasingly medical form in Islam; came to 
medieval Europe courtesy of Islamic conquests and contacts; were especially 
associated with Paracelsus and the iatrochemists who followed him; and 
which continued to affect medicine during the Scientific Revolution, while 
being gradually replaced by chemistry. Prominent in this tradition at different 
times were transmutation of elements, and the attempt to produce the - real 
or metaphorical- philosophers' stone. According to your heart's desire, the 
object was the attainment of illumination, immortality, longevity, health or 
simply gold. 
3.3. Pharmacology 
3.3.1. Similars and signatures 
Hahnemann insisted that the similia principle had been used in medicine, 
consciously or otherwise, long before him. He found traces of the doctrine as 
far apart as the Hippocratic writings - quoted in 'The medicine of experience' 
(Hahnemann 1805c; 1852b)- and the suggestion by Quarin's Viennese 
colleague Anton von Storck (1731-1803) that stramonium should be tried in 
some mental disorders because it can induce dissociation, mania and 
hallucinations (Storck 1762). Hahnemann claimed only to have hypothesized 
and validated the principle, via provings of known specifics such as cinchona, 
and systematized it as a means of discovering the sphere of action of new 
medicines. 
What relationship if any is there between the similia principle and alchemy? 
As a guide to pharmacology, Paracelsus taught not symptom similarity but 
the doctrine of signatures. This identified medicines for illnesses from their 
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shared appearances or qualities. These so-called correspondences could 
function at various semiotic levels. As Hahnemann (1817; 1880) indicates in 
'Examination of the sources of the common materia medica', doctors gave 
the testicle-shaped orchis-root in order to restore manly vigour; the 
phallus impudicus, to strengthen weak erections; ascribed to the yellow 
turmeric the power of curing jaundice, and considered hypericum 
perforatum, whose yellow flowers on being crushed yield a red juice (St 
John's blood), useful in haemorrhages and wounds. 
It is easy to see that such a doctrine may plausibly have originated in 
preliterate societies as an aide-memoire for reputed cures which happened to 
bear a resemblance to their target illness, but it had been turned into a magical 
dogma by the Renaissance. Some Paracelsan notions of signatures are 
imaginative to say the least: mercury was named for the god of the 
marketplace, where the French disease- syphilis- could be picked up 
cheaply. 
Signatures, and the astrological lore attached to them, were rejected in the 
strongest terms by Paracelsus' follower J.B. Van Helmont (1579-1644) in spite 
of his immersion in alchemical medicine (Pagel 1982a). Hahnemann expresses 
similar contempt for the doctrine in the essay just quoted, continuing that he 
would 'refrain from taunting' his medical contemporaries with the traces of 
the absurd superstition which could still be found in the most recent materia 
medicas - presumably because he had already taunted them in 'The value of 
the speculative systems of medicine' (Hahnemann 1808c), where many 
examples of the survival of the doctrine are enumerated. In his article on 
Chelidonium - whose bitter yellow juice bore the signature of bile, and hence 
all hepatic disease-he elaborated that it was impossible to use even those 
remedies which appeared to verify the doctrine because: (a) the alleged 
clinical indications were so imprecise; and (b) the plants had generally been 
compounded with many other ingredients in those cases where they were 
reputedly effective (Hahnemann 1811-21; 1880). He attacked the 'criminal 
frivolity' of those who were satisfied with such guesswork: 
Only that which the drugs themselves unequivocally reveal of their 
peculiar powers in their effects on the healthy human body - that is to 
say, only their pure symptoms - can teach us loudly and clearly when 
they can be advantageously used with certainty; and this is when they 
are administered in morbid states very similar to those they are able to 
produce on the healthy body. 
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3.3.2. Drug tests 
There is no doubt that Hahnemann's systematic investigation of materia 
medica gave a major impetus to the establishment of scientific drug testing 
and hence clinical pharmacology. Are there any Paracelsan or alchemical 
precedents? Apparently not. Or simply a link with earlier times? The Persian 
philosopher and physician Ibn Sina (Avicenna, 980-1037) is famous for his 
Kitab al-Qanun (Canon of medicine) which was still required reading in 
European medical schools centuries after it was written (e.g. Avicenna 1473; 
1564). It contains seven precepts for the scientific evaluation of drugs on 
humans, some of which derive from Galen. The principles include the idea, 
revolutionary for the time, of controlled tests of uncompounded single drugs 
on the sick (Crombie 1953). Hahnemann was well aware of Ibn Sina's central 
contribution to medicine, and even quotes - in Arabic - from Book ii of the 
Canon, on simples, in the thesis of 1812 that gained him the right to lecture at 
Leipzig University (see Ch. 2). This early call for a rational pharmacology was 
not for pathogenetic trials (provings) but empirical tests of possible curative 
agents. Even though it sought to avoid the time-honoured errors due to 
polypharmacy, it was a precursor of the random Baconian inductivism that 
Hahnemann rejected: 
Either a single drug must be tried in all diseases ... or all drugs must be 
tried in a particular disease ... Thus, after thousands upon thousands 
of blind trials with innumerable substances upon, perhaps, millions of 
individuals, the suitable, the specific remedy is at last discovered by 
accident. (Hahnemann 1811-21; 1880) 
A more probable origin for Hahnemannian provings can be found much 
closer to his time. He applauded Albrecht von Haller (1708-77), who had 
conducted physiological experiments on healthy animals and recommended 
their extension to humans. In fact, the first recorded test on a healthy human 
seems to have been made somewhat earlier by Van Helmont (1648), who 
noted the strange alterations in his perception after putting a piece of aconite 
root on his tongue, but this seems to have been an isolated instance before 
more systematic programmes emerged in the next century. Richard Mead 
(1673-1754), society physician and advocate of smallpox inoculation, tried a 
few poisonous substances on himself, including viper venom and opium, but 
from the standpoint of a contagionist who wished to find how epidemics 
were transmitted (Mead 1745). More therapeutically oriented were Storck's 
tests in which he tried one or two poisonous plants on himself before 
experimentally treating patients with them. Storck's work was so well known 
throughout eighteenth-century Europe that his self-test of Colchicum 
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autumnale appeared in English in the popular Gentleman's Magazine (Storck 
1764). From different starting points, Mead and Storck appear to have started 
a trend: others who tested drugs on themselves after this date include the 
Dublin doctor Alexander (1768), and Monro (1788) and Crumpe (1793) of the 
Edinburgh school. 
Yet there was another fundamental difference between Hahnemann's 
experiments and those of his immediate predecessors. Alexander set out to 
see whether common drugs such as castor and camphor did to him in a state 
of health what they were supposed to do in sickness; because castor was 
reputed to combat fever but didn't reduce his normal healthy temperature, he 
concluded it was valueless. Alexander may have been right about its efficacy 
in fever, but his method was hardly the way to find out. And as Hahnemann 
(1811-21; 1880) points out in his article on Camphora, earlier researchers had 
neglected the all important personal element, concentrating on rudimentary 
quantitative measures such as pulse and temperature: 
the pure effects of it, observed by Alexander, are very meagre and 
confined to mere general expressions. 
Hahnemann's orientation towards pure symptoms uninfluenced by a priori 
theories of drug action, and his emphasis on the existential subjectivity of 
illness states, differed completely from earlier investigations of the effects of 
drugs in the healthy. Still, he did not hide his debt, as claimed recently (Oliver 
1999): experimental symptoms discovered by Van Belmont, Mead, Storck, 
Alexander, Monro, Crumpe and many others were included and correctly 
referenced (along with a much greater number of alleged side-effects 
observed during Old School treatment of sick patients) under the appropriate 
drugs in his materia medica, and in the historical survey of 1807 that later 
served as the first introduction to the Organon. 
3.3.3. Therapeutic poisons and the minimum dose 
Hahnemann was well aware of the historical precedents for using highly 
poisonous plants in therapy - his Leipzig thesis, discussed in Ch. 2, concerned 
the use of hellebore in Classical Greece, Rome and Islam. Although Paracelsus 
had used such plants, and Hahnemann included Van Belmont's symptoms of 
self-poisoning with aconite in his materia medica, a far more likely initial 
stimulus for Hahnemann's interest again lay much closer to home, since it 
was a corollary of the proving idea. As mentioned, Storck (1760) was one of 
the first to envisage the systematic reintroduction of highly toxic plants to the 
official materia medica. This triggered widespread interest in the plants' 
therapeutic potential in the 1760s - for instance, Quarin (1761) published a 
monograph on cicuta at this time- but enthusiasm quickly waned because of 
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the unacceptable number of fatalities that occurred. Poisonous plants then re-
emerged in medicine-in parallel with Hahnemann's first homeopathic 
experiments-in suitably reduced doses. William Withering (1741-99) 
isolated digitalis from a folk remedy for dropsy containing many less useful 
plants (1785) and in 1789 wrote: 
Poisons in small doses are the best medicine; and useful medicines in 
too large doses are poisonous. 
Hahnemann's pre-homeopathic 'Description of Klockenbring during his 
insanity' (Hahnemann 1796a; 1852b) mentions a prescription of 2 grains of 
stramonium seed for mania made in 1792. The prescription is more 
remarkable for being the patient's own instruction to Hahnemann during a 
relatively lucid interval. Klockenbring was not a doctor, but an author and 
intellectual who had presumably become acquainted with Storck's conjecture, 
and Hahnemann comments favourably on the suitability of the medicine and 
the dose. Also in the early 1790s, John Alderson (1758-1829) was cultivating 
Rhus toxicodendron at the Hull General Infirmary, and used small doses in the 
treatment of various forms of paralysis. He mentions the novelty of giving 
such a toxic plant as medicine, and the trepidation felt by some of his patients 
(Alderson 1811). He reports some astonishing successes with longstanding 
well-attested paralyses, and symptoms from his monograph were included in 
the homeopathic materia medica (Hahnemann 1811-21). 
After announcing the similia principle in 1796, Hahnemann continued to use 
doses similar to those of his more cautious and scientifically minded 
contemporaries, and only after 1800 did he begin to reduce them gradually 
towards the levels that eventually made homeopathy notorious, as seen in 
'Cure and prevention of scarlet fever' (Hahnemann 1801b; 1852b). For 
instance, a letter to Stapf, dated 3 September 1813, shows provers were 
expected to take 1 oz of a simple dilution of helleborus niger containing the 
equivalent of 1/160 grain(= 0.0004 g), every two hours, as long as they were 
'not too severely affected' (Hahnemann 1889). This was a small dose, but 
certainly not 'infinitesimal'. In fact, ultra-small doses seem to have been 
reserved for treatments at this time, simply because patients were more 
sensitive than provers, not because smaller doses were more powerful. 
Paracelsus is well-known for his claim that small doses of poisons were the 
most effective medicines, but it is· unnecessary to invoke his influence on their 
use by Withering, Alderson, Hahnemann or other late eighteenth-century 
experimentalists. 
3.3.4. Drug preparation 
Hahnemann's pharmacopeia was mainly herbal in the first two decades of 
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homeopathy, and prepared solely from liquid tinctures. Juices were expressed 
from fresh plants, dried plants were steeped in alcohol for several hours, and 
in one or two cases metallic salts of various degrees of solubility, such as 
Causticum, were used to make a 'tincture' which could then be further diluted 
as needed (Hahnemann 1805b ). He modified the process of simple dilution 
with succussion as a more efficient means of mixing the material with the 
diluent, but there is no suggestion at this time that he had discovered 
processes which not only made the medicines safer- the original motivation 
for dilutions - but also released a hidden medicinal power. Dilutions were 
standardized in 1816, on a metric (centesimal) scale quite dissimilar to the 
traditional apothecaries' measures used in homeopathy until then. Two years 
later Hahnemann claimed that even substances declared to be biologically 
inert because of their insolubility were capable of pathogenetic and 
therapeutic action, after lengthy trituration with lactose, and he now began to 
call the process 'dynamization' and the attenuations 'potencies'. 
Plausible influences from alchemy are much easier to find here than with the 
similia principle, provings or poisonous plants. The call for common 
alchemical processes such as serial dilution to be used in the preparation of 
medicines was frequently heard in Europe from the time of Ramon Lull 
(c.1232-1315, but the works fathered on him belong to more than one author, 
like the Hippocratic, Jabirian and Paracelsan writings) and the experimentalist 
philosopher Roger Bacon (c.1214-92) onwards. Instructions for alchemical 
projection - the final process of transmuting base metal with the philosophers' 
stone to produce gold-demand accurately measured serial dilutions, 
typically of one part in 100 (Lully 1330). And, of course, the more times the 
process was repeated the more powerful it became, as the cynical but well-
informed Ben Jonson observed in 161011: 
For look, how oft I iterate the work, 
So many times, I add unto his virtue. 
As, if at first one ounce convert a hundred, 
After his second loose, he'll turn a thousand; 
His third solution, ten; his fourth, a hundred. 
After his fifth, a thousand thousand ounces 
Of any imperfect metal, into pure 
Silver or gold, in all examinations 
As good as any of the natural mine. 
Trituration of insoluble substances was another of alchemy's many processes, 
11 The Alchemist II. iii. 106-14. 
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and in his article of 1818 on Aurum foliatum Hahnemann records how he came 
to adopt the practice only after reading its history in early medico-alchemical 
texts: 
I was delighted to find a number of Arabian physicians unanimously 
testifying to the medicinal powers of gold in a finely pulverized form, 
particularly in some serious morbid conditions, in some of which the 
solution of gold [trichloride] had already been of great use to me. 
(Hahnemann 1818; 1880) 
The alchemists' legendary aurum potabile (drinkable gold) had of course 
disappeared from European medicine by the late eighteenth century, 
dismissed by nearly all Hahnemann's contemporaries as a primitive 
superstition. He recounts the history of gold therapy in Islamic and European 
medical alchemy, quoting Geber's celebrated phrase materia laetificans et in 
juventute corpus preservans (a substance that gladdens and preserves the 
youthfulness of the body) that he had found in De alchemia, in the edition of 
1598 brought out by Lazarus Zetzner, a leading publisher of alchemical works 
(Geber 1598). The book was attributed to Jabir ibn-Hayyan (c.721-c.815), the 
'father' of Islamic alchemy, until the twentieth century, when it was shown 
that it belongs to the thirteenth century and was probably written in Europe 
(Newman 1991). Nevertheless, the author of the Summa perfectionis, as it is 
usually called, had an intimate knowledge of Arabic alchemy, and the book 
has always been accepted as the fountainhead of the European alchemical 
tradition. Interestingly, this emergence of the 'gold as elixir of life' theme in 
Europe in the thirteenth century ties the practice ultimately to Taoist alchemy, 
rather than Hellenistic Egypt as previously thought: the Chinese took the 
immortality theme literally, unlike the Greek alchemists, and it was 
transmitted to Europe via the Middle East (Needham 1974). 
Hahnemann then cites Serapion the younger (c.900) and Ibn Sina for their use 
of gold in various conditions including cardiac disease and depression, 
showing his knowledge of Arabic in the process. One of the conditions Ibn 
Sina treated with gold could be 'talking to oneself' or 'dyspnea', depending 
on the diacritical mark: Hahnemann claims that his proving demonstrated it 
was the latter, and respiratory distress is certainly accepted now as an aspect 
of gold toxicology. The early methods of making pure gold biologically 
available are then detailed: Abu'l-Qasim al-Zahrawi (Abukasis, 936-1013) 
first showed how to prepare gold powder by rubbing it on a rough linen cloth 
in a basin filled with water, and Zacutus, the Portuguese, later rubbed gold on 
a grindstone. Hahnemann cites over 20 more recent alchemical and medical 
texts that recommend gold powder-including Francis Bacon's Historia vitae 
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et mortis (1623) - and decided the idea was worth testing empirically: 
But leaving these authorities out of the question, I thought I might 
attach more value to the testimony of the Arabians as to the curative 
powers of finely powdered gold than to the theoretical unfounded 
doubts of the moderns. 
Accordingly, trituration with lactose was introduced for the first time into 
homeopathic pharmacy, though it was a common technique elsewhere. Here 
for example are Storck's (1762) instructions for preparing aconite: 
Take extract of Blue Monkshood, two grains; white sugar, two 
drachms; mix and grind them together for a long time in a marble 
mortar, to the finest powder. 
Hahnemann's innovation combined an existing technique for preparing dried 
plant materials - previously unused by him, because he preferred to steep 
them in alcohol-with an alchemical technique that had been eclipsed: 
I triturated the finest gold leaf (its fineness is 23 carats, 6 grains) with 
100 parts of milk-sugar for a full hour, for internal medicinal use. 
(Hahnemann 1880) 
His provers took substantial quantities of triturate: 
100 grains of this powder (containing one grain of gold), and on others, 
200 grains (containing two grains of gold), dissolved in water, sufficed 
to excite very great alterations in the health and morbid symptoms. 
The results satisfied him that 
the assertions of the Arabians are not without foundation, as even 
small doses of this metal given in the form mentioned caused even in 
healthy adults morbid states very similar to those cured (in 
unconscious homeopathic manner) by those Orientals, who deserve 
credit for their discovery of remedies. 
Prior to 1818, metals had been available to homeopathy only as solutions of 
their salts such as copper sulphate, mercury sulphides and iron acetate 
(introduced respectively in 1805, 1811 and 1816). This seems to have been true 
of post-Paracelsan iatrochemistry generally: in spite of the example of gold 
powder, only the nitrate of silver had been used in Europe, notably by Robert 
Boyle (1627-91) whose renowned diuretic pills Hahnemann criticized for their 
large doses and antipathic action in his Argentum article (1811-21). Could 
Hahnemann have known of J.A. Chrestien's (1758-1840) successful revival of 
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gold powder in the treatment of syphilis (Chrestien 1811)? Burnett (1879) 
thought Hahnemann probably did, while Hughes (1893) took the opposite 
view. Whether or not Hahnemann was aware of contemporary allopathic 
experimentation is less important than the use made of the discovery in the 
two schools: gold powder therapy did not function as an exemplar in 
allopathy and soon fell out of fashion, whereas the homeopathic materia 
medica was transformed following the successful experiment in 1818. Pure 
metals such as silver and tin and insoluble minerals and plant materials were 
submitted to the trituration process for the first time. Many of the post-1818 
medicines are reputed to be the deepest-acting, in spite of their innocuous 
appearance before trituration: these include Silica, Carbo animalis and Carbo 
vegetabilis, and the notable triad of Calcarea, Lycopodium, Sulphur. 
Hahnemann did not record whether he adopted centesimal dilutions from 
alchemical sources - and he need not have as the metric scale was being used 
increasingly by scientists - but the date justifies the conjecture and his 
bibliographic references show he cannot have been unaware of the 
precedents. 
3.4. Disease theory 
3.4.1. Acute 'miasms' 
Hahnemann was orientated towards successful therapeutics, and his writings 
betray a comparative lack of interest in the causes of disease. This was a 
reaction to the theorizing about the ultimate nature of disease that had 
dictated treatments since Galen, and an admission of how little could be 
known with certainty at this date. Even when causes could be found, they 
were not to be confused with diseases - which were the response of the 
organism to the disease-provocation and knowable only by their symptomatic 
manifestations. 
It may be granted that every disease must depend upon an alteration 
in the inner working of the human organism. This disease can only be 
mentally conceived through its outward signs and all that these signs 
reveal; in no way whatever can the disease itself be recognized. 
The invisible disease producing alteration in the inward man together 
with the visible alteration in health (the sum of the symptoms) make 
up that which is called disease; both together actually constitute the 
disease. (Hahnemann 1810; 1913 §§ 5, 6) 
This idea corresponds to modern notions of disease as a response to 
disturbance of homeostasis, and Stahl is the most obvious precursor of this 
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aspect of Hahnemann's thought. Nevertheless, in our quest for alchemical 
sources, it is worth tracing the evolution of Hahnemann's theories about 
disease transmission and causation in the period 1790-1830. 
Following the decline of humouralism in official medicine, external causes for 
disease were sought. In the period 1700-1860 diseases that we now class as 
infectious were generally believed to result from miasma ta - nonspecific 
noxious atmospheres or effluvia (Greek miasma, pl. -ata, bad air). Hahnemann 
(1792 / 1795) begins conventionally enough, for a late eighteenth-century 
doctor: epidemic diseases were the results of these miasma ta, according to The 
Friend of Health. 
However, venereal disease was an obvious exception to the general 
nonspecific rule of disease transmission, since it was only contracted after 
intercourse with someone already infected. In Instructions for Surgeons 
respecting Venereal Disease, Hahnemann (1789; 1852b) states that gonorrhea 
and syphilis are primary and secondary manifestations of the same disease, 
and ascribable to contagion. Ironically the two diseases had been clearly 
distinguished in the sixteenth century by Jean Fernel (c.1497-1558) and others. 
However, Paracelsus claimed they were the same and his error was believed 
and perpetuated until after Hahnemann's time. Most famously, John Hunter 
(1728-93), the Scottish surgeon, had inoculated himself with matter taken 
from a gonorrheal patient in order to demonstrate that it was the same as 
syphilis (Hunter 1786). He thought the symptoms he produced had proved 
his point- unaware that the donor also had syphilis. Hunter's reputation 
ensured that his confounding of the two diseases was taken as definitive for 
many decades, as was his rejection of the possibility of inherited syphilis or 
extra-genital transmission. Hahnemann followed Hunter's teaching about 
venereal disease in many respects, and the explanation of the action of 
homeopathic medicines he put forward later was particularly influenced by 
Hunter's theory that mercury provoked a medicinal disease which acted as a 
counter-irritant to the infection. Nevertheless, Hahnemann was independent 
enough to observe the existence of congenital syphilis at this date. 
In his early homeopathic writings, such as 'Observations on the three current 
methods of treatment' (1801c; 1852b), Hahnemann thought disease was 
knowable purely by its symptomatology, and maintained that removal of the 
symptoms in toto was the radical cure. However, it is also at this date that he 
began - confusingly, and against contemporary usage - to restrict his use of 
the term 'miasm' to describe a transmissible principle that lay behind a 
specific contagious disease. (The quote marks are intended to distinguish 
Hahnemann's use of the term from orthodox miasma tic theory.) 'Cure and 
58 
prevention of scarlet fever' (1801b; 1852b) refers to the causal mechanism of a 
transmissible scarlatina 'miasm', or 'virus'. (The quote marks distinguish 
'virus' from the modern concept: from the eighteenth century to the mid 
twentieth, 'virus' meant morbid disease matter that could be inoculated thus 
passing on a disease and conferring immunity against future attacks.) The 
concept of a transmissible 'virus' was based on smallpox inoculation which 
had been introduced into European folk medicine from China and the Middle 
East in the sixteenth century. It was taken up by the medical profession in the 
early eighteenth century before the emergence of the much safer cowpox 
vaccination at the end of the century. Even more remarkably for the era, one 
section of Hahnemann's article- 'Prevention of scarlet fever in its first germs' 
(Keimen) - suggests the 'virus' contains or originates in a microscopic disease 
principle. 
The theory is generalized to a variety of specific diseases in 'The medicine of 
experience', where 'miasmatic' is employed as the equivalent of what we 
would now call 'infectious': 
We observe a few diseases that always arise from one and the same 
cause, e.g. the miasmatic maladies; hydrophobia, the venereal disease, 
the plague of the Levant, yellow fever, small-pox, cow-pox, the measles 
and some others, which bear upon them the distinctive mark of always 
remaining diseases of a peculiar [particular] character; and because they 
arise from a contagious principle that always remains the same, they 
always retain the same character and pursue the same course, 
excepting as regards some accidental concomitant circumstances, 
which however do not alter their essential character. (Hahnemann 
1805c;1852b) 
In Hahnemann's hands the concept of contagion was only applicable to a 'few 
diseases' but nonetheless allowed him to grant them a specific name and 
treatment (when discovered). And it was more than a precursor of the germ 
theory of specific diseases, which came to dominate medicine. The similia 
principle is based on the equivalence of diseases, poisons and medicines -
they are capable of producing similar states. In his letter on the 'regeneration 
of medicine' he pointed out that 
the little of a positive character to be found amid the enormous mass of 
medical writings, consists in the accidentally discovered mode of cure 
of two or three diseases which always arise from identical miasmata; 
these are, the autumnal marsh ague [malaria], the lues venerea 
[syphilis], and the itch of workers in wool; to these must be added that 
most fortunate discovery, the protection from variola [smallpox] by 
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means of vaccination. And these three or four cures take place only 
according to my principle similia similibus. (Hahnemann 1808a; 1852b) 
By the time of the first edition of the Organon, Hahnemann is talking about 
the difficulty of using specific diseases in provings: 
The invisible influences whereby the ordinary diseases of mankind are 
produced are all too little known, and are all too little under our 
command, for us to use them for the production of diseases at our will, 
and thus as remedies against diseases of longer standing. (Hahnemann 
1810; 1913 § 34) 
Using 'miasm' in his now familiar restricted sense of communicable disease 
matter, he continues, generalizing from smallpox vaccination to 
immunization against other diseases: 
Even the miasms, which might conceivably be inoculated for the 
removal of certain diseases, are too few in number to be used even to a 
limited extent as remedies. (ibid.§ 35) 
'On the venereal disease and its ordinary improper treatment' (Hahnemann 
1816; 1852b) develops the thesis further, on the basis of observation: acute 
infectious diseases with fever and skin rash, such as smallpox, cowpox, 
measles, gonorrhea-syphilis and others are systemic poisons. Nothing can 
prevent the rapid spread of the inoculated 'virus' through the body, as 
evidenced by hydrophobia which develops even after immediate excision of 
the bite wound. 
In 'Examination of the sources of the common materia medica' (Hahnemann 
1817; 1852b), the distinction between Hahnemannian 'miasms' and 
conventional miasmata could not be clearer. Specific remedies only exist for 
those diseases 
of a constant character ... some are produced by a miasm which continues 
the same through all generations, such as the venereal disease; others 
have the same exciting causes, as the ague of marshy districts ... 
In other words, he withholds the term 'miasm' from malaria, the very disease 
which appeared to confirm his contemporaries' theory of effluvia! miasmata. 
In a better-known passage from 'The mode of propagation of the Asiatic 
cholera', Hahnemann (1831; 1852b) returns to the microscopic origins of 
infectious disease hinted at in 1801. He claims that the cholera pandemic was 
not 'epidemically atmospheric-telluric' - i.e. not caused by a miasma - as his 
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contemporaries continued to think for many decades, but was probably 
transmitted by 
a swarm of infinitely small, invisible living organisms, which are so 
murderously hostile to human life, and which most probably form the 
infectious matter of cholera. 
Hahnemann was wrong in believing the bacteria multiplied in vapour rather 
than water, but correct in identifying human contact as an important vector. 
He warned that handling of patients by medical attendants without careful 
hygiene could spread the disease, and proposed preventive measures, such as 
sterilization of clothing and bedding, that would undoubtedly have been 
helpful if they had been followed. It is often forgotten that he recommended 
spirits of camphor to be used externally as an antiseptic, as well as diluted 
with water and taken orally, because of its homeopathicity to cholera 
symptomatology. 
3.4.2. Sources of acute 'miasm' theory 
Although theories of contagion had been advanced in Europe in the sixteenth 
century, in the wake of the great plague epidemics and the recent 
introduction of syphilis, the opposing effluvia! theory had gained the upper 
hand by the eighteenth century and was dominant in the first half of the 
nineteenth century. In spite of being an incorrect theory, the value of the 
public health measures it inspired is undeniable. For instance, Edwin 
Chadwick (1801-90), the great instigator of Victorian sanitary reform, was a 
convinced effluvialist and anticontagionist, as was Charles Creighton whose 
important late nineteenth-century work on epidemiology was motivated by a 
desire to refute germ theory (Creighton 1891-94). 
It seems unlikely therefore that Hahnemann could have been influenced by 
his contemporaries at a time when germ theories were almost totally 
unknown, so could there be an alchemical influence on homeopathic acute 
'miasm' theory? 
Traditional Hippocratic and Galenic medicine believed disease was due to an 
internally-generated - idiopathic - imbalance of the four humours: bilious, 
choleric, phlegmatic and sanguine. No surviving Greek text mentions 
contagion; even in epidemics, treatments were not aimed at protecting the 
community but at restoring the lost balance of the individual. Before 600 AD 
Chinese medicine held similar dyscrasic theories, but between then and 1600 
it began to conceptualize diseases as separate entities which could be attacked 
with specific treatments that were valid at the population level (Unschuld 
1998). Tellingly, the Chinese pictogram for cure includes the image of an 
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arrow in a quiver - conceptually related to Erlich's specific chemotherapy or 
'magic bullets' from the end of the nineteenth century. The idea of specific 
disease entities requiring specific treatments began to be reflected in Islamic 
sources in the ninth century, completely contradicting the stereotypical 
dismissal of Arabic medicine as a passive conduit for Galenism. For instance, 
in Book I of the Canon, Ibn Sina lists three main categories of specific diseases 
that can be passed on, either by infection, or by family or racial inheritance. 
Group 1 includes scabies, leprosy, smallpox and phthisis; groups 2 and 3 
include gout, phthisis, and endemic goitre. This concept of intrinsic disease 
entities only began to surface in European medicine during the Renaissance. 
Alchemical sources were among the first to reflect the shift of emphasis, and 
alchemical illustrations of the body as a castle, repelling invasion by different 
diseases from the four quarters, survive from the seventeenth century. 
This covert trend against the Galenism of the medical schools was made 
public by Paracelsus, who rejected humoural theory and replaced it with 
what he termed the archeus. Archeus is a Latinized Greek root, connoting 
rulership (-archy, in modern English) and fundamental principles (arche- or 
archi- in modern English). It is generally translated as life-force (although the 
theosophist Rudolf Steiner (1948) characteristically claimed that Paracelsus 
meant the etheric body). Paracelsus also believed that each disease has its 
own archeus, marking a clear break with the earlier theory of internal 
dyscrasias and imbalance, although he retained more primitive beliefs in 
attributing epidemics to the stars or the imagination. Moreover, the 
introduction of specifics for diseases in Europe, as against general treatments 
for imbalance, is also associated with Paracelsus: Spezifikum is in fact another 
Paracelsan coinage that quickly became common currency. 
Van Helmont, Paracelsus' most prominent successor, believed that disease 
came about because of the struggle between the host's vital force and the vital 
force of the disease factor, and elaborated his idea of the effects of the 
invasion of the body by alien spiritual beings (archei): 
Once they had established a foothold he supposed that they took over 
the vital processes of the host for their own benefit, producing waste 
products that were poisonous to the victim. (Harre 1983: 97f) 
Anachronistically viewed, this struggle between host and invader seems to 
prefigure modern germ theory. Unfortunately for what seems to promise an 
alchemical influence, in 'The value of the speculative systems of medicine' 
Hahnemann (1808c; 18526) had dismissed the Paracelsan and Helmontian 
archeus - in its sense of an externally imposed rulership of the body - as an 
example of the error of attributing an ontological essence to disease. He does 
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not seem to have been aware of the theory of independent disease archei, so 
any connexion remains highly conjectural. 
Are there any more likely sources? Contemporaneously with the essentially 
dynamic ideas of Paracelsus, the idea of infections as due to seminae or seeds 
is associated with Girolamo Fracastoro (1478-1553), possibly influenced by 
the atomism of Democritus and the philosophical poem De rerum naturae by 
Lucretius (Fracastoro 1546). Fracastoro is sometimes cited as the originator of 
European contagionism, but his 'seeds' seem to have been as dematerialized 
as Van Helmont's. In any case, the idea was lost during the ascendancy of 
effluvia! theory. However, it is possible to find an influence on Hahnemann's 
contagionism much closer in time and place than Paracelsus, Fracastoro or 
Van Helmont, one as plausible and immediate as Storck's anticipation of 
homeopathic pharmacology and method. 
Marcus Antonius Plenciz (1705-86) belonged to the generation immediately 
before Quarin and Storck. He practised successfully in Vienna from 1735, and 
summarized his theories about disease in Opera medico-physica, published in 
1762 at the same time as his younger contemporaries' monographs on 
therapeutic poisons (see 3.3 above). Plenciz (1762) seems to have been almost 
the sole voice of contagionism in the eighteenth century. His ideas have an 
extraordinarily modern ring because by continuing Anton van 
Leeuwenhoek's (1632-1723) investigations of microscopic lifeforms Plenciz 
became the first to realize the relevance of animalculae to disease transmission. 
He groups diseases according to whether they are epidemic, contagious or 
both. Infectious diseases are the results of specific causes, analogously with 
plants that only emerge from a seed of the same species. Noxious 
atmospheres do not satisfy this requirement, so disease transmission can only 
be explained by hypothesizing specific airborne disease germs that flourish 
under favourable conditions. Several terms are used for the means of 
infection, such as miasma animatum, miasma verminosum, and seminia animatum 
These 'minute worm-like living germs' possess the capacity to multiply 
rapidly once they have gained access to the host. Inoculation against smallpox 
supports the theory, since a minute amount of inoculated 'virus' can cause 
disease, and also demonstrates the way that evolutionary modification of the 
original germ can confer immunity. Plenciz even had a modern-sounding 
explanation for the action of the well-known specific drugs, mercury and 
cinchona: these were capable of killing the germs of syphilis and malaria 
respectively. Generally, he recommended that therapy should be directed at 
predatory microorganisms, and favoured investigation of the antibiotic 
properties of heavy metals. His book contains two further essays - on 
smallpox and scarlet fever -to illustrate the theory. 
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These prophetic ideas were forgotten, except by the biologist-historian Kurt 
Sprengel (1821-28) who derided them. Brettoneau (1778-1862) is remembered 
for identifying diphtheria as a specific illness in 1826, but his suggestion -
made only in a personal letter - of bacterial infection as the causal agent came 
twenty years after Hahnemann's cholera publications of 1831. The discovery 
in 1835 by Agostino Bassi (1773-1856) that the silkworm disease muscarine 
was probably due to a microscopic fungus is sometimes mentioned (Bassi 
1835-36), but the revival of germ theory is usually dated from 1840 when the 
pathologist Jakob Henle (1809-85) claimed - against great opposition - that 
infectious diseases were probably caused by living parasites (Henle 1840). 
Could Hahnemann's remarkably avant-garde contagionist ideas -which were 
only confirmed by the empirical discoveries of Pasteur and Koch in the 
second half of the nineteenth century- be connected with Plenciz's theories? 
The circumstantial evidence is strong. In his two main publications on scarlet 
fever, Hahnemann (1801b; 1808b; 1852b) acknowledges his reliance on the 
symptomatology in Opera medico-physica; and Plenciz's observational accuracy 
gained him the rare honour of Hahnemann's published approval (Organon 
edns 5 & 6, § 38) - which he accorded to Hippocrates, Sydenham, Haller and 
very few others. Scarlet fever seems to have been pivotal, not only for the 
greatly reduced doses introduced around 1800 to treat it, but also for the 
development of Hahnemann' s contagionism. 
3.4.3. Chronic disease theory 
A standard mid twentieth-century medical dictionary defined homeopathy 
inter alia as a system that holds: 'that eruptive diseases of the skin must be 
allowed to come out, and should not be driven in' (Jones, Hoerr, Osol 1949). 
Although related to his general rejection of symptom suppression, this is 
particularly pertinent to Hahnemann' s theory of chronic diseases which he 
developed in the 1820s, and which has been the most problematic part of his 
system, for homeopaths as well as critics. 
After his semi-retirement to Cothen, Hahnemann's patients were mainly 
those who travelled from many parts of the world to consult him with non-
urgent longstanding illnesses that had defied conventional treatments. It was 
at this time that he found that the acausal 'general' model of homeopathy that 
had been so effective in acutes was not always successful in chronic disease. 
The theory of chronic miasms he put forward in Chronic Diseases (Hahnemann 
1828-30; 1896) combined the ideas of infection and susceptibility: the sequelae 
of infectious episodes and other incidents gave rise to slowly developing 
conditions, leading to layered states of ill-health and susceptibilities to many 
other forms of illness. These all constituted blockages to cure using the 
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'general' model, and required sequential treatment. 
His three examples of primary causal infections are 'itch', syphilis and 
gonorrhea, which were rife if not endemic at the time, and led to the chronic 
miasms of 'psora', 'syphilis' and 'sycosis' respectively. 'Itch' has usually been 
identified with scabies, which was later found to be a parasitic infection 
requiring external treatment with parasiticides, but it also traditionally 
covered a larger category of eruptive, and often contagious, skin diseases 
(Jones, Hoerr, Osol 1949), and it is clear that Hahnemann included leprosy 
and psoriasis among many others in his classification. These eruptions had 
traditionally been suppressed by external means such as ointments, and 
driven inwards with repercussions for general health, according to his theory 
of the protective nature of symptoms. 
The possible origin of such a highly unusual theory has given rise to much 
speculation. Chronic Diseases was published two years after the appearance of 
an important article on homeopathy by Hufeland (1826). Although 
Hufeland's review was mainly favourable, especially regarding the benefits 
for patients of single pure drugs (see 3.5 below), he was critical of 
Hahnemann's apparent neglect of the causes of disease. The period 1800-50 
saw widespread attempts in the orthodox medical world to provide 
explanations for disease after the decline of humouralism. Effluvialism has 
already been mentioned in connexion with epidemics, but at same time the 
notion of diathesis was revived, and became enormously popular because it 
seemed to account for chronic disease. We succumb to particular illnesses 
because we are predisposed to them: cancer occurs because of a cancerous 
diathesis, tuberculosis because of a tubercular diathesis, to name just two that 
crop up repeatedly in the many different systems and lists of diatheses 
published by orthodox nineteenth-century doctors. Hufeland named 12 
'dyscrasias' in 1836, and Ackernecht (1982a) pointed out in his important 
review of the concept that eight of them had previously appeared in the list of 
diatheses in the Dictionnaire des sciences medicales of 1818. The 'explanation' is 
circular, however, and reminiscent of Moliere's doctors who believed opium's 
tendency to induce sleep was the result of its 'dormitive virtue'. So, although 
external pressure and example might have been influential in provoking 
Hahnemann into announcing a causal theory when he did, it does not help to 
explain the theory's content. 
There is some question over whether Hahnemann plagiarized Autenrieth's 
discussion of psora from 20 years earlier, or Wenzel's theories about 
syphilis-gonorrhea published in 1825 (Wood 2000: 69). Autenrieth (1807-08) 
had said that external suppression of psora led to metastasis, and severe 
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illness such as asthma, but Hahnemann rejected the influence, claiming that 
Autenrieth's treatment was unknown to him at the time. This seems 
reasonable since Hahnemann had already cited Juncker (1750) as a much 
earlier source of ideas about the consequences of suppressed psora, 
supported by scores of references from the literature. Hahnemann also used 
an analytic approach to symptomatology to differentiate syphilis and 
gonorrhea, unlike Wenzel. The question of whether syphilis and gonorrhea 
were one or two diseases was frequently debated between 1750 and 1850. As 
late as 1853, the erudite and highly qualified homeopath Robert Ellis 
Dudgeon (1820-1904) was able to dispute Hahnemann's opinion on this issue 
(Dudgeon 1853: 300f). Phillipe Ricord (1800-89) is still given priority in 
histories of medicine for the correction of Hunter's mistake in 1838, a decade 
after Hahnemann- and 45 years after Benjamin Bell (1749-1806), who seems 
to have been the first into print (Bell 1793; Ricord 1838). Yet Hahnemann's 
ideas on the source of chronic disease can be seen taking shape in 'On the 
venereal disease and its ordinary improper treatment' (1816; 1852b ), where 
the disastrous results of external suppression of contagious disease are 
detailed. The discussion includes psora and the venereal disease, i.e. 
gonorrhea-syphilis, which he still thought of as a single entity at the time, 
and confirms Hahnemann's claim that he developed the theory in the decade 
before Wenzel published. 
However, we are no nearer understanding why these three contagious 
diseases, and these three only, assumed such importance for Hahnemann. 
Could there be an alchemical origin? One of the alchemists' most pervasive 
doctrines was the sulphur-mercury theory of metallic composition. Although 
the development preceded him, Paracelsus is usually credited with the 
expansion of the sulphur-mercury doctrine into the tria prima, three universal 
principles of 'sulphur', 'mercury' and 'salt', which underlay the material 
universe. These metaphorical principles should not be confused with the 
chemical substances of the same name, since the quality of 'mercury', for 
instance, could be found in many other substances. In De natura rerum 
Paracelsus provided an esoteric interpretation as well: 
Mercury is the spirit, sulphur is the soul and salt is the body. (cited in 
Crosland 1962, i: 14) 
It has been claimed that when 'sulphur', 'salt' and 'mercury' are translated 
back into Arabic, it is easy to hear their alliterative equivalence to the terms 
for human qualities that initiates cultivated in order to bring about personal 
transformation; only later was this esoteric psychological code exteriorized as 
part of the well-known search for metallic gold (Shah 1964: 194f). 
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A resemblance between the chronic 'miasms' and the Paracelsan trinity has 
been pointed out many times (e.g. Voorhoeve 1936; Coulter 1977; Zissu 
1977-78). Hahnemann's diseases, it is claimed, must be related to the tria 
prima pharmacologically by homeopathic analogy: if 'sulphur', 'mercury' and 
'salt' are fundamental principles, then the diseases for which their 
eponymous material elements are homeopathic - itch, syphilis and sycosis -
must be fundamental conditions. Unfortunately, this only works for 
psora-Sulphur and syphilis-Mercurius; and proponents of the theory of 
Paracelsan influence have not offered to explain the connexion between 'salt' 
and Thuja. However, there is a way of saving appearances that involves 
recalling that Nitricum acidum was regarded as even more fundamental than 
Thuja by Hahnemann (1828-30), since he used it to complete the treatment of 
the sycotic 'miasm'. It may be objected that nitric acid is not a salt, but in 
metallurgical alchemy it was assumed that because acids precipitate salts they 
were merely salts in solution, and so 'salt' carried the quality of acidity: aqua 
fortis (nitric acid) was a prime 'salt' (Boas 1958: 84). Surely, then, there can be 
no coincidence that the remedies associated by Hahnemann with the chronic 
'miasms' happen to be identical in name with such fundamental alchemical 
terms and principles? 
The plausibility of such a relationship has to be measured against 
Hahnemann's opinion of the tria prima in 'The value of the speculative 
systems of medicine' (1808c): 
the Alchemists forced the infinite multiplicity of chemical substances 
into the triangle, salt, sulphur, mercury. What cared they for the 
numerous varieties of metals? They prided themselves on dictatorially 
fixing the number of metals at seven, and these they falsely and boldly 
referred to a single original substance, the metal-seed. 
It seems unlikely therefore that alchemy or numerology was involved, 
especially as Hahnemann believed that psora was responsible for by far the 
greatest proportion of chronic disease, syphilis and sycosis playing minor 
roles. Sulphur for skin conditions and infestation and mercury for syphilis 
just happened to be two widely used specifics of the day. Thuja and Nitricum 
acidum for sycosis seem to have been Hahnemann's own discoveries. 
3.5. Discussion 
At this point it is useful to outline the key stages in the development of 
Hahnemann's new medical orientation and therapeutics. 
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1789- abandonment and critique of traditional medical practice (Hahnemann 
1805a); 
1790- systematic pharmacological research with single pure drugs on healthy 
humans (Cullen 1790); 
1792 establishment of a humane asylum for the mentally ill (Hahnemann 
1796a); 
1796 announcement of a 'new principle for determining the curative power 
of drugs' which is acausal and analogical (Hahnemann 1796b); 
1800 drastic reduction of doses used in treatment (Hahnemann 1801d); 
1801- introduction of theory of infectious microorganisms; coupled with a 
dynamic theory of health and disease: symptoms are an expression of 
disease, which should not be confused with its immediate cause; 
1805- publication of a new pure materia medica, based on signs and 
symptoms expressed in the 'language of the patient' (Hahnemann 
1805b; 1811-21; 1828-30); establishment of a new method for careful 
examination and treatment of patients in their semiotic, psychological, 
social and ecological totality (Hahnemann 1805c; 1810); 
1816- development of the potentization principle: biologically inert 
substances used as drugs after serial trituration and agitated dilution 
(Hahnemann 1818); 
1821- theory that chronic disease originates from infections and other acute 
episodes (Hahnemann 1828-30). 
Most of the distinctive elements of homeopathy - provings, poisons as 
medicines, small doses, similars, miasms - had surfaced in rudimentary form 
in orthodox medicine in the three or four decades before Hahnemann began 
to synthesize his system, and it is easy to rule out alchemical or Paracelsan 
influence. Nonetheless, there is a documented direct link from alchemy to at 
least one important aspect of Hahnemann's technique: trituration of pure gold 
was a turning point in the evolution of homeopathic pharmacy and 
pharmacology, and its origin in authentic, pre-Paracelsan alchemical medicine 
is perfectly transparent. It led to the expansion of the pharmacopeia in a 
direction unimaginable to his immediate predecessors, and seems to have 
been the stimulus for the announcement of the dynamization principle. 
Can Hahnemann therefore be identified as an occultist, rather than an 
exceptionally open-minded scientist? Leaving aside the accusations of critics 
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such as Schultz (1831), the entry into homeopathy, after Hahnemann's death 
in 1843, of Paracelsan ideas from several sources has undoubtedly muddied 
the water. To mention only two streams (discussed in Ch. 4), there were organ 
remedies based on signatures (Rademacher 1841; Steiner 1948), and versions 
of Swedenborgian emanationism, itself traceable to the archetypal 
correspondences of Bohme and Paracelsus (Wilkinson 1857b; Kent 1900). 
Given such pervasive occult influences it is unsurprising to find the 
signatures doctrine misattributed to Hahnemann, not merely by anti-
homeopathic positivists and homeopathic occultists, but also by historians of 
ideas (Flaherty 1995). It is nonetheless important to distinguish those trends 
from Hahnemann's own writings, where not a trace of them can be found. 
Yet the possibility of a personal involvement with esotericism has continued 
to fascinate some of Hahnemann's later followers - perhaps anxious to 
attribute their own beliefs to their hero -who support their claims with 
circumstantial evidence such as the plate factory and the Hermannstadt 
episode. It must be admitted though that the evidence is thin. Bottger was 
long dead; and Hahnemann was admitted only to the first Masonic degree 
while in Hermannstadt, advancing no further for many years. Moreover, 
Austrian Freemasonry, as in France, was not under Papal interdiction- and 
was close to being an alternative state religion, centred on Enlightenment 
ideals of free intelligence, generosity and social progress (Kuess-
Scheichelbauer 1959). Lodges were one of the few places where people from 
different strata of society could meet on an equal footing, and many radicals 
and scientists like Hahnemann became Freemasons - along with many in the 
Austrian Catholic church hierarchy. In any case, it is easy to overestimate the 
authenticity of the esoteric teaching available. Freemasonry was a recently 
constituted movement, trying hard to invent a distinguished lineage for itself. 
The bogus Orientalism of Giuseppe Balsamo - or Count Cagliostro as he 
styled himself-was welcomed with open arms; and the Sethos novel by the 
hoaxer Terrasson was accepted as a genuine firsthand account of hermetic 
initiation in ancient Egypt well into the nineteenth century. Accounts of the 
rituals in many Viennese lodges of the day show they were fabricated even 
when they managed to avoid actual silliness (Palou 1966). And North German 
Freemasonry, which Hahnemann belonged to after his brief stay in Austro-
Hungary, was far less exciting. It was primarily a devout non-denominational 
ethical movement heavily coloured by the Protestant Pietism that Hahnemann 
had been born into, a branch of Lutheranism which sought the inner light 
through self-examination in a manner analogous to Quakerism. 
However, although Hahnemann's strong objections to 'magic, incantations 
and divinations' agree with this interpretation - if his Leipzig thesis and 
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disavowal of the Paracelsan writings are to be believed - and although he 
seems to have been entirely free of Pietist emotionalism - as evidenced by his 
preference for Confucius over Jesus - those determined to find a personal 
occult connexion bring forward a final unanswerable argument: Hahnemann 
hid his involvement, perhaps because he had been sworn to silence. This was 
true to some extent of Boyle, whose anti-Paracelsan pronouncements in the 
Sceptical Chymist have long been regarded as foundational for the Scientific 
Revolution, but actually concealed an immersion in alchemy as great as 
Newton's (Newman 1994; Principe 1998). Boyle's case allows a further twist to 
the argument, one that has so far not been advanced: Could Hahnemann have 
belonged to an anti-Paracelsan stream within an esoteric framework? Only 
recently has external scholarship penetrated far enough behind the deliberate 
mystifications of alchemical literature to realize that not all alchemists thought 
alike, allowing an explanation of the apparent contradictions between Boyle's 
and Van Helmont's alchemical interests and their highly selective approach to 
Paracelsan ideas. And there is a different kind of precedent in the example of 
the anti-Jesuit Bavarian Illuminist cult of 1785-90 (which was politically 
neutralized by absorption into Austrian Freemasonry after 1788): there the 
initiation into each degree involved repudiation of the revelations of the 
preceding level. Tempting though it might seem to impute both an esoteric 
vow of silence and anti-Paracelsanism to Hahnemann, once again the 
evidence is flimsy. His use of authentic alchemical documentation to justify 
his gold experiment makes it an improbable combination, especially when 
Chrestien's example would have provided the perfect mask. 
The two facets of homeopathy which particularly exercised critics such as 
Louis and Holmes, the similia principle and serial dilution, seem to have been 
part of a long-submerged tradition which they cannot have been aware of. 
However, Hahnemann acknowledged the new direction that alchemy had 
given to his researches as openly as one could wish for. Conceivably, the 
initial seed of his interest in some aspects of Islamic medicine - derived as we 
now know from Taoist alchemy- might have been planted in the pseudo-
Oriental atmosphere of Austrian Freemasonry, although his own professorial 
knowledge of pharmacological history seems more likely to have been 
ultimately responsible. What reveals most about his real source of inspiration 
is the fact that he did not simply take the archaic elixir at face value, however 
central a feature of alchemical medicine it might have been. Instead, he 
submitted the substance and the manufacturing process to empirical testing 
within the research programme he was creating out of the scattered hints and 
speculations of other scientists. 
The aspect of Hahnemann's thought and practice which Holmes said wasn't 
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worth the effort of refuting - infectious and chronic miasms - still causes 
much scorn (e.g. Vickers 2000). However, it was an early manifestation of the 
germ theory that swept all before it in the 1880s, and demonstrates the 
progressive nature and complexity of Hahnemann's thought, and the 
difficulties that created for many of his contemporaries. Although 
Hahnemann did not accept Plenciz's bactericidal explanation of the 
pharmacological action of specifics such as mercury and cinchona - preferring 
Hunter's counter-irritation theory-the parallels between Hahnemann's and 
Plenciz's notions of specific contagious diseases transmitted by 
microorganisms are obvious, and clearly distinguishable from Hunter's much 
more orthodox ideas. 
The development of acute 'miasms' into the source of chronic disease is 
further evidence that Hahnemann's ideas need to be seen in the context of 
eighteenth- and nineteenth-century medical debate rather than the hidden 
esoteric sources that later followers wished for. As suggested here, 
Hahnemann may well have responded to external pressure from critics such 
as Hufeland in announcing his theory of chronic disease when he did. 
Nevertheless, there is an important difference between Hahnemann's chronic 
diseases and the diatheses of nineteenth-century allopathy. Hahnemann 
believed the chronic 'miasms' were the superimposed sequelae of suppressed 
contagious disease, not essential characteristics or typologies. Moreover, he 
believed they could be treated and removed, quite unlike diatheses. The 
crucial distinction was obscured by later homeopaths such as Grauvogl, who 
refashioned Hahnemann's chronic diseases into conventional diatheses, 
opening a door to the introduction of Galenic humours and magical 
typologies into homeopathy (discussed in Ch. 4). 
There is little in Hahnemann that seems irrational or evidence of charlatanry 
or weak-mindedness once it is accurately described and some attempt made 
to understand its origins. A classical scholar and student of philosophy as 
well as chemist and physician, he was uniquely qualified to synthesize many 
factors into a coherent humane therapeutics. Hufeland (1826) listed the 
advantages and disadvantages of the system impartially. He faulted 
Hahnemann for lack of interest in the ultimate causation of disease, and 
seems to have regarded ultra-small doses as often no more than a placebo. He 
also felt reliance on drugs could sometimes prevent patients from receiving 
valid treatments such as blood-letting. Nevertheless, Hufeland concluded that 
if the system were generally adopted it would: 
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• prohibit large doses 
• simplify prescriptions 
• encourage accurate testing of drugs on humans (which he acknowledged 
had already begun to some extent following Hahnemann's example) 
• encourage better attention to drug preparation, and stricter supervision of 
druggists 
• prevent actual harm 
• allow the sick more time to recuperate quietly and naturally; and 
• reduce drug costs remarkably. 
Revolutionary for their time, these points are all now regarded as desiderata 
of any scientific pharmacopraxy, and are a further indication of the rationality 
of the Hahnemannian contribution to medical science. 
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4 HOMEOPATHY AFTER HAHNEMANN 
Background Hahnemannian homeopathy represents a distinct medical focus 
within the early history of biomedicine. However, present-day homeopathy 
contains a number of different approaches or schools, leading to dissension 
within the field and confusion for those outside. 
Questions What are the different approaches and schools? Are there real 
conflicts between them? 
Argument The evolution of the major streams in post-Hahnemannian 
homeopathy is outlined. A schema for the conceptualization of different 
homeopathic approaches is proposed, allowing them to be seen not as 
irreconcilable schools, but as foci within a coherent field of therapeutic 
information and action. Homeopaths frequently move freely within this 
therapeutic field treating individual patients on many levels, diachronically as 
well as syn chronically. 
4.1. The division 
200 years later, however, far from being a unified therapeutic 
approach, 'homeopathy' is probably best understood as an outlook 
with many interpretations, which sometimes contradict each other. 
(Kleijnen, Knipschild, ter Riet 1991) 
The principal division that Kleijnen and colleagues allude to is that between 
individualized and standardized treatments, both of which exist in more-or-
less pure forms, as well as in many intermediate mixed grades. Both 
approaches stem directly from Hahnemann: his normal procedure was to 
individualize, but he looked for collective medicines in epidemics or common 
traumas, for example. 
The later years of Hahnemann saw many refinements of these two heuristics, 
and the years after his death saw a trend towards polarization among his 
followers. The purists, such as Hering and Kent, based treatment almost 
entirely on symptomatology, usually weighting the diagnosis towards mind 
symptoms. They were at the opposite end of the spectrum from the more 
scientifically orientated homeopaths such as Griesslich in Germany and 
Hughes in England who were interested in correlating homeopathy with 
developments in orthodox physiology and pathology. 
The two groups were popularly called the 'highs' and the 'lows' respectively, 
because of a tendency to favour potencies above or below AN, and they also 
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insulted each other as 'metaphysical' or 'pathological' prescribers from time 
to time, but these terms caricature what was a complex debate about the 
direction homeopathy ought to take. 
The British homeopath J.H. Clarke (1840-1921) combined both streams in his 
own work and publications; he described the purist approach as 'classical', 
and the other as 'clinical' (Clarke 1911). The names he chose are memorable, 
descriptive and nonpejorative, and are used here. 
4.2. Symptomatic classical homeopathy 
Immediately after Hahnemann, the most influential figures in this stream are 
Constantin Hering (1800-80) and Clemens von Bonninghausen (1785-1864), 
followed much later by James Tyler Kent (1849-1916). Each made many 
contributions to homeopathic theory and practice, but only the principal 
theoretical innovations from each will be discussed here because of their 
significance in present-day homeopathy. 
4.2.1. Directions of cure 
Hahnemann had introduced the idea of chronic miasms which posed 
blockages to cure in Die chronischen Krankheiten (1828-30) (see Ch. 3). The 
miasms preceded the patient's current state and their persistence was 
believed to prevent the simillimum from acting, requiring antimiasmatic 
drugs to antidote them. In the foreword to the first translation into English of 
the Chronic Diseases, his close associate Hering observed that: 
Every homoeopathic physician must have observed that the 
improvement in pain takes place from above downward; and in 
disease, from within outward .... The thorough cure of a chronic 
disease is indicated by the most important organs being first relieved; 
the disease passes off in the order in which the organs had been 
affected, the more important being relieved first, the less important 
next, and the skin last. (Hahnemann 1845) 
This became formalized as a set of rules for evaluating the progress of 
treatment in any chronic case. Cure was supposed to proceed: 
• from within outward 
• from the most important organs to the least important organs 
• in the reverse order that symptoms had first appeared. 
These observations became known as 'Hering's laws of cure', naturally 
enough, in an era that unselfconsciously believed in 'laws' of nature, and 
clearly relate to Hahnemann's theory of the protective nature of symptoms. 
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They underpin a strong directional tradition in homeopathic case analysis, 
associated later in the nineteenth century with James Compton Burnett (1840-
1901), in which cases are seen as layered histories, requiring sequential 
treatment to unblock and remove each layer before cure can be said to have 
happened.12 
4.2.2. Repertories and keynotes 
Hahnemann (1805b, ii) provided an index to his first materia medica, 
allowing the pathogeneses to be searched by symptom. Hahnemann (1811-21) 
does not develop the idea, but his materia medica was limited to a few score 
medicines which were thoroughly known to him and the early homeopaths 
who compiled them. However, the expansion of the materia medica which 
began towards the end of Hahnemann's life, and continued unabated 
throughout the nineteenth century, posed an increasing strain on the 
practitioner's memory. The need for a comprehensive symptom-based index 
to the materia medica was recognized, and Hahnemann wrote the foreword 
to one of the first (Bonninghausen 1832). 
Bonninghausen's repertories were highly analytic: symptom complexes that 
had been found in provings were broken down into their components and 
listed in separate regional sections. For instance, Frau Sch-'s first symptom 
(see Ch. 2), 'Any movement, especially on stepping, and worst on making a 
false step, leads to shooting pain in the epigastrium, coming every time from 
the left side', might have occurred as a complete proving symptom. 
Bonninghausen could then have generalized from it to 'pain on movement', 
'pain on stepping', 'shooting pain in the epigastrium' and so on, if these 
modalities were found in enough provers and cured patients. 
This was seen as an advantage by some, allowing a new case to be covered by 
rubrics derived from medicines that had not shown the presenting symptom 
complex in any single prover, but generalization from fragmented symptoms 
has always been controversial. Bonninghausen seems to have answered this 
12 This idea of therapeutics as archeology later became an integral part of the psychoanalytic 
world view. Freud's apostate disciple Wilhelm Reich (1897-1957) then exteriorized the 
psychoanalytic process from the mind to the body, and originated the concept of 'character 
armour', where the patient's musculature is held to retain memories of psychological conflict 
and physical traumas (Reich 1942). Following Reich, various forms of deep massage were 
developed which were believed to allow the armour (or equivalent concepts) to be removed 
(Rolf 1977). Such therapies formed an important component of the personal growth 
movement associated with Esalen, California in the 1960s (Murphy 1993). 
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in part by laying greater stress on concomitant symptoms in subsequent 
editions of his repertory. However, Hughes (1886-91) in particular objected 
that the repertorial approach per se ignored the prover's records of the 
sequence of the pathogenesis - important, presumably, if the sequence of 
development of chronic illness was a factor. 
Combinatorial symptomatology went hand in hand with Bonninghausen's 
analytic approach to case-taking. It may have been his previous training as a 
lawyer which led him to amplify Hahnemann's approach to case-taking and 
symptom evaluation along classical juristic investigative lines: who?, what?, 
where?, accompanied by what?, why?, modified by what?, when?, derived 
from a Latin hexameter belonging to the medieval scholastics: 'Quis? quid? 
ubi? quibus auxiliis? cur? quomodo? quando?' (Bonninghausen 1908). Since his 
time it has been standard practice to use these questions to obtain a full 
description of each patient in terms of personality, sensation, location, 
concomitants, immediate aetiology, modalities and times of occurrence. 
Bonninghausen also began the process, still in use, of weighting medicines 
relative to each other in the repertory rubrics according to the prominence 
and frequency with which their component symptoms had appeared in 
provings and clinical responses. This early attempt at quantification 
(analogous to confidence intervals) led indirectly to the development of 
'keynote' materia medicas and prescribing. For instance, T.F. Allen (1837-
1902), compiler of an encyclopaedic 11-volume materia medica, also produced 
a single-volume primer, and there have been many others (Allen 1874-80; 
1936). Authors such as Allen always caution that their keynote handbooks are 
aide-memoires for the experienced, and a way into the subject for the student, 
and are not intended as a substitute for careful comparison of the patient's 
symptoms with the full materia medica. Nevertheless, 'keynote' prescribing 
developed, almost inevitably, in response to the pressures of busy clinics. 
4.2.3. Constitutional types 
Throughout the nineteenth century, repertories continued to be compiled 
from different theoretical positions. Kent is famous for the one most 
frequently used today (Kent 1945). He did not favour the combinatorial 
method, and his repertory is based on complete symptoms, although it 
includes in fact fewer concomitants than Bonninghausen's later repertories. 
Kent addressed the shortcomings of the repertorial method in a different 
manner. He used a retelling of the materia medica to lay the foundations for 
one of the strongest traditions in present-day classical homeopathy: the so-
called 'constitutional types' and 'drug pictures'. As noted in Ch. 2, 
Hahnemann stressed the importance of mental symptoms in individualizing, 
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and left rudimentary examples of how character states can be used to 
distinguish one medicine from another. This seems to be the germ from which 
an entire philosophy of prescribing grew. 
Kent (1912a) is on record as deprecating 'constitution' as a basis for 
prescribing, but he was probably referring to contemporary developments in 
German and French homeopathy (see 4.4.3 below). What is currently termed 
constitutional prescribing has its origins in the vivid descriptions of 'remedy 
types' that formed the subject of his lectures on ma teria medic a (Kent 1911). 
The fastidious and highly-strung dandy needing Arsenicum is worlds apart 
from the physically slothful but intellectually active 'ragged philosopher' 
needing Sulphur, though both might present with eczema. Kent's students 
and followers have continued and developed his tendency to conflate states 
with traits. In Tyler's Drug Pictures (1952) the indications for medicines 
become minor 'characters' from Victorian novels. Coulter (1986) turns the 
process round in her Portraits of Homeopathic Medicines, and diagnoses and 
prescribes for historical characters from life and literature, analogous to the 
procedure once popular in the psychoanalytic movement. Current theories of 
'essence' prescribing, where a unifying theme is sought in all the patient's 
symptoms - physical, psychological and situational- also derive from Kent. 
This rhetorically-worded summary of the Aurum picture by a mid twentieth-
century American homeopath is fairly typical: 
Heaviness runs through the whole picture. Heavy build, a heavy gait, 
heaviness of heart, a heavy mind. Darkness is the main color of this 
picture, a dark complexion, darkening of vision, dreams of darkness, a 
dark mind. Destruction is its meaning, slow destruction of the body, of 
the big glands, of the bones, finally destruction of the self through 
suicide. (Gutman 1978: 82) 
As with keynotes, what started as an aide-memoire took on a life of its own. 
4.3. Nosological and pathological homeopathy 
The 1830s saw the emergence of a movement within homeopathy which 
challenged many of Hahnemann's later ideas, such as miasm theory and 
exclusive use of high potencies (Gross 1837; Wolf 1837; Griesselich 1848). 
Known at the time as the 'critical'13 homeopaths, they encouraged a sceptical 
13 In his essay Bentham, first published in 1838, John Stuart Mill contemporaneously 
explained that the equivalent English term for the continental 'critical' philosophy was 
'subversive' (Mill 1867, 1: 334). 
77 
scientific attitude, leading to the systematic reevaluation of the materia 
medica, and comparative tests of potencies above Avogadro's number with 
molecular low potencies (see also Chs 7 & 8). 
4.3.1. Clinical 
The 'clinical' nosological perspective was a natural development of 
Hahnemann's epidemic remedies, which were found by seeking the central 
common symptoms from many cases of the same illness and comparing these 
with the symptoms in the materia medica. Hahnemann (1814) published 
evidence of the efficacy of this approach in treatment of a typhus epidemic in 
1813 (see Ch. 8). Most famously, he was able to calibrate treatments for 
cholera from case reports sent to him by colleagues in Russia, before the 
disease reached Germany (see Ch. 2). Empirical confirmations of the efficacy 
of medicines in particular clinical conditions, even when proving data was 
missing or incomplete, were incorporated later, by Griesselich (1848) an~ 
others who started a trend away from the predominantly psychological 
tendencies of classicists such as Bonninghausen and Hering, moving instead 
towards a materia medica of etiological and nosological 'specifics'. Later still 
began the correlation of the materia medica with the increasingly well-
defined pathological descriptions and categories of orthodox medicine. For 
example, the critical British homeopath Richard Hughes (1836-1902), made an 
extensive study of paralytic disease and was able to point to the similarity 
between the symptoms of progressive muscular atrophy and lead 
poisoning.(Hughes 1869; Hughes 1893: 752) It was this trend, marrying 
homeopathy with advances in pathology, but without introducing treatments 
aimed at hypothesized causes, that led Hughes's contemporary, Compton 
Burnett, to write: 
The pathologic simillimum is the furthest point yet reached in drug 
therapeutics, and embodies a very great and fertile idea. (Burnett 1896: 
78) 
Clinical homeopathy seems to have been most influential in Germany. The 
classical model was superseded there during the nineteenth century, only to 
resurface after translations of Kent began to appear in 1945. Before then it had 
been usual to make a conventional diagnosis and differentiate on the basis of 
etiology or lesional factors. As Leeser (1936: 369£) made clear, the use of 
Sulphur in every case of furunculosis was inappropriate, not because of 
neglect of mind symptoms or the total symptom-complex, but because: 
only if the furunculosis stands on the soil of such skin and metabolic 
alterations which lie in the sulphur trend, will the homeopathic 
physician select sulphur. It might be that he would select arsenicum if 
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there were a diabetic basis, or again arnica if there were a pyemic state 
in the degenerative condition of issue and skin, and a tendency to 
ecchymosis spoke particularly for it. 
Another reason for the emergence of the critical perspective was the doubt 
raised about the validity of many of Hahnemann's later provings, which seem 
to have been conducted on patients rather than healthy provers (Hahnemann 
1828-30). This led to cured symptoms being substituted for pathogenetic 
symptoms, as well as to the mistaken inclusion of symptoms of prior disease, 
and there were also many who were equally sceptical of provings based only 
on high potencies (Griesselich 1848; Dudgeon 1853; Kleinert 1863) (see Ch. 8). 
4.3.2. Complex 
Griesselich (1848: 146) summarized the task facing orthodox classical 
homeopaths. They were required to select a single medicine to cover: 
• the patient's whole individuality, constitution, predisposition 
• the symptoms, from their first appearance to their present state, including 
modalities and concomitants 
• the originating cause of the disturbance. 
The simultaneous use of more than one medicine as a response to the 
difficulties of selecting a single medicine for this entirety began during 
Hahnemann's lifetime. K.J. Aegidi (b. 1795) reported that he had found 
numerous combinations more effective than single medicines, and 
Bonninghausen and Hahnemann both welcomed this development (Aegidi 
1834). Hahnemann wrote a new section endorsing the approach for the fifth 
edition of the Organon, but was persuaded by colleagues that such an 
inclusion would be misinterpreted by the allopaths as conceding the principle 
of polypharmacy- one of the main objections that he had always raised 
against traditional therapeutics (Haehl 1927, ii: 253). Aegidi later repudiated 
double remedies (ibid. ii: 86), no doubt for similar reasons. Arthur Lutze 
(1813-70) published an unauthorized edition of the Organon including the 
omitted§ 274b (Hahnemann 1865), and his own case histories show the 
approach that he learned personally from Bonninghausen to have been worth 
following up (Lutze 1874). Majority opinion was against him, and an 
interesting development was thus nearly stifled at birth for political rather 
than scientific reasons. Research into complexes only reemerged at the end of 
the nineteenth century. British homeopaths have often used low-potency 
combinations of 2 or 3 medicines - such as SSC (Sulphur, Silica, Carbo-veg), for 
acne - but the principle was expanded greatly in Germany and France, where 
complexes of 10 or more components have been formulated since the 1900s. 
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Recent pathogenetic investigations suggest that complexes may have 
beneficial synergistic effects, not necessarily predictable from the individual 
components (Vakil & King 1997). They certainly form a researchable area in 
homeopathy. 
4.3.3. lsopathy and nosodes 
Treatment and prevention of diseases with their own morbid products, or 
snake bites with venoms, were widespread practices in folk medicine, but 
only gradually accepted by the medical profession in Europe after smallpox 
vaccination naturalized the concept. It has always been a controversial area in 
homeopathy, because the similia principle is believed by many to contradict 
the aequalia principle of isopathy. 
Against this, Hahnemann's case-records show he occasionally experimented 
with potentized isopathic preparations towards the end of his career, in a 
difficult tubercular case for instance, 60 years before Koch's experiments 
(Handley 1997: 102). Hering had been the first to potentize and prove nosodes 
(his coinage from the Greek nosos disease), derived from disease matter such 
as infectious pus and sputum.14 He even suggested treating rabies with 
Lyssin, potentized saliva from a rabid dog, which seems to be the first instance 
of isopathy within homeopathy. The veterinarian Johann Lux (b. 1776) then 
began the systematic use of isopathic nosodes in the early 1830s (Lux 1833). 
Hahnemann was following their precedent. 
The history of nosodes is closely bound up with isopathy for obvious reasons, 
and many homeopaths since Hahnemann's time who object to isopathy have 
nevertheless used the same medicines as individualized prescriptions. They 
have based this on proving data where available, and materia medicas of 
these provings eventually appeared (Swan 1888; Allen 1910). Ironically the 
nosodes etiologically connected with the chronic infectious miasms were 
widely used to treat the sequelae of the same miasms- but not the acute 
phase of the disease - in addition to the conventional anti-miasmatics. As a 
pragmatic complement to individualized prescribing, this and other sorts of 
isopathy have been fairly widespread, particularly in preventive homeopathy. 
Some classical homeopaths, however, believe isopathy is heretical, alleging 
that Hahnemann never used it, and disapproved of it. In the face of evidence 
14 He was one of the most innovative in the search for new materia medica from many 
sources, testing snake venoms, amyl nitrite, lithium carbonate and many others, well before 
their adoption by official medicine. His encyclopedia of materia medica is comparable with 
T.F. Allen's mentioned above (Hering 1879-91). 
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that he did, it is even suggested that if it worked it couldn't have been 
isopathy, but must have been homeopathy: the causal agent was in some way 
transmuted into something else during the potentization process. It is true 
that Hahnemann spoke out against isopathy, but it seems to have been 
against early enthusiasts who were trying to replace homeopathy with 
isopathy (Haehl 1927, 2: 292). As in the case of complex homeopathy, it is 
important to remember that many of Hahnemann's public pronouncements in 
the 1830s were political rather than scientific. 
Isopathy is an area of homeopathy closer than most others to orthodox 
immunology, and has been used not just for its clinical results, but as a 
convenient model to to test the efficacy of ultramolecular dilutions per se. In 
1892 Behring, who discovered antitoxin prophylaxis of diphtheria and 
tetanus, demonstrated immunity produced by infinitesimal doses of tetanus 
antitoxin (Behring 1905; Coulter 1994). Later, Paterson and Boyd used 
potentized diphtheria toxoid and Diphtherinum C201 to alter positive Schick 
tests to negative (Paterson & Boyd 1941). 
The English homeopath Charles Blackley (d. 1900) was the first (a) to offer 
empirical tests showing that hayfever could be attributable to pollen 
sensitivity (1873), and isopathic treatment with potentized pollen soon 
followed. Research to replicate this model was again undertaken to test the 
reality of biological activity of ultramolecular medicines, and its widely 
reported success has been influential in establishing the fact in recent times 
(Reilly, Taylor, Beattie et al. 1994). 
A related isopathic approach is termed tautopathy - potencies of chemical 
substances, especially conventional drugs and vaccines, used to antidote 
adverse effects and sequelae (see 4.5.2 below). 
4.4. Parahomeopathic concepts and homeopathic neorationalism 
During the nineteenth century several variants or simplifications of 
homeopathy emerged, in parallel with the miasm and keynote concepts. 
These often tried to tie homeopathy in with aspects of scientific physiology, 
and influenced mainstream homeopathy to a greater or lesser extent, and in 
some culture areas more than others. Some are still extant. At the same time 
occult etiological theories proliferated in areas of classical homeopathy. Both 
these trends had a rationalist basis, in that they tried to identify and treat 
causal factors in illness, material on the one hand, spiritual on the other. 
4.4.1. Organ remedies 
Johann Gottfried Rademacher (1772-1850) was a younger contemporary of 
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Hahnemann who explicitly revived Paracelsan ideas, and associated remedies 
with specific internal organs. He seems to have practised quietly as a country 
doctor, and published only one book on his method late in life (Rademacher 
1841). 
Hahnemann made a German abstract of a treatise on dysentery by 
Rademacher from Latin in 1810, and a few drug symptoms observed by 
Rademacher found their way into Hahnemann's materia medica, but it is not 
clear whether he knew of the younger man's medical system. Rademacher 
certainly knew of Hahnemann, and seems to have felt overshadowed by him 
(Ruckle 1942). He was not a homeopath, and his ideas were derived from a 
close study of Paracelsus, with treatments based on the doctrine of signatures 
and the phases of the planets. Rademacher's system involved a fundamental 
tripartite categorization of disease with an associated Paracelsan 'universal' 
for each: copper, sodium nitrate and iron. He also employed many other more 
specific 'organ remedies', again following Paracelsus and the doctrine of 
signatures. These subsequently became popular in French homeopathy as 
herbal 'drainage' remedies, and were given to detoxify specific organs and 
systems before prescribing more powerful potentized homeopathies. 
4.4.2. Biochemic tissue salts 
Mid nineteenth-century physiology knew of approximately 12 inorganic 
components of the human body. Wilhelm Heinrich Schussler (1821-98) 
devised a simplified therapeutic system based on 12 minerals given in low 
decimal (D6) potency (Schussler 1874), in an attempt to reconcile homeopathy 
with the cellular pathology of Rudolf Virchow (1821-1902). Schussler later 
reduced his original 12 medicines to 11, but all 12 have remained in use, 
possibly due to number mysticism. Some were already part of the 
homeopathic materia medica but others, such as Kali phosphoricum, were 
absorbed without having been the subject of pathogeneses. 
4.4.3. Constitutional biotypes and morphology 
The influential German homeopath Eduard von Grauvogl (1811-77) published 
a chemical-humoural system in the 1860s which echoes the much earlier one 
of J.B. Baumes, discussed in Ch. 2. Like Baumes, Grauvogl saw disease as 
attributable to chemical imbalance, but Baumes's five categories are covered 
by three - oxygenoid, hydrogenoid and carbo-nitrogenoid - possibly because 
Grauvogl also tried to correlate them with the three chronic miasms of 
Hahnemann (Grauvogl 1860; 1866). 
The French homeopath Antoine Nebel (1870-1954) later developed a tripartite 
system of constitutional physical types, carbocalcique, phospho-calcique and 
fluoro-calcique, which overlaps the earlier classification of Grauvogl, and has 
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prompted many modifications, mainly in French homeopathy. These are 
often correlated with body types, such as the ecto, endo- and mesomorphic 
builds of Kretschmer (1926). They are also believed to have different 
susceptibilities to disease, and are correlated with the chronic miasms. 
The fondness for tripartite divisions recalls the tria prima of the alchemists, 
and the relationship of the chronic miasms to alchemical theories of substance 
has been discussed in Ch. 3. Homeopathic neorationalism seems to have 
taken at least one of its cues from Hahnemann, even though he was not 
describing essential types, but the sequelae of infectious episodes. Attempts to 
fit the components of one or other of these parahomeopathic systems to each 
other could lead to scholastic absurdities of the sort Hahnemann had rejected 
so decisively: 
A considerable lack of clarity in the picture of copper arises from the 
fact that Grauvogl perceived copper as the chief remedy of the 
carbonitrogenoid constitutional type. He came to this conception by 
mixing the Rademacherian conception with his idea of the three 
chronic miasms of Hahnemann. For Rademacher copper was the third 
of his universals which were given for the two other constitutional 
types and, indeed, out of [a] natrium nitricum for the sycosis of 
Hahnemann or the hydrogenoid constitution of Grauvogl and [b] 
ferrum for syphilis of Hahnemann or the oxygenoid constitution of 
Grauvogl, only [c] copper remained for the psora of Hahnemann 
which was placed equal to the carbonitrogenoid constitution. (Leeser 
1936: 795) 
4.4.4. Spiritual neorationalism 
Kent, whose qualitative constitutional types were discussed above, is equally 
well known for his attempt to impose a top-down mentalist hierarchy on the 
perception and explanation of disease. Like many American homeopaths of 
the nineteenth century, he belonged to the Church of the New Jerusalem, 
founded 1787 in London by followers of Emmanuel Swedenborg (1688-1772). 
This Swedish scientist turned full-time visionary was in many ways far ahead 
of his time, originating ideas such as: the objective nature of the psyche; 
psychospiritual individuation; the use of the terms animus and anima to 
describe psychological functions; and dream guidance.15 Swedenborg also 
15 Ideas that were later appropriated by Freud's rival Carl Jung (1875-1961). Jung read 
Swedenborg early in his career but, as Larsen points out, was unwilling to acknowledge the 
obvious influence (Swedenborg 1984: 16). 
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revealed a 'doctrine of correspondences', a Paracelsan idea related to the 
signatures doctrine: every organ of the human body was governed by spirits 
who dwelt in a corresponding portion of the supersensible mystical body of 
God - an idea encapsulated many centuries earlier in the hermetic aphorism 
'As above, so below'. Swedenborg is equally well-known for his 'doctrine of 
uses' which provided a heavenly rationale for something close to the 
Protestant work ethic: souls were graded according to their usefulness to 
others and the divine plan, and he even claimed that illness and death were 
the results of sin. It is these darker aspects of Swedenborgianism which 
underpin Kent's severely hierarchical and judgemental homeopathy, aimed at 
the spiritual regeneration of fallen humanity: 
Eternal principles, themselves, are authority. The Law of Similars is a 
Divine Law. So soon as you have accepted the Law of Similars, so soon 
have you accepted Providence, which is law and order ... Psora is the 
evolution of the state of man's will, the ultimate of his sin ... Thinking, 
willing, and doing are the three things in life from which finally 
proceed the chronic miasms ... The body became corrupt because 
man's interior will was corrupt. (Kent 1926: 646-70) 
The English homeopath and New Church member John Garth Wilkinson 
(1812-99) was also active in the mid to late nineteenth century. His 
translations of Swedenborg's treatises on mystical anatomical 
correspondences became popular in New England transcendentalist circles 
and were adopted by many American homeopaths such as Kent (Treuherz 
1983). His own thought has not received much attention though. Wilkinson's 
approach to homeopathy was as ultimately Platonic as Kent's but is expressed 
in much gentler, less direly eschatological terms. He expressed another 
traditional hermetic idea-emanationism- using a concept that that became 
better-known from the teachings of Jung:16 
16 Jung's unacknowledged Swedenborgian borrowings extend to Wilkinson, who seems to 
have been an inspiration in more ways than one. Wilkinson (1857a) had advised: 'Let 
involuntary drawing be introduced then as a normal employment into asylums, and let the 
class of patients upon whom the spirit-cure is to be tried be those who are functionally 
deranged, and especially those who are suffering from disappointed affections, and in 
general mental and affectional causes ... Let each drawing be kept, dated, and numbered, as 
marking a progress of state'. The link from Wilkinson to Jung, an active proponent of 
painting as therapy, as well as the notion of psychological archetypes, has been traced via 
Jung's analysand and student Kristine Mann, another New Church member whose family 
were friends of Wilkinson (Webb 1976: 392). 
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There is an image-and-likeness psychology in man himself, for the soul 
is the archetype of the body as God is the archetype of the soul. 
(Wilkinson 1890: 16f) 
These sorts of beliefs were combined with a notion, attributed to Hahnemann, 
that the homeopathic materia medica acted 'spiritually'.17 'It comes from the 
mind, and remakes and inspires the nature of drugs', wrote Wilkinson, who 
claimed Hahnemann had 
established a materia medica of mental fineness ... able to enter into 
relations with the mind in the body, and thereby with the intimate 
body itself as a mere theatre and extension of the mind. (Wilkinson 
1889) 
In fact, the mind of the physician was possibly more important for Wilkinson 
than the tools of the trade. Because most homeopaths are not medical 
materialists, and inquire into their patients' inward experience, 
patients believe in them, not only for their mode or system, but for 
themselves. Mind touches mind here as it seldom does in specialism. 
(ibid.) 
Wilkinson is almost forgotten, perhaps unjustly,18 but his influence via 
American homeopathy and Kent on the development of twentieth-century 
homeopathy was considerable. Although Kent himself has been seen as one 
of the chief culprits behind the accelerating decline and marginalization of 
homeopathy in the first half of the century (Inglis 1964: 85f), his ideas were a 
dominant force in its revival in the latter half, when overtly 
spiritual-mentalist hierarchies were taught as the foundation of a 'science of 
homeopathy' by some (Vithoulkas 1980; 1991). 
17 Hahnemann's geistig and geistartig-immaterial, spiritlike-were consistently translated as 
if he had written geistlich -holy, spiritual. It is even claimed that Hahnemann wrote geistlicli 
(e.g. Coulter 1977: 343), although neither the electronic version of the sixth edition of the 
Organon nor the index of the variorum Organon-Synopse reveal any such usage when searched 
(Hahnemann 1921; 2000). 
18 A Blake scholar as well as translator of Swedenborg, he was friends with many of the great 
figures of the day, such as Carlyle, Froude, Dickens and Tennyson, according to the 
Dictionary of National Biography. Another friend, the New England transcendentalist Ralph 
Waldo Emerson (1850), wrote that he 'threw all the contemporary philosophy of England into 
shade', and possessed a 'vigor of understanding and imagination comparable only to Lord 
Bacon's.' 
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The related essentialist notion that homeopathic constitutions represent 
Jungian archetypes was also taken up enthusiastically (e.g. Gutman 1978; 
Whitmont 1982). This happened possibly without awareness that some of 
Jung's most apparently innovative ideas may derive as much from a stream 
within late nineteenth-century homeopathy (itself deriving from 
Swedenborg), as from more overtly alchemical and astrological sources (for 
the latter, see Noll 1992). 
It is nevertheless important to separate these trends from Hahnemann's own 
writings, where hardly a trace of them can be found. Despite his origins in a 
pietist environment, Hahnemann seems to have been an eighteenth-century 
deist (borne out by his freemasonry) more in tune with staid Confucian ethics 
than visionary esoteric Christianity, let alone hellfire American 
fundamentalism (Haehl 1927, 2: 387f). It is unlikely that his 'dynamic' concept 
of life, disease and medicinal action is identical with the 'spirituality' of many 
of his later Swedenborgian and occultist followers. 
4.5. The modern synthesis 
Many homeopaths have never accepted miasma tic theory, either because they 
found it implausible (Dudgeon 1853), or because they objected to the 
reintroduction of causality into a phenomenological discipline (Ledermann, 
Sutherland, Lunt 1954). Many others have regarded it as a fruitful theory, 
indispensable for understanding and treating chronic disease. Rau said in 
1837 that, in spite of being wrong in details, its importance lay in the 
acknowledgment of the need to account for internal hidden conditions and 
dyscrasias (Haehl 1927, 2: 163). This opinion has been echoed by several of the 
most prominent critical homeopaths (for example Wolf 1837; Hughes 1893; 
Eizayaga 1991). A further linguistic problem lies in Hahnemann's use of the 
term 'miasm', leaving the misleading impression that he was reliant on an 
abandoned theory of intangible miasmata, when he was in fact a contagionist 
and pioneer of germ theory. The historically uninformed retention of 'miasm' 
in the present day to describe a concept that has moved away from infection 
towards metabolism, structure and genetic predisposition is particularly 
unfortunate, and no doubt explains the disappearance of 'miasms' from 
modem French homeopathic terminology. Mode reactionel (reactional mode) 
has become the preferred term, with collective and individual categories, and 
subcategories such as acute, constitutional or diathesic (Meriadec 1990). 
4.5.1. Layer theory 
Homeopaths from Bonninghausen onwards had noticed that during 
treatment certain drug pictures tended to follow each other in predictable 
sequences, Sulphur, Calcarea and Lycopodium being the best known. Explicit 
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acknowledgement of these 'zig-zags' and 'ladders of cure' came from Burnett 
(1887: 53), but they have been developed furthest in French homeopathy (e.g. 
Zissu 1977-78). This approach has been formalized more recently by 
Francisco Eizayaga. Eizayaga began as a classicist, but objected to what he 
saw as antiscientific occultist tendencies in much neo-Kentian homeopathy. 
Over many years, he developed a rigorous method of analysis in chronic 
disease, related to the French reactional modes, which involves breaking the 
case down into three layers, which may require entirely different medicines: 
1. lesion, consisting of local, general and mental symptoms of acute phase, 
plus precipitating factors; 
2. fundamental: mental and general symptoms specific to the patient during 
the disease, which may involve the chronic miasms; 
3. constitution: non-pathological general characteristics, correlated with a 
small number of mineral biotypes. 
Eizayaga (1991: 251) states that in 'severe and organic cases, when the remedy 
for the disease (similar) and the remedy for the patient (simillimum) are 
different, one should prescribe the similar first'. He also points out that 
constitutional treatment will only be successful if the remedy chosen happens 
(accidentally or not) to include or overlap any lesion, but that starting 
treatment at the lesional level is frequently so successful as to make 
subsequent constitutional treatment unnecessary. 
He has treated many thousands of cases of serious pathology, including 
malignant tumours and multiple sclerosis, using this approach. Results of 
treatment using his system in chronic asthma have also been published 
(Eizayaga, Eizayaga, Eizayaga 1996). 
4.5.2. Sequential therapy 
The Swiss Jean Elmiger (1998) also developed a clinical algorithmic approach 
to chronic disease after experiencing similar disillusionment to Eizayaga with 
purist neo-Kentianism and the fetish of the single constitutional remedy. In 
Elmiger's sequential therapy, treatment follows an explicit timeline (reverse 
chronology) using homeopathic prescriptions for traumas and unresolved 
acute episodes, intercalated with constitutional prescriptions. In each patient 
this is followed by antimiasmatic treatment with nosodes. He has claimed 
particular success with the chronic sequelae of immunizations, antidoted by 
the potentized vaccine (tautopathy), and has evolved a schedule for pre- and 
post-treatment of conventional immunization. These potencies are made from 
the whole vaccine, including the fixatives such as formaldehyde and 
aluminium phosphate and the preservative thiomersal, a mercury compound. 
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They are claimed to minimize adverse effects and maximize the positive 
immune response to vaccines. 
4.6. Conclusion 
Jewson (1976) proposed a sociological explanation for the cosmologies that 
have dominated Western medicine since the eighteenth century. His theory 
was that eighteenth-century 'bedside' medical practice was mainly 
determined by the patronage of well-off patients but was displaced by 
nineteenth-century medicine aimed at the masses. It is not necessary to accept 
his thesis to see the usefulness of this categorization in explaining some of the 
difficulties faced by homeopathy. Table 4.1 shows Jewson's original table, 
modified only by the introduction of a column containing Hahnemannian 
homeopathy. 
It is clear that homeopathy shared some of the aspects of bedside medicine, 
including holistic attention to the individual patient, that were being 
displaced by a rapidly industrializing medical profession. It is also clear that 
its extreme precision in differentiating states that are usually lumped together 
causally or nosologically is radically different from anything before or since. 
No doubt the acausal diagnosis of these unique illness states in terms of their 
treatment contributed further to the difficulty faced by allopathy in 
understanding homeopathy. 
Table 4.1 Western medical cosmologies, 1770-1900, adapted from Jewson 
(1976) 
Bedside Medicine Homeopathy 1790- Hospital Medicine Laboratory Medicine 
-1850 (Chronic disease 1790-1900 1870-
1821-) 
Subject matter of Total symptom complex Total symptom- Internal organic events Cellular function 
nosology complex (historical symptom-
complex) 
Patient-practitioner Central Central Minimal Peripheral 
involvement 
focus of pathology Systemic-dyscrasias Systemic (miasms, Local lesion Physico-chemical 
constitution) processes 
Research methods Specu I at ion and Provings; Statistically Statistically oriented Laboratory experiment 
inference oriented clinical clinical observation according to scientific 
observation and method 
comparison 
Diagnostic technique Qualitative judgement Structured anamnesis Physical examination Microscopic 
cf pathogeneses before and after death examination and 
(timeline) chemical tests 
Therapy Heroic and extensive Optimistic; simillimum Sceptical (with the Nihilistic in minimum dose exception of surgery) 
Mind-body relation Integrated: psyche and Integrated: psyche and Differentiated: Differentiated: 
soma seen as part of soma seen as part of psychiatry a specialized psychology a separate 
the same system of the same system of area of clinical studies scientific discipline 
pathology pathology 
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Moreover, Jewson's categories are useful in explaining the tensions 
observable within homeopathy. Paradoxically, at the same time that the 
individual patient's subjective experience became the central focus of 
homeopathy, to a far greater extent than in bedside medicine, the same 
homeopaths were pioneering the investigation and therapeutic use of 
pathogens derived from morbid matter, and were extending the similia 
notion to the level of the lesion. 
Although the results of classical, clinical, complex and isopathic versions of 
homeopathy have been categorized and quantified in recent systematic 
reviews of clinical trials, authors have avoided making qualitative 
comparisons (Kleijnen, Knipschild, ter Riet 1991; Linde, Clausius, Ramirez et 
al. 1997). Even within the qualitative literature, detailed comparisons of 
different homeopathic approaches are rare. The British Jungian psychiatrist 
and homeopath Anthony Campbell (1984) rearticulated the nineteenth-
century distinction made by Hughes concerning the 'two homeopathies': the 
clinical and the classical, roughly corresponding to Hahnemann's pre- and 
post-1810 periods respectively (Hughes 1893: 90). Campbell concluded that 
although the pathological approach might be more acceptable to science, it 
lacked patient-appeal, which is amply provided for by the metaphysical 
version, however logically unsustainable the latter. 
Van der Steen and Thung (1988) make a similar contrast between two 
contemporary homeopaths: the neo-Kentian Vithoulkas (1972; 1980), an 
advocate of homeopathy as 'grand theory'; and Mossinger (1984), who does 
not accept the similia principle as more than a useful heuristic, or the 
potentization principle at all, and has investigated empirical disease-based 
homeopathic specifics in a number of trials (see Part III). 
Although our culture favours arguments based on binary oppositions, they 
tend to oversimplify. Hughes, for instance, has been consistently painted as a 
sceptical opponent of classical homeopathy and high potencies, but, contrary 
to received wisdom, was highly sympathetic to the classical viewpoint which 
took Hahnemann's mature method as its starting point: 
The individualisation of each case ... is the only certain method of 
arriving at the true simillimum ... The more we generalise, and refer it 
to a class, the less happy we shall be ... Subjective symptoms outweigh 
objective ones ... because they present less of the common than of the 
peculiar features of a case. They are, moreover, of great value, as being 
the earliest signs of disorder, before organic change has begun; they 
constitute the main phenomena of a malady at a stage in which it is 
still curable. (Hughes 1893: 89) 
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As for chronic disease theory, he felt that it was of immense benefit in 
allowing the possible constitutional origin of local and superficial complaints 
to be treated. Indeed, this was the area classical homeopathy was most suited 
to, rather than large-scale treatment of acute disease, and was the 'best hope 
of making certain and speedy cures, whose brilliancy shall recall the earlier 
days of our history' (ibid.: 91). Again, he easily accepted the pathogenetic 
effects and therapeutic efficacy of ultramolecular potencies when these were 
demonstrated in trials of acceptable scientific quality (ibid.: 103, 106). 
From the opposite side, Kent devoted some essays to 'pathological' 
prescribing that make startling reading when compared with the anticlinical 
and antiepidemiological pronouncements of some of his recent followers (e.g. 
Vithoulkas 1991). He acknowledged that the study of disease is essential to 
the study of homeopathy, that semiology is only half the story, the other half 
being pathology; and went on to say that medicines which could not produce 
the pathological tissue changes found in any disease could not cure that 
disease homeopathically (Kent 1885; 1912b). Similarly, Burnett is often 
presented as a high-potency opponent of Hughes, yet as noted above, Burnett 
believed the pathological simillimum was a great advance. 
Species Complexes Clinical specifics Tissue salts Pathological lsoprophylaxis 
Heel 1900 Griesslich 1840 Schussler 1870 simillimum Hering 1830 
Hughes 1880 
Population Genius Epidemic Constitutional Allergology 
epidemicus prophylaxis biotypes Blackley 1880 
Hahnemann 1800 Hahnemann 1800 Grauvogl 1860 
Family Constitutional Physical generals Chronic miasms Nosodes 
psychology Bonninghausen Hahnemann 1830 Hering 1830 
Kent 1880 1830 
Individual Mentals & Symptom-complex Keynotes lsopathy Tautopathy 
generals Hahnemann 1800 e.g. Allen 1880 Hering 1830 Hering 1830 
Kent 1880 
Semiology Nosology Physiology Pathology Etiology 
Figure 4.1 Homeopathy 1800-1900: the main approaches, their attributions and 
decade of appearance 
Figure 4.1 shows how these allegedly irreconcilable approaches can be 
mapped straightforwardly onto a graph. Along the y axis this moves from 
individual to species, and along the x axis from subjective symptom to 
external causation. The overlaps and interrelationships between the variants 
are too complex to indicate visually. 
As we have seen, by the 1830s Hahnemann had prescribed across most areas 
of the field using the individual, epidemic, chronic disease, traumatic and 
isopathic models. Subsequently, classicists have tended to work in the 
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semiotic-individual area, moving into nosology and pathology only to 
narrow down the choice of medicines for a patient, or occasionally to treat 
chronic miasms using nosodes; while some clinical homeopaths have worked 
from the opposite quadrant, probing symptomatology only to refine a much 
narrower palette of nosological and pathological specifics. In practice, many 
have regarded function and lesion as complementary, neither less 'real' than 
the other. And although some neo-Kentian homoeopaths use a single-remedy 
version of the acute 'general' model heavily weighted towards mental 
symptoms and 'constitution', even in chronic disease (Vithoulkas 1980; Seghal 
1994; Candegabe 1996), reanalysis of Kent's own published cases has shown 
that, because of limitations in nineteenth-century pathological knowledge, he 
often thought he was prescribing for the individual when we now know he 
was actually prescribing- successfully-for the lesion (Eizayaga 1989). 
The generally pragmatic approach found in British homeopathy is typified by 
Burnett and Clarke, who both managed to use high-potency simillima, 
nosodes, and isopathy, with low potency combination and organ remedies. 
Clarke (1900) compiled an important materia medica based on classical 
semiology, which also did justice to clinical nosology. More recent methods, 
such as those of Eizayaga and Elmiger, systematically traverse the whole field 
in any one chronic case. Present-day clinical trials of individualized 
homeopathy have hardly begun to reflect this widespread synthetic approach, 
as shown in Part III. 
A.N. Whitehead famously said that Western philosophy was a series of 
footnotes to Plato, and Campbell (1984: 22) has pointed out that present-day 
homeopathy bears the same relationship to Hahnemann. With the exception 
of occultist homeopathy (e.g. Evans 2000), most of the different trends within 
the therapy are traceable to Hahnemann's own guidelines, but brought into 
sharper focus by his immediate followers and their descendants. It is easy to 
overstate the differences between homeopaths, as if each belongs to a separate 
warring sect, when in fact they share much common ground. However, it is 
reasonable to conclude that the possibility of many different approaches 
within the field of homeopathy is less problematic than is sometimes thought; 
even the most pessimistic reading must perceive an underlying unity: a 
shared belief in the efficacy of Hahnemannian potentized medicines in many 
different contexts, and chosen by many different heuristics. 
Meanwhile, the preoccupation of orthodox internal medicine has been to 
establish treatments of causation in the species-lesion and extra-species areas 
(antibiosis), while disputing the need to bother with functional semiology 
once the solution has been found in the laboratory. Early homeopaths claimed 
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the appropriate arena for testing their system versus its dominant rival was 
not the debating hall or the press but the field of experience, i.e. in clinical 
trials, at a time when allopathy was generally uninterested in or opposed to 
trials. Evaluation of the results of those early trials forms the subject of Part II. 
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PART II: HOMEOPATHY AND THE DEVELOPMENT OF CLINICAL 
EVALUATION. A SYSTEMATIC REVIEW OF CLINICAL TRIALS OF 
HOMEOPATHY, 1821-1953 
5 Why look at historical trials of homeopathy? 
6 The earliest observational studies, 1821-35 
7 Comparisons with allopathy, 1844-86 
8 Placebo controls - in trials and in practice, 1810-1920 
9 Adoption of the biomedical research perspective, 1914-53 
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5 WHY LOOK AT HISTORICAL TRIALS OF HOMEOPATHY? 
Background The history of the evolution of the clinical trial has been 
surprisingly neglected considering the centrality of the trial in biomedicine. 
The early trials of homeopathy have been particularly neglected. 
Questions Are the historical trials of homeopathy relevant to present-day 
concerns? Is a review warranted? 
Argument 
because: 
An account of the historical trials of homeopathy is essential 
• they were an important component in the evolution of the clinical trial; 
• the judgements made by influential nineteenth-century opponents of 
homeopathy, ostensibly based on evidence from clinical trials, still colour 
debate today; 
• valid trials of homeopathy in clinical contexts dramatically different from 
those found in the present day may increase our understanding of the 
therapy's potential, and indicate areas for future research. 
5.1. The neglect of the pre-modern clinical trial 
Clinical trials are a neglected area in the historiography of pre-twentieth-
century medicine. This is particularly surprising considering that evidence 
from controlled trials is regarded today as a fundamental precondition for the 
practice of effective medicine and healthcare. The lacuna is explained most 
obviously by the fact that not many trials were carried out until randomized 
clinical experiments became accepted as a central dogma of scientific 
medicine in the second half of the twentieth century. There are two principal 
reasons for the late acceptance of trials compared with the institutionalization 
of the scientific experiment. First, they constitute an empirical procedure 
which tends to undermine the traditional Galenic authority of the physician 
and his institutions. Only a profession transformed or willing to be 
transformed by the penetration of empirical thinking could accept impartial 
trials which might overturn received wisdom, and would be expected to 
inform subsequent clinical decisions. The prospect of constant revision of 
working practices was unwelcome for most of history, and was resisted 
strongly in medicine, long after experimentation became the guiding 
principle of the scientific world view during the seventeenth century (Bacon 
1620). Second, even though the idea of therapeutic comparisons and 
controlled trials became tentatively established in the early nineteenth 
century, aggregated results of treatments imply probabilistic rather than 
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certain knowledge of efficacy in individual patients. However unlikely the 
latter objective may seem now, it was the basis for the widespread rejection of 
empirical trials in the mid to late nineteenth century, and was endorsed by 
Claude Bernard's (1813-78) project to place clinicophysiological science on an 
equal footing with nineteenth-century positivist physics (Canghuilhem 1991). 
Although there undoubtedly were some trials before the twentieth century, 
medical historians have continued to reflect a general lack of interest in the 
topic. There appear to be three main reasons. First, the groundwork of 
medical historiography had been put in place before the randomized clinical 
trial emerged after the 1939-45 war as the 'gold standard' of contemporary 
clinical research (Garrison 1917; Singer 1928; Castiglioni 1941; Guthrie 1945; 
Shryock 1948; King 1958). Second, Bernardian doubts about the scientific and 
ethical validity of empirical evidence from controlled trials were common 
well after then, even among historians who were themselves trialists. For 
instance, Bull (1959) wrote a history of the clinical trial, but then cast doubt on 
the importance of his contribution by comparing trials to uninductive 
technological advances, because 
the full sequence of observation-theory-hypothesis-experiment-
validation is not usually invoked. The 'hypothesis' is usually very 
simple - that the test treatment is better than some other treatment. 
Lastly, although a 'new' history of medicine emerged in the final third of the 
century, often originating from outside the medical profession, it has been 
concerned - like Foucault (e.g. 1963) who was influential in establishing the 
orientation - principally with the sociology of medicine, rather than its 
internal methodological processes. 
Even when early clinical trials have been considered, they have been 
sidelined. For instance, although several extensive treatments of the 
emergence of statistical thinking have appeared recently (MacKenzie 1981; 
Porter 1986; Stigler 1986; Gigerenzer, Swijtink, Porter et al. 1989), clinical trials 
have been presented, if at all, as a mid twentieth-century, post-Fisherian 
development. In contrast, the 'numerical method' of P.-C.-A. Louis (1835), in 
which survival rates under competing treatments were collected and 
compared, has been presented as a false start, and subordinated to the much 
more impressive applications of statistical inference developing outside 
medicine in the first half of the nineteenth century. 
Recent authoritative and systematic coverage of the history and 
historiography of medicine has reflected and perpetuated this lack of interest 
in trials as a distinctive medical domain (e.g. Porter 1993; Slinn 1995). Only in 
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textbooks of epidemiology is the early clinical trial treated briefly, if at all, as a 
corollorary of the evolution of epidemiological method (e.g. Lilienfeld & 
Lilienfeld 1980). Typically, reference is made to the 1747 trial of limes and 
oranges versus other sour-tasting substances in the prevention of scurvy by 
James Lind (1716-94), and the 1847 trial by Ignaz Semelweiss (1818-65) of 
elementary hygienic measures in medical attendants to prevent puerperal 
fever (ibid.: 30f, 39). 
Thus, as regards the early history and evolution of the clinical trial, the 
coverage is disappointingly thin. Even Shryock's (1961) otherwise important 
paper on quantification in medicine again mentions only Semmelweis's trial. 
Leaving aside brief popular overviews which have occasionally appeared 
(e.g. Rawlins 1990), the most sustained treatments of early clinical trials are 
those contained in academic theses. Bull (1951) includes a narrative account of 
the main historical experiments, later published separately from the main 
thesis (Bull 1959). Trohler (1978) shows that priority for quantification in 
medicine belongs properly to eighteenth-century Britain rather than 
nineteenth-century France, as popularly supposed, but he is concerned with 
the emergence of statistics more than the trial. Two theses that were later 
published are mainly concerned with twentieth-century developments: 
Rosser Matthews (1995) on quantification in medicine, which focuses on 
selected case studies without aiming to be comprehensive; and Marks' (1997) 
study of US trial policy which challenges the notion that the modern clinical 
trial was solely or mainly a product of the medical profession's self-critical 
scientific advance (see Ch. 7 for discussion of this theory in the light of mid 
nineteenth-century homeopathic trials). Another national historical thesis 
(Cox-Maksimov 1998) explores the development of the controlled trial in 
Britain. Important papers include A. and D. Lilienfeld's review of case-control 
studies (1979), and A. Lilienfeld (1982) which places the emergence of the 
clinical trial within an evolutionary framework. 
5.2. The neglect of homeopathic trials in particular 
Although there were many nineteenth-century therapeutic trials which 
involved homeopathy, none of the above sources mentions them. 
This notable neglect of homeopathic trials seems to be based on the general 
reasons given above, compounded by the hostile reception that homeopathy 
received from the allopathic profession. Jiitte (1999) has recently pointed out 
that early positivist accounts of homeopathic history made little or no attempt 
to evaluate the system, but assumed that a statement of its tenets was enough 
to demonstrate its self-evident absurdity. It is undoubtedly true that the 
historiography of medicine was until recently overwhelmingly an internalist 
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discipline, written by doctors for each other (e.g. Faber 1921) or occasionally 
in simplified form for the general public (e.g. Robinson 1931; Lloyd 1936). It 
was given above all to a Whiggish celebration of the triumphal advance of 
medical knowledge. This in turn rested on a rationalist conception of medical 
science which sought single overarching answers to clinical problems, as if 
medicine could be modelled on Newtonian physics and its search for a 
unified theory of physical forces. However embarrassing individual patients 
might be for this approach, a pluralist medical philosophy which could allow 
the possibility of divergent answers to specific therapeutic problems was 
inadmissable - a blindspot in the biomedical worldview noted in the early 
twentieth century by the allopaths Crookshank (1923 [1946]) and Bier (1925). 
Moreover, because it was believed that homeopathy had been shown 
conclusively in clinical trials to be a popular delusion like phrenology 
(Holmes 1842), there was clearly no need for the discussion of trials of non-
medicine. Only one 'trial' was regularly mentioned in the century-and-a-half 
after its publication. This was Andral's observational study of 1834 (Anon 
1834; Academie de Medecine 1835a), which constituted Holmes's top level of 
evidence against homeopathy, and was still being cited more than a century 
later as an example of how homeopathy had failed the test of 'exact, critical 
appraisal' (Shryock 1948). 
In fact there were a number of genuine prospective clinical trials of 
homeopathy in the mid nineteenth century, which involved the medical 
establishment, but they have been entirely left out of orthodox histories. And 
once again, the sociological orientation of the late twentieth-century 'new' 
historiography of medicine meant that homeopathy was dealt with in terms 
of its spread, its clientele, its personalities, its political and economic conflict 
with allopathy, its relationship to other forms of alternative medicine such as 
herbalism and hydropathy, and its decline (e.g. Haller 1984; Barrow 1986; 
Roberts 1986; Brown 1987; Barrow 1988; Cooter 1988; Rankin 1988; Fye 1990; 
Gevitz 1994; Gijswijt-Hofstra 1996; Weatherall 1996; Jutte 1998). In this almost 
random selection of representative studies, clinical trials are mentioned 
hardly at all. 
5.3. Homeopathic demands for trials 
The widespread nineteenth-century indifference towards, and even rejection 
of, evaluation of allopathic procedures in clinical trials contrasts sharply with 
the homeopathic community's interest in and demand for trials. Internal and 
external factors seem to have contributed to this. 
The early homeopaths rejected the standard accusations of charlatanry 
levelled at them, and stressed the scientific nature of their pharmacological 
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research. The homeopathic drug proving bears an obvious similarity to the 
phase I clinical (screening) trial as it is known today. The need for lack of bias 
in the collection of signs and symptoms had been appreciated by homeopaths 
from the beginning (see Ch. 2), and placebo-controlled provings and 
reprovings emerged relatively early on, possibly influenced by the 
therapeutic use of placebo stemming from Hahnemann (see Ch. 8). The 
dilution and dosage experiments performed by the early homeopaths were 
another source of internal therapeutic comparison, and seem to have been far 
ahead of their time (see Ch. 7). 
Equally importantly, homeopathy had emerged from the most 
comprehensive critique that nosology and therapeutics had received until that 
time, and it would have been inconsistent if it could not itself be subject to 
external comparison and evaluation. As noted in Ch. 2, Hahnemann (1817; 
1852b) declared that homeopathy could only be validated by clinical 
experiment, not by argument. Homeopaths responded to the orthodox a 
priori rejection of their 'infinitesimal' doses (Holmes 1842; Routh 1852) by 
pointing to their success in practice, and insisted that 'Does it work?' was the 
relevant question, not 'Should it work?' (e.g. Bayes 1856: 22). Their advocacy, 
from the 1830s cholera epidemics onwards, of statistical comparison of 
mortality rates, time to recovery and drug costs under allopathy and 
homeopathy places them in the vanguard of evidence-based healthcare, as it 
is now known (Irvine 1844; Anon 1852; Ozanne 1853; Gallavardin 1860). The 
record shows that homeopaths and their supporters were anxious to conduct 
trials of homeopathy versus allopathy, confident that they would 
demonstrate the superiority of their therapy. 
5.4. Historiography of homeopathic trials 
5.4.1. Internal accounts 
There are of course many internal histories of homeopathy, and nearly all 
commemorate a few of the better-known trials, but, as with orthodox 
medicine, there has been no comprehensive coverage of historical data from 
prospective trials. 
J.-P. Gallavardin (1824-98) mentions a few of the trials conducted in the 30 
years before he wrote, particularly those of the Paris school, and provides 
useful background data missing from some primary reports (Gallavardin 
1860). Somewhat later, Wilhelm Ameke (1847-86) wrote about what he called 
'trials of homeopathy by its opponents', including those by the Paris school, 
and others that Gallavardin did not mention (Ameke 1885: 312ff). 
The historian of Russian homeopathy, Boyanus (1882), describes the setting 
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up of various homeopathic hospitals, and mentions two prospective trials. 
The first comprehensive presentation of a body of statistical evidence relating 
to the efficacy of homeopathy appeared at the end of the nineteenth century, 
when T.L. Bradford (1900), an American homeopathic librarian and 
biographer of Hahnemann, published The Logic of Figures: or Comparative 
Results of Homoeopathic and Other Treatments. This was not a review, but a 
compilation of reports from Europe and the USA that had appeared in the 
half-century after 1850. Many of these consisted of large-scale comparisons 
between mortality rates in orthodox and homeopathic hospitals during the 
numerous epidemics that swept Europe and America in the nineteenth 
century. The tabulated results are as much a commentary on the 
ineffectiveness of pre-modern orthodox medicine and public health as they 
are on the apparent efficacy of homeopathy. Bradford also included cost 
comparisons where they could be found, derived from reports by the 
administrators of public institutions that had employed the two systems in 
parallel or alternately for several years. These invariably show that the costs 
of homeopathic medication at that time were a small percentage of the costs 
of orthodox treatment. Unfortunately, however useful his compilation is as a 
starting point for the researcher, Bradford seems only to have included 
examples which favoured homeopathy, and thus cannot be considered to be 
an unbiased source. His references are mainly secondary reports from the 
English-language journals, and in some cases it has not been possible to trace 
his citations of secondary references, let alone the primary reports they were 
based on. Another problem with the majority of statistics presented by 
Bradford was his extensive use of mortality rates from institutions which 
were geographically remote - the treatment of cholera or pneumonia by 
homeopathy in Vienna cannot be compared directly with the results of 
allopathic treatment of the same diseases in Edinburgh, since, however 
accurate the diagnosis of the disease, the severity of the epidemic and baseline 
comparability of patients may well have been different. This 
incommensurability had been recognized long before by homeopaths more 
scientifically grounded than Bradford (e.g. Bayes 1856). 
Some early twentieth-century trials were mentioned by Donner (1948), and 
more recently Coulter (1977: 552ff) described two trials undertaken by the 
Paris school, including Andral' s. 
5.4.2. External accounts 
External accounts of homeopathic trials, other than the alleged falsifications of 
homeopathy by members of the Paris school such as Andral and Trousseau, 
are predictably scarce. 
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A systematic review of mid twentieth-century placebo research until 1959 
contained a brief overview of historical pharmacological experiments, 
including the work of the Vienna Provings Union in the 1840s (Haas, Fink, 
Hiirtfelder 1959). A scholarly history of Italian homeopathy recounts in some 
detail the controversy surrounding two trials that took place in Naples in 
1828-9 (Lodispoto 1961: 39ff). 
Cassedy (1984) examined the debate over mortality rates under homeopathic 
and allopathic treatment in epidemics in North America and found evidence 
that some of the comparisons between homeopathic and allopathic treatment 
in the same institution at different times may have been flawed. For instance, 
there were (unproven) accusations that homeopaths had removed hopeless 
cases from the institutions, in order to improve their averages of cure. 
Although Bradford (1900) relied heavily on retrospective time-series data of 
this sort, it must be viewed with scepticism. Formal prospective trials do not 
seem to have been undertaken in the US until 20 years after Cassedy's study 
concludes, so a noteworthy trial of allopathy versus homeopathy which took 
place in Chicago in the 1880s is described only by Kaufmann (1971). 
Some details of historical trials are given by Aulas (1991: 87ff), although the 
author's overtly anti-homeopathic stance undermines the objectivity of the 
account at many points, particularly where conflicting reports of the same 
trial exist (see Ch. 6). Appearing while the present review was in progress 
were two articles relating to the history of blind assessment and placebo 
controls which include some early experiments (Kaptchuk 1997; 1998a). 
An exception to the generally disappointing neglect of historical trials, both 
orthodox and heterodox, is a very recent project designed to give them the 
coverage they deserve. The website set up by the Royal College of Physicians 
of Edinburgh jointly with the Cochrane Collaboration appears to be 
committed to an inclusive approach to the history of clinical trials, regardless 
of the therapy tested (Cochrane Collaboration & 
Royal College of Physicians of Edinburgh 1998). It already contains details of 
a few early ostensible or rhetorical tests of homeopathy (see Ch. 8) and will be 
updated as new material comes to light. 
5.5. Justification for reviewing early homeopathic trials 
From a present-day perspective therefore, it is important to review early 
homeopathic trials systematically. Historically speaking, this contributes to 
our knowledge of: 
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• the internal history of homeopathy; 
• evaluation of the external judgements made on homeopathy; 
• the historiography of the clinical trial; 
• the reciprocal relationship between homeopathy and the growth of 
scientific clinical evaluation. 
Clinically, because of the changing patterns of disease, it allows a search for 
evidence of: 
• homeopathy's efficacy in diseases which are not prevalent now, or those 
where homeopathy would not be considered now; 
• similarities and differences in homeopathic prescribing styles between 
then and now. 
An overview of the early evaluations of homeopathy indicates a 'hierarchy of 
evidence', comparable to that recognized today (Last 1995: 76). In ascending 
order of probable bias this comprises: 
1. Prospective clinical trials with concurrent controls, such as the quasi-
randomized trial at the Ste Marguerite hospital, Paris (Tessier 1852). 
2. Quasi-experiments (a) - Prospective clinical trials with closely comparable 
historical controls, as above (Tessier 1850). 
3. Quasi-experiments (b)- formal large-scale prospective comparisons of 
mortality rates under concurrent homeopathic and allopathic treatment in 
epidemics in the same location, such as the 1854 London cholera epidemic 
(House of Commons 1854-55). 
4. Quasi-experiments (c) -prospective interrupted time-series comparisons 
of therapies in the same institution at different times, e.g. trials of different 
potency regimes (Eidherr 1862). 
s. Prospective observational studies with protocols for admission, 
dispensing and reporting (Schmit 1831). 
6. Retrospective consecutive case series and statistics from epidemics, e.g. 
during the influenza pandemic 1918-2017 000 cases were treated by 
homeopathy in the USA, with a mortality rate of 0.3% compared with the 
expected 20% (Foubister 1989: 11). 
7. Individual case reports, widely distributed throughout the literature for 
illustrative and teaching purposes. 
A systematic review of all this material would be impossible within the 
constraints of this thesis, especially since the bulk of reports exist in 
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unindexed nineteenth- and early twentieth-century journals, monographs and 
textbooks. For this reason, it is proposed to look only at prospective 
evaluations. 
5.6. Method 
A systematic literature search, without language restrictions, was undertaken 
for published reports of trials that took place before 1965 (the date Medline 
starts). The designs had to correspond with levels 1-5 in 5.5 above, which 
comprise: 
• prospective comparative therapeutic trials of homeopathy versus another 
treatment or 
• prospective observational studies with or without historical controls. 
In the light of the historical importance of placebo controls in clinical 
evaluation, the search was extended to include nineteenth-century placebo-
controlled provings (see Ch. 8). 
Modern and historical homeopathic texts and their bibliographies, and early 
homeopathic journals were handsearched for reports of nineteenth- and early 
twentieth-century clinical therapeutic trials. Embase, Hominform, Medline 
and Psychinfo computerized databases were queried for articles on the 
history of homeopathic and placebo research. Reference Works computerized 
database (Warkentin 1994) of nineteenth-century homeopathic materia 
medica and provings was searched, using the terms 'control', 'placebo', 
'saccharum lactis', 'sac. lac.', 'test' and 'trial'. Historians, researchers and 
librarians in the field were contacted. 
Details from identified trial and study reports were entered into a standard 
computer database. The extracted data included location, principal trialists, 
size, design, condition, type of homeopathic and other treatment, evaluation, 
problems - and reception where traceable. 
5.7. Results 
The search for prospective clinical evaluations of homeopathy uncovered 45 
relevant studies and trials from 1821-1953. Four groups are identified and 
covered in Chs 6-9, an analysis which respects their chronological evolution. 
Brief details of the 44 hospital-based trials found in the literature search are 
shown in Table 5.1. 
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Table 5.1 Prospective hospital-based evaluations of homeopathy 1821-1953 
T ria list, Date Source Condition Design Model Control 
Stapf, 1821 Ameke, 1885: 312 Mixed Case series Classical None 
Wislicenius, 1821 Ameke, 1885: 312 Mixed Case series Classical None 
Marenzeller, 1828 Schmit, 1831 Mixed Case series Classical None 
de Horatiis, 1828 de Horatiis, 1829 Mixed Case series Classical None 
de Horatiis, 1829 Panvini, 1829; Esquirol, 1835; Mixed Case series Classical None 
Peschier, 1835; Rapou, 1847 
Herrmann, 1829 Herrmann, 1831 Mixed Case series Classical None 
Herrmann, 1829-30 Lichtenstadt, 1832; Seidlitz, Mixed Open label Classical Allopathy 
1833 Expectant+ 
placebo 
Attomyr, Ringseis, Attomyr, 1832 Mixed Case series Classical None 
1830-31 
Gueyrard, 1832 Gueyrard, 1833a; Gueyrard, Mixed Case series Classical None 
1833b; Pointe, 1833; 
Gallavardin, 1860 
Simon, Curie, 1834 Academie de Medecine, 1835; Mixed Case series Classical None 
Simon & Curie, 1835; 
Gallavardin, 1860 
Andra!, 1834 Anon, 1834; Irvine, 1844 Mixed Case series Naive None 
Andra!, 1835 Academia de Medecine, 1835 Mixed Case series Naive None 
Stern, 1844 Stern, 1845 Mixed Case series Classical None 
Stender, 1847-54 Johannsen, 1848; Boyanus, Mixed Open label Classical Allopathy 
1882:123-124 
Tessier, 1847-49 Tessier, 1850 Pneumonia Historical Classical Allopathy 
idem Jousset, 1862 [Re-analysis of Pneumonia Historical Classical Expectant 
Tessier (1850) + 10 
unpublished cases] 
Tessier, 1849 Tessier, 1850 Cholera Cohort control Classical Allopathy 
Tessier, 1849-51 Editorial, 1849; Ozanne, 1850; Mixed Open label Classical Allopathy 
Tessier, 1852; Ozanne, 1853; 
Ozanne, 1857; Gallavardin, 
1860 
Casper, Wurmb, Eidherr, 1862 Pneumonia Time series Classical 3 potencies 
1850-59 
Balfour, 1854 West, 1854: 600 Scarlet fever Open label Clinical No treatment 
Charge, 1854 Charge, 1855; Sirus-Pirondi, Cholera Open label Classical Allopathy 
1859; Gallavardin, 1860 (see Ch. 7) 
London Hom. General Board of Health Cholera Open label Classical Allopathy 
Hospital, 1854 (1854-55); House of 
Commons, 1854-55; Medical 
Council, 1854-55a, b, c, d 
Burnett, 1870s Burnett, 1888:1-10 Fevers Open-label Clinical Allopathy 
Cook County Chicago Herald, 1881; Cook Mixed Open label Unknown Allopathy 
Hospital, 1880-86 County Hospital, 1885; 1888; 
Chicago Medical Society, 1922; 
Cook County Board of 
Commissioners, n.d. 
Key: d-b, s-b, double- or single-blind; p-c, placebo-controlled 
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Table 5.1 Prospective hospital-based evaluations of homeopathy 1821-1953 (cont.). 
Chadwell, 1914 Wesselhoeft, 1917 Scarlet fever Quasi-random Clinical Placebo 
Wesselhoeft, Wesselhoeft, 1917 Scarlet fever Open label Clinical No treatment 
1914-16 time series 
Wesselhoeft, 1915 Wesselhoeft, 1925 Diphtheria Open label Clinical Antitoxin 
Wesselhoeft, 1917 Wesselhoeft, 1917 Scarlet fever Open label Clinical No treatment 
Wesselhoeft, Wesselhoeft, 1924 Orchitis from Historical Clinical Classical/ 
1921-23 mumps allopathy 
Bier, 1925 Bier, 1925 Furunculosis Case series Clinical Allopathy 
Joachimoglu, 1925 Donner, 1948: 34 Skin D-b p-c Clinical Placebo 
conditions 
Simonson, 1938 Donner, 1948:54-57 URTI, (5 S-b p-c + Unknown Placebo; 
trials) Open label allopathy 
allopathic 
Schilsky, 1938-39 Schilsky, 1941 Whooping Open label Classical Allopathy 
cough 
Paterson, Boyd, Paterson, 1941 Diphtheria Historical lsopathy Untreated 
1941 immunity population 
Hess, 1942 Hess, 1942 Diphtheria Open label Clinical Serum 
Paterson, British Homoeopathic Society, Mustard gas Random, d-b Clinical; Placebo 
Templeton, 1943 burns, (4 p-c lsopathy 
1941-42 trials) 
Ledermann, Ledermann, 1954 Surgical Random, d-b Classical Placebo 
1951-53 tuberculosis p-c 
Key: d-b, s-b, double- or single-blind; p-c, placebo-controlled 
With few exceptions, the trial designs fall into three clearly distinguishable 
phases: 
1. Observational studies of classical homeopathy in mixed conditions 
(1821-35); 
2. Pragmatic open-label comparisons of classical homeopathy with allopathy 
or no treatment, for mixed or specific conditions (1844-86); 
3. Controlled trials of clinical homeopathy (nosological specifics) (1914-53). 
This demonstrates a clear chronological evolution in the design of prospective 
therapeutic trials of homeopathy towards what became the accepted 'gold 
standard' in clinicopharmacological research after 1950. In view of these 
natural divisions, the most appropriate method of evaluation would seem to 
be to respect the evolutionary categories and divide the sample into three. 
This contextualizes the trials, allowing them to be evaluated in historically 
appropriate terms, and most importantly allows avowedly evidence-based 
judgements on homeopathy made at the time of, and in response to, the trials 
to be evaluated as well. Accordingly, the three phases are dealt with 
separately in Chs 6, 7 and 9. 
Placebo was only used as a control in one hospital-based therapeutic trial 
(Lichtenstadt 1832). Because of the importance that the issue of placebo 
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controls had in nineteenth-century clinical evaluation of homeopathy, this 
trial is discussed separately in Ch. 8 along with an abortive placebo-controlled 
trial in general practice (Potter 1880), 5 placebo-controlled provings and 3 
trials of placebo alone (as a presumed or rhetorical equivalent of 
homeopathy), which were also uncovered in the literature search. 
105 
6 THE EARLIEST OBSERVATIONAL STUDIES, 1821-35 
Background The rejection of homeopathy by the medical establishment has 
been portrayed as a watershed in medical history because it is deemed to 
have been based on evidence rather than prejudice: homeopathy was given a 
fair trial, especially by the pre-eminent Paris School, and was found wanting. 
This belief forms the basis of an influential thesis that the development of 
modern scientific medicine, as a unified discipline, can be dated to that 
rejection in the 1830s and 1840s. 
Questions How valid was the trial evidence used by sceptics such as the 
French Academie de Medecine (1835) and Holmes {1842) in their rejection of 
the claims of homeopathy? Was their use of evidence biased in any way? 
Argument A systematic review of prospective trials of homeopathy that 
took place before 1842 shows not only that the individual trial evidence used 
by the most notable critics was wholly invalid, but also that virtually no fair 
trials of homeopathy had taken place by that time. 
6.1. Introduction 
In March 1835 the Academie de Medecine in Paris debated homeopathy 
(Academie de Medecine 1835a; 1835b). It was decided that homeopathy 
should on no account be accepted into the newly self-constituting body of 
scientific medicine, and a recommendation was made to the government that 
permission for a free homeopathic hospital be denied. Among the heated 
opinions informing this seminal judgement, some mention of evidence from 
clinical trials could be heard. The celebrated Gabriel Andral (1797-1876) gave 
an account of trials he had conducted in the Pitie in Paris, and Bailly, medical 
director of the Hotel-Dieu, spoke of another trial at his own institution. A 
review of an account of an earlier trial in Naples was also prepared for the 
debate by Edouard Esquirol. All the evidence brought forward appeared to 
support the contention that homeopathy did not cure patients. A few years 
later, in a tract whose extraordinary influence since that time has been noted 
above (see Ch. 3), Holmes (1842) wrote that homeopathy was a delusion. Not 
only was the system completely implausible; most crucially in his hierarchy of 
evidence, it had also been falsified by clinical experiment. The examples used 
by Holmes were Andral's trials, and Esquirol's review. 
These seemingly evidence-based judgements have been echoed ever since. A 
century later, discussing the emergence of the scientific biomedical 
worldview, Shryock (1948: 138f) could write: 
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The manner in which critical methods undermined the old order is 
well illustrated by the history of homeopathy. This system was 
established in Germany during the last days of the Naturphilosophie, 
and was characterized ... by a monistic pathology and therapeutics ... 
Hahnemann was as 'regular' a medical philosopher as Brown, Rush or 
Rasori, but unfortunately was born just too late. The views of Brown 
could neither be proved nor disproved by the rationalistic 
controversies of 1800 ... but Hahnemann's works appeared just in time 
to be subject to exact and critical analyses. 
Holmes's top level of evidence against homeopathy is then cited: 
The French clinicians seemed willing to give homeopathy a trial. 
Andral, in particular, checked the system with care, trying it out in his 
wards in Paris with negligible results, and reporting to the Academy of 
Medicine that he had systematically experimented with the materia 
medica without finding any of the results Hahnemann reported. 
Shryock, a founder of modem scientific historiography of medicine, then 
makes his largest claim: 
It was as a result of such apparently inductive checks on the new 
school that that it was eventually forced out of regular medicine ... this 
expulsion, this transfer from the status of a system to that of a sect, 
affords one of the best criteria for dating the final advent of modem 
medicine. When a monistic pathology and a related therapeutics were 
no longer tolerated in regular medicine, that medicine had come of 
scientific age. 
Leaving aside Shryock's mischaracterization- as monistic- of homeopathy's 
fundamental requirement of a constantly recalibrated therapeutics to match 
constantly varying pathologies, there can be little doubt of the importance of 
this judgement - if true. The question underlying a review of the first phase of 
homeopathic trials is therefore: did these clinical trials show conclusively that 
homeopathy was, as the Academie and Holmes thought, a delusion? Was it as 
we would say nowadays (less rhetorically, no doubt) no more than a placebo? 
6.2. Results 
Table 6.1 shows 12 studies conducted between 1821 and 1835. All the trials 
used homeopathic medicines for mixed conditions, acute or chronic, with 
little attempt at selection of patients. Half were terminated abruptly, either 
because of external opposition, or because of internal problems with 
allopathic staff compliance. The trials fall chronologically into two subgroups: 
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firstly those taking place in Germany and German-dominated areas (Austria, 
Italy, Russia), and secondly the French studies. Most of the first group 
employed some form of protocol for conduct and evaluation, but the second 
group did not. None of the French trials was the subject of an authorized, 
published report. 
Table 6.1 
1821-35 
Prospective observational studies of homeopathy in mixed conditions 
Trialist 
Date 
Stapf 
1821 
Wislicenius 
1821 
Marenzeller 
1828 
de Horatiis 
1828 
de Horatiis 
1829 
Herrmann 
1829 
Herrmann 
1829-30 
Sources Hospital 
Ameke, 1885: 312 Berlin, Charita 
Ameke, 1885: 312 Berlin, 
Garrison Hospital 
Schmit, 1831 Vienna, 
Garrison Hospital 
de Horatiis, 1829 Naples, Trinita 
Panvini, 1829; Esquirel, 1835; Peschier, Naples, Trinita 
1835; Rapou, 1847 
Herrmann, 1831 Tulzyn, 
Military Hospital 
Lichtenstadt, 1832; Seidlitz, 1833 St Petersburg, Military 
Hospital 
Attomyr, Ringseis Attomyr, 1832 
1830-31 
Munich, 
General Hospital 
Gueyrard 
1832 
Gueyrard, 1833a; Gueyrard, 1833b; Pointe, Lyons, Hotel-Dieu 
1833; Gallavardin, 1860 
Andra I Anon, 1834; lrvi ne, 1844 Paris, Pitie 
1834 
Andra! Academie de Medecine, 1835 Paris, Pitie 
1835 
Simon, Curie Academie de Medecine, 1835; Simon & 
1834 Curie, 1835; Gallavardin, 1860 
Paris, Hotel-Dieu 
Key: ! = terminated prematurely. 
6.3. Germanic trials 
6.3.1. Berlin 1821: Stapf, Wislicenius 
Model N 
Control Length 
Classical ? 
None ? I 
Classical ? 
None ? 
Classical 43 
None 40d ! 
Classical 200 
None 5mon 
Classical 60 
None 40d 
Classical 164 
None 3mon I 
Classical 395 
Allopathy 341 
Expectant+ 521 
placebo 5mon 
Classical >100 
None 5mon 
Classical 15 (10) 
None 4 d I 
Naive 54 
None 5mon 
Naive 140 
None 3 man? 
Classical ? 
None ? 
The earliest prospective public trials of the new system seem to have taken 
place in 1821. J.E. Stapf, one of Hahnemann's personal students and closest 
allies, was invited to demonstrate the clinical benefits of homeopathy at the 
Charite hospital, Berlin. According to Ameke (1885), the trial was abruptly 
halted by the hospital authorities as soon as it became apparent that Stapf was 
successfully treating patients with chronic diseases. 
Wislicenius, another close colleague of Hahnemann, undertook another 
public series in 1821 also in Berlin, at the Garrison Hospital. Again according 
to Ameke (ibid.), Wislicenius achieved success, but the trial was not halted 
this time. Instead, the journal kept by Wislicenius detailing his treatments and 
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observations was taken away by the allopathic doctors in charge of the trial 
and never returned. The military surgeon responsible said that it was not the 
business of the highest functionaries to give an account of the experiments, 
but that some day the results would be made known. The results were still 
unpublished 60 years later, when Ameke pointed out that if the trial had 
contained the slightest evidence against homeopathy it is doubtful whether 
the same functionaries would have lost any time in publicizing the fact. 
6.3.2. Vienna 1828: Marenzeller 
The trial at the Garrison Hospital, Vienna, was conducted by imperial decree, 
and a real effort was made to establish acceptable conditions for a valid study 
(Schmit 1831). The objective was to conduct a preliminary trial to see if 
homeopathic medicines were efficacious in any respect, not to evaluate its 
effectiveness in life-threatening conditions. A formal protocol for supervision, 
admission, consultation, prescription, dispensing and reporting was created. 
Marenzeller, the homeopath, was a surgeon-major recalled from active duty 
in Prague. 43 patients were admitted, and of these 32 were cured, 1 died, 5 
passed to other departments, and 5 were recuperating on day 40 when the 
trial was mysteriously terminated. Seven of the eight allopathic 
commissioners called for further trials, saying that the study had shown 
nothing that could be held against homeopathy, but that the short duration 
and small number of patients meant it could not be conclusive. The eighth 
commissioner was implacably opposed. The main problem seems to have 
been that allopaths in the same hospital tried to subvert the trial by 
threatening patients with dire consequences from homeopathy, and they had 
to be excluded as happened later in Naples. The report and tables were 
written by J. Schmit, who attended every visit of Marenzeller but does not 
seem to have been a homeopath. The validity of the report can also be gauged 
from the fact that it was communicated by Hahnemann himself to a journal 
for publication, with an endorsement of Schmit's trustworthiness. 
6.3.3. Naples 1828: de Horatiis 
Homeopathy was introduced into Italy in the 1820s following the Austrian 
invasion of Naples, when Necker, the Austrian commander's personal 
physician, taught the system to four Italian doctors. During a trial from 14 
March to 10 August 1828 at the Trinita hospital, Naples, the Royal physician 
Cosmo de Horatiis treated 180 patients with diverse illnesses, acute and 
chronic. There was only one death, from smallpox. According to the primary 
report, nearly all experienced relief, and a large number were cured (de 
Horatiis 1829). 
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6.3.4. Naples 1829: de Horati is 
Following the encouraging results of the first Naples study, de Horatiis got 
permission from Ferdinand, King of Naples to conduct a second trial in front 
of a commission of allopaths headed by Pasquale Panvini. The Neapolitan 
allopaths made repeated attempts to subvert the study, apparently trying to 
influence patients against homeopathy by spreading untrue rumours of many 
deaths, and they had to be excluded from the open wards. This was partly 
due to nationalist opposition to the Germanic medical system, and partly 
from the economic threat posed by homeopathy (Rapou 1847, 1: 136ff). 
Because of the conflict, the King attended the hospital in person, and is 
alleged to have remarked drily: 'These patients must all have risen from the 
dead' (ibid.). A hostile report by Panvini (1829) appears to have been 
deliberately and systematically biased, even claiming that the trial was 
terminated after 40 days because of the large number of deaths. In fact, the 
homeopaths withdrew because of the impossible working conditions, even 
though of 60 patients, 52 were declared cured, 6 significantly improved, and 
only 2 had died. 
6.3.5. Tulzyn 1829: Herrmann 
Herrmann (d. 1836) received a 1-year contract in February 1829 to test 
homeopathy with the Russian military (Lichtenstadt 1832). His first study 
took place at the Military Hospital in the market town of Tulzyn, in the 
province of Podolya, Ukraine. At the end of three months, 164 patients had 
been admitted, 123 cured, 18 were convalescing, 18 still sick and 6 had died 
(Herrmann 1831). The homeopathic ward received many gravely ill patients, 
and the small number of deaths were shown at autopsy to be due to advanced 
gross pathologies. 
6.3.6. St Petersburg 1829-30: Herrmann 
Following the Tulzyn trial, Herrmann was ordered to remove to the Regional 
Military Hospital in St Petersburg, where he again participated in a trial from 
September 1829 until February 1830, supervised by a Dr Gigler. At the same 
time that the homeopathic ward was set up, Gigler allocated another ward to 
expectant treatment - the then medical euphemism for no treatment over and 
above normal nursing care (Lichtenstadt 1832). During the 5 months of the 
trial, Herrmann treated 395 patients, of whom 341 were cured, 23 died, and 31 
were transferred to other wards. The expectant arm received 341 patients, of 
whom 260 were cured, 53 transferred (9 of whom subsequently died), and 28 
unaccounted for. During the same period, the general mortality in the 
allopathic wards was the same as under homeopathy - of 521 patients, 60 
died. Seidlitz (1833) later selected 47 unfavourable homeopathic cases as the 
basis of a hostile and at times abusive report. As a result of the report by 
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Gigler, homeopathy was banned in Russia for some years. (See also Ch. 8 for 
further discussion of the role of placebos in this trial.) 
6.3.7. Munich 1830-31: Attomyr & Ringseis 
The difficulties faced in the trial at the General Hospital, Munich, seem 
extraordinary (Attomyr 1832). There was a smallpox epidemic during the 
study period, and all the patients were vaccinated. There was serious 
allocation bias - simpler cases were invariably sent to the allopathic wards, 
while homeopathic wards received no-hopers and malingerers who wanted 
to overwinter in hospital. Two doctors were overtly hostile to homeopathy, 
and the dispensing physician was supposed to administer the medicines, but 
instead gave them to nurses who mixed them up. There was further lack of 
compliance from nurses, who provided the patients with tobacco, wine etc. 
The patients' food was tampered with to make it inedible, or served cold, and 
the hospital water supply was so tainted that patients often got diarrhea after 
drinking it. Attomyr notes that the conditions were so bad that a 99% 
mortality rate could not have been held against homeopathy. However, he 
claims Dr Ringseis and he did effect cures which allopathy couldn't approach. 
Details and prescriptions for 33 individual successful cases are given, many of 
which had not responded to previous allopathic treatment, including 
syphilitic lesions, gonorrhea, epilepsies, pneumonias and migraines. A series 
of 40 cases of scabies was also mentioned. (See also Ch. 8 for further 
discussion of the role of placebos in this trial.) 
6.4. French trials 
6.4.1. Lyons 1832: Gueyrard 
The professor of clinical medicine at the Hotel-Dieu in Lyons, Dr Pointe, 
wrote an article published on 12 October 1833 in the Gazette Medicale de Paris, 
which declared that recent calls in the French medical press to test 
homeopathy were superfluous - such a trial had already taken place: 
During April 1832, I made a ward of 30 beds available to Dr Guerard 
[sic], one of the most renowned doctors in our city. He was free to 
choose the number of patients he placed, and to prescribe anything he 
needed for the success of the Hahnemannian doctrine. I made one 
condition, that the visits would be made at a prespecified time every 
day, so that any assistants he required would be free. 15 acute and 
chronic cases - fevers, pneumonia, erysipelas, pulmonary catarrh, 
measles, jaundice, diabetes and so on - were chosen by Guerard, and 
each day, in front of 60 students and several of the town physicians, he 
examined the patients with care, gave them homeopathic medicines 
himself, and prescribed the regime. The trial lasted 17 days, and only 
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stopped when Guerard voluntarily withdrew. During this period no 
benefit or noteworthy change was observed that could be attributed to 
homeopathy alone ... What then is the use of a method which fails in 
precisely the most necessary places, where it is most frequently 
needed, and where the brilliant success of the old school is seen every 
day? (Pointe, 1833) 
Naturally Gueyrard was compelled to reply to this, in spite of the difficulty of 
giving details of a trial that had taken place 20 months earlier. In the Gazette of 
9 November he pointed out that, after being invited by Pointe to conduct the 
trial with promises of support for homeopathy, he found the conditions at the 
H6tel-Dieu were appalling (Gueyrard, 1833). As in Munich, it had been 
impossible to get the staff to co-operate, and nurses would give the medicine 
prescribed for one patient to another, since they believed it was just sugared 
water. He prescribed for about 10 patients only during the first 3 days, and 
withdrew from the trial on day 4, when he found that a patient had been bled 
in his absence. Pointe's account was therefore substantially incorrect. As 
regards Pointe' s assertion concerning the brilliant success of orthodox 
medicine in these circumstances, Gueyrard points out that the hospital 
statistics tell quite another story. 
The editor of the Gazette gave Pointe the space to reply to Gueyrard in the 
same issue- a courtesy he had not extended to Gueyrard when Pointe's 
original account was published. However, Pointe avoided all mention of 
Gueyrard's specific allegations about the unacceptable conditions and 
conduct of the trial, or its true duration and abrupt cessation. Instead he 
concentrated on the question of the usual cure and mortality rate at the Hotel-
Dieu. 
6.4.2. Paris 1834: Andral 
Andral's first observational study took place in the Pitie, Paris, in 1834. 
Published anonymously, the report congratulated Andral's assistant Maxime 
Vernois for his meticulous observation, but Vemois later admitted he had 
written the report himself (Anon 1834; Vernois 1835). It briefly describes 35 
mixed cases, from 54 admitted to the trial, and the prescription for each case. 
It is clear from the report that treatment was given in complete ignorance of 
homeopathic methodology: Andral believed that out of the many signs and 
symptoms presented by any patient, he was required to select a single 
important one to prescribe for. The chosen symptoms themselves often 
appear arbitrary - an incipient smallpox described as gastritis, for example -
and most bear no recognized homeopathic relationship to the prescription. 
The reasons for this are discussed below. 
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6.4.3. Paris 1835: Andra! 
Andral's report of further trials in the Pitie, made orally to the Academie de 
Medecine (1835), is worth quoting extensively, in view of the enormous 
weight given to it in the rejection of homeopathy: 
I have submitted this doctrine to experiment; today I can count 130 to 
140 cases collected in good faith, in a large hospital, with many 
witnesses. 
Andral was sensitive to the criticisms made of his earlier study: 
To avoid any objection, I have obtained the medicines from M. Guibert, 
a stringently exact homeopathic pharmacist. The regime was 
scrupulously observed as required by Hahnemann. It has been said 
that for several months I did not faithfully observe all the precepts of 
this doctrine. I therefore took the trouble to begin again; I studied the 
practice of the Parisian homeopaths just as I studied their books, and I 
am convinced that they would act in no other way than I did, and that I 
was as rigorous as any. 
After mentioning an unsuccessful attempt to conduct provings, he indicates 
his highly selective mode of evaluation: 
I took for this [second] series the most clear-cut cases; and firstly 
intermittent fevers. Some of these were treated with globules of 
quinine;19 some recovered, but they would have recovered anyway; 
these partial successes don't prove anything. Others resisted 
stubbornly, and finally I was forced to resort to the usual method 
[blood-letting] which quickly brought them out of it. A case like this is 
still in my wards. 
He had still not grasped the fundamental principle of individualization. In the 
following series he refers to an equally vague fever awarded a discrete 
nosological category by Pinel, but unrecognized by Hahnemann: 
A crowd of patients presented with the symptoms of Pinel's angiotenic 
fever. According to Hahnemann, this always requires aconite 
regardless of the nature and seat of the affection which accompanies it. 
I gave aconite in more than 40 cases, without the least effect; pulse and 
temperature stayed the same. It was unnecessary in these cases to wait 
19 Andral used quinine sulphate, not the Cinclwna of the homeopathic materia medica. 
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a week for the effects of the medicine, and then say: The fever has 
gone. One knows that it would have gone anyway in that time. 
After wrongly attributing a doctrine of specifics to Hahnemann, Andral 
confounds syphilis with gonorrhoea, even though Hahnemann (1828-30) had 
clearly distinguished them: 
I fought syphilis in all its forms, ulcers, excrescences, and so on, with 
Mercurius solubilis Hahnemannii, and above all with Thuja, in which 
the German reformer has such great confidence. The disease did not 
stop progressing. I dressed the ulcers with Neapolitan ointment, and 
healing was rapid. 
Just as in the earlier trial, each patient was given one dose of one medicine, for 
one symptom only. The patient was then left without treatment for a few 
days, and if recovery was not apparent, the case was transferred to orthodox 
treatment and counted as a failure for homeopathy: 
I treated rheumatisms, with or without fever, with Bryonia, Colchicum 
and so on. The pain was never reduced by these means. Three days 
later I bled and returned completely to the usual method, which 
promptly cured. 
Hahnemann does not recognize pneumonia, properly speaking. He 
sees only a collection of symptoms from which he chooses the 
predominant to fight. I did likewise ... sometimes with Aconite, 
sometimes Belladonna. Mild pneumonias progressed as usual; grave 
cases went from bad to worse, and soon forced me to finish with this 
illusory therapy. 
In fact, Andral's renewed study of homeopathy had not advanced his 
understanding at all (see below). 
6.4.4. Paris 1834: Simon, Curie 
During the 17 March session of the Academie, at which Andral's account was 
heard, another appeal to clinical evidence against homeopathy was made. Dr 
Bailly, director of the Hotel-Dieu, rose and said that although he had not 
made tests personally, he had requested that experiments be performed. 
Trials had been conducted by the homeopaths Leon Simon and Curie, and 
were unsuccessful according to Bailly. He claimed that the record of these 
failures was available on demand. After the debate, Simon and Curie 
disputed his verdict and publicly demanded that the full record of the trial be 
produced, publishing at the same time the objections they had made in 
writing in 1834 to Bailly about the conditions of the study (Simon 1835). 
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Incredibly, Bailly claimed in response to have lost the hospital journal while 
rearranging his library (Gallavardin 1860). 
6.5. Discussion 
The early attempts to evaluate homeopathy by observational studies in public 
hospitals are interesting, mainly for what they reveal about the difficulties of 
introducing rational clinical evaluation into medical practice in the period 
1820-35. It is hard to avoid the conclusion that early and later critics of 
homeopathy who cited these trials as conclusive evidence of the inefficacy of 
the system vastly overrated the validity of uncontrolled studies that were 
carried out by unskilled allopaths, or, when performed by experienced 
homeopaths, were frequently subverted. Revealingly, the one trial from 
before 1835 that seems to have avoided the worst excesses of the others and 
managed to reach a valid conclusion, Marenzeller's in Vienna, was not 
mentioned anywhere. 
The chauvinistic attitude of the Neapolitan allopaths was seen again in the 
Paris School's reaction to homeopathy, and is another factor which must be 
included in discussions of the emergence of the clinical sciences. For instance, 
an article bearing the initials of Edouard Esquirol appeared in 1833 in the 
Gazette Medicale de Paris (E. E. 1833). The author objected to homeopathy 
because it originated from across the Rhine, and he expressed his revulsion at 
the contamination of Gallic medicine: 'This mystical system has already 
invaded our belle France.' 
The Academie relied on the trials mentioned by Andral, Bailly and Esquirol to 
justify their recommendation that the French government should expel 
homeopathy from the body medical. In fact, the transparent inadequacy of 
Andral's grasp of homeopathic method make his experiments some of the 
least reliable clinical studies to have been performed. Bailly never produced 
the case records that Simon and Curie insisted showed his account was 
biased. And Esquirol's review of the trial in Naples was a double travesty: 
Panvini's polemic was systematically biased, and Esquirol's 'review' 
consisted of nothing more than a single case history extracted from Panvini's 
hostile report, by way of illustrating how homeopathy was killing patients. It 
was left to the homeopaths to introduce some genuine statistics: they pointed 
out that the 'opinion that homeopathy was lethal had been given the most 
formal refutation possible by the [Neapolitan] registrar of deaths' (Peschier 
1835a). 
The French debate was also coloured by Pointe's subsequently refuted (and 
undefended) account of Gueyrard's aborted Lyons trial, and Trousseau's 
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(1834) trial of placebo alone, without control (see Ch. 8). Making his case 
against homeopathy in 1842, Holmes's highest level of evidence consisted 
once again of Esquirol's review and Andral's trials. Many critical accounts of 
the latter had appeared in the homeopathic press in Europe and America 
before 1842, but shortly after Holmes's intervention and partially in response 
to it, Irvine (1844) wrote by far the most devastating critique of Andral's Pitie 
trials. He showed that Andral was unable to apply the homeopathic materia 
medica, not only from a complete misunderstanding of the method as 
demonstrated by the published cases and comments, but because he had no 
knowledge of German: Hahnemann's Reine Arzneimittellehre had not been 
translated into French in 1834, and although Die chronisclzen Krankheiten had 
been translated (Hahnemann 1832), Andral failed to use any of the 22 new 
medicines listed there. Thus he 
abstained from using the only medicines of which he had the means of making 
a right application. (original emphasis) 
Andral's incompetence had even been admitted by his own assistant, Vernois 
(1835). Irvine continues that Vernois, 
while admitting ... the incapacity of his professor to perform 
homeopathic experiments from not knowing the action of the 
medicines, excuses his ignorance by saying it was unavoidable ... 
surely the consciousness that he did not possess the means of testing 
the system, should have prevented him from stating before the 
Academy that he had given it a fair trial in his wards. (Irvine 1844) 
As noted in Ch. 2, homeopathy was not the only subject to suffer from the low 
level of ostensibly evaluative debate at this time. The discrediting of Broussais 
came about from the death of a single celebrity, rather than from his general 
mortality rates in cholera (Hacking 1990: 84) 
Be that as it may, Andral's trials have retained their status as foundational 
exemplars of the vaunted rigour of the biomedical worldview. It would 
appear, in fact, that if homeopathy is the target any evidence is adequate, 
however biased or unreliable. But what did Andral think of homeopathy, 
after Vemois's later admissions? Carroll Dunham, the eminent American 
homeopath, used to attend Andral's clinic at the Charite in 1850-51, and one 
morning asked if he hadn't once published a report on homeopathy (Dunham 
1852). Andral replied that nothing had ever been published with his 
authority, but Vernois's anonymous 1834 report was substantially correct. He 
had come to believe homeopathy deserved the closest examination by every 
physician, and volunteered that he no longer thought his trials had been at all 
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conclusive. Perhaps the early homeopaths' protests to the government that 
they wanted, above all, 
judges, but ones that are true not counterfeit;- trials, that are real, 
logical, and replicable in front of rigorous but knowledgeable 
witnesses; - in a word, truthful information with the power to allow a 
judgement to be deduced (Simon 1836), 
had not been entirely in vain. 
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7 COMPARISONS WITH ALLOPATHY, 1844-86 
Background The middle years of the nineteenth century saw significant 
advances in the application of statistics to the evaluation of medical 
treatments. It has been forgotten that homeopathy also played a part in this 
stage of the development of the modern clinical trial, and was evaluated 
pragmatically by comparison with orthodox treatments. 
Problems How did trials of homeopathy come to be performed in the 
latter half of the nineteenth century, given the exclusion of the therapy from 
medicine? How valid is the evidence from these trials? How did these trials 
disappear from the historical record? 
Argument Authentic trials of homeopathy took place- against allopathic 
opposition - because of interest shown by governments and hospital 
administrations. Homeopathy was compared with allopathy in treatment of 
serious conditions such as cholera and pneumonia, and some good quality 
fair trials provide confirmation of evidence that had been dismissed when 
obtained retrospectively. Contemporaneous attempts to suppress or discount 
the homeopathic results show that they constituted a serious embarrassment 
to orthodoxy, which reacted by attempting to outlaw homeopathy. 
7 .1. Introduction 
The verdicts of the Academie and Holmes discussed in Ch. 6 are generally 
believed to have closed the door on the nineteenth-century investigation of 
homeopathy in clinical trials (a view endorsed by, among others, Coulter 
1977; Poitevin 1987; Aulas, Bordelay, Royer 1991). Their summary 
judgements, which had such a devastating and long-lasting effect on the 
acceptance of homeopathy, led to rifts in the medical professions that were 
emerging in most advanced countries. Nevertheless, prospective clinical trials 
of homeopathy continued to appear in surprisingly high-profile 
environments, making it possible to identify two periods of nineteenth-
century evaluation. The first, reviewed in Ch. 6, lasted from 1821-35 and 
comprised trials by early adopters and opponents of homeopathy; the second 
wave, from 1844-86, involved trials of the system by more experienced 
practitioners, from a variety of backgrounds. The earlier phase looked at 
uncontrolled applications of the system as a whole in the treatment of many 
conditions within a single study; phase two saw the acceptance of the need 
for controls, historical or active, and the emergence of trials for specific 
conditions, and even of specific medicines for named conditions - clinical 
homeopathy, as described in Ch. 4. This development seems inevitable 
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enough when seen against its historical background. After Louis's (1835) 
simple enumeration of survival rates in tuberculosis under bleeding and 
without, more advanced statistical activity spread through medicine from the 
late 1830s onwards: 
Humboldt reported statistical observations on yellow fever to the 
Prussian Academy, and Dupuytren performed a like service for the 
French Academy. Numerical studies of the causes and remedies for 
various diseases - for cholera and scurvy, as well as for typhoid and 
tuberculosis - began to appear. During the forties there followed 
dramatic demonstrations of the role played by doctors in spreading 
puerperal fever ... based on statistical evidence first suggested by 
Holmes in Boston, and later independently collected in a systematic 
manner by Semmelweis in Vienna. (Shryock 1948: 141) 
Homeopaths were quick to seize the opportunity that the emergent 
acceptance of empirical statistical evaluation offered, and demanded 
comparative trials. The results of the second phase of trials are examined in 
this chapter, and reasons for their neglect advanced. 
7.2. Results 
Details and results of the 11 trials (and 1 re-analysis with a different historical 
control) are shown in Table 7.1. It will be seen that nearly all involved some 
form of comparison: historical at first, followed by simultaneous controls. 
Four trials can be classed as large, involving comparisons of several thousand 
patients. Notes about the individual trials follow. 
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Table 7.1 Prospective hospital-based clinical trials of homeopathy 1844-86 
Trialist Sources Hospital Condition Design Model n ( t> 
Date Duration Control 
Stern Stern, 1845 Miskolz, Mixed Case series Classical 121 (0 t) 
1844 Temporary (patient None 
preference) 
15mon 
Stender Johannsen, 1848; Boyanus, 1882: St Petersburg, Mixed Open label cf cf Classical 5999 (756 t) 
1847-54 123-124 Women's 7y Allopathy 2789 (413 t) 
Tessier Tessier, 1850 Paris, Ste Pneumonia Historical Classical 41 (3 t) 
1847-49 Marguerite 2y Allopathy 106 (32 t) 
idem Jousset, 1862* Historical Classical 50 (3 t) 
Expectant 100 (31 t) 
Tessier Tessier, 1850 Paris, Ste Cholera Cohort control Classical 20 + 80 (48 t) 
1849 Marguerite 1 mon Allopathy 100 (59 t) 
Tessier Editorial, 1849; Ozanne, 1850; Paris, Ste Mixed Quasi-random Classical 4663 (399 t) 
1849-51 Tessier, 1852; Ozanne, 1853; Marguerite Open label cf Allopathy 3724 (411 t) 
Ozanne, 1857; Gallavardin, 1860 3y 
Casper, Wurmb Eidherr, 1862 Vienna, Pneumonia Time series Classical 140 (8 t) 
1850-59 Leopoldstadt 9y D6 31 (19.5 d) D15 54 (14.6 d) 
D30 55 (11.3 d) 
Balfour West, 1854: 600 London, Scarlet fever Quasi-random Clinical 76 (2 cases) 
1854 Royal Military prevention Open label cf (belladonna) 75 (2 cases) Asylum <l man No treatment 
Charge Charge, 1855; Sirus-Pirondi, 1859; Marseilles, Cholera Open label cf Classical 26 (21 t) 
1854 Gallavardin, 1860 Hotel-Dieu 3d Allopaths using 31 (18 t) homoeopathies 
London Hom. General Board of Health, 1854-55; London, Cholera•• Open label cf Classical 87 (16 t) 
Hospital House of Commons, 1854-55; Golden Square 2 mon + 1 y Allopathy 3188 (1467 t) 
1854 Medical Council, 1854-55a, b, c, d retrospective 
Burnett Burnett, 1888: 1-10 Barnhill Parochial, Unspecified Open label cf Clinical ? 
After 1872 Glasgow fevers ? (aconite) Allopathy 
Cook County Chicago Herald, 1881; Cook County Chicago Mixed Quasi-random Unknown 1242 (8.2% t) 
Hospital Hospital, 1885; 1888; Chicago Open label cf Allopathy 4692 (8.6% t) 
1880-86 Medical Society, 1922; Cook 6y 
County Board of Commissioners, 
n.d. 
• Re-analysis of Tessier (1850) with a further 10 unpublished cases from Tessier's series, compared with expectant treatment 
instead of allopathy as the historical control. 
•• Form B cases only: see Table 7. 
7.2.1. Miskolz, Austro-Hungary 1844: general 
Although this observational study in a specially set-up prison hospital at 
Miskolz, Hungary, appears to belong methodologically to the previous group 
of trials reviewed in Ch. 6, it also marked a conceptual advance: patients 
entered the study only after having been allowed to choose whether to 
undergo allopathic or homeopathic treatment. The report by F. Stern (1845), 
an orthodox doctor who had become convinced of the value of homeopathy, 
mentions vehement prior allopathic opposition, in the press and elsewhere, 
but the trial appears to have run smoothly for 15 months. Of 121 patients 
treated for many conditions, including gastric fevers and a considerable 
number of pneumonias and other inflammatory lung diseases, 96 were cured 
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and 22 were significantly better when discharged because their sentence was 
completed. There were no deaths. Stern believed the success of the trial 
warranted making homeopathy available as a regular part of the hospital 
service, but allopathic agitation succeeded in obtaining a government decree 
forbidding it. Reasons given include the unsuitability of homeopathy to treat 
the conditions which Stem was curing, and the cost of building a new clinic 
and funding homeopathic treatment. Stern points out that the building 
already existed, and the salary of a homeopath was less than a quarter of the 
amount saved by using homeopathic medicines. 
7.2.2. St Petersburg 1847-54: general 
In an article on the state of homeopathy in Russia, Johannsen (1848) wrote 
that the new system suffered no discrimination there, and doctors were free 
to practise it, unlike in several other European countries. Although there were 
few medical services of either school, homeopathy appeared to be particularly 
popular with the large estate owners, who purchased medicines in bulk from 
the two licensed suppliers. As an example of the lack of discrimination in 
Russia, Johannsen mentions that an official in the Ministry of the Interior had 
wished to devote the Women's Hospital in St Petersburg to homeopathy. 
However, the Minister believed that it would be more useful if the 100 beds 
were divided equally between homeopathy and allopathy, so that a valid 
comparison could be made. Johannsen gives brief details of the experiment 
which had been going on for 2 years at the time of writing. It is clear that a 
great deal of effort had been expended to ensure a fair trial, in contrast to 
nearly all the previous studies in Europe. 
Boyanus (1882) allows the proponent to be identified as Dr. Vladimir Dahl 
(whose conversion to homeopathy in the 1830s is mentioned below in Ch. 8), 
employed in the Ministry of Interior from 1841-49. The pro-homeopathic 
Minister was Count Lev Perovsky, and the homeopathic trialist was Dr 
Stender, assisted by Drs Lindgren, Johansen, Rosa, Gastfreund and Villers. 
The large-scale trial took place over 8 years, and as well as crude mortality 
rates, average length of stay and drug costs were computed. Table 7.2 (under 
7.2.5 below) gives a tabulated comparison with a similar large-scale trial in 
Paris. Unlike that trial, no details of the homeopathic prescriptions are 
available, and Boyanus claimed that Stender's homeopathy was compromised 
by his desire to avoid conflict with officialdom. 
7.2.3. Paris 1847-49: pneumonia 
Jean-Paul Tessier (1811-62), a former student of the physiologist Franc;ois 
Magendie (1783-1855) and the surgeon Guillaume Dupuytren (1777-1835)-
and apparently the favourite of the latter, who left him a medical legacy in his 
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will (Milcent 1862) - was one of the most highly regarded younger members 
of the orthodox Paris school when he began his exploration of homeopathy in 
1846 or 1847. This was more than a decade after interest in testing 
homeopathy had died down in Parisian allopathic circles, although the 
therapy itself continued to win converts all over France (Garden 1992). In fact, 
Tessier had been advised to investigate homeopathy by Magendie, just as 
William Henderson (1810-72) had by his teacher John Abercrombie 
(1780-1844), in Edinburgh.20 
Tessier published the report of his consecutive case series in the treatment of 
pneumonia and cholera after 3 years of research (Tessier 1850). There he 
recounts with great thoroughness and precision the steps he took in his 
evaluation of homeopathy and its eventual incorporation into his hospital 
practice. Beginning with a preliminary study of the general principles from 
the works of Hahnemann and his disciples, he moved on to accounts of 
treatments for specific illnesses. After he had 'grasped the spirit' of the new 
doctrine he began a 6-month test of the medicines to ascertain their safety and 
biological activity, on patients who he was sure would not be harmed by their 
use. Although he became convinced of the activity and harmlessness of the 
ultramolecular homeopathic medicines after a few days, he continued the 
experiments for the full 6 months he had originally planned, in both acute 
and chronic cases. Only after this period did he feel able to begin his 
evaluation of the 'therapeutic value' [original stress] of homeopathy. 
He says that he chose pneumonia for the first prospective series because it 
was a well-known, unambiguous disease with clear diagnosis and prognosis. 
Although there are now many identifiable etiological factors, Tessier's 
description fits 'classical' community pneumonia from Streptococcus 
pneumoniae infection, which still accounts for 50% of cases in the UK (Davies 
1990). In the 1840s the standard therapy consisted of up to 4 bleedings, 
blistering with vesicants, and dosing with antimony tartrate. His cautious 
approach was to substitute homeopathic Phosphorus for antimony, while 
leaving the other elements of the treatment unchanged. When he found that 
20 Henderson was the second Professor of Pathology at Edinburgh, and a pioneer 
microscopist. His researches included the first minute examination of the lung in pneumonia 
(1841), and he is credited with distinguishing typhus from relapsing fever in 1843 (Comrie 
l932, 2, p. 623). He published details of 500 cases that he had treated homeopathically 
(Henderson 1845), causing one of the biggest storms in British medical life before or since, 
and was nearly forced from his chair. Nicholls (1988) describes the affair in detail. Only the 
fact that his case series was retrospective prevents its inclusion in this review. 
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this was successful in every case, he began to reduce the number of bleedings, 
one at a time, until it was evident that they could be stopped altogether 
without detriment to the patient. After this he moved to purely homeopathic 
treatment. 
The main medicines used by Tessier in individualized treatment were 
Aconitum napellus, Bryonia alba, Phosphorus, Sulphur, Atropa belladonna, 
Arsenicum album and Iodum, given in centesimal potencies - 6, 12, 15, 18, 24 
and 30. Medication was usually administered as 4-6 globules dissolved in 4 oz 
filtered water, one teaspoonful hourly for 2 or 3 hours, following 
Hahnemann's latest instructions (see Ch. 8). Aconitum was given as one drop 
of C6 medicating tincture. 
The case histories and assessment of the 41 patients treated purely 
homeopathically are given in detail. To counter bias in reporting the effects of 
treatment, Tessier arranged for the observations and reports to be made by 
two allopathic interns, Timbart and Guyton. 
Tessier anticipated the argument that the same results would have been 
obtained from expectant treatment (no treatment except ordinary nursing 
care). He admits that there were no available statistics of mortality under 
expectant treatment to compare with those he had produced for homeopathy, 
but he rejects the argument on the basis of five observations: 
1. In every case, the illness progressively worsened until the moment 
treatment began. 
2. Soon after treatment began, a predictable homeopathic aggravation was 
experienced, of generally less than 24 hours duration, followed by rapid 
remission. Sometimes remission began within a few hours without 
aggravation. 
3. Bryonia had an extraordinary effect on pulse rate, which could drop 20 or 
30 beats from one day to the next. 
4. Not a single old person died, even though they might have had 
pneumonia for a week before seeking help, or have reached the stage 
when consolidation was inevitable. In fact, old people recovered scarcely 
more slowly than the others. 
s. Suppuration did not occur in any patient who had not presented with it, 
and it was arrested in most of those who did, with one exception 
(excluding the two terminal cases). 
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Tessier concluded that homeopathy appeared to be equally beneficial as 
regards the symptoms, progression and duration of pneumonia, and 
reasonably called for the method to be tested further in the crucible of 
observation and experiment. He also provided a case control: the statistics 
collected by Louis (1835) on the mortality of pneumonia in institutional care 
in Paris at that time had shown that a death rate of one in three could be 
expected with orthodox treatment. Tessier included in his series two cases 
that were terminal on admission and which he felt should have fallen outside 
the conditions of the experiment. Without them, there would have been only 
one death to report, but nevertheless, three deaths from 41 cases under 
homeopathic treatment was still less than 7.5%. 
7.2.4. Paris 1849: cholera 
Tessier (1850) next presented a consecutive series of the first 20 cholera cases 
he had treated. In all he saw nearly 100 cases in the 1849 epidemic, and 
compared his mortality rate with that in the allopathic wards in the same 
hospital. Although the homeopathic mortality rate was 10% lower, his results 
do not approach those found elsewhere. Reasons for this may include 
Tessier's unfamiliarity with the disease, and his use of potencies (C3 and C6) 
that, although lower than those that had worked so well in pneumonia, were 
higher than used elsewhere in cholera (see 7.3.2 Generalizability). His account 
is mainly important for the accurate clinical picture of cholera he gave. 
7.2.5. Paris 1849-51: general 
Tessier's experiments in pneumonia and cholera led to a large-scale 
prospective comparison of homeopathy and allopathy (Tessier 1852). The trial 
also took place at the Sainte-Marguerite Hospital, and pragmatically 
attempted to compare and evaluate homeopathy and allopathy as complete 
systems of internal medicine, rather than limiting the field of action to specific 
conditions. 
The trial is historically remarkable because of the means used to avoid 
allocation bias. As seen in Ch. 6, allopathic doctors had generally assigned 
whom they liked to homeopathic treatment, but the potential for 
manipulation was minimized during this trial. One in 5 patients could be 
selected by either the allopathic and homeopathic doctor, but only in the 
presence of the other and, crucially, for treatment in their own ward, not that 
of their opposite number. More importantly, the great majority of patients 
were independently assigned to treatment. Each morning the central hospital 
administration of Paris received a list of available beds at the suburban 
hospital. New patients were allocated to a ward of 100 homeopathic or 99 
allopathic beds strictly on the basis of the first empty bed; and the hospital 
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administrators made clear at the time that 'the test of the two methods takes 
place as far as possible under the same conditions' (Gallavardin 1860). 
Reference was made to this arrangement in the medical press. A leading 
article on the front page of the Union Medicale for 8 December 1849 expressed 
outrage that patients were being sent by the central bureau to Sainte-
Marguerite, where a doctor employed by the administration was 'openly 
practising homeopathy' (Editorial 1849). 
As well as the quasi-randomization, several other features are noteworthy for 
the time. The trial was conducted over 3 years (1849-51), accepted more than 
8000 patients, and used objective outcomes including costings for drugs and 
medical supplies as well as rates of bed occupancy and mortality. The 
administration reported a higher throughput and lower mortality rate in the 
homeopathic ward, for a hundredth of the cost in medical supplies, 
paralleling and improving on the results of the St Petersburg trial, as shown 
in Table 7.2. 
Table 7.2 St. Petersburg 1847-54, Paris 1849-51. Large-scale pragmatic 
economic evaluations of classical homeopathy vs allopathy 
Trialist 
Dates 
Stender 
1847-54 
Tessier 
1849-51 
7.2.6. 
Hospital 
Women's Hospital, 
St Petersburg 
Sainte-Marguerite, Paris 
N Ct or case-mortality) 
Mean days of bed occupancy 
Total trial drug cost (mean cost per patient) 
Homeopathic Allopathic 
• 5999 (756 tor 12.6%) • 2789 (413 tor 14.8%) 
• 24.75 d • 27.5 d 
• 930 roubles (0.15 r) • 5600 roubles (2.01 r) 
• 4663 (399 tor 8.6%) • 3724 ( 411 tor 11.0%) 
•nd •~d 
• <300 francs ( <0.06 fr) • 23,552 francs (6.32 fr) 
Vienna 1850-59: pneumonia 
As well as external comparisons, there were questions of homeopathic 
method that required answers. For instance, the homeopathic community 
itself was aware that internal arguments about the activity of high potencies 
could not be resolved on the basis of conflicting and subjective accounts of 
success and failure from proponents or opponents. It even seemed that the 
higher potencies were more effective in pneumonia, but less so in cholera. A 
protracted interrupted time-series study comparing the relative efficacy of 
molecular and ultramolecular potencies, particularly in pneumonia, was 
carried out at Leopoldstadt Hospital, Vienna, from 1850 to 1859 by the doctors 
Casper and Wurmb (Eidherr 1862). During three consecutive 3-year periods, a 
single potency only was used in the trial: D30 from 1850-52; D6 from 1853-55; 
and D15 from 1856-59. The outcomes measured were the classical diagnostic 
stages of infiltration, resolution and exudation, as well as total length of stay. 
The individual patient data was tabulated, and mean times for each group 
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calculated, as shown in Table 7.3. These appear to be inversely related to the 
potency used: the higher the potency, the speedier the recovery. The 
argument that the results may be biased because the trialists would have 
become better at prescribing over time seems invalid: the best results were 
obtained in the first period, the least good in the second, with the third 
intermediate. Interestingly, the experimenters were low potency prescribers 
by persuasion, and the superiority of higher potencies in pneumonia went 
against their assumptions, although it confirmed Tessier's findings. The trial 
was impressive enough for it to be cited by the low potency advocate Hughes 
(1893: 89) as evidence of the biological activity of ultramolecular potencies. 
(See also Ch. 4.) 
Table 7.3 Vienna, pneumonia 1850-59. Results of prospective comparison of 3 
potencies of indicated medicines: mean time in days to clinical stages of pneumonia 
Years Potency N lnfi ltration Resolution Resolution Infiltration Exudation Length of stay 
start complete signs gone signs gone 
1850-2 D30 55 3.0 3.0 4.9 7.1 12.3 11.3 
1853-5 D6 31 4.1 3.5 6.9 9.3 20.5 19.5 
1856-9 D15 54 3.0 3.2 6.3 10.3 18.1 14.6 
7.2.7. London 1854: scarlet fever prevention 
The homeopathic recommendation that belladonna could be used to treat the 
'mild smooth scarlet fever of Sydenham' (Hahnemann 1801b) was taken up in 
medicine generally- Hufeland even wrote a literature review of case series 
that appeared to support the hypothesis. It was also believed to have a 
preventive effect, although Hahnemann's strictures about the uselessness of 
specifics that had not been worked out on the basis of the symptomatology of 
each fresh epidemic were forgotten. The allopath T.G. Balfour tested the 
prophylactic virtues of belladonna during an outbreak of scarlatina at the 
Chelsea Royal Military Asylum (West 1854). He assembled a group of boys 
who had probably not had the disease and dosed every alternate one, 
although nothing is known about the preparation or form of the medicine. 
Only two cases occurred in each group, and Balfour used the trial to make the 
methodological point that if he had not alternated but given belladonna to all 
he would probably have erroneously attributed the small number of cases to 
successful treatment. Clinically, he drew the lesson that the trial could show 
little about the efficacy of belladonna because it was clear that the epidemic 
was on the wane by the time the experiment was conducted. This reasonable 
interpretation stands in marked contrast to the conclusion of the 
epidemiologist and statistician W.A. Guy (1860). In the fifth of his Croonian 
Lectures on medical statistics, Guy gratuitously called Hahnemann's sanity or 
honesty into question, and cited Balfour's trial as all the refutation that was 
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needed to demolish anything as fanciful as a homeopathic hypothesis. 
7 .2.8. Marseilles 1854: cholera 
In 1853, Charge had reported the success of homeopathy in treating cholera in 
Lyons. The following year, it was decided to compare the two schools during 
an outbreak in Marseilles. Unfortunately, the 1854 outbreak seems to have 
been more virulent than the previous year, and as in previous trials (see Ch. 
6), the homeopaths withdrew after only 3 days complaining of exceptional 
allocation bias at the Hotel-Dieu: 21 dead from 26 treated would have been a 
bad result whatever method used, and Charge (1855) seems to have been 
expected to treat only patients in a state of collapse. The validity of the 
comparison is further undermined by the revelation a few years later that the 
allopaths in this trial had in fact used well-known homeopathic medicines 
(Sirus-Pirondi 1859): indeed they claimed the most effective of their 
treatments were ipecacuanha, nux vomica, chamomilla and veratrum album -
unused in the allopathic treatment of cholera at that time, as the London 
returns make clear (see 7.2.9) - as well as camphor, although nothing is 
known of how the medicines were prepared or the mode of administration. 
This appears to be the first wholesale appropriation of homeopathic materia 
medica by allopathy, a phenomenon generally associated with the 1870s and 
later, as discussed in Ch. 3. 
7.2.9. London 1854: cholera 
The General Board of Health under Sir Edwin Chadwick (1801-90) had been a 
non-governmental organization. Chadwick's crusade for administrative 
reform as the necessary springboard to bring about improved public health, 
allied with a zealous lack of tact, had been enormously unpopular with the 
laissez-faire elements in mid nineteenth-century British society, and led to his 
removal in August 1854 (Lewis 1952). The Board was reconstituted, with 
greatly reduced powers, as a government ministry on August 12, on the lines 
of the Poor Law Board. In charge was Sir Benjamin Hall (1802-67) - a Member 
of Parliament and bureaucrat of the class that had provoked Chadwick's 
scorn, and previously known mainly as a supporter of mild ecclesiastical 
reform. Incongruously, given this inauspicious background, Hall's first act on 
August 12 was to set in motion a coordinated public health and medical 
response to the 1853-54 cholera epidemic then in full spate. By September, 
Hall had gone on to commission a major epidemiological survey of the 
epidemic. He was also anxious to know which treatments were most 
efficacious. His letter circulated at the beginning of September to all 
practitioners appearing in the Medical Register for 1854 states that he had 
established a Medical Council 'representing all branches of the medical 
profession' because of 
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the great want that is now felt of some systematic record of cases of 
choleraic disease, their treatment, and results, with a view to 
determine, in so far as may be possible, the best mode of meeting this 
formidable epidemic. (Medical Council 1855b suppl. I: 67) 
The Council consisted of 12 members nominated by Hall, the Royal Colleges 
and the Society of Apothecaries, under the chairmanship of John Ayrton 
Paris, President of the Royal College of Physicians. Three committees would 
facilitate the survey: Scientific Inquiries, to look into the nature, extent and 
probable causes of cholera; Treatment, to assess the relative advantages of 
rival methods; and Foreign Correspondence, to glean relevant information 
from scientists abroad. 
But it was Hall, not the profession, who produced the first draft of the form 
used to collect the data required for a comparative clinical evaluation, as his 
letter of September 6 shows (General Board of Health, 1854-55). All probable 
cases seen in London hospitals were diagnosed and entered into newly 
printed record sheets. These used a 5-level clinical staging: Form A was 
reserved for levels 1 and 2 ('mild' and 'choleraic' diarrhea), while cases 
classed as cholera proper were entered into Form B - levels 3 and 4 were for 
those admitted without or with 'collapse' respectively, and level 5 for cholera 
terminating in 'consecutive fever' (Medical Council 1855b suppl. I: 80ff). As 
well as biographical data and dates of admission, details of previous 
treatments were noted. Cases could move from one form to the other, an 
arrangement which allowed an analysis of the progression of the disease and 
assessment of response to prescriptions made in hospital. The Medical 
Inspectorate set up in August was also required to visit each hospital 
regularly during the epidemic to ensure that accurate and truthful records 
were maintained, and to verify the diagnoses. 
The Medical Council's report devoted much of its analysis to the possible 
causes of cholera: meteorological factors were most prominent, in keeping 
with the prevalent (pre-Hahnemannian) miasmatic theory of noxious vapours 
(Medical Council 1855a). The state of the water supply was also examined, 
and recommendations made for improving its quality.21 As the report made 
21 Remarkably, considering the priority usually given to Robert Koch's 1883 discovery, the 
report presented evidence from the microbiologist and food safety expert Arthur Hill Hassall 
of 'myriads of vibriones ... in every drop of every sample of rice-water discharge', on the 
soiled clothing and bed linen of cholera victims, and in the water supply (Medical Council 
1854-55: 289££). One of Hassall's illustrations, Plate 26, Rice water evacuation of cholera, (ibid. 
following p. 90) is an engraving of a composite slide showing shreds of muscle fibre, mucus 
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clear, the historic importance of the treatment evaluation was not lost on the 
Medical Council: 
The duties of the Treatment Committee consisted ... in the invention of 
a mode by which the individual experience of practitioners might be 
brought under one comprehensive view, and thus has the science of 
statistics, for the first time, been applied on a large scale to medical 
treatment. (Medical Council 1855c: 7) 
The tables presented in the report showed that 46% of those treated as in-
patients or out-patients in London hospitals had died in the epidemic, and 
that treatment of whatever kind had been largely useless: the expectation of 
mortality in untreated cholera was approximately 50%, then as now (Medical 
Council 1855b suppl. II, table I). 
The epidemic is best remembered for the activity of John Snow (1813-58), 
epidemiologist and pioneer of anaesthesia, whose theory that cholera was 
waterborne had been published after the 1848 epidemic (Snow 1849). In 1854 
he visited the epicentre of the new outbreak, the Golden Square area of Soho 
where 500 deaths occurred in 2 weeks. As well as his celebrated removal of 
the Broad Street pump handle, he began correlating the pattern of mortality 
with the water supply to each house. It could not be denied that the 
Southwark and Vauxhall Company supplied water full of untreated sewage, 
or that the mortality rate in the homes it supplied was eight or nine times that 
of the homes in the same area supplied by the Lambeth Company - which 
had begun to draw its water from higher up the Thames. Nevertheless, 
Snow's empirically plausible explanation of a waterborne 'cholera poison' 
was still rejected in 1855 by the Committee for Scientific Inquiries. This was in 
spite of William Farr (1807-83) - one of Hall's appointees to the Medical 
Council- having written not long before in his official report on the 1848--49 
epidemic that Snow's was 'in many respects the most important theory that 
has been propounded' (Farr 1852: lxxiv). 
and other fragments (x 220) surrounded by many vibrios singly and clumped together 
(x 350); other plates clearly distinguish the much smaller vibrio from countless other 
unicellular organisms found in the water supply. There were two reasons why Hassall and 
the Medical Council considered and rejected the vibrio as a causal factor: it was believed to be 
a product of enteric decomposition; and it was also found in samples from those who had died 
from other diseases (ibid.: 56). The understanding that the cholera vibrio was (a) the 
pathogen, and (b) must be present in the gut in sufficient numbers to poison its host lay in the 
future. 
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By coincidence the London Homoeopathic Hospital in Golden Square had 
been set up as a charitable foundation in 1849 by the many well-connected 
and aristocratic patrons of homeopathy, and had opened its doors in 1850. 
During the 1854 epidemic it was decided to waive the usual requirement of 
letters of recommendation, and to turn the tiny 30-bed hospital over to the 
treatment of the 'indigent poor' of the district. The hospital had to make 
several requests to be sent the forms to make the official returns, and even 
after it succeeded found its returns were omitted from the report of the 
Medical Council. The report listed the names of those who had contributed 
returns, and pointed out that: 
Among the names occur some of homoeopathic practitioners, from 
whom returns were received; but the Committee for Scientific Inquiries 
desire it to be understood that none of these communications have 
been used in the construction of the report. (Medical Council 1855b 
suppl. I: 68) 
This omission was raised in a parliamentary question from Lord Robert 
Grosvenor and the matter was laid bare in the extensive correspondence that 
ensued (House of Commons 1854-55). Asked by Hall to explain its 
suppression of the homeopathic results, the Council's chairman22 reported the 
unanimous resolution of the gentlemen of the Medical Council: 
That by introducing the returns of homoeopathic practitioners, they 
would not only compromise the value and utility of their averages of 
cure, as deduced from the operation of known remedies, but they 
would give an unjustifiable sanction to an empirical practice alike 
opposed to the maintenance of truth and to the progress of science. 
(ibid.: 194) 
As noted in Ch. 2, in the mid nineteenth century the term 'empirical' still had 
a pejorative connotation. At the same time, useless or dangerous allopathic 
treatments were sanctioned by virtue of the categories they were held to 
belong to: calomel, chalk, ether and castor oil acquired therapeutic dignity, if 
not efficacy, when classed respectively as 'alterative', 'astringent', 'stimulant' 
or 'eliminant' (Medical Council 1854-55d) - the very same rationalist terms 
satirized half a century earlier by Hahnemann (1801d). 
22 Paris was already well-known as a vitriolic opponent of homeopathy. Previously, when Frederic 
Hervey Foster Quin (1799-1878), who introduced homeopathy to Britain, tried to join the Athenaeum 
Club, Paris had organized a notorious blackball. 
130 
The returns from the homeopathic hospital in Golden Square showed a 
mortality rate in both Forms A and B decidedly below that obtained 
elsewhere in London, and in line with the homeopathic results reported in 
Europe since the 1832 pandemic. The Medical Council's suppression of the 
superior results of the heterodox treatment ironically undermined its 
intended outcome: the homeopathic returns were then formally published in 
far greater detail than the allopathic statistics, in a Parliamentary Return of 
May 1855, ensuring their survival long into the future (House of Commons 
1854-55). A comparison of the results is shown in Table 7.4, broken down by 
clinical stage, and it can be seen that fewer died in each stage under 
homeopathy. The Medical Council report includes a few extra-metropolitan 
results for stages 4-5 only, underlined, making it impossible to separate the 
London returns, but since the provincial mortality rate of 45.6% was virtually 
the same as the metropolitan rate of 46.02%, the comparison is informative. 
Table 7.4 London, cholera 1854 Diarrhea (Form A) and cholera (Form B) cases 
and mortality 1 July 1853 to 31 December 1854 from completed hospital returns 
Homeopathic hospital Allopathic hospitals 
N t % N t % 
Form A 481 0.2 17 460 109 0.6 
Stages 1- 2 
Form B 87 16 18.4 3188 1467 46.0 
Stages 3-5 
Stages 4-5 only 48 16 33.3 Zill l@ 
.6U 
sources: Medical Council (1854-55b suppl. II, table Ill); House of Commons (1854-55) 
Complete data are given for 568 individuals -identified by age, gender and 
occupation - treated by homeopathy during the general evaluation period, 
including prescriptions, with appended comments. From these it is possible 
to see that the doctors of the homeopathic hospital used a full range of 
individualized medicines such as Veratrum album, Arsenicum album, Cuprum 
and Secale, given singly. They were prepared according to the first British 
homeopathic pharmacopeia (Quin 1834), and were administered as drops of 
the first three decimal potencies repeated every 10, 15 or 30 minutes, or every 
1, 2 or 4 hours. In addition, tincture of camphor (1 part to 6 of pure spirit) was 
prescribed in many cases at the beginning of treatment, a few drops every few 
minutes. 
How valid are the homeopathic returns? Although the Inspector appointed 
for the district refused to visit, another commissioned Inspector, David 
Maclaughlin, agreed - reluctantly, according to his unsolicited letter of 22 
February 1855 to the Homoeopathic Hospital, included in the Parliamentary 
Return: 
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You are aware that I went to your hospital prepossessed against the 
homoeopathic system; that you had in me, in your camp, an enemy 
rather than a friend, and that I must therefore have seen some cogent 
reason there, the first day I went, to come away so favourably disposed 
as to advise a friend to send a subscription to your charitable fund, ... 
As important as his prior hostility towards homeopathy was the fact that he 
had spent 20 years in India: 
I need not tell you that I have taken some pains to make myself 
acquainted with the rise, progress, and medical treatment of cholera, 
and ... claim for myself some rights to be able to recognise the disease, 
and to know something of what the medical treatment ought to be; ... 
This experience makes his comments on the homeopathic results particularly 
valuable. He went on: 
That there may be no misapprehension about the cases I saw in your 
hospital. I will add, that all I saw were true cases of cholera, in the 
various stages of the disease; and that I saw several cases which did 
well under your treatment, which I have no hesitation in saying would 
have sunk under any other. 
He concludes with what he had already told the homeopaths, 
and what I have told everyone with whom I have conversed, that 
although an allopath by principle, education and practice, yet was it 
the will of Providence to afflict me with cholera, and to deprive me of 
the power of prescribing for myself, I would rather be in the hands of a 
homoeopathic than an allopathic adviser. 
In a postscript Macloughlin also mentions his research into the premonitory 
diarrhea of cholera. He had claimed for some years, against the opposition of 
the rest of the profession, that if treated early enough it could prevent 
development of full-blown cholera. Now there was renewed interest in his 
theory, and he had been asked to submit his work as a prize essay to the 
French Imperial Institute. Observing that all the homeopathic cases of cholera 
had suffered diarrhea first, he ensured in his essay that the homeopathic 
results were placed 'for accurate observation of the disease by the side of St 
Toomas's, St Bartholomew's, St Mary's, the Westminster and the University 
College hospitals' (House of Commons 1854-55: 93). 
A possible objection to the comparison was that the allopaths only recorded 
the more serious cases; the homeopath Joseph Kidd made this point at a 
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meeting of the British Homoeopathic Society at the time (cited in Leary 1987). 
Table 7.4 makes it clear that the proportion of Form B cases was similar under 
both systems: 18.1 % in the homeopathic hospital, 18.3% in the others. Apart 
from the Inspector's testimony, and the comparable proportions of the clinical 
stages treated, another clue to the reliability of the homeopathic returns is 
their use of intention-to-treat as a fundamental principle: even patients who 
died in the street before admission were included as if they were homeopathic 
failures. This was not the policy of all London hospitals, some of which 
discharged hopeless cases to improve their own mortality rates, as Florence 
Nightingale objected a decade later in Notes on Hospitals (cited in Iezzoni 
1996). 
7.2.10. Glasgow 1870s: mixed fevers 
James Compton Burnett (1840-1901) was a brilliant student with medical 
degrees from Vienna and Glasgow. During his internship at Barnhill 
Parochial Hospital and Asylum, Glasgow, he was in charge of a fever ward 
where children were admitted for assessment before being passed to other 
wards for treatment. Dissatisfied with allopathy, he read about homeopathy 
but was unable to believe the reports of its successes, and decided to expose it 
as a sham. Aconitum napellus appeared to be suitable for many of the fevers, 
and accordingly Burnett instructed the nursing sister to give Fleming's 
aconite tincture (a proprietary non-homeopathic dilution) to the boys on one 
side of the ward only, while the others received treatment as usual. The 
homeopathic group appeare~ to benefit, and Burnett continued the 
experiment for some time, always finding the same result. However, he 
arrived one morning to find that the boys on both sides of the ward appeared 
decidedly better than the previous evening. The sister explained that she had 
decided to bring the 'cruel experiment' to an end, and dosed both groups 
from 'Dr Burnett's Fever Bottle'. Burnett (1888) later recounted this 
anecdotally as the first of his Fifty Reasons for Being a Homoeopath - the name of 
the book in which he recorded his conversion from allopathy. 
7.2.11. Chicago 1880-86: general 
A randomized pragmatic trial was planned in the Cook County Hospital, 
Chicago, but the allopaths objected on the grounds that the patients might be 
assigned to an unwanted treatment. However, it was soon found that the 
patients did not know the difference between allopathy and homeopathy, so a 
compromise was reached involving alternate allocation. Two sets of results 
from two separate years show an approximate equivalence between the two 
methods. Unfortunately, nothing is known about the sort of homeopathy on 
offer, or the extent to which homeopathic medicines were used in the 
allopathic wards at this date. 
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7.3. Discussion 
7.3.1. Planning and design 
The traditional interpretation of the evolution of the clinical trial sees it as a 
product of the internal transformation of medicine from craft to science. 
Marks (1997) has challenged this notion-that the modern randomized 
clinical trial was solely a product of the medical profession's self-critical 
scientific advance - and put forward the idea that controlled trials assumed 
their pre-eminent position in the latter half of the twentieth century as much 
because of governmental and bureaucratic requirements designed to keep the 
medical profession in check. Whether ultimately accepted or not, Marks's 
thesis appears to find a remarkable pre-confirmation in the pragmatic 
homeopathic trials of the mid nineteenth century. Although homeopaths were 
vocal in their demands for statistical comparison of their results with 
allopathy, it is unlikely that the more important trials would have taken place 
without the active involvement and encouragement of hospital 
administrations or governments. Bureaucrats, commissioners and boards of 
guardians were often uninterested in the doctrinal component of the battle 
between the two principal medical systems of the day, and saw it as their 
duty to serve the best interests of their patients, and the communities which 
funded their hospitals. 
In fact hospital statistics had been collected in Britain since the sixteenth 
century, often as a way of showing benefactors the value of their 
contributions (Iezzoni 1996). The comparisons of homeopathy and allopathy 
in the mid nineteenth century can now be seen as an interesting development 
in a long tradition of ad hoc cost-benefit analysis. This is true not only of trials 
in this review, but can be found in many other contemporary sources where 
comparisons were made retrospectively. For instance, an allopath alleged in a 
French political journal that the administrators of the hospital at Thoissey 
near Lyons were about to forbid a Dr Gastier from practising homeopathy 
there, as he had been doing since 1832. The hospital board, which included 
the mayor and priest of Thoissey, replied in a letter of 2 January 1846: 
We cannot remain silent about a purely gratuitous allegation, which 
supposes we do not know the limits of our competence ... Hospital 
administrations exist to regulate the goods and revenues of these 
establishments, to see they are well kept, to ensure that each member 
of staff meets his obligations exactly, but not to order doctors how to 
practise ... Our records attest that since Dr Gastier has practised here, 
the number of deaths relative to the number of admissions is less than 
before; that pharmacy expenses are almost zero; and the hospital 
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service, simpler and more efficient, has been demonstrably improved. 
(cited in Gallavardin 1860: 28£) 
It was clear to many such impartial administrations that homeopathic 
medicines cost a small fraction of allopathic drugs, yet seemed no less 
effective. The large trials in St Petersburg and Paris explicitly incorporated 
economic evaluation in their design, as shown in Table 7.2, and the later large 
trial in Chicago occurred after the hospital commissioners had already 
allowed homeopathy into the service in the belief that it would 
be beneficial in increasing the efficiency of the hospital work, and 
reducing very materially the expenditure for drugs and liquors. 
(Chicago Herald 1881) 
Hospital boards also seem to have been aware of the need for impartial 
assignment of patients to treatments. The quasi-randomized allocation to the 
first empty bed in either ward at Sainte-Marguerite seems to have been an 
elegant pragmatic solution to something which might have posed problems 
for strict alternation or randomization, because of the reduced length of stay 
in the homeopathic ward. Opposition to pragmatic trials per se and to 
randomization came mainly from the allopaths: as noted, calls to halt 
Tessier's trial were prominently featured in the allopathic medical press; the 
Medical Council's Treatment Committee obstructed the London 
Homeopathic Hospital's request for the forms needed to return their results, 
and suppressed the returns once they were made; and a proposed 
randomized design in Chicago was abandoned because of allopathic protests. 
It would seem that allopaths were only in favour of trials of homeopathy 
when placebo was used as the comparator, rather than orthodox medicine 
(see Ch. 8). Nevertheless, the results in Paris so impressed the administrators 
that they allowed Tessier to continue - in the face of non-stop allopathic 
hostility - what became in effect a 15-year open trial of homeopathy, first in 
Sainte-Marguerite, then Beaujon and finally the Enfants Malade~ (Milcent 
1862). As in Thoissey, the Paris hospital administration refused to participate 
in a professional dispute and answered the allopathic attacks solely by citing 
the mortality rates, bed occupancy and drug costs under the rival systems (as 
shown in Table 7.2). Moreover, they added, 
far from hindering medical freedom by forbidding M. Tessier to use 
homeopathy in his ward, we urge him to pursue his studies for the 
benefit of humanity. (Gallavardin 1860: 26) 
7.3.2. Generalizability 
Not all reports specify the type of homeopathy used, so it is impossible to 
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comment on the validity of many results. Nevertheless, several of the studies 
are exemplary in this respect, including full details of the prescriptions made 
for each patient. Were the results found in these trials comparable with those 
found elsewhere? It would seem that in most cases they were. The pneumonia 
mortality rates reported in Paris and Vienna seem entirely representative: for 
instance, the London Homoeopathic Hospital returns for 1850-55 show the 
results of treatment and mortality in scores of conditions, from tuberculosis to 
heart disease, and only 3 of 60 pneumonia patients died (Editorial 1857). In 
other words, the most reliable evidence found in this review endorses a 
phenomenon reported throughout Europe and America, from many 
independent sources. Even opponents were forced to admit the startling 
efficacy of homeopathy in pneumonia (e.g. Routh 1852). 
The cholera statistics appear equally plausible. Although Tessier had found 
that high potencies worked well in pneumonia- a phenomenon later 
confirmed by Casper and Wurmb in Vienna- their use in cholera was less 
successful. In fact, a consensus emerged among homeopaths to use low 
potencies and tinctures in cholera, as shown in the London returns. Why there 
should be such empirical differences in the efficacy of the potencies best 
adapted to different diseases has never been explained. Nevertheless, the 
London results happen to be the best controlled ones available, and occurred 
in the area of London where the epidemic hit hardest; there, treatment 
exclusively with low potencies achieved results that are in line with those 
reported by experienced practitioners elsewhere. The clinical staging of Forms 
A and B, and the testimony of an independent Inspector with expert 
knowledge of the disease, make it possible to conclude that these are among 
the most reliably diagnosed cholera cases of the time. More successful results 
reported elsewhere under homeopathy no doubt conflated fullblown cholera 
with less serious and earlier manifestations. 
To what extent can the apparent superiority of the homeopathic results be 
attributed to the mere absence of harmful allopathic procedures, such as 
blood-letting, blistering and dosing with calomel? Cholera and pneumonia 
were homeopathic causes celebres of the day, and it is reasonable to use them 
here as test cases. The natural case fatality rate in untreated cholera remains 
close to 50%, the same as in the earliest untreated epidemics in nineteenth 
century (Gale 1959: 67f), and very close to the aggregated returns from British 
hospitals in 1854 under various forms of allopathic treatment (7.2.9). Louis 
(1835) found a case fatality rate in conventionally-treated pneumonia of >30%, 
and in the next 3 decades observational studies of no treatment other than 
nursing care showed similar losses (7.3.3). 
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Political will and public health measures consigned cholera to the history 
books well before the end of the century-in northern Europe at least- but 
accounts such as the Report of the 13th Annual Meeting of the Children's 
Homoeopathic Dispensary (1927) indicate that the apparent superiority of 
homeopathy in pneumonia was being demonstrated well into the twentieth 
century: deaths of children treated at the London Homoeopathic Hospital 
were still half of those elsewhere (Leary, Lorentzon, Bosanquet 1998). Not 
until 1938 and the introduction of sulphapyredine did orthodox treatment of 
pneumonia approach homeopathic rates of cure: 46% of those aged over 45 
with the disease were still expected to die before then (Cruikshank 1942). 
7.3.3. Reception 
Allopathic attempts to prevent trials taking place, or to suppress results when 
these emerged, are the strongest evidence of the reluctance to allow the 
results of homeopathic treatment to influence the development of medical 
science. 
Tessier's results were doubly embarrassing for allopathy: he was a highly 
respected allopath, and homeopathy had been declared to be a placebo. The 
earliest reactions to all homeopathic results in pneumonia, not just Tessier's, 
were to dispute the diagnosis. When this became impossible, and the positive 
results could be denied no longer, the only possible conclusion for sceptics -
homeopathic efficacy being an impossible conclusion, of course - was that 
orthodox treatment actually killed patients who would survive without 
treatment. Tessier's former student Pierre Jousset (1862) tells us that in 1860 
the Academie de Medecine even offered a prize for a study of expectant 
treatment in pneumonia. In response, Jousset republished Tessier's 1849 
results plus 10 cases from the same series thathad remained unpublished, 
along with a detailed account of several case seriei'of expectant treatment 
drawn from the international literature. As Jousset showed, the trials of no 
treatment had failed completely to support the sceptical hypothesis: they had 
returned mortality rates of 31 %, strictly comparable with the expected rate 
under allopathy. 
As seen in the quotation from Shryock in the Introduction (7.1), this came 
against a background in which all sorts of statistical comparisons were 
emerging. What Shryock's Whiggish account of the canonical examples of 
statistics in the service of biomedical progress completely neglects to mention 
is the professional reaction that these comparisons attracted when changes in 
medical practice were indicated - ranging from tight-lipped denial to 
hysterical opposition. Louis's demonstration of the inefficacy of bloodletting 
was ignored - it was still recommended in pneumonia in the most 
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authoritative textbooks in the twentieth century (e.g. Osler 1912: 99); and 
Semmelweis was sacked from his job in Vienna for showing that the 
unsterilized hands of surgeons fresh from dissecting cadavers were infecting 
the women they handled in the delivery room (Semmelweis 1861). 
Homeopathy was not alone in enraging the old guard. 
Given the way medical historiography has evolved and the unreliability of 
nearly all external accounts of homeopathic treatment until very recently, it 
should be no surprise that of all mid nineteenth-century statistics, those from 
large successful homeopathic trials have been forgotten or are left out of 
accounts of the development of the clinical trial, or medicine in general. While 
Semmelweis is rightly honoured for reducing the mortality from puerperal 
fever from 18.27% to 1.27% in his clinic (ibid.: 170), the comparable 
homeopathic achievement in reducing the mortality in pneumonia from over 
30% to around 5% or better is ignored. This is in marked contrast to the earlier 
invalid trials of homeopathy which are still held to have demonstrated the 
illusory nature of the therapy. Tellingly, the 1854 cholera treatment evaluation 
in London has even been recognized as a defining moment in the evolution of 
the clinical trial by Lilienfeld (1982), but the existence and suppression of the 
superior homeopathic results is not mentioned - presumably because they 
were unknown to him. It is doubly unfortunate that internal homeopathic 
accounts of the affair have tended to confuse the issue by attributing the 
suppression to the Board of Health, rather than the Medical Council which 
was in fact responsible (e.g. Mitchell 1975; Coulter 1977; Leary 1987). 
The administrators of the Thoissey hospital made a further point about the 
regulation of professional medical practice in their eloquent dismissal of the 
claims of their allopathic detractor: 
Medicine is a liberal art, and at the same time perfectly liberal in its 
application. Never, and it is this which proves our point, never, at any 
time, in any country, under any regime, has the most absolute public 
power tried to forbid or dictate to doctors, this or that treatment .... 
(Gallavardin 1860: 29) 
Predictably, homeopathy had been outlawed by imperial decree in Austria 
from 1819 onwards, a ban that was lifted only after Fleischmann's mortality 
rate at the Gumpendorf Hospital, Vienna, in the cholera epidemic of 1836 was 
half that of the allopaths. And even mid nineteenth-century liberal 
democracies could not prevent the rapidly professionalizing allopaths from 
conducting their own witchhunts. Serious embarrassment coupled with an 
inability to put patient care ahead of professional politics seem ultimately to 
have hardened allopathic opposition. In France, Tessier was ostracized and 
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passed over for promotion in spite of his extraordinary single-handed 
achievements, and died a disappointed man (Milcent 1862). In Britain, the 
allopaths failed to get homeopathy outlawed in the Medical Act of 1858 
despite some vitriolic lobbying - the memory of the cholera episode would 
still have been fresh in both Houses. Instead the British Medical Association 
imposed its own internal rules forbidding any member to practise 
homeopathy, or even to consult professionally with homeopaths. The 
American Medical Association was constituted in 1847 specifically to control 
and regulate medical practice in opposition to the recently formed 
homeopathic association, and imposed even more draconian restrictions on 
its members than the BMA's. Notorious incidents followed on both sides of 
the Atlantic. In 1865, the American Surgeon General narrowly escaped 
prosecution for saving the life of the Secretary of State (seriously wounded at 
the same time as the Lincoln assassination), having collaborated with a 
homeopath (Coulter 1973). And in 1881, during Disraeli's final illness, when 
Queen Victoria asked the leading allopathic chest physician Richard Quain to 
consult with the only doctor Disraeli had ever respected - the homeopath 
Joseph Kidd-Quain at first refused. The Queen's advisers forced him to 
reconsider by letting him believe he was guilty of disloyalty to the Crown, but 
he only gave way with the permission of his trade union leader, who allowed 
him to take the case on condition that Kidd signed a paper ceding 
responsibility to the allopath, and - implausibly - swearing that he had not 
used homeopathy to treat Disraeli (Buckle 1920: 609-611). 
Homeopaths and their supporters continued to press the case for comparative 
trials, but were rebuffed. An offer of £5000 (equivalent to approximately £1 
million today) was made by Major Vaughan Morgan in the 1880s to establish 
a homeopathic ward in a London hospital for 5 years, to allow a genuine 
prospective evaluation of the system. It was refused by St George's and every 
other hospital that it was subsequently offered to (Ameke 1885: 321). The 
public had little say in matters of professional conduct, and homeopathic 
practice came to mean professional suicide for all but the most dedicated or 
foolhardy doctors. Empirical statistics counted for as little as they had 50 
years earlier when the Bulletin General de Therapeutique announced that the 
clinical results of homeopathy were irrelevant, however successful, because 
the end could not justify the means (Editorial 1834). The script could have 
been written by Moliere: 'Better to die according to the rules, than to pull 
through against them.'23 
23 'Il vaut mieux mourir selon les regles, que de rechapper contre les regles.' L'Amour Medecin 
(II, v: 58-59). 
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8 PLACEBO CONTROLS- IN TRIALS AND IN PRACTICE, 1810-1920 
Appeared as: Dean M.E. (2000). A homeopathic origin for placebo controls: 'An invaluable 
gift of God'. Alternative Therapies in Health and Medicine. 6(2): 58-66; Dean M.E. (2000). Debate 
over the history of placebos in medicine. Alternative Therapies in Healtlt and Medicine. 6(4): 
18-20. 
Background Placebo controls were used in drug trials by homeopaths well 
before they were considered necessary in orthodox medicine. This practice is 
acknowledged by medical historians, but is currently thought to have been 
prompted by prior external use of placebo controls to discredit the system. 
Question Is it possible to locate the origins of, and assign priority in, the 
use of placebos in homeopathic research? 
Argument The normative claim of external prompting is reexamined in the 
light of a comprehensive literature search for nineteenth-century homeopathic 
therapeutic trials and provings using placebo. Single-blind placebo controls, 
used in a similar manner today, are shown to have originated independently 
within homeopathy's own disciplinary matrix before the first external 
evaluations. They are the most likely source for the first allopathic placebo-
controlled evaluations of homeopathy as well as later placebo-controlled 
crossover and parallel group experiments by homeopaths. 
8.1. Introduction 
'Placebo: A medicine having no pharmacological effect, but given for the 
purpose of pleasing or humoring the patient' (Jones, Hoerr, Osol 1949). The 
medical dictionary entry dates from 1949 when well-meaning fraud was still 
the conventional use for placebo, as it had been for centuries - for example in 
the treatment of troublesome patients, or to mask the lack of valid remedies in 
palliative care. The dictionary omits any mention of sham comparison 
treatments in clinical research, an evaluative use of placebo generally believed 
to have arisen only in the 1930s. It is true placebo controls were not common 
until the 1950s when randomization, blind assessment and statistical analysis 
finally came together to determine the form of the present-day clinical trial 
(Lilienfeld 1982), but in fact blind assessment has been traced back to the 
emergence of scientific pharmacology in the nineteenth century, as Haas and 
colleagues (1959) showed in a comprehensive early review of placebo 
research. A more recent general history of placebo controls and blind 
assessment by Kaptchuk (1998a) cites even earlier placebo tests of new 
therapies in the late eighteenth and early nineteenth centuries, and advances 
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the theory that they were first introduced to expose allegedly quack systems, 
such as mesmerism and homeopathy. This helped to define and legitimate the 
territorial claim made by orthodox medicine, at a time when it often did more 
harm than good, and was losing face (and patients) to novel and more 
attractive therapies (Daniels 1971: 171ff). 
Although the early adoption of placebo controls in trials by homoeopaths has 
been cited in support of a progressive outlook (Kaptchuk 1997), the same 
author has also suggested that they probably incorporated placebo in 
response to external rather than internal pressure (Kaptchuk 1998a). The 
evidence for this normative hypothesis consists of studies using placebo in 
parallel with homeopathy, or alone (as a presume? equivalent), conducted by 
sceptics and critics of homeopathy, dating from as early as 1834. 
As an assessment of the validity of this argument, an account is given here of 
all published nineteenth-century placebo-controlled therapeutic trials of 
homeopathic medicines, or 'homeopathic' placebos without active controls 
found in the comprehensive literature search. As described in Ch. 5, the 
general literature search was widened in this instance to include any 
nineteenth-century placebo-controlled therapeutic trials or drug-tests. The 
review presented here is followed by earlier evidence which showed that the 
comparative and evaluative use of placebo had arisen and was well-accepted 
within homeopathy's own disciplinary matrix before the first external 
evaluations took place - and is still used in an identical manner today. 
8.2. Placebo-controlled provings 
As already noted (see Ch. 3), Hahnemann came to use higher potencies in 
treatment during the 1820s, and standardized this at C30 in 1829. Crucially, 
he also standardized the proving potency at the same level, and the 
symptoms from these ultramolecular tests were included in the materia 
medica without supporting evidence from material doses. Since healthy 
provers were presumably still as insensitive compared to the sick as 
Hahnemann had found originally, the rationale for this leap of faith was 
elusive to some homoeopaths and most sceptics. 
Their doubts were compounded by Hahnemann's later bad habit of deriving 
indications from medicines tested on sick patients rather than healthy 
volunteers, which led to the inclusion in the materia medica of some 
symptoms obviously due to prior illness and not the test substance (Hughes 
1893). As a result, placebos were introduced into homeopathic trials. The five 
placebo-controlled provings found in the literature search are summarized in 
Table 8.1, and discussed below. 
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Table 8.1 Placebo-controlled provings, 1834-1901 
Report Provers Design Proving drug Placebo Result 
Seidlitz, 1834 Hospital staff Crossover 
s-b 
Carbo-veg C30 Similar tablets 0 
Liihner, 1835 General public Quasi-random Natrum-mur liquid Snow water n/a 
parallel d-b potency 
Wesselhoeft, 1877 Medical students Time series and Carbo-veg Identical powders 0 
crossover potencies 
s-b 
Potter & Starke, Homeopaths Parallel d-b Aconite C30 Identical tablets null 
1880 
Bellows, 1906 Homeopaths and Parallel d-b Belladonna 0 and Identical tincture + (0) 
medical students potencies and powders 0 (potencies) 
Key: d-b, s-b, double- or single-blind.; +, 0, - placebo-controlled results 
The earliest account of any placebo-controlled proving that historians have so 
far found must be counted as evidence for the normative hypothesis. It took 
place at the Naval Hospital, St Petersburg in January 1834. Seidlitz, the 
allopathic physician in charge, had been contacted by Dr Dahl (see 7.2.1) 
about the new therapy taking root in Russia. Seidlitz (1834) countered Dahl's 
enthusiasm by offering to demonstrate the illusory nature of homeopathy, 
and asked a Dr Godechen to give potentized Carbo vegetabilis (vegetable 
charcoal) or dummy tablets to healthy medical staff. Each prover received a 
verum tablet once daily for a few days followed by placebo. The tablets were 
all dispensed single-blind by Godechen, and according to Seidlitz's account 
the appearance or non-appearance of symptoms was unrelated to whether 
placebo or verum was taken, but correlated with the psychological 
characteristics of the prover. Seidlitz later repeated the experiment but 
dispensed the tablets himself, and got substantially the same results. His 
report is sarcastic throughout, so the objectivity of his data collection and 
reporting cannot be taken for granted, any more than in his abusive account 
of the 1829-30 clinical trial by Herrmann, also in St Petersburg (Seidlitz 1833) 
(see Ch. 6, as well as 8.4.3 below). 
Further external pressure on homeopathy to adopt placebo controls came in a 
double-blind test of potentized Natrum muriaticum (common salt) in liquid 
form with distilled water as control from 1835. It was not organized by 
allopaths but by G. Lohner (1835), a journalist in Nuremberg, and Kaptchuk 
(1998a) notes that the atmosphere seems to have resembled a seance more 
than a sober scientific experiment. This inconclusive study even attempted 
random assignment, by haphazardly shuffling the verum and placebo vials. 
In contrast to these external evaluations, the scientific importance and quality 
of the work of the Vienna Provings Union, in the 1840s, was favourably 
appraised more than a century later in Haas and colleagues' (1959) review of 
historical and contemporary placebo research referred to above. The Vienna 
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experiments included single- and double-blind tests of many potencies of the 
same medicines in the same subjects with washout periods of no treatment. 
Their reprovings (of Aconite, Bryonia, Colocynth, Natrum muriaticum, Sulphur 
and Thuja) and primary provings (of Argentum nitricum, Coccus cacti and Kali 
bichromicum) are preserved in Hughes and Dakes's Cyclopaedia of Drug 
Pathogenesy (1886-91), an important late nineteenth-century recension of the 
homeopathic materia medica which aimed to include only reliable proving 
and toxicological symptoms: high potency data was admitted on condition 
that it was supported by information derived from more material doses. 
Following this type of internally-generated comparison of different potencies 
and no treatment, homeopaths elsewhere began the regular employment of 
placebo controls in provings, well before they were considered necessary in 
medicine generally. This seems to have started at Boston University Medical 
School in 1877. At that time it was a homeopathic institution, and Conrad 
Wesselhoeft Sr, a professor of materia medica, performed a single-blind 
crossover trial specifically 'for the purpose of demonstrating the necessity of 
countertests in drug-proving' (Wesselhoeft 1877). His students knew they 
were reproving Carbo-veg, but not that some of them received unmedicated 
lactose to begin with. There is little quantitative or qualitative difference 
between the symptoms produced in the two phases of the crossover, and 50 
provers failed to show any symptoms at all. 
This experiment was probably the inspiration for the Milwaukee Academy of 
Medicine's double-blind placebo-controlled reproving of Aconitum napellus 
C30 (monkshood) in 1879-80 (Potter and Storke 1880). The 25 homeopathic 
physicians who volunteered as provers were invited to distinguish between 
vials of verum and identical placebo; only nine replied, none correctly. 
However, a contemporary comment by the homeopath Samuel Swan (1888) 
about idiosyncrasy and provings is still relevant: 'In this varying sensitiveness 
of individuals to different potencies and different drugs lay the entire failure 
of the Milwaukee Test.' The Milwaukee Academy also conducted a similar 
therapeutic trial mentioned below. 
During the 1880s, placebo controls were used increasingly, as the following 
references to saccharum lactis (milk sugar) in zinc provings indicate. They are 
quoted here as they appeared in the Cyclopaedia of Drug Pathogenesy (Hughes 
& Dake 1886-91): 
JOSEPH RHODES, aet. 24, health good. Proved 3x [D3] trit. [iodide] in 
2 gr. powders. 1st, 2nd and 4th d.-Took powder in m., which caused 
temporary nausea (as sac. lac. does), soon relieved by food. On latter d. 
repeated dose at 3 p.m., when nausea was followed by burning in 
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stomach and cramp-like pains in bowels. These soon passed off while 
walking. Doses were repeated on 6th and again on 19th d., with no 
further effect. (Trans. of Amer. Inst., 1888: 167.) 
CHAS. H. WELLS, aet. 29, health good. Sac. lac. test negative. Took 
several 3 gr. doses of 6x [D6] trit. of phosphate without effect. Then, 
after an interval of two weeks, began the 2x [D2] trit. On 1st d., at 9.30 
a.m., he took 3 gr., and soon began belching a gas resembling 
sulphuretted hydrogen. At 1 p.m. repeated dose, which made belching 
more marked, and soon slight disturbance of stomach bordering on 
nausea was experienced. Later, felt weakness in bowels, as if diarrhoea 
would come on. Some confusion of ideas. 2nd d.-Passed comfortable 
n. At 5 p.m. took 3 gr., and soon experienced the belching; then nausea 
and a diarrhoeic stool ensued, with confusion of mind. (Trans. of Hom. 
Med. Soc. of Pennsylvania, 1889: 202.) 
These low-potency reprovings support Hahnemann's much earlier findings 
published in Chronic Diseases (1828-30, iii), and it is worth noting that gastric 
irritation, vomiting and diarrhoea are acknowledged side-effects of present-
day oral zinc salts (Fastner 1980). Paradoxical benefit from zinc sulphate in 
the treatment of benign gastric ulcer has also been found in a double-blind 
placebo-controlled trial (Morgan 1978). 
The culmination of the late nineteenth-century American efforts to eliminate 
suggestion was undoubtedly a multicentre double-blind placebo-controlled 
crossover reproving of Atropa belladonna (deadly nightshade) in molecular 
and ultramolecular potencies, which took place between 1901 and 1903 
(Bellows 1906). It provided some confirmation for the accepted Belladonna 
drug picture, mainly from provers taking large doses of mother tincture. 
8.3. Therapeutic trials involving placebo 
8.3.1. Placebo-controlled trials 
The second trial by Herrmann in St Petersburg in 1829-30 has been discussed 
in Ch. 6 (Lichtenstadt 1832). As well as comparison with the usual allopathic 
treatment, another control group was established by the trial supervisor, 
Gigler: patients received expectant treatment- nursing care, tisanes, baths 
and so on. This group was also prescribed placebos consisting of such things 
as bread pills or lactose powders. The significance of this is discussed below 
(8.3.2). 
Following Herrmann's second trial, no further deliberate parallel or crossover 
placebo controls in therapeutic trials of homeopathy were found before 1879, 
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when the Milwaukee Academy of Medicine (at the same time as its proving 
referred to above) asked homeopaths in private practice to distinguish 
identical vials of verum and placebo by assessment of their patients' response 
to treatment (Potter & Storke 1880). Out of 47 physicians who agreed to 
participate, only one returned a result- correct as it happened. 
8.3.2. Trials of placebo without homeopathic treatment 
There were at least two early prospective placebo trials considered by 
opponents and sceptics of the day to provide evidence against homeopathy, 
included here even though they did not in fact involve treatment with 
homeopathic medicines. Three such trials were found altogether, and are 
listed in Table 8.2. 
Table 8.2 Trials of placebo alone as presumed or rhetorical equivalent of 
homeopathy 
Report Condition Design Equivalence Control Result 
Pigeaux, 1834; Mixed Case series Presumed None n/a 
Trousseau & 
Gouraud, 1834 
Forbes, 1846 Diarrhea Parallel s-b p-c Rhetorical Allopathy no difference 
Lisle, 1861 Mixed Case report Rhetorical None n/a 
Key: s-b, single-blind; p-c, placebo-controlled 
At the Hotel-Dieu, Paris, in 1834, Armand Trousseau (1801-67) and 
colleagues gave an uncontrolled single-blind placebo treatment to patients 
with various illnesses (Pigeaux 1834; Trousseau and Gouraud 1834). It 
consisted of bread pills, labelled as if they contained one or two decillionths of 
a grain of valerian, a herb popular in the folk and orthodox treatment of 
anxiety and depression. As Hughes (1893) notes, it was hardly ever used in 
homeopathy, although Valeriana had been one of Hahnemann's earliest 
provings to be published (Hahnemann 1805b). Some patients responded to 
the bread pills and others did not, although there is no indication whether 
any reported symptomatic improvements - in tuberculosis for instance - were 
more than transient. Trousseau seems genuinely to have believed this was a 
valid test of homeopathy - a system whose absurdity he was in no doubt of. It 
has been pointed out that he was equally capable of errors of design and 
inference in his own sphere of orthodox pharmacology, even dismissing one 
of the most effective specifics known to history - colchicum for gout - as a 
placebo, in the same way that he did homeopathy (Goodwin & Goodwin 
1984; Reubi 1986). 
Another account of a trial involving alleged homeopathic treatment appeared 
from the pen of Sir John Forbes (1783-1861). Unable to decide which 
allopathic treatment was best (or worst) in a diarrhea epidemic, Forbes (1846) 
claimed to have prescribed bread pills to half his patients, with no difference 
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in outcome from treatment as usual. He gives an elaborate description of the 
manufacture of the bread pills as if they were homeopathic medicines - and 
for all his readers knew, they were - but it is Dickensian tongue-in-cheek, and 
the therapeutic comparison was intended to be as unflattering to allopathy as 
to homeopathy. His readership seems to have realized this: in spite of his 
position as Fellow of the Royal Society and Household Physician to the Royal 
family, cancellation of subscriptions forced the closure of the journal Forbes 
edited in the months following the publication of his- by then notorious-
review article. 
Forbes also mentions the existence of placebo-controlled experiments in 
German hospitals, prior to 1846, which were apparently 'unfavourable to the 
claims of homeopathy'. Unfortunately his article lacks any details of these 
trials, and it was not possible to identify them conclusively in the literature 
search. However, a possible solution to the mystery of Forbes's missing 
German trials is offered below (footnote 2). 
The rhetorical use of the term 'homeopathic' to denote 'illusory' or 'placebo' 
can also be seen in a report by Lisle (1861), who recounts some experiences 
giving bread pills to patients with neurotic symptoms. Lisle called this 
'orthodox homeopathy', because, as he said, 'Bread pills or globules of 
Aconitum C30 or C40 amount to the same thing.' 
8.4. Placebo in homeopathic practice 
There is no doubt that placebo had begun to be used in the evaluation of 
homeopathy by sceptics and opponents as early as 1829, first in therapeutic 
trials then provings. It is hard to find another example of drug placebo 
controls in any field at this date, adding weight to the proposition that 
homeopathy only adopted them as early as it did because of external 
pressure. Left out of any account of interactions between homeopathy and 
orthodoxy, though, is a standard homeopathic practice dating from before 
then. This involves the deliberate use of placebo in case-taking and 
prescribing for chronic and non-urgent medical conditions. The practice was 
undoubtedly made possible because lactose ( discovered in 1615) was used in 
both the preparation of homeopathic medicines (insoluble substances were 
triturated with lactose), and as a carrier for dispensing liquid potencies when 
the process was complete, in the belief that it was pharmacologically inert. 
This meant it was easy for homeopaths to employ a surrogate treatment 
indistinguishable from verum, at a time when allopathy would have found it 
difficult. Hahnemann's developing use of placebo reveals an alternative route 
to placebo controls, originating in homeopathic practice rather than allopathic 
expose. 
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8.4.1. Hahnemannian usage 
Hahnemann's publications mention placebo in discussions of case-taking, -
assessment and -management. As early as the first edition of the Organon (§ 
75), Hahnemann (1810) discusses psychosomatic reactions, such as 
exaggerated responses to placebo or no treatment. It is clear that he is 
referring here to the traditional use of placebo, but the sophistication and 
holism of his concept of illness is apparent when he urges that the tendency to 
exaggerate sufferings should not be disregarded or palliated with placebo, as 
was usual, but should be included as an important psychological factor in the 
patient's overall symptom picture. 
Hahnemann also stresses that a patient's presenting symptoms may well be 
confounded by previously-prescribed allopathic medication. In an essay of 
1805, The Medicine of Experience, he had advised discontinuing any medication 
for a few days to allow an accurate symptom picture to emerge (Hahnemann 
1805c), and he repeats this in §70 of the 1810 Organon, which grew out of the 
earlier essay. In the equivalent section (§ 97) of the second edition he 
additionally suggests providing a placebo during the washout (Hahnemann 
1819a). 
There is even evidence from this period that Hahnemann began to use 
placebo during homeopathic treatment itself. In 1813 he was personally 
responsible for treating many patients in a typhus epidemic which broke out 
in Leipzig during the Napoleonic wars. After the first stage of the illness, for 
which he gave a single dose of Bryonia, he waited for the second stage to 
manifest, which was then treated with a single dose of Rhus toxicodendron: 'In 
this interval, before the second medicine is needed, we may, in order to meet 
the demands of the patient for medicine and to put his mind at rest, give a 
placebo every day, such as a few teaspoonfuls of raspberry juice, or some 
powders of milk-sugar' (Hahnemann 1814). In the article on Rhus-tox in 
Materia Medica Pura (1811-21) he notes the huge allopathic mortality rate in 
this epidemic and comments: 'Of 183 cases treated by me in Leipzig, not one 
died: this created a great sensation among the Russians (then ruling in 
Dresden), but was ignored by the medical establishment.' 
Ten years later, in the theoretical part of Chronic Diseases, Hahnemann 
(1828-30: 215ff) expands the role of placebo. He had maintained for three 
decades that a single dose of the indicated medicine, however attenuated, 
should not be repeated until it had 'worked itself out' over days or weeks if 
necessary, and he reiterates that here. Recommending that numbered 
medicated doses should be followed with numbered placebo powders, 
Hahnemann makes it clear that this was not only to harmonize with current 
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dosage expectations, but also to address his concern about the tendency of 
patients to produce psychosomatic reactions to the single homeopathic doses. 
He states that intercalated lactose powders help to reduce non-specific 
responses, allowing a more accurate assessment of the patient's progress. 
Hahnemann enthuses that lactose used in this manner is 'an invaluable gift of 
God'. 
8.4.2. Early adoption by fol lowers 
This phrase appeared unchanged in the second edition of Chronic Diseases 
(Hahnemann 1835: 161ff), but a new footnote refers to an internal debate 
between the 'purists', who worried that lactose used as a substrate might be 
pharmacologically active or become so during trituration and potentization, 
and those like Hahnemann who were convinced that it remained inert. As far 
as I have been able to discover, the debate originated with the Swiss 
homeopath C.G. Peschier, who informed the Congress of the Universal 
Homeopathic Association, held at Leipzig on 10 August 1832, that his patients 
often produced new or worsening symptoms after unmedicated lactose 
(Peschier 1835b ). After the congress, Peschier put this to Hahnemann, who 
said it needed experimental replication. Indeed Hahnemann himself went on 
to conduct a proving of lactose in potencies up to Cl8 which, according to his 
footnote, failed to produce symptoms in reliable subjects. Peschier's account 
of the debate also refers to the ensuing discussion in the German homeopathic 
press. Although some practitioners attributed the appearance of new 
symptoms to the natural course of the disease, or to carryover effects from 
previous medicines, G.W. Gross (1794-1847), one of Hahnemann's closest 
associates, seems to have summed up majority opinion when he wrote: 
'Patients look for something in the powders that is not there.' Unconvinced, 
Peschier substituted sucrose and his Genevan patients apparently had no 
further problems from placebo. 
8.4.3. Hahnemannian placebos in trials 
Reports of three prospective trials by the homeopaths Attomyr and 
Herrmann (discussed in Ch. 6) make it clear that Hahnemann's indications for 
the use of placebos in homeopathic treatment were swiftly adopted by his 
followers, and medicated and unmedicated powders were routinely used 
before the lactose debate. 
The first study by the German homeopath D. Herrmann (1831), contains the 
earliest evidence of the use of placebo in addition to verum. It took place in 
1829 at the Military Hospital in Tulzyn, province of Podolya, Ukraine, on the 
instructions of the Russian Tsar, Nicholas I. Herrmann faced a number of 
difficulties in this trial, and not just from the allopathic evaluators as was 
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expected. His patients were hard-living Russian soldiers unwilling to give up 
their tobacco and absinthe to follow the minimalist homeopathic regimen. 
Their distrust of the distinctly unheroic white powders was not tempered by 
the intercalated doses of unmedicated lactose that Herrmann provided. 
The second trial by Herrmann in St Petersburg in 1829-30 included a parallel 
group receiving expectant treatment at the instigation of Gigler. According to 
the report by Professor Lichtenstadt (1833) these patients not only received 
baths, tisanes, good nutrition and rest: they also received placebos modelled 
on those used as part of normal homeopathic practice: 
During this period, the patients were additionally subjects of an 
innocent deception. In order to deflect the suspicion that they were not 
being given any medicine, they were prescribed pills made of white 
breadcrumbs or cocoa, lactose powder or salep infusions,24 as 
happened in the homeopathic ward. 
Interestingly, a second report on this trial was published by Seidlitz (1833) 
who then went on to conduct the first known placebo-controlled proving four 
years later (Seidlitz 1834; see above 8.2.). 
Attomyr's trial at the General Hospital, Munich, in 1830-31 provides evidence 
not only of the use of Hahnemannian placebos, but also an unintentional 
interrupted time-series comparison of homeopathy and placebo (Attomyr 
1832). Noting that the first 10 of a series of 40 patients with scabies had 
recovered within 10 to 14 days after treatment with Sulphur, Attomyr was at a 
loss to understand why the next 30 patients took much longer to recover -
typically, three to four weeks. It turned out that the second group had been 
given unmedicated lactose or nothing at all. Whether the comparison 
favouring homeopathy was due to negligence or malice is unknown, since it 
was not part of the trial protocol. Attomyr's report mentions many serious 
threats to validity: the worst seem to have been allocation bias (the sickest 
patients were always assigned to the homeopaths), and non-compliance of 
regular staff. The allopathic dispensing physician was openly hostile, and 
instead of administering the prescribed medication himself as per protocol, 
gave it to nurses -who then either failed to deliver it or gave it to the wrong 
24 Salep and saloop are English corruptions of salzlep, Arabic for the starchy extract of the 
ground tubers of various species of orchid. It was popular in the nineteenth century and 
earlier when prepared and served as an infusion in boiled water, and was often given to 
invalids (Grieve 1931). I am indebted to Roger Britt of the Institute of Translators and 
Interpreters for the translation and definition of Salepabkoclwng. 
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patients. Problems like these were commonly faced by homeopaths invited to 
conduct trials in allopathic hospitals, as discussed in Ch. 6. 
8.4.4. Divided doses and placebo 
As discussed in Ch. 2, Hahnemann' s scrupulous concern not to inflict 
avoidable iatrogenic harm on patients had led him to abandon allopathy 
before 1790, and subsequently to reduce homeopathic medicines to 
infinitesimal dilutions given in single doses. It seems that he could be equally 
fastidious concerning harmless surrogate medication. A letter of 5 August 
1830 from Hahnemann to his trusted associate Stapf observes: 'The 
homeopathic physician must come to the point when he refuses to give 
placebos and will only give the helpful remedy when and where it is 
required' (Haehl 1927, 1: 327). 
He eventually reached a possible resolution of his dilemma in his revised 
instructions for administration of potencies (Hahnemann 1837: iiiff): a single 
medicated powder or globule was to be dissolved in a glass of water and 
succussed before each administration of a teaspoonful. Hahnemann believed 
the extra succussion, referred to nowadays as the 'plus' method, meant 
patients did not receive a harmful identical stimulus, allowing safe repetition 
of medicines. The procedure was adopted by many homeopaths throughout 
Europe. For example, an appreciative mention of the 'new and wise rule' for 
repetition of doses is included in a balanced critique of Hahnemann by J.-P. 
Tessier (1856). In spite of this opportunity to abandon the use of placebo 
during treatment, Hahnemann's case-notes from 1842 show that he continued 
to prescribe intercalated lactose - but dissolved and succussed in the new 
manner - until the end of his career (Hahnemann 1852b: 773ff). 
Hahnemann also retained placebo for washout. §281 of the 1842 revision of 
the Organon (unpublished until 1921) even extends this to homeopathy: 
placebo should follow a course of treatment, to establish whether any 
remaining symptoms are an expression of the natural disease or reactions to 
the homeopathic medicines (Hahnemann 1921). 
8.4.5. Later evidence 
Notwithstanding Hahnemann's later divided doses, single dry doses 
intercalated with lactose continued to be used. The plus method appears not 
to have been well-known in North America, and did not usually find favour 
with the ultrahigh-potency school which came to prominence there at the end 
of the nineteenth century. For instance, J.T. Kent (1888), the best known 
exponent of 'metaphysical' homeopathy, acknowledged that divided doses 
given in water were 'in harmony with correct practice', but appears not to 
have used them. 'Sac. lac.' is frequently referred to in his case reports, itself 
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often given in single doses at long intervals (e.g. Kent 1912c) and he believed 
it was impossible to practise homeopathy without knowing how to make use 
of placebo. 
Later evidence of placebo used as washout and run-in can be found within 
the European repeated-dose tradition. In the 1920s, for example, the German 
homeopath and teacher Erwin Scheidegger regularly prescribed numbered 
powders of unmedicated lactose for one or two weeks in chronic and non-
urgent cases before changing to numbered powders of verum; his student 
Fritz Donner (1948: 61) cited this approvingly as an instance of the ease with 
which homeopathy can incorporate scientific controls against bias. Donner 
subsequently became bitterly critical of homeopaths because of what he 
believed were their anti-scientific tendencies, unaware that Scheidegger had 
adopted a historic practice which predated emergent biomedical evaluative 
procedures by a century (Donner 1969). 
Placebo is still prescribed by many homeopaths today, to judge by its frequent 
(and unremarked) occurrence in the single case reports readily found in most 
classical homeopathic journals. It is discussed in standard modern textbooks 
with varying emphases. One author in the classical tradition regards it as 
indispensable, given still-current expectations of medication repeated daily 
(Dhawale 1985: 418ff). Another recent author, associated with the critical 
tendency in homeopathy, advocates repeated doses of verum, following the 
later Hahnemann, and concludes that the practice of giving placebo may 
alienate patients who discover they have received it (Eizayaga 1991: 251). 
8.5. Discussion 
As discussed in Chapter 6, a received idea in medical historiography indicates 
that the development of modern scientific medicine, as a unified discipline, 
can be dated to the rejection of homeopathy in the 1830s and 1840s. The 
notion advanced by Kaptchuk (1998a) that placebo controls in trials of 
homeopathy were first adopted in 1834 to expose the system seems to be a 
corollorary of that argument. 
Nevertheless, the evidence of placebo in early therapeutic trials reviewed here 
shows a clear priority of internal homeopathic usage. The chronology of trials 
mentioning placebos before 1835 - given either as part of Hahnemannian 
practice, unintentionally, or as deliberate external controls - is shown in Table 
8.3. 
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Table 8.3 Occurrence of Hahnemannian (internal) and external placebo controls in 
homeopathic trials 1829-35 
Location Report Design Placebos Comments 
Date Language 
Internal External 
Tulzyn Herrmann, 1831 Observational Yes No Hahnemannian usage 
1829 German therapeutic 
St Petersburg Lichtenstadt, 1832; Parallel therapeutic Yes Yes Hahnemannian usage; placebos identical to 
1829-30 Seidlitz, 1833 those used in the homeopathic arm were 
German also given to an expectant group. 
Munich Attomyr, 1832 Observational Yes No Hahnemannian usage, but unmedicated 
1830-31 German therapeutic lactose also given to some patients 
negligently or maliciously instead of verum. 
St Petersburg Seidlitz, 1834 Time series No Yes Seidlitz had reported the 1829-30 St 
1834 German proving Petersburg study. 
Paris Pigeaux, 1834; Observational No Yes Placebo only, no verum. 
1834 Trousseau & therapeutic 
Gouraud, 1834 
French 
Nuremburg Uihner, 1835 Parallel No Yes No clear relationship to above. 
1835 German proving 
The normative thesis of external pressure prompting the adoption of placebo 
controls in trials by homeopaths seems difficult to sustain given the diffusion 
of within-patient placebo controls in homeopathy before 1830, their explicit 
imitation in the first known trial with a separate placebo arm in 1829-30, and 
the poor design and conduct of later allopathic challenges.25 The early 
homeopaths' own disciplinary matrix was fertile enough to generate research 
into the system's internal validity, such as time series provings and trials in 
the 1850s, and there can be little doubt that placebo-controlled provings by 
homeopaths in the 1870s, as well as single-blind n-of-1 trials in the 1920s, 
sprang from the same source. Outside everyday practice, homeopaths only 
used placebo in provings, and then specifically to test problem areas in their 
discipline, such as high potencies or substances with low toxicity. The results 
seemed to bear out the doubts of the critical homeopaths about Hahnemann's 
nomination of C30 as the exclusive proving potency after 1828, since lower 
potencies were a more reliable source of clinical indicators when applied to 
healthy provers. Unfortunately, the debate that should have followed, on 
25 Table 8.3 also shows, incidentally, the likely candidates for Forbes's unspecified and 
allegedly placebo-controlled German trials (see 8.2.2.2, above). Nearly all the reports were 
published first in German, and were conducted by German doctors. Russia has been spoken 
of as an intellectual dependency of German thought in the second quarter of the nineteenth 
century (Berlin 1978: 122). A French 'expose of German trials' (Martins 1835), which actually 
contains a translation of the 1834 Carbo-veg proving in St Petersburg by Seidlitz, demonstrates 
geographical and medical dependency also. This group of trials and provings could well 
have been remembered as 'trials in the German hospitals' by Forbes (1846), writing more than 
a decade later. 
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whether the pure pathogenetic symptoms of the earlier materia medica had 
been contaminated or enriched by uncontrolled high potency provings, never 
really took place. The definitive statement of the critical position was given by 
Hughes (1884: Ch. XII) in his lecture on 'The future of pharmacodynamics' to 
the Boston University Medical School. But, as Hughes points out, the other 
side had been unwilling to counter the critique, or were too easily refuted 
when they did. All too typically, high potency enthusiasts such as Samuel 
Swan (1888) retorted that provers who showed as many symptoms from 
placebo as verum were actually proving Sac-lac. 
However, by contrast with proving data, higher potencies continued to be 
found as or even more effective in treatment of some clinical conditions such 
as pneumonia (see Ch. 7). Convinced of the fundamental soundness of their 
therapy, homeopaths seem to have been uninterested in placebo-controlled 
therapeutic trials at this date, but instead demanded pragmatic trials of 
homeopathy versus allopathy. 
In reply to this argument (Dean 2000), Kaptchuk (2000) has emphasized the 
relevance of the - undisputed - priority of parallel group placebo controls in 
tests of mesmerism which occurred in the 1780s, and the fact that homeopaths 
were aware of this. There is no doubt that influential homeopaths were not 
just passive observers of the mesmeric debate, but conducted their own 
investigations. Hahnemann's ally G.W. Gross - who wrote about nocebo 
effects in medicine as early as the 1830s, as mentioned above (8.4.2) - was well 
aware of the effects of suggestion. His earlier critical investigation of dowsing 
had demonstrated that the pendulum responded to unconscious muscular 
movements of the diviner's hand, and not to direct external influence from 
metals as the mesmerists thought (Gross 1822). But there is little hard 
evidence that the use of wooden rather than metal rods to test mesmerism as 
a system affected internal homeopathic practice or experimentation. 
The designs of the earliest placebo-controlled experiments by homeopaths 
help to clarify the difference in outlook. The placebo-only trial by Trousseau 
in 1834, and the parallel group proving by Lohner in 1835 may have been the 
first of their kind, and may have been influenced by the design of mesmeric 
studies, but did they exert any direct influence on internal homeopathic 
trials? The first placebo trials by homeopaths were crossover and time series 
studies - as indeed was Seidlitz's proving in 1834- using the single-blind 
washout and intercalated placebos that had been institutionalized in 
homeopathy since 1810 and witnessed by allopaths in hospital trials from 
1829 onwards. Not until the late nineteenth century did homeopaths 
introduce parallel placebo arms. It can even be argued that the homeopaths 
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adopted the more rational approach - using within-patient controls during 
treatment - at a time when it was scarcely possible to assemble equivalent 
parallel groups. 
Kaptchuk (2000) also objects that all doctors had traditionally handed out 
placebos instead of medicine, and were aware that it could be used as a 
comparison. However, Kaptchuk's own earliest instance of 'occasional' 
orthodox within-patient placebo control dates from the 1950s (Shideman & 
Beckman 1958; Kaptchuk 1998b). In fact there is no evidence that anything 
like Hahnemannian usage was ever institutionalized in allopathy before the 
twentieth century: the first orthodox proposal for placebo-controlled n-of-1 
trials is currently attributed to the German researcher Paul Martini in the 
1930s (Martini 1932; Shelley & Baur 1999), who may even have been aware of 
Scheidegger and traditional homeopathic placebo usage. (Martini's 
subsequent placebo-controlled provings are mentioned in Ch. 9.) Equally 
noteworthy, homeopaths do not seem to have given placebo alone in the 
time-honoured manner, but always before, during or after treatment with 
verum. In the 1900s, when prominent orthodox doctors such as Richard Cabot 
(1909, 1, 23), were beginning to question the ethics of their 'innocent 
deception' of patients with placebo, others equally eminent could still argue 
that it was in the patient's best interest Ganet 1925, 1, 337f). Placebo as within-
patient control was not even mentioned in that debate. 
All the evidence points to the early homeopaths thinking they were more 
scientific than the regulars. They had pharmacological tests, fine 
discrimination of diagnoses at the symptom level and statistics on their side, 
and they used placebo as a control in everyday practice, not merely to palliate 
troublesome patients or to expose quackery. 
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9 ADOPTION OF THE BIOMEDICAL RESEARCH PERSPECTIVE, 
1914-53 
Background The emergence of the clinical research orientation that came to 
define biomedicine in the twentieth century is believed to have sounded the 
death knell for homeopathy. 
Questions How did emergent models of scientific medicine affect the 
design of homoeopathic trials in the first half of the 20th century? Are the 
results contingent on the designs used in any way? 
Argument Early twentieth-century homeopaths quickly adopted the 
conventions of the controlled trial, ahead of orthodox medicine in some cases. 
Homeopaths were also able to adopt an explanatory research model, exposing 
the discipline to an internal critique. 
9.1. Introduction 
The marginalization of homeopathy was virtually complete by 1900. In the 
countries where clinical trials had been conducted during the nineteenth 
century-Germany, Italy, Russia, France, Britain and the USA- rigorous 
exclusion from clinical and academic debate ensured that Hahnemann's 
research programme was disregarded, even where quasi-legal sanctions 
designed to encourage allopathic guild monopoly had failed to suppress its 
practice (Ameke 1885; Lodispoto 1961; Coulter 1973; Nicholls 1988; Faure 
1992a; Jutte 1998; Kotok 1999). Only the very greatest allopaths dared break 
ranks. Joseph Lister (1827-1912) said that if he had known earlier what the 
homeopaths knew about the vascular effects of aconite and belladonna he 
might have been able to save his father, who died after extensive blood-letting 
(cited in Haller 1984). Emil von Behring (1854-1917), the discoverer of 
antitoxin treatment and prophylaxis for diphtheria and tetanus, repeatedly 
cited Hahnemann's influence and importance in the development of 
immunology (Behring 1893; 1898; 1915). Behring even demonstrated the 
paradoxically enhanced immunogenic activity of continued serial dilutions to 
the Berlin Physiological Society in 1892, but was advised to suppress this 
experiment because it gave comfort to the homeopaths, and only recalled the 
event in public after becoming the first Nobel laureate for medicine (Behring 
1905: xxvii). 
Against a background of increasing biomedical hegemony the 30-year gap 
between the last homeopathic treatment trial of the nineteenth century and 
the first of the twentieth century found in the literature search becomes easier 
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to understand. 
9.2. Results 
Twenty separate trials were reported in 10 publications in 2 languages, 
English and German (see Table 9.1). 
Table 9.1 Hospital based evaluations 1914-53 
Reference Trialist Condition Design N Model Resu It by group 
(trial date) Hospital Main outcome Control(s) 
Wesselhoeft, 1917 Chadwell Scarlet fever; Parallel quasi- Clinical (Bell D3) control slightly 
(1914) Massachussetts time to discharge random Placebo? No treatment? favoured Homoeopathic 
Wesselhoeft, 1917 Wesselhoeft, Scarlet fever Open label time 26 Clinical (Bell D3) 38.5% 
(1914-16) Massachussetts prevention; series 26 Atropine D3 38.5% Homoeopathic incidence 
28 No treatment 35.7% 
Wesselhoeft, 1925 Wesselhoeft, Diphtheria; Parallel open 56 Clinical (Merc-cy 03) t0% (1915) Massachussetts mortality label 252 Antitoxin t11% Homoeopathic 
Wesselhoeft, 1917 Wesselhoeft, Scarlet fever; Parallel open 114 Clinical (Bell D3) 46.4d 
Massachussetts time to discharge label 113 No treatment 50.2d Homoeopathic 
Wesselhoeft, 1924 Wesselhoeft, Orchitis from Historical 67 Clinical (Plumb-ac 03) 1.5% 
(1921-23) Massachussetts mumps; 428 Classical 28% Homoeopathic incidence 
8153 Allopathy 18% 
Bier, 1925 Bier Furunculosis; Case series 34 Clinical (Sul-iod 06) 100% 
Berlin Polyklinik cure 0 Allopathy 0% 
Donner, 1948: 34 Joachimoglu Skin conditions; Parallel 1 Clinical (Sul-iod 03) ? 
(1925) Berlin Polyklinik identify verum d-b 1 Placebo ? 
Donner, 1948: 54-57 Simonson Acute and chronic Parallel 314 Unknown 72-87% 
(1938) New York Flower URTI: 5 trials; s-b + open 95 Placebo 50-73% (Children) cure by date label allopathic 
448 Allopathy 19-80% 
Schilsky, 1941 Schilsky Whooping cough; Quasi-random 88 Classical A. 66.6; B. 54.8 d 
(1938-39) Hamburg A.sly;B.~ly open label 82 Allopathy A. 67.4; 8. 52.8 d Rothenburgsort duration; 
Paterson, 1941 Paterson, Boyd Diphtheria; Historical 33 lsopathy (APT C30 or 20/33 (60.6%) 
Glasgow immunity after control Diphtherinum C201) 
Homoeopathic +ve Schick test 3743 Untreated populations 33% 
Hess, 1942 Hess Diphtheria; Para I lei open 69 Clinical (Merc-c, Mere-bi, t 18.6% 
Missing mortality label Lach, Nit-ac) 
Serum t 11.4% 
British Homoeopathic Paterson Mustard gas Random 14 lsopathy (Mustard gas Highly significant 
Society, 1943 Glasgow burns: ltrial; d-b; partial C30) for homeopathy 
(1941-42) Homoeopathic intact or crossover 14 Placebo (see Apps 2.2, 2.4) medium/deep 
British Homoeopathic Templeton Mustard gas Random 127 Clinical or isopathy Highly significant 
Society, 1943 London burns: 3trials; d-b; chi 2 tests; 113 Placebo for homeopathy (1941-42) Homoeopathic superficial, meta-analysis (see Apps 2.2, 2.4) 
medium or deep 
Ledermann, 1954 Ledermann Surgical TB; Random, 29 Classical A: nsd 
(1951-53) Burton-on-Trent, progress: masked, 30 Placebo B: 9/27 vs 3/24 Bretby Hall A. general; chi 2 test (p=0.08) Orthopaedic B. unexpected 
Key: d-b, s-b, double- or single-blind 
The reports ranged from anecdotal to detailed, and the trial conditions ranged 
from boils to surgical tuberculosis, with acute infectious diseases constituting 
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the majority. The trials were conducted in 3 countries only, USA, Germany 
and Great Britain, and are discussed here in relation to the homeopathic 
research climate in each country. 
9.3. USA 1914-38 
The unsatisfactory state of doctoring was obvious to many in late nineteenth-
century America, and was satirized by Mark Twain (Ober 1997). The 
preservation of a free market in medicine - despite allopathic attempts to 
create a monopoly - had allowed a proliferation of medical systems, 
practitioners and the colleges that turned them out. However, with no 
externally imposed objectives, the standards of many institutions were deeply 
suspect (Hudson 1972). The report prepared for the Carnegie Foundation and 
the AMA by Abraham Flexner (1910) was designed to bring about root-and-
branch reform of medical training and practice, in which the research 
perspective that had taken root in Germany would be institutionalized in the 
US (Berliner 1977). One of its immediate effects was the closure of many 
medical schools, and the casualties included lesser allopathic institutions, as 
well as some naturopathic, chiropractic and homeopathic colleges (e.g. 
Roberts 1986). This seems to have been less because of allopathic 
protectionism (which was already waning by this time, the battle against 
homeopathy won), than because of a fundamental ideological shift -
henceforth, treatments required justification in practice, and practices could, 
in principle, be supplanted by others when supported by better evidence. 
Although the example of homeopathy throughout the nineteenth century had 
been instrumental in bringing about this medical watershed, by the end of the 
century in many respects homeopathy itself had become far less forward 
looking and experimental than in Hahnemann's time. J.T. Kent was the best 
known homeopath of the day, and he expounded the texts of the previous 
hundred years as if they were evidence of divine revelation (see Ch. 4). From 
such a vantage point research facilities were irrelevant, and it is no surprise 
that Kent's Chicago college was closed following the Flexner report. 
However, from another point of view, the report can be seen as endorsing the 
attempts of the critical stream that emerged in homeopathy in the 1830s to 
evaluate the components of the discipline. The introduction of placebo-
controlled provings in the USA in the 1870s was discussed in Ch. 8, and 
following Flexner an increasingly critical detachment can be noted in 
homeopathic debate of the day concerning therapeutics. Hospital statistics 
were no longer an automatic demonstration of allopathic brutality and 
inefficacy as mortality rates under the two systems began to converge in some 
illnesses (Askenstedt 1915). It is at this moment that therapeutic trials 
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designed to test internal homeopathic hypotheses emerged in the USA. The 
principal exponent was Conrad Wesselhoeft Jr., a member of a prominent 
German-American homeopathic family stretching back to the introduction of 
homeopathy to the US in the 1830s. Wesselhoeft not only had a secure base in 
a Boston homeopathic medical school that survived Flexner, but was able to 
use his position as consultant physician at the Massachusetts Homoeopathic 
Hospital to compare clinical and classical homeopathy with allopathy and no 
treatment in prospective case series and parallel group trials. 
At the same time, basic research into the effects of high potencies in animal 
systems was under way in the US. The geneticist Mary Stark collaborated 
with the homeopath G.B. Stearns in investigations into the genetic effects of 
clinical homeopathy and nosodes in hereditary tumours in fruit flies (Stearns 
& Stark 1925). Stearns (1932) went on to investigate objective physical 
reactions to potencies in humans, continuing a line of work begun by the San 
Francisco physiologist Prof. Albert Abrams (1863-1924), and developed and 
replicated in Britain (see 9.5). Abrams (1916) noticed that percussion of the 
abdomen of a patient with a cancerous lip emitted a distinctive note, only 
when the patient faced west. Patients with other pathologies showed similar 
reactions when facing in different directions. Abrams hypothesized this was 
an electromagnetic phenomenon, and constructed a circuit with variable 
resistance to investigate it. He found that specific diseases caused replicable 
changes in resistance: cancers reacted at 50 ohms, tuberculosis at 15, and so 
on. Drugs and other substances introduced into the circuit also caused 
changes in the reactions of healthy subjects. As a bitter opponent of 
homeopathy he thought this would be an ideal opportunity to demonstrate 
that its medicines were placebos, and was surprised to find that they 
appeared to be responsible for the strongest of all the reactions he was able to 
measure in his subjects. 
9.3.1. Boston 1914: scarlet fever 
According to the only source (Wesselhoeft 1917), Chadwell orally presented 
the results of a scarlet fever trial in Autumn 1914. There are no details of 
numbers treated, or indeed whether 'receiving no medicine' is intended to 
indicate 'no treatment' or 'treatment with placebo'. Chadwell gave every 
other case Belladonna D3 and found, if anything, a slight disadvantage from 
homeopathy. Wesselhoeft reports that these results were a shock to many in 
view of Belladonna's reputation in scarlet fever, and Chadwell was censured in 
the ensuing discussion for his assumption that each case required the same 
medicine. However, Wesselhoeft says in defence that 
he was not examining the fundamental principle of homeopathy. On 
158 
the contrary he was investigating the accuracy of one of the myriad of 
notions which have arisen in the past hundred and twenty years and 
which have become part of the practice and teachings of a large 
element of the homeopathic school. The notion he investigated 
concerned the much vaunted value of belladonna in scarlet fever. What 
he showed very conclusively was that this drug in the third decimal 
dilution was not as efficacious in the average case of scarlet fever as 
one is led to believe from homeopathic teachings. Further criticism as 
to the dosage employed was irrelevant to the proposition and to the 
conclusions drawn. 
This trial may well have been the trigger for the series of literature reviews 
and trials in common contagious diseases that Wesselhoeft subsequently 
undertook. 
9.3.2. Boston 1914-16: scarlet fever 
Beginning in the winter of 1914, and in the two subsequent winters of 1915 
and 1916, Wesselhoeft (1917) tested the prophylactic efficacy of homeopathy 
or no treatment in scarlet fever. The subjects were nurses in the fever wards of 
the Massachussetts Homoeopathic Hospital, and the first medicine to be 
tested was Belladonna. The same D3 potency tested by Chadwell was used in 
1914 and again in 1915, when the test medicine was Atropine, the principal 
alkaloid of belladonna. In 1916 the nurses received no treatment. The 
incidence of the disease was virtually the same in each of the 3 years. 
9.3.3. Boston 1915: diphtheria 
In a paper read to the Bureau of Clinical Medicine, Cleveland in 1924, 
Wesselhoeft (1925) situates his review and trial of homeopathic treatment of 
diphtheria in the context of the available evidence in favour of Behring's 
antitoxin serum treatment, which was still fairly controversial. Wesselhoeft 
notes that Mercurius cyanatus had been recommended in the homeopathic 
literature, supported by published case series, and he therefore chose it for 56 
cases out of 308 admitted with diphtheria to his hospital in 1915. There were 
no deaths or complications from treatment with Merc-cy D3; all made 
uneventful recoveries, while the mortality rate in those treated with serum at 
the same time was 11 %. The report offers the opinion: 
It may be assumed that there were others that did not require 
antitoxin, but our judgement was certainly correct on this 17 per cent. 
In milder years it may have run to a much higher percentage. 
Wesselhoeft still recommended antitoxin as the first line treatment in serious 
cases, and also hinted at the close family resemblance between antitoxin 
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treatments and homeopathy, acknowledged by Behring (see 9.1): 
Like Schulz and Bingel, I am not an opponent of serum therapy. My 
interest in homeopathic therapeutics in its widest sense prompts me to 
seek the safest, the promptest, and at the same time the least 
disagreeable methods of dealing with cases of this dangerous disease. 
[added emphasis] 
9.3.4. Boston 1917: scarlet fever 
Chadwell's treatment trial of 1914 was repeated by Wesselhoeft (1917), and 
the numbers involved were large enough to discount random variation 
between groups. The main outcome was days to discharge, showing a slight 
trend in favour of homeopathy. As with Chadwell's trial, it is unclear from 
the report whether placebo was given; if patients were simply given no 
treatment any superiority of Belladonna could well be due to other factors. The 
report also tabulates the complications in each group: the most common were 
otitis, mastoiditis, nephritis and arthritis, and there was no difference between 
the two groups in incidence or type of complication. Wesselhoeft pointed out 
that this should surprise nobody, since Belladonna proving symptoms bore 
only a slight resemblance to the currently prevalent form of scarlet fever, or to 
its complications. 
9.3.5. Boston 1921-23: mumps 
In 428 adult cases of mumps treated by classical homeopathy in the 
Massachussetts Homoeopathic Hospital during 1917-18 no real benefits from 
the remedies were observed. In fact, the 28% incidence of orchitis, a common 
complication of mumps, was 10% higher than in 8153 male cases of mumps 
that Wesselhoeft (1924) was able to find in the orthodox literature. This 
disparity prompted him to investigate the materia medica along the lines 
proposed long before by Hughes and Burnett, to find if possible a 
pathological simillimum for the condition. Out of many medicines that 
affected the salivary glands and testes, only one produced the parotitis with 
orchitis and nervous symptoms that characterize mumps. That was lead, 
which interestingly was not mentioned in the homeopathic literature 
regarding mumps, but which deserved a trial. From 1921 until July 1923, 
when the paper was read to the Bureau of Pedology of the American Institute 
of Homeopathy, all cases of male mumps at or above puberty admitted to the 
Massachussetts Homoeopathic Hospital were given Plumbum aceticum D3 
every 3 h for the first week. Of 67 cases so treated, there were no 
complications and the single case of orchitis developed 3 days after 
admission. Wesselhoeft continued: 
This is not individualizing our cases. It is crude homeopathy, but it is a 
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closer approach to homeopathic prescribing in mumps than when 
untrustworthy symptoms in the materia medica are selected for 
indications. Routine treatment is a precarious thing, but in epidemics 
and in hospital work individualization is well-nigh impossible except 
in the severe cases. Unless subsequent results upset our results from 
plumbum in mumps, it would appear that the homeopathic school has 
found the first efficacious medicine in this disease, not so much for the 
acute symptoms as a prophylactic for the complications which render 
this disease dangerous. 
9.3.6. New York 1938: URTI 
The results of 5 trials of homeopathy vs placebo and allopathy in various 
acute and chronic upper respiratory conditions that took place in 1938 seem 
to be mentioned only in a series of lectures published in German 10 years 
later (Donner 1948: 54-57). The trials were conducted by J.T. Simonson with 
children attending the Flower Hospital attached to the homeopathic New 
York Medical College. Details of the trial and homeopathic methodology are 
absent from Donner's report, although the number of children receiving each 
treatment was tabulated and percentages of cure given (see Table 9.2). 
Table 9.2 Results from 5 trials in URTI conducted in 1938 at the New York Flower 
Hospital 
Condition N Homeopathy Placebo Allopathy 
Outcome n (% cure) n (% cure) n (% cure) 
Acute feverish headcold 37 12 (nd) 14 (nd) 11 (nd) 
Acute rhinopharyngitis 207 34 (76) 22 (73) 151 (40) 
Cure at 2 w 
Acute sinusitis 92 26 (85) 7 (72) 59 (66) 
Cureat3w 
Chronic rhinopharyngitis 327 118 (87) 52 (52) 157 (57) 
Cure at 1 mon 
Chronic sinusitis 194 124 (72) <= 194 (36) 
Altogether, 857 patients were involved in the trials. There was no noticeable 
difference in efficacy between any treatment in acute feverish headcold, but 
homeopathy was superior to placebo or allopathy in the other 4 trials. The 
most notable homeopathic successes occurred in chronic conditions that 
resisted any of the several parallel orthodox treatments used such as 
ephidrine and silver nitrate. Trial 5, for chronic sinusitis, differed from the 
other parallel group trials: from the original intake of 194, 124 failed to 
progress under conventional treatment and were then given homeopathy. 
The German homeopath Fritz Donner, who late in life became one of 
homeopathy's bitterest critics (e.g. Donner 1969), wrote in 1948 that although 
numbers were small under some treatments, the statistics could not be 
gainsaid, and bore out the persistent claims of homeopaths that their daily 
practice showed homeopathy was sometimes superior to allopathy in 
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sinusitis and upper respiratory infections. 
9.4. Germany 1925-42 
In Germany, high-potency individualized homeopathy had almost 
disappeared in the latter part of the nineteenth century, reemerging only after 
1945, with the publication of Kent's works in German translations. 
Homeopathy had received some scientific endorsement around 1900, from 
independent researchers such as Hugo Schulz and Behring, but their results 
were violently repudiated by orthodoxy. Representative clinical homeopaths 
of the period are Alfons Stiegele (1941) and Otto Leeser (1936). A temporary 
renaissance of homeopathy in German Schulmedizin in the first half of the 
twentieth century can be dated from the publication of a substantial article by 
the leading Berlin surgeon, August Bier (1925), in the respected national 
journal, Miinchener medizinische Wochenschrift. Bier's title asked 'What position 
should we take regarding homeopathy?', and, although by no means 
interested in Hahnemannian dogma, he answered by advocating general 
critical investigation of the similia principle. He based this on an historical 
review, and the successful experiments which he had himself undertaken in 
dermatology following Stiegele's advice (discussed below). Despite some 
fierce a priori opposition, homeopathy then began to enjoy a brief period with 
a comparatively high profile in Germany, and the review by Guttentag (1940) 
outlines the events following Bier's intervention which eventually led to the 
creation of two academic posts in homeopathy at Berlin in 1940. Fritz Donner 
also formed a link between clinical research in the US and Germany, 
translating several of Wesselhoeft's articles and commenting on their 
relevance to problems found in the treatment of infectious diseases 
(Wesselhoeft Jr 1928; 1929; Donner 1942). 
Some indication of the level of orthodox interest in evaluating homeopathy at 
this time is shown in the pathogenetic drug tests (provings) performed by 
Paul Martini, a clinical pharmacologist whose claims as a pioneer of the 
modem clinical trial have been overlooked in English-language 
historiography, but are as strong as those of R.A. Fisher in Great Britain 
(Martini 1932; Shelley & Baur 1999). Whether the results of Martini's placebo-
controlled provings provided any support for homeopathy is disputed - Haas 
et al (1959) claiming they did, and Donner (1969) the converse - but they are 
only relevant here as an indication of the seriousness with which the 
investigation of homeopathy was undertaken in the Third Reich as part of the 
Neue deutsche Heilkunde programme. Announced by Rudolf Hess at a 
homeopathic conference in 1938, this seems to have been inspired as much by 
a search for cost-effective (rationell) healthcare, as by nationalist pride in 
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homeopathy's origins. Although it had previously been feared the results of 
the homeopathic investigations in the Nazi period were lost for ever (Ernst 
1995a), the literature search for this review found reports of two clinical 
therapeutic trials, along with discussions of them in the contemporary 
homeopathic press. 
9.4.1. Berlin 1925: furunculosis 
Bier was not a homeopath, but a renowned skin specialist and surgeon. He 
notes (1925) that the well-known and uncontroversial toxic effects of high 
doses of sulphur taken internally - such as abscesses, eruptions and 
furunculosis - lent support to its use for those conditions in homeopathy. The 
choice of Sulphur iodatum D3 as the homeopathic medicine for chronic 
furunculosis was at the suggestion of the leading homeopath Alfons Stiegele, 
and Bier reports that this gave good results at his Polyklinik. He then went on 
to test Sul-iod D6, a much more dilute preparation, in a series of 34 cases, 
many of whom had constantly relapsed after orthodox treatments such as 
quartz lamp, yeast, arsenic, irritants and autohemic therapy. Bier reports that 
all were cured under homeopathy, including 3 cases who relapsed under D6 
but then responded to D3. The success rate in 28 cases of acute furunculosis 
was equally good, but less convincing because of the unknown natural 
recovery time in the acute condition. Bier also reported good results in acne -
vulgaris, indurata and rosacea - but notes that some cases did not respond, 
suggesting that sulphur was less generally homeopathic in those conditions 
than in furunculosis. He noted equally good results in dermal 
staphylomycoses such as pyodermia following scabies and impetigo. His 
conclusion was unambiguous and challenging: Sulphur was 'better, simpler 
and cheaper' than even the best of the other therapies, such as the Finsen 
quartz lamp, and 
An accurately chosen internal remedy, given in the proper dosage in a 
case of clearly infectious type, where other remedies are considered 
useless, will give a greater result than any other measure, including 
especially immunization, physical and surgical therapy. It is important 
to emphasize this in these days when internal drug therapy is looked 
down on with an air of condescension. 
9.4.2. Berlin 1925: skin conditions 
Joachimoglu, a researcher at the Berlin Pharmacological Institute, 
subsequently challenged Bier to distinguish coded vials of Sul-iod D3 and 
placebo, by assessing the clinical response of patients in his clinic. Bier 
apparently passed the test, but the anecdotal report gives no details of the 
numbers involved or Bier's success rate (Donner 1948: 34). 
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9.4.3. Hamburg 1938-39: pertussis 
The trial of classical homeopathy for whooping cough at Hamburg's 
Rothenburgsort Hospital was interrupted by the outbreak of war (Schilsky & 
Bayer 1941). Patients were categorized into those below or above 1 year old, 
because of the difference in the normal course of the disease in those age 
groups, and were alternately assigned to homeopathy or treatment as usual. 
Nursing staff were trained to note the symptoms and record the number and 
severity of coughing fits. There was little difference in the length of stay 
between the two treatment groups. The report lists a series of problems in the 
trial which may have affected the result, most of which seem plausible: the 
hospital setting made prescribing difficult, mainly because the cases were 
taken by nurses who reported the symptoms to the doctor; a lot therefore 
depended on the temperament and memory of the data collectors; parents are 
normally more aware of the individualizing modalities; homeopathic 
treatment did not start on the day of admission; and all the patients were 
mixed together in the wards. 
Contemporary homeopaths complained that the potencies used by Schilsky 
were not reported, evidently believing this held the key to the negative results 
(Schier 1942). Schilsky (1942b) had published details of the medicines and 
potencies he used in treatment of pertussis in the winter of 1940-41, and they 
are clearly the standard low potencies used in German homeopathy at that 
date (e.g. Cuprum D4, 6, 8; Coccu~ cacti DB; Drosera and Ipecac D15). Although 
these presumably bore some resemblance to those used in the trial, he replied 
that he would give details at a later date (Schilsky 1942a). However, when 
Donner (1942) came to write a review article on homeopathy for infectious 
diseases, later the same year, Schilsky had still not obliged his critics. 
9.4.4. ? 1942: diphtheria 
The trial of serum vs homeopathy plus serum in diphtheria by F.O. Hess 
(1942) was reported in an oral presentation to a meeting of the Medical 
Society of Oberlausitz, and the location of the trial was unspecified. The 
published details are scanty, giving no indication of assignment method, and 
omitting complete numbers of patients treated. Four homeopathic medicines 
are listed, without any indication of dosage or whether they were prescribed 
classically or clinically. Serum plus homeopathy was markedly less effective 
in reducing mortality than serum alone- suggesting either a danger from 
homeopathic medicines, or assignment bias. Hess also reported that 
homeopathy was totally ineffective in malignant diphtheria, a fact confirmed 
to him by Stiegele in a personal communication. Discussion of the trial in the 
homeopathic press raised the standard objections: the report gave no 
indication that Hess had any first-hand knowledge of homeopathic 
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prescribing, nor why the medicines were chosen above others. One criticism 
seems highly pertinent: homeopaths had already observed that serum doses 
needed to be halved when given concurrently with homeopathic treatment 
(Schmitz 1942; Schwartzhaupt 1942). 
9.5. Great Britain 1941-53 
The decline of British homeopathy at the beginning of the twentieth century 
paralleled events in Germany and the USA. However, Kent's influence was 
introduced and perpetuated in the UK after it had begun to wane in the US as 
the result of a scholarship programme which enabled British homeopaths to 
study in Chicago. Inglis (1964: 85ff) described the effects of the Kentian 'take-
over bid' for British homeopathy after 1912. An exclusive classical orthodoxy 
was promulgated by Sir John Weir, Margaret Tyler and a dwindling band of 
followers, and by the 1970s British medical homeopathy had become heavily 
involved with anthroposophy. 
As noted, clinical research was not part of Kentian homeopathy, and the 
research figures to emerge in the inter-war years were somewhat unusual. 
John Paterson and William Boyd were both based at the homeopathic hospital 
in Glasgow. Both published regularly, and their presentations to the 11th 
Congress of the International Homeopathic League are representative of their 
individual work immediately before they collaborated on clinical trials. 
Paterson (1936) had continued the investigations of bowel flora and their 
relation to homeopathic treatment begun by Edward Bach and C.E. Wheeler. 
Boyd (1936) had conducted biochemical and biophysical tests into potency 
variation. The latter tests were done using equipment that Boyd had 
developed to refine the early investigations of Abrams into homeopathic 
action at a distance, and were thought to allow an objective test of the 
medicines and potencies suited to any individual. It is worth recounting some 
of the story since it contains details of an early British placebo-controlled test 
of human reactions to homeopathic potencies. 
Boyd was interested in Abrams's techniques, but quickly realized that 
Abrams had wrongly identified resistance as the electrical factor and replaced 
the original resistors with variable conductances and a variable condenser. 
His more rigorous method, which involved placing the subjects in a Faraday 
cage, was tested by an independent committee, led by Sir (later Lord) Thomas 
Horder, in a fraudbusting exercise funded by the Royal Society of Medicine 
(Horder 1924). In 5 blind test series Boyd's team was almost completely 
successful in distinguishing coded vials of substances such as sulphur or 
morbid matter from placebo or other substances. The only errors occurred 
twice in one series of 20 Bernoulli trials, and Whately Smith, the investigating 
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scientist, believed this was probably due to operator error. In another series of 
25 successful trials Smith calculated the odds against the results being due to 
chance as 33 554 432 to 1. Horder, who seems to have been unaware that some 
of the coded vials contained homeopathic Sulphur-which were also correctly 
identified - reported the results to a closed meeting of the RSM. According to 
a journalist from the Morning Post who managed to gatecrash, there was 
unanimous agreement not to discuss the matter further, and no further funds 
were made available to investigate the phenomenon, even though it pointed 
to a possible diagnostic test for cancer and other serious disease (Russell 1973: 
44ff). 
It is still not known whether the reactions were primarily electromagnetic, 
perhaps involving some form of quantum effect at levels excluded by 
mainstream biology, or whether they were primarily psychic (assuming such 
a distinction is valid). The whole area of dowsing effects, homeopathic action 
at a distance and related biophysical phenomena was thoroughly reviewed at 
the end of the period in question by a university physicist and geologist, and 
the title of his book, Psychical Physics, seems apt enough {Tromp 1949). In the 
1940s Boyd also conducted a protracted series of more orthodox experimental 
tests of the effects of potentized substances, such as mercuric chloride on 
enzyme production by yeast. This work is still accepted as being among the 
most rigorous pre-clinical research conducted in homeopathy, and the cost of 
replicating it to the standards set by Boyd was estimated at £100,000 at 1982 
prices by Kollerstrom (1982). 
9.5.1. Glasgow 1941: diphtheria 
At this time, the Schick test was widely used to ascertain acquired post-
vaccination immunity to diphtheria. Paterson and Boyd (1941) designed an 
experiment using the test as a measure of whether high potencies were 
biologically active. They were explicit that it was not designed initially to test 
whether homeopathy might have a prophylactic effect in diphtheria, although 
claims of the prophylactic effects of isopathy have been common in 
homeopathy, and disputed equally frequently. 
Four case series with a historical control were undertaken to explore whether 
homeopathic potencies of vaccine (alum-precipitated toxoid C30) or the 
diphtheria nosode (Diphtherinum C201) could bring about an increased 
proportion of negative tests in subjects previously testing positive. Out of 33 
subjects originally testing positive, 20 {60%) tested negative after treatment. 
While acknowledging the problems inherent in the Schick test and in 
retrospective comparisons generally, the authors believed their preliminary 
result compared favourably with the (recent) historical control of 3743 
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untreated Glaswegian children, only 33% of whom were Schick negative 
when retested. 
9.5.2. Glasgow & London 1941-42: mustard gas burns 
Following its use during the First World War, mustard gas was known to 
cause not just the well-known signs of conjunctivitis and blistering, but to 
compromise immune functioning by attacking blood-cell production in the 
bone-marrow (Kurmbahaar 1919). The renewed threat of chemical attacks in 
the early years of the Second World War meant that research into methods of 
prevention and treatment of mustard gas lesions assumed a high priority. 
British homeopathic researchers and clinicians offered their services to the 
Ministry of Home Security, and this led a series of preventive and treatment 
trials at the homoeopathic hospitals in Glasgow and London (British 
Homoeopathic Society 1943). The 10% solution of mustard gas in benzene 
was supplied by the Ministry, and trials took place under carefully controlled 
conditions. Application of the solution to the forearm, area affected, room 
temperature, preparation of the skin and surgical dressing were all 
standardized, as was the age, sex and physique of the volunteers as far as 
possible. In Glasgow an ad hoc method of randomization to treatment was 
used. Coded vials were laid out on a table, alternately potentized Mustard gas 
C30 (prepared by London Homoeopathic Laboratories) and placebo, and 
volunteers were paired. The first of each pair took any vial, and the second 
any serial number above or below the one taken by his colleague. The London 
trials used what was to become the standard modern randomization method, 
in which vials were coded in advance by an independent source (in this case 
Nelson's pharmacy, London) that held the code until after the experiment 
was over. The two approaches are reflected in the equal numbers of verum 
and control in Glasgow, and unequal numbers in London. 
The outcome measure used in all the trials was the appearance of the lesion 7 
days after first application. Visual inspection and photographic records were 
used in Glasgow to categorize the lesions as either superficial (skin intact) or 
deep (breach of surface). The first 12 cases showed no deep lesions in the 
verum group and conversely no superficial lesions in the controls. Further 
volunteers were tested, with similar results, although the report is unclear 
whether the tabulated 'summary of 28 cases' (p. 5) represents new cases or 
includes the 12 original ones. 13 of the tested cases then took part in a 
randomized crossover, approximately 4 weeks later, also double-blind and 
placebo-controlled. This led to 4 groups: placebo-verum (7 cases) 
verum-placebo (3 cases), verum-verum (2 cases) and placebo-placebo (1 
case). The results seem to confirm those found in the first series, even 
extending them: the verum-placebo group still produced superficial lesions a 
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month after verum. The one placebo-placebo case produced marked and 
extensive dermatitis, suggesting sensitization to mustard gas. This was 
treated with Rhus-tox C30, matched to the presenting symptoms; intense 
itching was relieved quickly, and rash disappeared within 2 days. 
Two medical officers in London used visual inspection only to grade each 
lesion on a 3-point scale of superficial, medium or deep. This difference, as 
well as the larger numbers involved in London, meant that the Glasgow 
figures were not included in the statistical analysis of results conducted by 
H.O. Hartley of the Statistical Computing Service. The first London series 
tested C30 potencies of Mustard gas (2 preparations), Rhus toxicodendron, Kali 
bichromicum, Opium and Cantharides, each against its own placebo group. 
Analysis was conducted for all groups combined, and each medicine 
separately, and the results are shown in more detail in Apps. 2.2 and 2.4. The 
combined analysis established a statistically significant positive result for 
verum (chi 2 = 8.44). Mustard gas (chi 2 = 3.58) and Rhus-tox (chi 2 = 5.24) 
approached significance on their own, despite the very small numbers 
involved (23 and 21 respectively). The second series retested Rhus-tox as a 
treatment and Mustard gas as prophylactic, adding Variolinum (smallpox 
nosode) and Rhus-tox as prophylactic. According to Hartley, further analysis 
confirmed the efficacy of Mustard gas as prophylactic (chi 2 = 10.39). 
Moreover, the efficacy of Rhus-tox as a treatment was 'definitely established' 
(chi 2 = 7.04), especially when the results from series 1 and 2 were combined 
(chi 2 = 11.78). 
The Glasgow and London trials' homeopathic interest stems from their 
suggestion that isopathy (i.e. Mustard gas) can protect against but not treat 
mustard gas lesions, and that an unrelated natural substance which causes a 
clinical analogue of the lesions (i.e. Rhus-tox), can treat but not protect. This 
appears to support experimentally the traditional neglect of isopathy and 
nosodes in treatment of their source conditions, while allowing them a role as 
prophylactics (see Ch. 4). It was later shown that the original statistical 
analysis underestimated the efficacy of Kali-bich in series 1 because the 
placebo group in that experiment was atypical (Owen & Ives 1982). The 
conduct of the trials as a whole is remarkable for the era, and the London 
series included what are probably the first randomized double-blind placebo-
controlled clinical experiments to incorporate not only individual statistical 
analysis but a simple meta-analysis as well. 
9.5.3. Burton-on-Trent, 1951-53: surgical tuberculosis 
A trial of classical homeopathy in tuberculosis of bones and joints was 
conducted by E.K. Ledermann in the early 1950s. Ledermann had previously 
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published a case series of serious mixed chronic diseases including surgical 
TB, and later had argued that homeopathy was perfectly suitable for 
evaluation in clinical trials, but should be tested against placebo, not 
conventional therapies (1945; 1949). The randomized trial at Bretby Hall 
Orthopaedic Hospital, Burton-on-Trent, was a development of that research 
interest. Ledermann (1954) randomized patients single-handed by tossing a 
coin, and was aware which patient received verum or placebo, on top of 
treatment as usual - bedrest, immobilization, surgery, diet, antibiotics. 
However, the hospital staff, including R. Lunt, the orthopedic surgeon who 
made the clinical evaluation, were not aware which treatment had been given. 
The main outcome was 'general progress' measured on a 5-point scale, and 
showed no statistical difference between groups. A secondary binary measure 
of 'unexpected improvement' was applied to the first 51 patients only (27 
verum, 24 placebo), and showed a trend in favour of homeopathy: 12 met the 
criterion, 9 of whom had received verum. There were many obstacles to the 
satisfactory conduct of the trial. Sutherland, the MRC statistician, noted that 
the homeopathy group appeared to contain more advanced cases at 
admission, and that concurrent antibiotics may well have masked longer term 
benefits from homeopathy. Ledermann himself had a 5-hour journey to the 
hospital from London, preventing consultations of the frequency and length 
normally expected. Lunt was anxious to try the new antibiotics, marsilid and 
isonicotinic acid hydrazide, and stopped evaluation of 'unexpected 
improvement' prematurely as noted. 
9.6. Discussion 
9.6.1. Conditions treated 
Homeopaths had always claimed that chronic disease could be treated 
successfully, but after some early trials for mixed conditions (see Ch. 6), 
clinical trials had focussed almost entirely on acute illnesses. This represents 
the clinical concerns of the pre-antibiotic era, but also some of the 
administrative difficulties in conducting lengthy trials for chronic illness. The 
exceptions in this group were chronic furunculosis, chronic URTI and surgical 
tuberculosis. 
9.6.2. National styles of homeopathy 
National styles of prescribing are apparent in the trials found here, and reflect 
the research climate in each country. In Germany, the subject was approached 
from the clinical low-potency quadrant shown in Figure 4.1. In the USA, low-
and high-potency advocates were both represented, but human clinical trials 
were only conducted using low potencies. The absence of French clinical trials 
in this period is notable, although in vitro and animal research into the 
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physico-chemical basis of dynamization was more advanced there than 
elsewhere, as the result of the formation of three major research-orientated 
homeopathic pharmacies around 1930 26• In Britain, in the 1930s, basic 
research into potency variation paralleled the French and American efforts, 
and towards the end of the period British researchers managed to synthesize 
the different national trends of the previous 40 years, investigating the effects 
of ultramolecular potencies on healthy and sick humans, using clinical, 
isopathic and classical methods. 
The content of the trials shows that some homeopaths at least were willing to 
expose homeopathy to an internal critique. The trial designs show a retreat 
from the pragmatism of the previous 50 years, and the development of a 
much narrower focus, testing hypotheses about specific treatments such as 
those seen in the American trials before 1923. Trials of increasingly clearly 
defined conditions became the norm, allowing the rejection of traditional 
clinical recommendations which had outlived their usefulness. However, the 
trialists were quick to point out that the average group effect of a specific was 
not a test of homeopathy per se, but only a test of the specific medicine and 
potency used. 
It is worth noting the retreat from traditional ideas of individualizing 
treatments that created the need for these trials. Hahnemann repeatedly 
pointed out that each epidemic required a genius epidemicus to be worked out 
to match the current symptoms. Although he recommended Belladonna for the 
'mild smooth scarlet fever of Sydenham' that was prevalent in about 1800 
(Hahnemann 1801b), he warned later that the same treatment was not suitable 
for a much more severe disease (probably hemorrhagic scarlet fever) that 
began to emerge in his lifetime, but which was still given the generic 
diagnosis and treatment for 'scarlet fever' by German physicians 
(Hahnemann 1808b ). Records of the virulence of the disease in Great Britain 
from the mild, rarely fatal disease that Sydenham observed in 1675 until the 
1950s, seem to confirm Hahnemann's observations: 
It seems clear that bad epidemics occurred in the eighteenth century, 
that there were quite long intervals between them, and that sometimes 
in the early years of the nineteenth century- probably about 1803 - the 
disease became milder, although it was still common. The mild phase 
26 Boiron (1990 Chs 3-5) reviews French basic research 1900-1950, as part of a broader 
historical treatment of the potency problem in homeopathy, culminating in the 
Beneveniste-Nature 'memory of water' controversy. 
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... lasted until about 1830, but from then on the disease began to 
increase in severity again ... In 1840 the number of deaths nearly 
doubled and, for a generation after, scarlet fever was the leading cause 
of death amongst the infectious diseases of childhood. (Gale 1959: 89ff) 
Hahnemann called the more virulent disease purpura miliaris, and 
recommended Aconitum at one time. However, his continued emphasis on the 
need to recalibrate treatments was forgotten, and Belladonna was used, with 
little success, by homeopaths and allopaths for the rest of the nineteenth 
century (see Ch. 7). The three trials of Belladonna by Chadwell and 
Wesselhoeft Jr were clearly designed to test an outdated treatment they had 
reason to believe had become a millstone round homeopathy's neck. 
Wesselhoeft showed by reanalysis of the symptomatology that the Belladonna 
provings only corresponded to the mildest cases of the disease - as 
Hahnemann had pointed out. Wesselhoeft (1924) also went on to show that 
reanalysis of collective symptoms in mumps, according to the traditional 
method used in epidemics, could lead to an effective treatment that was 
unlisted in the homeopathic clinical guides. This was for a condition where 
classical individualization of symptoms had been found to be ineffective -
and in fact with a higher complication rate than under allopathy - in the same 
hospital (see 9.3.5). 
Nosological categories also determined the treatments in the earliest German 
trials of this group. A contemporary account by the homeopath Otto Leeser 
indicates the vehemence of some of the a priori allopathic opposition to Bier's 
trials, and also views the affair from a perspective of greater homeopathic 
experience than Bier's. 
In his polemic publication W. Heubner denies that the action of 
sulphur in furunculosis, even if it should be confirmed, is concerned 
with a homeopathic effect. He states: 'Because the introduction of a 
disease like furunculosis through the ingestion of large doses is not 
held possible even among the homeopathic profession and much less 
has not been demonstrated.' I must contradict him: In Hahnemann's 
Chronic Diseases, one finds under sulphur the symptom, boil. In the 
depiction of the action of sulphur by Hugo Schulz one finds: 'Increased 
sweating occurs, eruptions of the most diverse type develop, 
particularly furunculosis.' But we may permit a contemporary of 
Heubner who is unsuspected of any homeopathic conceptions to 
speak. L. Lewin states:' After the ingestion of sulphur, occasionally an 
acne or miliaria-like eruption appears, very rarely swellings and 
carbuncle-like formations.' From more recent times the experiences of 
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A. Bier as well as his pupil Abegg may be added. 
I have mentioned this controversy in order to show that the use of 
sulphur is well founded homeopathically and that A. Stiegele, who at 
one time recommended a retesting of sulphur iodatum to A. Bier, was 
entirely justified from the standpoint of the homeopathic method. But 
what Stiegele surely did not wish and what, as he himself has stressed 
repeatedly, would be entirely nonhomeopathic, is the generalization to 
which Bier's reports gave occasion in the medical world, namely that 
sulphur is indicated for any furunculosis. With such an unselected 
procedure only a certain percentage of results will be obtained. It is not 
homeopathic when one proceeds to give sulphur on the basis of the 
diagnosis furunculosis. Only if the furunculosis stands on the soil of 
such skin and metabolic alterations which lie in the sulphur trend, will 
the homeopathic physician select sulphur. It might be that he would 
select arsenicum if there were a diabetic basis, or again arnica if there 
were a diabetic basis, or again arnica if there were a pyemic state in the 
degenerative condition of issue and skin, and a tendency to ecchymosis 
spoke particularly for it. To know the homeopathic use of sulphur 
means to know the homeopathic materia medica as completely as 
possible so that one may proceed differentially-therapeutically. (Leeser 
1936: 368ff) 
Later trials of clinical homeopathy in Britain screened a range of clinical 
medicines inductively in order to establish the most promising ones which 
were then retested with larger numbers. Isopathy was also used as a test of 
the biological activity of high potencies per se. The last trial in the review 
tested individualized high potency classical homeopathy demonstrably 
similar to that practised today. 
9.6.3. Trial design 
Received opinion states that the self-critical ideal of biomedicine was reflected 
in the gradual emergence of the modern clinical trial by about 1950, 
combining randomization, blinding and statistical analysis (Lilienfeld 1982). 
At the same time, the emergence of the clinical research orientation that came 
to define biomedicine in the twentieth century was also believed to have 
sounded the death knell for homeopathy. 
Against this, early twentieth-century clinical trials show that homeopaths 
quickly adopted the conventions of the controlled trial, ahead of orthodox 
medicine in some cases. The use of placebos as a control was already 
institutionalized within homeopathy in a way that it had not been elsewhere 
(see Ch. 8), and homeopaths appear to have been eager to grasp the 
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opportunity to apply more modern statistical analyses to their therapy than 
had been possible in the previous century. In particular the emergence of 
standard deviation was welcomed, since it helped to remove a notorious 
source of bias that had affected comparisons of unbalanced treatment groups 
(Guttentag 1940). Some British trials in the group reflect advanced 
experimental thinking for their day, and were designed with independent 
statistical analysis of the results in mind. Beginning in 1941, reports began to 
contain enough detail about experimental conditions and results for them to 
be assessed for internal validity using modern methodological quality scales. 
The era of modem clinical evaluation of homeopathy can be dated to circa 
1940, and it is appropriate therefore to use that as the starting date for the 
review of contemporary trials in Part III. 
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PART Ill: IS HOMEOPATHY CLINICALLY RELEVANT? A SYSTEMATIC 
REVIEW OF CLINICAL TRIALS, 1940-98 
10. Rationale 
11. Methods 
12. Results 
13. Discussion 
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10 RATIONALE 
Background Public demand for alternative and complementary medicine has 
never been greater, and homeopathy is high on the list of sought-after 
therapies. Purchasers and providers looking for evidence to justify funding 
naturally turn to published reports of clinical trials or reviews of those trials. 
Questions What reviews have been conducted? Did their design and 
conduct affect the conclusions drawn? Is a further review justified? If so, what 
areas of interest should it explore? 
Argument Traditional narrative reviews are giving way to systematic 
literature reviews. With regard to homeopathy, these have mainly been 
limited to the placebo question. The most inclusive review was published in 
1991, since which time many trials have been published. All of the reviews 
provide only scant detail of trial content. A new review of trials with placebo, 
orthodox and no treatment controls is justified. It should contain enough 
detail to provide the foundation for a searchable database of homeopathic 
trials, and should also look at areas neglected in previous reviews, such as 
intrahomeopathic differences, safety and clinical relevance. 
10.1 Previous reviews of homeopathic clinical trials 
Recent reviews of clinical trials of homeopathy fall into two main groups, 
narrative and systematic. Traditional narrative reviews, often found in 
textbooks and monographs, have tended to survey a variety of experimental 
evidence, including controlled therapeutic trials in humans (e.g. Sankaran 
1978; Coulter 1981; Scofield 1984; Aulas, Bordelay, Royer 1991; Righetti 1991; 
Bellavite & Signorini 1995; Meyer 1996). The criteria for inclusion and 
assessment are not stated in any of these sources, and the most trials reviewed 
in any was 31 (Aulas, Bordelay, Royer 1991). Overall conclusions are 
generally declared to be positive or negative according to the number of trials 
that found statistically significant differences between homeopathy and 
placebo. Authors' allegiances regarding the plausibility of homeopathy 
sometimes interfere with the reporting and interpretation of evidence. Some 
sources attempt to explain away any positive results for homeopathy, in 
keeping with the authors' rejection of homeopathy's plausibility (e.g. Aulas, 
Bordelay, Royer 1991; Meyer 1996), while only interpretations favouring 
homeopathy are found in another source, coupled with overt anti-allopathic 
bias (Coulter 1981). 
However useful discussions in sources not subject to peer review may be in 
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other respects, narrative reviews are clearly open to many sorts of bias in the 
framing of study questions, literature search, data extraction from primary 
reports, interpretation of results and presentation of overall conclusions - a 
widespread problem by no means confined to reviews of homeopathy (Cook 
& Leviton 1980). The presence of any of these potential biases poses a threat to 
the purpose of literature review, which can be summarized concisely as the 
synthesis of results from individual studies with the intention of allowing 
generalizations to be made about, or from, an intervention or population of 
interest. 
By contrast with narrative reviews, systematic reviews are expected to be 
conducted according to a transparent protocol from the outset, allowing 
method and results to be independently replicated, as in scientific 
experimentation generally (e.g. Oxman, Cook, Guyatt 1994; NHS CRD 1996; 
Mulrow & Oxman 1997). The literature is searched, and data extracted, in a 
predefined way, and quality scales are often used to allow comparison of 
individual trials and to give greater weight to results from trials with higher 
internal validity (Moher, Jadad, Nichol et al. 1995). Overall conclusions are 
either based on rigorous overviews, or increasingly on quantitative estimates 
of effect, coupled in both cases with sensitivity analyses of the robustness of 
evidence. It is generally regarded as unwise to dichotomize trial results into 
'positive' and 'negative' on the basis of 95% significance tests, since p values 
of 0.04 and 0.06 indicate similar strength of evidence. The technique of meta-
analysis tries to avoid this by converting a single (main) outcome from each 
study to an odds ratio, or similar. Ratios are then weighted for sample size 
and pooled. Combining results, especially of small studies which may have 
insufficient power to reject a null hypothesis, can allow a more definite 
answer to a question (Cook & Leviton 1980; Pogue & Yusuf 1998). 
The science of conducting reliable systematic reviews is a recent one (Light & 
Pillemer 1984; Chalmers & Altman 1995; Russell, Di Blasi, Lambert et al. 
1998), and developments typifying the evolution of the field as a whole can be 
traced even in the small sample of 5 found here after a literature search was 
undertaken for systematic reviews of homeopathy. The essential 
characteristics of those that were not restricted to specific conditions or 
medicines are shown in Table 10.1. 
The earliest review (Hill & Doyon 1990) does not appear to have followed an 
explicit protocol, other than screening reports for adequate randomization. 
The authors extracted data concerning trial design, treatments and outcomes 
from 40 randomized trials of homeopathy vs placebo, orthodox or no 
treatment controls chosen from an unspecified number found in the literature 
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search. No quality assessment instrument for grading internal or external 
validity was used. Results were displayed as positive or negative declarations 
of the original authors, presumably depending on whether statistical 
significance of p::;0.05 was found -19 positive, 19 negative, 2 undecided. The 
reviewers declared that there was not enough evidence from large high-
quality trials to support the idea that homeopathic medicines might be 
efficacious. 
Table 10.1 Inclusive systematic reviews of clinical trials of homeopathy, 1990-98 
Reference Design Homeo. type N found N incl. Question Quality tool 
Hill & Doyon 1990 Systematic review All ? 40 General overview no 
Result 
-ve 
Kleijnen, Knipschild Systematic review All 107 105 General overview yes +ve (?) 
and ter Riet 1991 
Beissel, Cucherat, Meta-analysis All 189 20 > than placebo? no p<.001 
Haugh and Gauthier 
1996 
Linde, Clausius, Meta-analysis All 186 89 > than placebo? yes OR 2.45 
Ramirez, et al. 1997 
Linde & Melchart 1998 Meta-analysis Classical 35 32/19 > than placebo? yes RR 1.65 
Kleijnen, Knipschild and ter Riet (1991) used an explicit protocol and a very 
extensive literature search for trials with placebo, orthodox or no treatment 
control (including historical controls, uniquely among these reviews). The 
quality assessment tool devised by the reviewers awards points for the usual 
internal validity factors such as randomization and masking, but imposes 
heavy discounting of positive evidence found in small trials, which 
immediately attracted adverse comment (Fisher, Huskisson, Scott et al. 1991). 
The scale (0-100) awards up to 30 points for trial size alone, and small trials 
are further penalized, as they can receive only 10 out of the 20 points possible 
for randomization - no matter how well they were randomized. Small trials 
with good internal validity are inevitably labelled as 'poor quality', inherently 
unable to surpass the 55 point cut point (as discussed in Dean 1998). The scale 
also deducts points if the manufacturing procedure for a test medicine was 
not described in full, which attracted further criticism from Fisher et al. (1991) 
who observed that most biomedical journals impose strict word limits that 
restrict the amount of detail that can be included in trial reports. The test 
medicine in the (small but well-conducted) trial by Fisher et al. (1989), for 
example, was made in accordance with the French national homeopathic 
pharmacopeia, but there was no opportunity to mention this in the space 
allowed. The vote count in the review was again based on individual 
significance tests, but showed evidence of homeopathic superiority in 81 of 
105 of trials (77%), a trend which seemed independent of trial quality to the 
reviewers. They stated that they would be more likely to modify their prior 
incredulity about homeopathic efficacy- which led them to conduct the 
review -when independent replications of successful trials had been 
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published. 
Another very extensive literature search was conducted using a rigorous 
protocol for data extraction in order to answer the placebo question by meta-
analysis, for the first time in reviews of homeopathy (Boissel, Cucherat, 
Haugh et al. 1996). No previously developed quality assessment tool was 
used, because trials were required to meet all the inclusion criteria - mostly 
standard internal validity points relating to masking and randomization. 
However, the decision to exclude any trial that was not explicitly analysed as 
intention-to-treat restricted the meta-analysis to only 20 trials of the 189 
found. The criterion was adopted to exclude biases that can affect treatment-
only analyses, but in this case left out many trials where the assigned and 
analysed numbers were the same because there had been no attrition. The 
authors acknowledged that their meta-analysis technique of pooled p values 
from separate trials was problematic, but a positive result survived sensitivity 
analyses such as exclusion of poor quality trials and the addition of 
hypothetical trials with null results (p=0.5) to the pool. An overall value of 
p<0.001 led the reviewers to conclude that at least one of the review trials 
must have shown superiority to placebo, although it was not possible to 
identify which one. 
A parallel review with an explicit protocol designed to answer the placebo 
question also used an extensive search strategy and uncovered 186 trials, of 
which 133 were placebo-controlled and 119 were also randomized and/or 
double-blind (Linde, Clausius, Ramirez et al. 1997). The quality scale was 
again developed by the review team, and does not contain any of the 
contentious items or weightings noted in the scale devised by Kleijnen et al. 
(1991). Although only 89 trials results were reported in a manner allowing 
them to be expressed as odds ratios, the positive meta-analysis of those trials 
survived all the sensitivity analyses conducted: for each of classical, clinical, 
isopathic and complex homeopathy alone; for ultramolecular dilutions above 
Avogadro's constant (D24 and C12 or above in homeopathic potencies); for 
Medline-only trials; and for 26 high-quality studies only. However, the 
authors were clear that there were no implications for clinical practice, since 
they found no evidence that homeopathy was effective in any single clinical 
condition. 
Two of these authors then reviewed trials of classical homeopathy, again to 
answer the placebo question (Linde & Melchart 1998). A refinement of their 
quality scale was used to assess 32 of 35 reports suitable for inclusion in the 
overview. A meta-analysis similar to that carried out in the sensitivity 
analysis for classical trials in the previous review was performed with 19 
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trials containing results that could be converted to rate ratios. Although an 
overall RR of 1.65 was found, little convincing evidence of superiority to 
placebo was found in trials with high quality scores - RR 1.12. 
10.2 Is another systematic review of homeopathic trials justified? 
In view of the evidence overviewed here, what is the justification for another 
systematic review? If it were to try to answer the placebo question once again, 
there would be little point. The painstakingly thorough meta-analysis by 
Linde et al. (1997) is generally regarded as the strongest evidence yet 
published of homeopathic superority over placebo. There is a case for 
updating it when a substantial number of new randomized placebo-
controlled trials has emerged - ~20% new trials are recommended to avoid 
the risk of Type 1 error (Pogue & Yusuf 1998) - but that is not the same as a 
new review. 
However, all of the reviews discussed were explicitly or implicitly designed 
to answer the scientific question 'Are homeopathic medicines any better than 
placebo?'. Various eligibility criteria for study inclusion, such as placebo-
controlled only, or randomized only, or intention-to-treat only, might have 
left out trials of interest from the point of view of planning further research 
and replications. Moreover, although the review with the least restrictive 
criteria assessed 105 trials altogether (Kleijnen, Knipschild, ter Riet 1991), 
many more trials with no treatment and orthodox treatment as control have 
been published or discovered since it was conducted. It must also be noted 
that all the reviews provide only brief details of the trials. 
These observations taken together suggest the need for a comprehensive and 
systematic literature search to create a detailed database of prospective 
clinical trials of homeopathy with controls, including no treatment and 
orthodox treatment as well as placebo. From a number of recommendations 
concerning future research made by Scofield (1984), two in particular stand 
out as not having been addressed in any of the above reviews: (1) that the 
safety of homeopathy cannot be taken for granted, despite the assurances of 
many of its proponents; and (2) that homeopathy needs to provide evidence 
of clinical relevance, not mere statistical superiority to placebo. Questions 
about the following areas should therefore be posed in a new review: 
Intrahomeopathic differences Although some previous reviews have identified 4 
basic homeopathic subgroups - classical, clinical, complex and isopathy-
little attention has been paid to differences in content and treatment validity. 
Safety The safety of homeopathic medicines has often been assumed Gonas 
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1998), and few empirical studies have been published (Hentschel, Kohnen, 
Hahn 1998). A new review should look for evidence of adverse treatment 
effects as reported in trials. 
Holism Classical homeopathy is claimed by its proponents to be a 
holistic therapy, dissimilar to biomedicine which tends to target the specific 
causes or symptoms of pathology. Global response to treatment as measured 
by effects on comorbidity and intercurrent illness should be included. 
Efficiency Homeopathy is often said to be economically efficient because of 
the low cost of medicines. Cost-benefit and cost-utility data should also be 
looked for in a new review. 
Clinical relevance Statistical superiority over placebo does not guarantee 
clinical relevance. Other points of comparison can be looked for in trials of 
homeopathy vs orthodox treatments, and in placebo-controlled trials for 
conditions where orthodox treatments are unavailable or of low efficacy. 
In the light of these considerations, a new comprehensive database and 
review incorporating the points above as objectives seemed to be justified, 
and was therefore undertaken. The methods are discussed in Ch. 11. 
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11 METHODS 
11.1 Literature search and data sources 
Medline, Embase and the Cochrane Library databases were searched for 
controlled clinical trials of homeopathy using the terms 'homeopat*' and 
'homoeopat*' for the period to 31 December 1998, and the entire result of the 
searches was manually screened. 
The great majority of alternative therapy reports are not indexed by the 
principal biomedical data extraction services such as Index Medicus and 
Embase, so a comprehensive search was conducted of the so-called grey 
literature, including: 
• British Library AMED/CATS and RCCM CISCOM databases of references 
from alternative medicine journals not indexed elsewhere 
• cumulative indexes of the principal international homeopathic journals 
not included in Medline or Embase 
• the bibliographies of monographs (e.g. Sankaran 1978; Coulter 1981; 
Aulas, Bordelay, Royer 1991; Righetti 1991; Bellavite & Signorini 1995; 
Meyer 1996) 
• international and national homeopathic congress proceedings (e.g. Liga 
Homeopatica Internationalis and GIRI - International Congress on Ultra 
Low Doses) 
• the paper archive of 348 trial reports and review articles collected by 
Hominform (Glasgow Homeopathic Hospital Library) on behalf of the EU 
Homeopathic Medicine Research Group (Boisse!, Cucherat, Haugh et al. 
1996). 
The bibliographies of original research reports and review articles cited in the 
sources above were also screened. Internationally, researchers and librarians 
in the field were contacted and asked to provide further references. 
11.2 Language restrictions 
Results of systematic reviews are highly susceptible to bias when based only 
on reports in English (Moher, Fortin, Jadad et al. 1996). Because of the 
international spread of homeopathy and the high proportion of non-English 
language reports, the literature search included reports irrespective of 
language. 
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11.3 Inclusion and exclusion criteria 
The criteria established for selection and exclusion of trial reports are listed 
below. 
11.3.1 Therapy definition 
Homeopathy was defined as any of the methods described in Ch. 4, and their 
variants, and broadly classified as classical, clinical, complex or isopathy. 
The definition did not include therapies or diagnostic systems related to 
homeopathy, such as anthroposophical medicine and radionics (Steiner 1948; 
Russell 1973), which sometimes employ homeopathic medicines but with 
fundamentally different reasons and methods for their selection. 
11.3.2 Medicine definition 
Homeopathic medicines were defined as substances prepared according to 
homeopathic pharmacopeia, and included in the homeopathic materia medica 
and repertory (e.g. Schroyens 1993). Although some reviews accept only 
potentized medicines (e.g. Linde, Clausius, Ramirez et al. 1997; Dantas & 
Fisher 1998), it was decided to include unpotentized mother tinctures (0) as 
well. The boundary between homeopathy and phytotherapy is fuzzy in 
certain areas, but the review relates to homeopathy as practised and its 
clinical relevance rather than the dilution-placebo question. A number of 
homeopathic medicines were adopted from folk medicine before being 
subject to provings, and are widely used in homeopathy as both mother 
tincture and potencies, with similar indications. An example would be 
marigold (Calendula officinalis) for wound healing. 
The definition excludes electronically and radionically simulated potencies 
(e.g. Thomas 1994; Dittmann, Kanapin, Harisch 1999). 
11.3.3 Trial design 
Given the small number of trials found in previous systematic reviews 
(maximum = 189) for the field as a whole, the inclusion of pseudo- and 
nonrandomized trials meeting these criteria was felt to be justified, especially 
as a quality assessment instrument purposely designed for this was used (see 
11.6). 
Studies were eligible for inclusion if they were: 
• prospective human clinical (curative, palliative or prophylactic) trials 
with 
• one or more concurrent or historical control groups that received either no 
treatment, placebo or an orthodox treatment 
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• a mean of ~10 patients in each treatment arm. 
Studies not eligible for inclusion were: 
• retrospective 
• single-group designs (including placebo-controlled time series or before-
and-after designs) 
• trials with surrogate outcomes only 
• pathogenetic drug tests (provings) designed to elicit symptoms in healthy 
volunteers 
• experiments to measure physiological effects of homeopathy on healthy 
subjects. 
11.4 Data extraction 
The primary data extraction form created for the review was successfully 
piloted in a review of trials of classical homeopathy, and was refined for the 
present review. It contains 43 fields which were filled in for all trials, and a 
further 7 relating to classical homeopathy only. 
Studies were indexed under the following heads: 
Bibliography including publication type and language. 
Clinical including trial condition, clinical area, levels of disease (acute, chronic, 
subacute) and treatment (curative, palliative, symptomatic). 
Population including country, number assigned, number analysed, age, 
gender, inclusion and exclusion criteria. 
Design including number of centres, masking, randomization, overall follow-
up period. 
Pharmacy including type of homeopathy, medicines, potencies, dosage and 
repetition, manufacture. Dilutions above An (equivalent in homeopathic 
potencies to ~C12, D24) were also classed as 'ultramolecular', while those 
below were classed as 'molecular'. 
Treatment including the number of homeopaths required to decide a 
prescription, whether follow-ups were included, and the interval between 
them. 
Outcomes including primary and secondary outcome measures, in order of 
importance as far as could be ascertained; reporting of adverse reactions; 
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effects on comorbidity and intercurrent illness. 
Results including authors' reports and estimates of effect; statistical tests 
(where given). Confidence intervals were not reported in most trials and were 
not collected here. 
Trials of classical homeopathy were also assigned to 1 of 3 overall categories 
defined according to the accrual policy and initial availability of treatment 
options: 
open when therapists made a free choice from the homeopathic materia 
medica; 
restricted when individualization was limited to a choice from a pre-defined 
list of medicines intended to be used for all subjects whether appropriate or 
not; 
selective when subjects were admitted to a trial only provided they had 
previously been matched with a medicine from a pre-defined list. 
The following fields were also completed for classical trials: 
• degree of choice of initial potency: fixed, limited or free 
• freedom or otherwise to change medicine, potency or repetition: fixed, 
limited or free 
• the number of homeopaths required to decide a prescription 
• the treatment rationale in the words of the original author or authors. 
11.5 Representing strength of results 
As noted, vote counts based on totalling dichotomized 'positive' and 
'negative' results are not recommended (Cook & Leviton 1980). Yet in a 
review of widely different designs and treatments where pooled estimates of 
effect are not intended, an adequate means of summarizing results is 
required. A compromise was adopted based on the creation of a 5-point 
stratified vote which takes account of statistical trends and secondary 
outcomes as well as significant differences in a primary outcome. Trials 
controlled by placebo or no treatment were assigned to one of 5 levels: 
+ significant result favouring homeopathy in primary outcome 
( +) statistical trend favouring homeopathy in primary outcome, or 
significant results in secondary outcome(s) 
0 statistical equivalence 
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(-) statistical trend favouring control in primary outcome, or 
significant results in secondary outcome(s) 
significant result favouring control in primary outcome. 
In view of the difficulties attached to the interpretation of equivalence in 
pragmatic trials of competing treatments Oones, Jarvis, Lewis et al. 1996), 
trials of this sort were graphically distinguished from no treatment and 
placebo-controlled trials, and assigned to one of 3 levels: 
> significant result favouring homeopathy in primary outcome, or 
equivalence of primary outcome plus significant result favouring 
homeopathy in secondary outcome(s) 
= statistical equivalence, including insignificant trends in either 
direction 
< significant result favouring orthodox treatment, or equivalence of 
primary outcome plus significant result favouring orthodox 
treatment in secondary outcome(s). 
For trials that compared homeopathy with more than one control treatment, 
the vote was based on a single comparison: orthodox treatment, placebo, no 
treatment, in that order of preference. 
11.6 Methodological quality instrument 
Instruments for evaluating the validity of clinical trial conduct, analysis and 
reporting have become popular since one of the first was published two 
decades ago (Chalmers, Smith Jr, Blackbum et al. 1981). However, 
methodological quality (MQ) scales can easily mislead, and their use is being 
increasingly questioned. Because many scales conflate reporting standards 
with internal validity in a single score, this can lead to separate reports of the 
same trial receiving widely different scores on the same scale (Dean 1998). 
Moreover, a comprehensive evaluated review of 25 MQ scales and 9 
checklists - including Kleijnen et al. (1991) - showed that the same trial might 
score 20% or 70% depending on the scale used, and criticized all of the scales 
for not having been developed scientifically, with the exception of one 
developed by the reviewers (Moher, Jadad, Nichol et al. 1995; Jadad, Moore, 
Carroll et al. 1996). The conclusions were that many scales failed to define the 
constructs they sought to measure; and that checklists were probably of 
greater use to the authors of trials than to reviewers. Because of problems 
such as these, some sources now advise against quality scoring altogether, or 
suggest reviewers use them merely as a primary exclusion filter (NHS CRD 
1996; Mulrow & Oxman 1997). 
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In a fresh attempt to develop a reliable and valid instrument, a preliminary 
wish list of 49 items thought to be indicative of internal validity was reduced 
to just 3 core items: randomization; double-masking; and analysis of dropouts 
and withdrawals Gadad 1994). Although this scale is now used widely, a 
weakness is that trials that report randomization are scored as being properly 
randomized even when details of the randomization method are not given. 
This may be related to the scale's original development as part of an effort to 
review an archive of several thousand pain trial reports. It appears to have 
been designed at least initially as a simple primary filter to allow extraction of 
ostensibly high quality trials from a mountain of data. 
The situation in homeopathy is completely different: with fewer than 300 
trials found in all it seems wasteful to discard preliminary evidence of lesser 
quality which might nevertheless stimulate further more rigorous research. 
Bearing the above-mentioned problems in mind, it was decided that the use 
of a preexisting MQ scale would be justified if it allowed meaningful 
weighting of trials with widely different designs in a review not intended to 
include a post-filtration meta-analysis of results derived from one design 
alone. Moher et al.'s (1995) review of scales contained at least one instrument 
(Cho & Bero 1994) that appeared to have been developed and tested for 
interrater reliability in a similar manner to that by Jadad et al. Although this 
scale suffers from some of the shortcomings common to others- conflation of 
reporting with internal validity, scoring of precision of results - it was 
adopted here in preference to other scales reviewed for 3 compelling reasons: 
1. It is designed to allow meaningful inclusion and weighted comparative 
evaluation of many different study designs, including prospective case series, 
case-controlled studies and longitudinal cohort studies, not just randomized, 
masked pharmacological trials. This would be important if a decision were 
made at a later date to enlarge the database to include designs excluded from 
the present review. 
2. It contains 23 questions (plus a further 7 on clinical relevance - see 11.7), 
corresponding in many respects to the revised checklist of 22 items prepared 
by The Consolidated Standards of Reporting Trials Group (CONSORT) (e.g. 
Moher, Schulz, Altman et al. 2001), in contrast to the streamlined 5-item tool 
developed by Jadad et al. The answers to these 23 (or 30) questions are worth 
retaining in any searchable database that might be created from this review, 
regardless of the plausibility of the combined scores. 
3. All questions apart from no. 1 (study design) and no. 2 (study question) are 
scored on a 3-point scale of O ('no'), 1 ('partially') and 2 ('yes'), rather than the 
more usual binary 'yes', 'no'. This acknowledges the distance between trial 
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conduct and reporting that sometimes exists, and is comparable with the 
checklist created by the original Standards of Reporting Trials Group (1994). 
The MQ instrument used here is shown in Table 11.1. 
Table 11.1 Methodological quality instrument, after Cho & Bero (1994) 
AU(PY) ________ Tl ____________________ _ 
1 Study design (check 1 only) 
Experimental, randomized trial: 
Placebo-controlled 
_ Comparative, no placebo 
Time series 
Crossover 
2 What was the study question? 
Experimental, unrandomized trial: 
Placebo-controlled 
_ Comparative, no placebo 
_Time series 
Crossover 
_ Natural experiment 
Nonexperimental: 
_ Cohort, prospective 
_ Cohort, retrospective 
_ Cross-sectional 
_ Case-control 
_ Case reports or case series 
SCORES FOR Qs 3-23: YES= 2 PARTIALLY= 1 NO= 0 Not applicable= strike through 
3 Was the study question sufficiently described? 
4 Was the study design appropriate to answer the study question? 
5 Were both inclusion and exclusion criteria specified? 
6 Were subjects appropriate to the study question? 
7 Were control subjects appropriate? (If no controls were used, score 0) 
8 Were subjects randomly selected from the target population? 
9 If subjects were randomly selected, was randomization sufficiently well described? 
10 If subjects were randomly allocated to treatment groups, was allocation truly concealed? (If unrandom, strike out) 
11 If blinding of investigators to intervention was possible, was it reported? (If not possible, strike out) 
12 If blinding of subjects to intervention was possible, was it reported? (If not possible, strike out) 
13 Was measurement bias accounted for by methods other than blinding? 
14 Were known confounders accounted for by study design? (If no known confounders, strike out) 
15 Were known confounders accounted for by analysis? (If no known confounders, strike out.) 
16 Was there a sample size justification before the study? 
17 Were post hoc power calculations or confidence intervals reported for insignificant results? 
18 Were statistical analyses appropriate? 
19 Were the statistical tests stated? 
20 Were exact P values or confidence intervals reported for each test? 
21 Were attrition of subjects and reason for attrition recorded? (If no attrition, strike out.) 
22 For those subjects who completed the study, were results completely reported? 
23 Do the findings support the conclusion? 
QUALITY SCORE [TOTAL/NUMBER OF SCORED Qs]: L 
In Question 1 each reviewed design receives a score of 1-5: 1 for case reports, 
2 for time series or uncontrolled experiments, 3 for cohort or case-control 
studies, 4 for unrandomized controlled trials, 5 for randomized controlled 
trials. In this review, designs scoring lower than 3 were excluded. Questions 
3-23 are scored as shown. Question 10 originally asked: 'If subjects were 
randomly allocated to treatment groups, was allocation sufficiently well 
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described?'. It was felt the second clause could be modified to 'was 
randomization truly concealed?' with no loss of the authors' original intent, 
but a considerable gain in clarity and salience. 
Final scores can be weighted in one of 3 ways, shown here with the interrater 
reliability of overall quality scores in tests conducted by the instrument's 
authors: 
1. all questions equally weighted: r = .81 (95% Cl, .58-.93) 
2. Question 1 multiplied by 3: r = .89 (95% CI, .73-.96) 
3. points for design, randomization, masking, statistical analysis, and 
support of conclusions by result given more weight: r = .85 (95% CI, 
.65-.94). 
Scheme 2 was adopted for this review, giving possible design scores of 9, 12 
or 15. 
To ensure consistency, an extensive key to filling in the form was created for 
the review (efforts to elicit a response from the authors having failed). The 
key included rules for adjudicating difficult or borderline cases. 
External comparisons between MQ scores obtained in this review and the 
scores of the same trials as rated by Kleijnen et al. (1991) or Linde et al. (1997) 
were made. 
11. 7 Clinical relevance instrument 
A literature search revealed only one instrument for evaluating clinical 
relevance (Cho & Bero 1994). This was presented in the same source as the 
methodological quality instrument, and was developed in the same manner. 
Table 11.2 Clinical relevance instrument (Cho & Bero 1994) 
SCORES FOR Qs 1-7: YES= 2 PARTIALLY= 1 NO= 0 
1 Were the therapeutic outcomes measured in the study important? 
2 Were subjects representative of those who would actually use the treatment? (Insufficient info= 0) 
3 Was the comparison group clinically meaningful? 
4 Was the treatment effect clinically meaningful? 
5 Were side effects adequately measured? 
6 Was approval from an institutional ethics committee explicitly reported? 
7 As far as could be determined from the article was the study ethical? 
CLINICAL RELEVANCE SCORE [TOTAL/14]: Q,_ 
It contains 7 questions relating to efficacy, generalizability and ethics (Table 
11.2). A key was created to ensure consistency of scoring for the clinical 
relevance (CR) instrument, similar to that for the methodological tool. 
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11.8 Quality control and data integrity 
The primary data extraction form was created in a computer database 
(FileMaker Pro), and was successfully piloted in a review of classical 
homeopathy only. The form allowed visual identity between the paper form 
used for the initial handwritten recording of the information for each trial and 
the subsequent on-screen data entry. After data entry the complete file was 
proofchecked by an experienced technical editor against the original 
handwritten forms. A random selection of 20 (9.8%) included trial reports 
were entered manually into the data extraction form twice, and there were no 
significant disagreements at this level. 
The MQ and CR forms were again designed in FileMaker Pro and integrated 
with the data extraction file. Similar quality procedures to those for the 
primary data extraction form were followed. Additionally, before on-screen 
entry, each handwritten sheet for the two instruments was checked by the 
editor against the keys created for them, to ensure the rules had been 
observed consistently. 
11.9 Sensitivity analysis and statistics 
The review was not hypothesis-driven, and descriptive statistics, charts and 
data plots were the primary means used to explore data. Intrahomeopathic 
differences were looked for in many areas including trial design, clinical area, 
publication type or language, potency level and results. Adequacy of 
assignment and masking methods and attrition handling were looked at for 
effects on strength of results. Possible correlations with MQ scores were 
investigated in, e.g. publication type or language, type of homeopathic or 
control treatment, attrition handling, potency levels and adverse events 
reporting. 
The MQ scale used here does not contain a high-quality cut point. Both 
Kleijnen et al. (1991) and Linde et al. (1997) independently stated that the best 
10% of trials in their sets could be regarded as having good internal validity. 
In the context of the present review objectives, such a narrow band seemed 
unduly restrictive so the top 20% of scores were used as an objective standard 
for inclusion of trials in more detailed discussion. 
Score totalling, rounding and conversion to percentages were automated in 
Filemaker Pro for both the MQ and CR instruments. Inferential statistics were 
used in some cases to test the strength of apparent relationships and trends, 
but are exploratory in nature. All analyses were performed in DataDesk. 
The results of the analysis are presented in Ch. 12. 
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12 RESULTS 
Reports of 279 prospective controlled trials of homeopathy were found in 264 
separate publications dating from 1941 to December 1998. The 74 excluded 
trials are tabulated in Appendix l, along with reasons for exclusion. 205 
reports in 191 separate publications met the inclusion criteria, and details of 
each trial can be found in Appendix 2 as follows: 
App. 2.1 
App. 2.2 
App.2.3 
App. 2.4 
Classical homeopathy 
Clinical homeopathy 
Complex homeopathy 
Isopathy. 
Basic characteristics of the set are shown in Table 12.1. 
Table 12.1 Characteristics of 205 controlled clinical trials of homeopathy 
Design n Control treatment n Publication type n 
Parallel 191 Placebo 153 Journal article 148 
Crossover 11 Orthodox treatment 37 Thesis 25 
Case control 1 No treatment 15 Conference proceedings 21 
Cohort control 1 Report 7 
Historical control 1 Disease level Book section 3 
Acute 109 Book 1 
Patients Chronic 87 
Sum 46 790 Subacute 8 Language 
Mean 228 Acute and chronic 1 English 117 
Median 60 French 38 
SD 1704 Clinical areas German 36 
• excluding Castro & Nogueira (1975): Respiratory infections & ENT 39 Italian 5 
Sum 22426 Surgical trauma 30 Spanish 4 
Mean 110 Musculoskeletal & rheumatology 21 Dutch 2 
Median 60 Neurology & psychiatry 21 Portuguese 2 
SD 189 Dermatology 17 Norwegian 1 
Gastroenterology 16 
Attrition Gynecology and obstetrics 16 Country 
Sum 823 Infections (misc) 12 Germany 48 
Mean(%) 4 (8) Asthma & allergy 11 France 37 
Median 0 Cardiovascular 7 UK 37 
SD(%) 49 (13) Metabolic disorders 6 Italy 14 
Range(%) 813 (80) Oncology 4 India 13 
Trauma 3 S. Africa 10 
Assignment Ophthalmology 2 Greece 7 
Random 153 Brazil 6 
Nonrandom 33 Homeopathy type Austria, USA 4 
Pseudorandom 9 Clinical 88 Netherlands 3 
Matched Pairs 6 Classical 54 Israel, Mexico, Nicaragua, 2 
Missing 4 Complex 37 Norway, Poland, Romania 
lsopathy 26 Australia, Belgium, Chile, 1 
Masking Cuba, Ghana, Iran, Nepal, Peru, 
Double 145 Potency level Ukraine, Zaire 
Open 37 Molecular i.e. <Cl2, D24 93 
Single 23 Ultramolecular i.e. ~Cl2, 024 70 
Missing 42 
12.1 Design 
Patients were assigned to parallel treatment groups in 94% of trials, a further 
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5% also included a crossover, with 1 each of historical, cohort and case-control 
studies.27 Methods of creating balanced comparison groups included 
randomization (75%), pseudorandomization (4%) and matched pairs (3%) in 
82% of trials, while 16% were nonrandom, and information was missing in 
the remaining 2%. Most trials were controlled by placebo or no treatment, 
although 18% compared homeopathy with orthodox treatments. Evaluation 
was double masked in 71 % of trials, single masked in 11 % and open in 18%. 
The total number of patients was 46 790, trial mean 228, although excluding a 
single outlier (Castro & Nogueira 1975) approximately halved those totals. 
The chronological distribution of trials found is shown in Figure 12.1. 
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Figure 12.1 Distribution of trials by date 
In all, 4 types of homeopathy were trialled: classical, clinical, complex and 
isopathy. Dilution data were missing from 20% of reports, but molecular 
potencies (i.e. those not diluted beyond An) were tested in 57% of the 
remainder. 120 separate conditions in 14 clinical areas were treated, the 
largest single group comprising ear, nose and throat (ENT) and general 
respiratory infections (19%). Acute ailments were treated in 53% of trials, 
chronic in 42%, with negligible numbers of sub-acute or mixed conditions. 
Trials were conducted in 27 countries, with nearly 60% taking place in one of 
3 countries: Germany (23%), France and the UK (18% each). They were 
reported in 8 different languages, but only 7% were in languages other than 
English (57%), French (18%) and German (18%). Journal articles accounted for 
72% of reports. 
12.2 lntrahomeopathic differences 
Considerable differences of size and clinical objectives between the 4 different 
27 In the text of this chapter, all percentages are based on the set of 205 trials, and rounded to 
the nearest whole number. 
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types of homeopathy on trial were visible. Even the median dates were 
different, indicative of changing research interests and prescribing trends. 
Classical homeopathy trials were the smallest on average despite accounting 
for more than 26% of the whole set. Conversely, even after excluding Castro 
& Nogueira (1975), the mean size of isopathic trials was more than twice that 
of the second most populous group, complex, although isopathy constituted 
fewer than 13% of the set (Table 12.2). 
Table 12.2 Populations and median dates of homeopathy types 
Homeopathy Count Median date Sum Mean SD 
Classical 54 1991 3706 68.62 54.89 
Clinical 88 1986 8098 92.02 127.2 
Complex 37 1992 4375 118.24 186.02 
lsopathy 26 1988 30611 1177.35 4745.4 
lsopathy excl. 25 6247 249.88 400.57 
Castro & Nogueira 
(1975) 
There were notable differences in the disease level and clinical areas as well. 
Chronic diseases were treated in classical trials 3 times as often as acute 
disease, but less than half as often across the other 3 categories (Table 12.3). 
Table 12.3 Homeopathy type and disease level 
Disease level Classical Clinical Complex lsopathy 
Acute 13 54 25 17 
Acute + chronic 0 1 0 0 
Chronic 39 29 10 9 
Subacute 2 4 2 0 
total 54 88 37 26 
Striking differences were even reflected in publication language: 81 % of 
classical trials were published in English, representing 38% of the English-
language total, while they accounted for only 19% of German-language trials, 
and none at all were found in French (Table 12.4). 
Table 12.4 Homeopathy type and publication language 
Language Classical Clinical Complex lsopathy 
Dutch 0 0 0 2 
English 44 44 14 15 
French 0 17 13 8 
German 7 20 9 0 
Italian 0 3 1 1 
Norwegian 1 0 0 0 
Portuguese 1 1 0 0 
Spanish 1 3 0 0 
total 54 88 37 26 
There were also dear differences beween the clinical areas researched within 
each homeopathic category. For instance, the largest single group (20%) of 
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classical trials accounted for more than half of all trials in neurology and 
psychiatry. This contrasted with more than one-third of complex and nearly 
one-half of isopathic treatments aimed at respiratory infections and ear, nose 
and throat problems. A predominance of trials for trauma and the sequelae of 
surgery was apparent in clinical homeopathy, accounting for 79% of all such 
trials. 
Table 12.5 Homeopathy type and clinical areas 
Clinical area Classical Clinical Complex lsopathy 
Asthma & allergy 0 5 2 4 
Cardiovascular 5 1 0 
Dermatology 7 6 2 2 
Gastroenterology 7 7 2 0 
Gynecology and obstetrics 4 7 2 3 
Infections (misc) 7 3 0 2 
Metabolic disorders 1 4 0 1 
Musculoskeletal & rheumatology 6 8 7 0 
Neurology & psychiatry 11 4 6 0 
Oncology 4 0 0 0 
Ophthalmology 0 2 0 0 
Respiratory infections & ENT 5 9 13 12 
Surgical trauma 1 25 2 2 
Trauma 0 3 0 0 
total 54 88 37 26 
Quantitative intrahomeopathic differences were reflected in the choice of 
controls: clinical homeopathy and isopathy were predominantly interested in 
the placebo question (which accounted for 86% and 77% of their respective 
totals), while classical and complex homeopathy comprised 70% of pragmatic 
or equivalence trials. 
Table 12.6 Homeopathy type and control treatment 
Homeopathy No treatment Orthodox Placebo 
Classical 5 14 35 
Clinical 3 9 76 
Complex 3 12 22 
lsopathy 4 2 20 
total 15 37 153 
Category differences were also found when potency levels were compared. 
Leaving aside missing data, Table 12.7 shows that over three-quarters of 
classical homeopathy and isopathy trials reported the potency level tested as 
ultramolecular, in contrast to molecular dilutions only in complex 
homeopathy. Both levels were reported to be tested more often in clinical 
homeopathy. Underreporting of potency data was most prevalent in classical 
trials, accounting for 64% of all missing dilution data. 
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Table 12.7 Homeopathy type and potency level 
Homeopathy Molecular Ultramolecular No data 
Classical 6 21 27 
Clinical 48 32 8 
Complex 34 0 3 
lsopathy 5 17 4 
total 93 70 42 
Further evidence of intrahomeopathic category difference was found in 
attrition levels (Table 12.8). Since proportionally more clinical homeopathy 
trials were placebo-controlled than among other types, this may also help to 
account for the increased attrition found in placebo-controlled trials (Table 
12.9). 
Table 12.8 Homeopathy type and percent attrition 
Homeopathy Total No data Mean% SD 
Classical 53 1 7.79 10.86 
Clinical 82 6 10.32 16.04 
Complex 36 1 3.89 8.35 
lsopathy 23 3 6.09 7.52 
F-T est p s 0.0001 
Table 12.9 Control type and percent attrition 
Control Total No data Mean% SD 
No treatment 15 0 5.63 7.68 
Orthodox medicine 35 2 5.75 9.81 
Placebo 144 9 8.70 13.83 
F-T est p s 0.0001 
12.3 Treatment effects 
The majority of trials reported positive effects, either significant or strong 
trends, regardless of the type of control or homeopathy that was trialled. 
However, when stratified by homeopathy type and control, it was apparent 
that 28 (67%) of 42 negative results were reported in a single category: clinical 
homeopathy, including 25 placebo-controlled negative results (Table 12.10). 
Table 12.10 Votes for homeopathy type by control 
Homeopathy No treatment Placebo Orthodox treatment 
( ·) 0 (+) + ( ·) 0 (+) + < = > 
Classical 0 1 0 4 1 5 13 16 2 6 6 
Clinical 0 0 0 3 1 24 13 37 3 3 3 
Complex 0 1 0 2 0 2 4 17 1 8 3 
lsopathy 0 0 0 4 0 1 6 13 0 2 0 
total 0 2 0 13 2 32 36 83 6 19 12 
No relationship between potency level and vote was apparent. Results were 
related to characteristic indicators of internal validity, such as concealment of 
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randomization (Table 12.11) and levels of masking (Table 12.12), however. In 
both cases, placebo-controlled trials were more likely to include negative 
results the more rigorously randomized and masked they were. 
Table 12.11 Assignment method and vote 
Assignment (-) 0 (+) + < = > total 
Matched pairs 0 0 1 2 0 2 6 
Missing 0 1 0 2 0 1 0 4 
Nonrandom 0 4 1 21 2 2 3 33 
Pseudorandom 0 2 0 4 0 1 2 9 
Random 2 27 34 67 4 14 5 153 
total 2 34 36 96 6 19 12 205 
Table 12.12 Masking and vote 
Masking (-) 0 (+) + < = > 
None 0 2 0 14 2 12 7 
Single 0 4 15 0 1 2 
Double 1 32 32 67 4 6 3 
total 2 34 36 96 6 19 12 
In 74% of classical trials, therapists had a free choice of materia medica and 
results were largely positive (Table 12.13). Only 7 trials restricted therapists to 
a predefined selection of medicines, too few to observe a pattern, divided as 
they were between explanatory and pragmatic designs,. However, 7 placebo-
controlled trials that accepted only patients who firmly matched a preselected 
trial medicine reflected the direction of results in the open category. 
Table 12.13 Classical group and vote 
Prescribing (-) 0 (+) + < = > total 
Open 1 3 11 14 1 5 5 40 
Restricted 0 2 1 1 1 1 1 7 
Selective 0 1 1 5 0 0 0 7 
12.4 Adverse reactions 
Adverse reactions were included as predefined outcomes in 15 trials, and 
were looked for in 97 (47%) trials altogether. The remainder either made no 
reference to them, or in a few cases included statements to the effect that 
homeopathy is free from risk per se. Side-effects, including initial 
aggravations, were reported in 41 homeopathy groups, while a further 15 
trials found side-effects only in control groups. A clear trend for under-
reporting in the clinical group compared with the other 3 categories can be 
seen in Table 12.14. The most fastidious category regarding reporting side-
effects was complex homeopathy. 
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Table 12.14 Homeopathy type and adverse reactions reporting 
Classical Clinical Complex lsopathy 
Not reporting 29 56 9 14 
Reporting 25 32 28 12 
total 54 88 37 26 
Chi-square= 16.21 with 3 df (p = 0.001) 
Details of the 56 trials that reported side-effects are given in Appendix 3. Such 
adverse reactions as were found were nearly all mild and transient and 
difficult to distinguish from reactions to placebo. Exceptions included one 
trial of palliative care for lung cancer in which initial aggravations of 
symptoms led to 2 dropouts (Hadjikostas & Diamantidis 1990b), and a large 
influenza prevention trial (n = 1573) where reactions to verum were clearly 
different in onset, intensity and prevalence (RR 4.7) from those in the placebo 
group (Attena, Toscano, Agozzino et al. 1995). The reporting of adverse 
events was also found to be related to the type of control treatment (Table 
12.15), with only 27% of equivalence trials failing to mention the subject. 
Table 12.15 Adverse events reporting and control treatments 
No treatment Orthodox Placebo 
treatment 
Not reporting 9 9 90 
Reporting 6 28 63 
total 15 37 153 
Chi-square = 14.57 with 2 df {p = 0.0007) 
Occurrence of adverse events appeared not to be correlated to whether acute 
or chronic disease was treated (Chi-square= 6.808 with 6 df, p = 0.3389). 
12.5 Holism, quality of life and economic evaluation 
Only 8% of trials mentioned assessment of holistic effects of homeopathy, 
such as response of comorbidity to treatment, or improvements in general 
wellbeing. When stratified by homeopathy type it can be seen that the 
question was hardly considered outside classical homeopathy (Table 12.16). 
Table 12.16 Holism and homeopathy type 
Holism Classical Clinical Complex lsopathy total 
No 41 85 36 26 188 
Yes 13 3 1 0 17 
total 54 88 37 26 205 
Even of classical trials mentioning the subject, most had low MQ scores 
making unquantified claims of improvements. Of better quality trials, only 3 
included measures of general wellbeing as a predefined outcome - patient-
rated scales in each case (Owen 1990; Brigo & Serpelloni 1991; Kuzeff 1998). 
Changes in baseline comorbidity were noted only in a trial for primary female 
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infertility (Gerhard, Reimers, Keller et al. 1993). 
A validated quality-of-life instrument (SF-36) was used in 1 trial only (Weiser, 
Strosser, Klein 1998). 
Cost benefits of homeopathic medicines were referred to loosely in several 
reports, particularly those for diseases of poverty and malnutrition, but 
formal cost-benefit evaluation was included only in the infertility trial just 
mentioned (Gerhard, Reimers, Keller et al. 1993). 
12.6 Methodological quality 
It was possible to accept 197 trials for scoring with the methodological quality 
(MQ) instrument, mean 69.7, median 72 (SD 13.6). The full results for all trials 
are shown in Appendix 4. 
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Figure 12.2 Distribution of methodological quality (MQ) scores 
The approximately normal distribution of MQ scores in the set can be seen in 
Figure 12.2. 
Q 90 • • * ; ♦ • + •*•. 
u ~·~ 
a 75 . ~t♦4t•a.· 
I • ♦ .... 4i.~ ... ♦ ♦ ♦ ♦ •• i 60 • ......... ·•: ♦ t ♦ •• , 44~ ... • 
• • * * • y 45 
♦ • 
• t:: * • ♦ ♦ + • 
s • 
C • 
0 
r 1950 1970 1990 
e 
Year 
Figure 12.3 MQ scores by date 
Figure 12.3 shows a scatterplot of the same scores and interestingly some of 
the earliest trials were near the mean for the whole set (British Homoeopathic 
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Society 1943). 
Table 12.17 MQ and publication type 
Source Included Excluded Mean Median SD 
Book 1 0 67.0 67 
Book section 3 0 63.3 58 10.12 
Conference 18 3 55.3 55 14.30 
proceedings 
Journal article 143 5 71.3 73 13.09 
Report 7 0 61.8 61 9.42 
Thesis 25 0 73.9 75 10.08 
Publication type and MQ were related (Table 12.17), with theses at the top of 
the scale, slightly outperforming journal papers. Conference proceedings 
were likely to score poorly, even though conference abstracts were excluded 
from quality assessment. 
Language of publication was not an indicator of quality as between English, 
German and French (93% of all sources), while sources in other languages 
were too few to generalize from. 
Table 12.18 MQ and publication language 
Language Included Excluded Mean Median SD 
Dutch 2 0 72.5 72 2.120 
English 110 7 70.3 72 13.70 
French 38 0 69.4 70 12.00 
German 35 1 69.l 73 14.29 
Italian 5 0 57.2 57 18.54 
Norwegian 0 87.0 80 
Portuguese 2 0 75.5 75 6.36 
Spanish 4 0 66.0 71 14.63 
Small differences in MQ score were apparent between homeopathic 
categories (Table 12.19), and much larger differences between control 
treatments (Table 12.20). 
Table 12.19 MQ and homeopathy type 
Homeopathy Included Excluded 
Classical 50 4 
Clinical 84 4 
Complex 37 0 
lsopathy 26 0 
Table 12.20 MQ and control treatment 
Control Included Excluded 
No treatment 15 0 
Orthodox treatment 36 1 
Placebo 146 7 
F-test p s 0.0001 
Mean 
68.56 
70.12 
71.67 
67.50 
Mean 
49.0 
67.9 
72.2 
Median 
71.0 
72.5 
75.0 
70.0 
Median 
51.0 
69.5 
73.5 
SD 
13.74 
12.37 
14.91 
15.17 
SD 
8.46 
13.77 
12.02 
198 
Surprisingly, no relationship could be found between results and the scores 
for adequacy of handling exclusions and dropouts (Table 12.21). 
Table 12.21 Adequacy of attrition handling 
Attrition score (-) 0 (+) + < = > 
Inadequate 0 4 2 9 0 4 3 
Partial 0 3 6 8 0 3 0 
Adequate 1 17 19 33 3 7 4 
No attrition 0 9 7 43 3 4 5 
total 33 34 93 6 18 12 
A scatterplot also shows no obvious relationship between percentage attrition 
and MQ scores (Figure 12.4). 
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Figure 12.4 MQ and percentage attrition 
The relationship between MQ scores and reported results was also 
problematic (Table 12.22). Except for a single trial which reported marginally 
better results in the placebo group (Walach, Haeusler, Lowes et al. 1997), only 
small MQ differences could be seen between negative and positive results in 
trials with no treatment or placebo controls, or between negative and 
equivalent results in pragmatic trials. The largest discrepancy came in trials 
reporting superiority of homeopathy to orthodox treatment. 
Table 12.22 MQ and vote 
Vote Included Excluded Mean Median SD 
(-) 2 0 84.5 84.5 9.19 
0 34 0 69.4 73 14.32 
(+) 32 3 72.0 73.5 10.90 
+ 93 3 69.3 72 14.05 
< 6 0 69.3 71 10.97 
= 18 1 69.1 72 14.15 
> 12 0 65.4 63 15.11 
Rigour of randomization was strongly related to results (Question 10), with 
nearly all null and marginal placebo-controlled votes for homeopathy 
occurring in trials with adequate concealment (Table 12.23). 
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Table 12.23 Concealment of randomization and vote 
Concealment (-) 0 (+) + < = > 
None 0 5 9 24 2 9 3 
Inadequate 1 2 2 8 1 1 0 
Adequate 1 20 18 33 1 3 2 
No data 0 7 3 28 2 5 7 
total 2 34 33 93 6 18 12 
Although the primary quality scale did not look for adverse reaction 
reporting, a statement that side-effects were sought - regardless of whether 
they were reported or not reported by participants - seemed to be a predictor 
of general trial quality. 108 trials (mean 66.7, SD 13.0) omitted to mention 
side-effects, and scored significantly worse than 97 that mentioned looking 
for adverse reactions (mean 72.7, SD 13.5) (2-Sample t-Test p = 0.0019). 
12.6.1 Comparison with other quality scales 
Table 12.24 compares the 197 trials in the set eligible for MQ scoring with 81 
of these previously reviewed by Kleijnen et al. (1991), and 81 of those 
reviewed by Linde et al. (1997). 
Table 12.24 Scores under 3 methodological quality instruments 
MQtool Included Excluded Patients Mean Median SD r 
Cho & Bero 197 8 13725 69.67 72 13.56 .985 
Kleijnen et al. 81 124 3453 42.60 40 20.37 .988 
Linde et al. 81 124 4848 59.85 57 21.21 .989 
The two sets of 81 were not identical but came from a pool of 113 eligible for 
quality scoring in this review that had also been scored in either or both the 
other 2 reviews. The individual trial scores for the comparison scales were 
derived from the same publications. The mean scores under the 3 scales differ 
strongly. 
Table 12.25 Rank correlations between methodological quality instruments 
MQ tool 
Cho & Bero 
Kleijnen et al. 
Linde et al. 
Cho 
1.000 
0.743 
0.827 
Kleijnen 
1.000 
0.635 
Linde 
1.000 
However, all 3 scales showed approximately normal distribution, and the 
rank correlation between the scale used for this review and the other 2 scales 
was good (Table 12.25). The correlation between the 2 comparison scales was 
somewhat less good, perhaps because of the smaller number of trials in 
common. 
12.7 Highest quality trials 
A sample was taken comprising 20% of trials with the highest scores (n = 40, 
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score ~ 81 %) (Table 12.26). 
Table 12.26 Vote by homeopathy type of top fifth of tria ls (MQ ~81 %) 
Homeopathy (-) 0 {+) + < = > total 
Classical 1 5 2 0 0 0 9 
Clinical 0 5 0 6 0 1 13 
Complex 0 2 2 7 0 2 1 14 
lsopathy 0 0 0 4 0 0 0 4 
tota l 8 7 19 0 3 2 40 
Although the proportion of equivalence trials was similar to that in the whole 
set, the overall proportion occupied by 2 of the homeopathic types in the top 
fifth was clearly different, with clinical homeopathy relatively 
underrepresented and complex homeopathy more prevalent. Results were 
strongest for isopathy and complexes. Classical results were more equivocal, 
and clinical homeopathy posed the most problems. Trials in the sample are 
discussed in detail in Ch. 13. 
12.8 Clinical re levance 
Quality scoring of the 197 reports also included assessment with the clinical 
relevance (CR) tool (Cho & Bero 1994). Individual scores for each question 
appear in Appendix 4, and showed approximately normal distribution (r = 
.988). 
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Figure 12.5 CR and MQ scores 
All 197 trials were scored, including those with negative results, and a 
scatterplot shows the direction of the relationship between CR and MQ scores 
(Figure 12.5). The distribution of CR scores is shown in Table 12.27, where 
considerable overlap between trials returning positive and negative results 
can be seen in the standard deviations of the adjacent groups. 
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Table 12.27 CR and votes 
Vote Included Excluded Mean Median SD 
(-) 2 0 57.5 57.5 30.41 
0 34 0 57.8 57 18.52 
(+) 32 4 66.6 71 17.28 
+ 93 3 72.3 71 14.50 
< 6 0 60.7 64 16.03 
= 18 1 75.5 79 15.20 
> 12 0 71.9 71 14.18 
Less quantifiable aspects of clinical relevance are discussed in Ch. 13. 
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13 DISCUSSION 
Arguments included in this chapter have appeared in or as: 
Dean M.E. (1998). Out of step with the Lancet homoeopathy meta-analysis. More objections 
than objectivity? Journal of Alternative and Complementary Medicine. 4 (4): 389-398. 
Dean M.E. (2000). More trials, fewer placebos, please. British Homoeopathic Journal. 89 (4): 
191-194. 
Dean M.E. (2001). Study shows double standards in evaluation of homeopathy. British Medical 
Journal. 322 (20 January): 169-170. 
13.1 Overview 
Analysis of the trial set showed that intrahomeopathic differences were 
readily apparent in the choice of clinical areas and conditions, but also in 
choice of control treatments and in efficacy. Homeopathy was equivalent or 
superior to orthodox treatment in most cases where it was compared. 
Homeopathic medicines appeared to be relatively risk-free in terms of 
adverse reactions and unwanted effects. Global effects, e.g. on comorbidity, 
wellbeing and quality of life, were generally not included in outcomes, and 
neither was economic evaluation, but they tended to favour homeopathy 
when they were. The methodological quality (MQ) scale chosen appeared to 
function as well as others previously used to grade homeopathic trials, but 
was significantly more informative. Homeopathy's clinical relevance cannot 
be measured in the same way as treatments regarded as plausible in 
biomedicine - decisions to research or reject homeopathy remain as value-
laden as in the nineteenth century. Each of these areas is now covered in more 
detail. 
13.2 Efficacy 
As mentioned in Ch. 11, the MQ scale used here does not have a cut point. A 
decision was made to base detailed discussion on the 20% of trials with the 
highest scores (n = 40, MQ = 81-96%), extended to include trials that were 
replicated in the highest quality group, or others that had particular clinical or 
methodological interest. Of the top 40, 27 were published after Kleijnen et al.'s 
review (1991), indicative of the chronological trend of improved 
methodological standards seen across the set. The proportional difference in 
styles of homeopathy from the set as a whole is interesting, and also 
noteworthy is the presence of 5 equivalence trials in which homeopathy was 
compared with orthodox treatment (Tables 13.1-4). The most problematic 
areas were classical and clinical homeopathy. 
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13.2.1 Classical 
From a set of 40 trials just 4 classical studies were considered by Hill & Doyen 
(1990). Kleijnen et al. (1991) evaluated 105 trials comparing homeopathy with 
either placebo or orthodox treatment, but only 14 classical studies (13%) could 
be included. Linde et al. (1997) included 13 classical trials from a total of 89 
(15%). By contrast, 54 of 205 trials (26%) in the present review could be 
described as classical homeopathy. The inclusion of orthodox treatment 
controls is partly responsible, since proportionally more classical trials used 
these. Important also is the increasing familiarity of therapists with research 
methods, and of researchers with homeopathy. Hill & Doyen (1990) 
presumed that researchers probably imagined controlled trials of 
homeopathy had to test a standard homeopathic treatment, but this limitation 
no longer holds. Chronologically, classical homeopathy has emerged since the 
1980s as the preferred mode in many parts of the world, including those 
where clinical homeopathy was the norm previously (e.g. Rasky, Freidl, 
Haidvogl et al. 1994). 
Table 13.1 Characteristics of 9 classical homeopathy trials MQ ~81 
First author, date Condition Control Vote MQ scores 
Cho Kleijnen Linde 
Jacobs 1994 Diarrhea (acute childhood) p + 91 ni 86 
Walach 1997 Migraine p (-) 91 ni ni 
de Lange-de Klerk Upper respiratory infections p (+) 87 ni 100 
1993 (recurrent childhood) 
Lokken 1995 Post-extraction dental p 0 87 ni 86 
neuralgia 
Straumsheim 1997 Migraine p (+) 87 ni ni 
Whitmarsh 1997 Migraine p (+) 87 ni ni 
Brigo 1991 Migraine p + 86 68 79 
Jacobs 1993 Diarrhea (acute childhood) p (+) 84 ni 64 
Kuzeff 1998 Well-being p (+) 84 ni ni 
As shown in Table 13.1, the top fifth of this set included 9 (22%) classical 
trials, 2 of which were placebo-controlled studies in infantile diarrhea Gacobs, 
Jimenez, Gloyd et al. 1993; Jacobs, Jimenez, Gloyd et al. 1994). These belong to 
a series of trials of the ultramolecular potency C30 by the same team in 
different parts of the world where diseases of poverty and malnutrition are 
endemic, but the most recent replication was available only as a conference 
abstract and could not be evaluated Gacobs, Malthouse, Chapman et al. 1997). 
All children in verum and placebo groups received oral rehydration therapy 
(ORT) at the same time, and it is impossible to say whether this affected the 
estimate of specific homeopathic effect in either direction. The difficulties of 
conducting ethical and valid trials of homeopathy in situations where an 
orthodox treatment exists and should not be withheld are obvious, and they 
are complicated further in this case by the fact that it is unusual for children 
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to receive ORT in comparable regions. A survey of childhood dysentery in 
rural Bangladesh found only 25% of patients were treated with ORT 
(Ronsmans, Bennish, Chakraborty et al. 1991) and Jacobs et al. mention the 
prohibitive cost of ORT packs for the poor. These 3 trials can also be viewed 
as independent replications of an earlier Mexican trial for the same condition 
with acceptable methodology (MQ = 76%), just out of the top 20% (Villatoro 
Cadena & Luis Cuevas 1991). The same treatment model was used - ORT 
with either classical homeopathy or placebo -with the exception that a 
potency below An was used (C6). Inferential statistics were not presented, but 
the effect size seems comparable. In this trial parents prepared ORT at home, 
reducing costs, but their ability to read instructions and access to clean water 
would be questionable. In spite of problems, this group of 4 trials appears to 
demonstrate the superiority of single-medicine individualized homeopathy 
plus ORT to placebo plus ORT in an acute vector-borne illness. 
Another high-quality placebo-controlled trial produced a positive result in 
chronic migraine (Brigo & Serpelloni 1991). However, 3 attempted 
replications in the top fifth produced negative or marginally positive results 
(Straumsheim, Borchgrevink, Mowinckel et al. 1997; Walach, Haeusler, Lowes 
et al. 1997; Whitmarsh, Coleston-Shields, Steiner 1997). There is clear evidence 
that the patients were atypical in each of the unsuccessful trials (Whitmarsh 
2000), and the issue is complicated in terms of homeopathic theory since the 
epidemiology of migraine suggests the condition may reduce the risk of more 
serious cardiac disease (Waters, Campbell, Elwood 1988), thus requiring even 
more extended treatment than the longest follow-up periods of 4 months 
found in these trials. However, even though marginal evidence of efficacy 
was found in 2 trials, the results are disappointing for proponents of single 
high-potency medicines in the treatment of chronic disease (see Ch. 4). The 
director of the foundation that funded the least successful of the 3 has said 
that further similar research into classical homeopathy for migraine is not 
warranted (Albrecht 1999). The results of these failed replications have also 
been used to question the positive effects of homeopathy found in the meta-
analysis by Linde et al. (Ernst & Barnes 1998). However, a more systematic 
literature search for randomized placebo-controlled trials that were published 
after Linde et al.'s cut-off date of October 1995 found this view had ignored 
many positive trials that met the meta-analysis criteria (Dean 1998). The risk 
of Type-1 error in premature and unsystematic updating of meta-analyses 
has been noted in Ch. 10 and elsewhere (Pogue & Yusuf 1998). 
Two further classical trials in the highest 20% also failed to produce 
convincing advantages over placebo in recurrent upper respiratory tract 
infections (URTI) (de Lange-de Klerk 1993), or in postextraction dental 
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neuralgia (Lokken, Straumsheim, Tveiten et al. 1995). The URTI comparison 
was complicated by the inclusion of 'careful dietary counselling' in both 
groups, not normally a feature of everyday general practice. The bilateral oral 
surgery prescriptions could only be made from a restricted predefined set of 
medicines, regardless of the presenting symptoms in any individual, and 
repetition of doses was based on a highly unusual and rigid scheme. 
In keeping with classical theory, patients with many different conditions were 
accepted for an innovative trial in the top 20% in which the main outcome 
measure was mental-emotional and physical wellbeing (Kuzeff 1998). Patients 
rated their own progress on separate 10-point VAS, and although baseline 
measurements were missing, a trend for mental-emotional wellbeing and 
significant superiority for physical wellbeing were found in the verum group. 
Another trial that probably did not contain serious threats to validity (MQ = 
70%), but suffered from poor reporting, showed substantial patient-rated 
benefits from homeopathy in myalgic encephalitis/postviral fatigue 
syndrome (ME/PVFS) at 12 months in 33% of patients, with no 
corresponding benefit from placebo (Awdry 1996). The clinical relevance of 
this result in a neglected group of patients is discussed further in 13.6.5.2. 
below. 
All the classical trials in the top group were placebo-controlled, but it is worth 
mentioning a double dummy equivalence trial to compare classical 
homeopathy and chloroquine for treatment of malaria that took place in 
Ghana and also scored well (MQ = 79%) (Van Erp & Brands 1996). An 11 % 
superiority of homeopathy over orthodox treatment was found. However, the 
generalizability of this comparison is problematic because although the 
checklist of signs, symptoms and modalities used to repertorize each patient 
appears rigorous, the outcome measure of improvement on ~3 of 9 symptoms 
could have been more detailed. 
13.2.2 Clinical 
Although 88 clinical homeopathy trials constituted the largest single group 
(43%), only 13 (32%) appeared in the top 40 (Table 13.2). 
The most successful subgroup in this category were the allergic rhinitis 
studies (Wiesenauer, Haussler, Gaus 1983; Wiesenauer, Gaus, Haussler 1990; 
Wiesenauer & Ludtke 1995) that are part of a long-running series of 
replications using Galphimia glauca in very low potencies. The author's own 
meta-analysis was highly positive, showing success rates comparable with 
standard antihistamine therapy, but with no side-effects (Wiesenauer & 
Ludtke 1996). 
206 
Table 13.2 Characteristics of 13 clinical homeopathy trials MQ ::::81 
First author, date Condition Control Vote MQ scores 
Cho Kleijnen Linde 
Lievre 1992 Burns OT > 94 ni ni 
Grecho 1989 Postoperative ileus p 0 92 90 86 
Rahlfs 1978 Irritable bowel syndrome p + 90 50 79 
Valero 198l(ii) Postoperative ileus p + 89 70 64 
Hofmeyr 1990 Childbirth p 0 86 ni 100 
Eid 1994 Childbirth p + 85 ni ni 
Friese 1997 Adenoidal growths p 0 84 ni ni 
Hart 1997 Postoperative pain and p 0 84 ni ni 
infection 
Wiesenauer 1995 Allergic rhinitis p + 84 ni ni 
Wiesenauer 1987 Hypotension OT = 83 58 ni 
Wiesenauer 1990 Allergic rhinitis p + 83 ni 86 
Bignamini 1987 Hypertension (essential) p 0 82 58 ni 
Wiesenauer 1983 Allergic rhinitis p + 81 75 79 
Traditional homeopathic recommendations of Opium for constipation and 
Raphanus for abdominal bloating and pain were the subject of 2 trials in the 
top fifth for postoperative intestinal stasis (ileus) (Valero 1981; GRECHO, 
U292 Inserm, ARC et al. 1989). They were part of a series of replications 
(Castelain 1979; Estragnin 1979; Chevrel, Saglier, Destable 1984; Aulagnier 
1985; Dorfman, Amodeo, Ricciotti et al. 1992), and all were positive except the 
large GRECHO trial (n = 600). A meta-analysis of the series found a positive 
effect for low potencies, and a negative one for ultramolecular potencies 
(Barnes, Resch, Ernst 1997). 
Part of native North American herbal lore, Caulophyllum thalictroides has 
featured in homeopathic obstetrics since the nineteenth century largely on 
empirical grounds. The C7 potency was tested for prolonged labour in 2 trials, 
the one in the top fifth being a replication of a case-control pilot study (Eid, 
Felisi, Sideri 1993; Eid, Felisi, Sideri 1994). The randomized trial found mean 
duration of labour of 3.5 hours under verum vs almost 6 hours with placebo 
(p = 0.0). Caulophyllum CS was also successful in a small trial for false labour 
and dystocia (MQ = 80%): favourable responses were observed in 13/17 vs 
2/17 under placebo (p < 0.005) (Deguillaume 1981). Ultramolecular 
Caulophyllum was also given in a pragmatic comparison with standard 
obstetric preparation in the following sequence at 30-minute intervals: 
Pulsatilla M, Secale C50, Caulophyllum C50, Actea racemosa C200, Arnica M 
(Ventoskovskiy & Popov 1990) (MQ = 78%). Homeopathy was as or 
significantly more effective on each outcome, including uterine inertia (nsd), 
ineffective first stage (p < 0.05), false labour (p < 0.05), blood loss (nsd) and 
Apgar scores (nsd). A homeopathic complex containing Caulophyllum is 
discussed in 13.2.3. 
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There were only 2 equivalence trials of clinical homeopathy vs standard 
treatments in the top group. Haplopappus D2 was found to be equivalent, with 
a weak trend for slightly greater effectiveness, than etilefrin in raising low 
blood pressure (Wiesenauer & Gaus 1987). A standard homeopathic wound 
treatment, Calendula, yielded results in first- and second-degree bums 
superior to placebo or the orthodox proteolytic ointment (Lievre, Marichy, 
Baux et al. 1992). It is discussed further in 13.6.2. 
A successful trial of Asafoetida D3 for irritable bowel syndrome (Rahlfs & 
Massinger 1978), also in the top group, was conducted to validate a clinical 
Asafoetida subgroup found in the pilot study (Rahlfs & Massinger 1976), and 
entry was restricted to patients who matched ~3 of 9 Asafoetida symptoms. 
This trial was part of an interesting methodological subgroup on the borders 
of clinical and classical homeopathy, requiring very abbreviated symptom 
matching (Alibeu & Jobert 1990; Fisher 1986; Shipley, Berry, Broster et al. 
1983). 
Turning to the unsuccessful high-quality trials, another schematic sequence of 
clinical medicines was used in one, but had little influence on adenoidal 
growths (Friese, Feuchter, Moeller 1997). Another tested Arnica and showed 
little difference from placebo in post-partum recovery, although the D30 
potency appeared to produce a worse outcome than D6 or placebo (Hofmeyr, 
Piccioni, Blauhof 1990). Although Arnica has rarely been recommended as an 
analgesic, the C30 potency was trialled for postoperative pain and again 
showed no difference from placebo (Hart, Mullee, Lewith et al. 1997). Based 
on the toxicology of soluble barium salts, a high-quality trial of Baryta 
carbonica C15 for essential hypertension showed no difference from placebo 
overall, although good reductions in arterial BP were found in all prescreened 
patients who matched Baryta symptomatology, while equivalent responders 
who received placebo experienced a net increase in BP (Bignamini, Bertoli, 
Consolandi et al. 1987). 
The appearance in the clinical category of 65% of all failed trials in the whole 
set requires additional explanation, especially since it can no longer be 
assumed that homeopathic trials of high internal validity will automatically 
yield null results. As noted in Ch. 4, the earliest attempts to simplify the ideal 
of full individualization led in one direction to keynote prescribing and in 
another to nosological homeopathy. Keynotes are still patient-based rather 
than disease-based and do not belong in the clinical category. On the other 
hand, nosological prescriptions, often based on traditional empirical 
recommendations rather than fresh analysis of a prevalent condition, 
constitute the majority of trials in this sector. The attractions of the model for 
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biomedically-orientated research, and the inherent problems of the model in a 
homeopathic framework, should be apparent by now, and need little further 
comment. As discussed in Chs 7 and 9, historical trials of Belladonna for scarlet 
fever, regardless of fluctuations in virulence and prevalent symptomatology, 
showed the limitations of this sort of nosological homeopathy (West 1854: 
600; Wesselhoeft Jr 1917). Many trials here continued this line, often testing 
prescriptions of doubtful validity. For example, although empirically 
recommended for whooping cough, the provings of Drosera were shown long 
ago to bear little resemblance to the disease (Wesselhoeft Jr 1917), a finding 
apparently confirmed in an unsuccessful trial (Lewis 1984). Homeopaths in 
the nineteenth century were highly critical of the routine homeopathic use of 
Colchicum for gout (Kent 1911: 430), and a recent trial bore out their scepticism 
(Puterman 1994). Blatta orientalis was used empirically for asthma because a 
patient found relief after drinking tea in which the Indian cockroach had been 
accidentally infused (Clarke 1925). No proving data is available, and Blatta 
was not found to be significantly different from placebo in a randomized 
asthma trial (Freitas, Goldenstein, Sanna 1995). Arnica in particular was 
favoured in many of these trials, including some in the top 20%, probably 
because it is the best known medicine used in homeopathy, with a traditional 
reputation as a first-aid treatment for bruising and shock, and because 
researchers have often looked for a standard treatment model to test the 
ultramolecular hypothesis. However, it was adopted from folk medicine -
Hahnemann (1828) recommending its use as an unpotentized lotion, even in 
his high-potency phase - and there is scant physiological evidence of its 
homeopathicity to trauma (Baillargeon, Drouin, Desjardins et al. 1993). It is 
arguable that potentized medicines only, and not collective similia, were 
tested in many trials in this category. 
In contrast to trials of traditional and essentially empirical clinical 
prescriptions, pathological homeopathy has received little attention since the 
reanalysis of mumps on a lesional basis (Wesselhoeft Jr 1924) (Ch. 9), and only 
a few contemporary trials took this approach. The trial of Baryta for 
hypertension has been mentioned above, and suggested further research with 
presecreened responders could be indicated. Based on the physiological 
action of physostigmine, which contracts the ciliary muscles and impairs 
accommodation, infrequent local application of an aqueous Physostigma 
solution in high potencies produced promising long-term results in 2 placebo-
controlled trials for myopia (Basu 1980; 1981) (MQ = 61 %). If genuine, these 
results are astonishing given current understanding of the cause and 
treatment of errors of accommodation, and it would be relatively easy to 
replicate the trials with greater rigour. Copper's toxicology includes muscular 
spasm, and a placebo-controlled trial of Cuprum metallicum Cl5 for 
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hemodialysis-related cramps appeared to bear out the similia principle in this 
instance (Hariveau, Nolen, Holtzscherer 1991) (MQ = 75%). The similarity 
between phosphorus toxicology and the lesions seen in experimental liver 
disease induced by trichloroethylene has led to many in vitro and animal 
experiments (e.g. Bildet, Bonini, Gender et al. 1984), but the model was tested 
in only 1 human trial found here (Chirila 1990). This was a conference report 
of uncertain quality (MQ = 45%), but showed substantially reduced hospital 
stays for children with type-8 hepatitis who received Phosphorus C7 compared 
with placebo (8 days vs 20 days). Repertorization of the common symptoms 
of acute hypertension led to a successful randomized trial of the snake venom 
Lachesis mutus C200 in a hospital A&E department (Ochoa-Bernal, Ruiz-
Hernandez, Searcy Bernal 1995) (MQ = 76%). Interestingly, conventional 
renin-angiotensin inhibitors are based on a chance discovery of a bradykinin 
potentiating factor in the venom of Bothrops jararaca (Krieger, Salgado, Assan 
et al. 1971). However, the symptomatology of Lachesis has been well 
recognized in homeopathy since the mid nineteenth century- the repertory 
used by the authors may have been computerized but was actually Kent's-
and suggests that the boundary zone between biomedicine and homeopathy 
could be fruitfully explored, not just by homeopathic researchers. 
13.2.3 Complex 
A completely different approach to improving the accuracy of nosological 
prescriptions is found in complex homeopathy, and there appear to be fewer 
problems with the design and conduct of trials in this category. 
Table 13.3 Characteristics of 14 complex homeopathy trials MQ ~81 
First author, date Condition Control Vote MQ scores 
Cho Kleijnen Linde 
Bohmer 1992 Sprains and contusions p + 96 ni 100 
Weiser 1998 Vertigo OT = 96 ni ni 
Weiser 1994 Sinusitis (chronic) p + 89 ni 79 
Zell 1990 Sprains p + 89 80 100 
Maiwald 1988 Influenza OT > 86 65 ni 
Hill 1996 Mosquito bites (experimental) p (+) 85 ni ni 
Ferley 1987 Influenza p 0 84 68 79 
Hill 1995 Mosquito bites (experimental) p (+) 84 ni ni 
Lasserre 1986 Childbirth p + 84 80 71 
Nahler 1996 Osteoarthrosis OT = 84 ni ni 
Mccutcheon 1996 Anxiety p 0 83 ni ni 
Wiesenauer 1991 Chronic polyarthritis p + 83 ni 79 
Abelson 1996 Allergic conjunctivitis p + 82 ni ni 
Ernst 1990 Varicose veins p + 82 ni 71 
One reason for this could be the heavy involvement of homeopathic 
pharmaceutical companies. Traditional single-medicine homeopathy is 
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overwhelmingly based on freely available and unpatentable materia medica, 
and offers few obvious commercial opportunities. In contrast, unique 
proprietary combinations can be tested and marketed like conventional 
drugs, as is the case with all but 1 of the 14 complexes in the highest 40 (Table 
13.3). 
The relatively high MQ scores of complex trials compared with the other 
categories may also be related to the trend towards contracting out the design 
and running of trials of complexes to independent specialist clinical trial 
organizations (e.g. Weiser, Strasser, Klein 1998). Conditions showing 
homeopathic superiority to placebo in the top group include: allergic 
conjunctivitis (Abelson 1996); sprains and bruising (Zell, Connert, Mau et al. 
1990; Bohmer & Ambrus 1992); chronic polyarthritis (Wiesenauer & Gaus 
1991); chronic sinusitis (Weiser & Clasen 1994); mosquito bites (Hill, Stam, 
Tuinder et al. 1995; Hill, Stam, Haselen 1996); and varices (Ernst, Saradeth, 
Resch 1990). 
Indicative of the high level of development of complex homeopathy, and the 
confidence of the manufacturers, were randomized trials of proprietary 
homeopathies vs biomedical treatments. Homeopathy was found to be 
equivalent to or better than standard treatments in vertigo (Weiser, Strosser, 
Klein 1998), influenza (Maiwald, Weinfurtner, Mau et al. 1988), and 
osteoarthritis (Nahler 1996). 
Less successful was the placebo-controlled trial of another proprietary 
complex marketed as L.72 in France and Anti-anxiety in the USA 
(McCutcheon 1996). It showed no reduction in state or trait anxiety, but did 
show a significant reduction (p = 0.05) in another prespecified outcome: 
insomnia. This hypnotic effect supports the finding of an earlier randomized 
equivalence trial that compared L.72 with diazepam (Heulluy 1985), and 
suggests that L.72 may well be formulated and marketed inappropriately for 
its target condition (the 9 listed ingredients have stronger indications overall 
for insomnia than anxiety in the materia medica and repertory), but it does 
not follow that it is therefore pharmacologically inert. However, L.52 from the 
same manufacturer showed no significant difference from placebo in 
prevention of influenza (Perley, Poutignat, Azzopardi et al. 1987). 
The historical origins of the ideological objections of most classical 
homeopaths to polypharmacy are well-known (see Chs 3 and 4), but they 
have led to neglect of research into useful interactions and combinations of 
safe homeopathic medicines. Apart from the products of the pharmacies, 
there were few trials in this area altogether, and only 1 in the top group. A 
low-potency (CS) combination containing Actaea racemosa, Amica, 
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Caulophyllum, Gelsemium and Pulsatilla was compared with placebo in 
preparation for labour (Lasserre 1986). Highly significant (p < 0.001) 
reductions in both duration of labour (5.1 hours vs 8.5 hours) and incidence of 
dystocia (6/53 vs 16/40) were seen, comparable with similar obstetric trials in 
the single-medicine clinical group (13.2.2). 
Also worth mentioning, for its methodology rather than results, is a factorial 
trial (MQ = 69%) for vaginal discharge that allowed the traditional clinical 
prescription Borax C30 to be compared and combined with the nosode 
Candida C30 (Carey 1986). The combination appeared to have a more 
powerful effect than its components individually. The trial was too small to 
be more than suggestive of a line for future research, but factorial designs are 
probably the best way of analysing combinations. Single medicine trials for 
post-surgical pain and recovery have often been unsuccessful, whether 
clinical using only Amica (e.g. Hart, Mullee, Lewith et al. 1997), or classical 
(e.g. Lokken, Straumsheim, Tveiten et al. 1995). However, two clinical 
homeopathy trials which alternated Amica with Hypericum (traditionally 
recommended for bruising and neuralgia respectively) were highly successful 
(Bendre & Dharmadhikari 1980; Albertini, Goldberg, Sanguy et al. 1985) (MQ 
= 69% and 68%). Another successful trial (MQ = 60%) alternated Arnica with 
Apis to treat edema following rhinoplasty (Michaud 1981). There is a case to 
be made for factorial trials in the area of homeopathic first-aid and 
traumatology, and other areas where individualization can be unfeasible. 
13.2.4 lsopathy 
Only 4 trials of isopathy were included in the top fifth, from 26 isopathy trials 
altogether. Because direct causal agents are unknown for so many 
contemporary patterns of illness, isopathy has clear limitations as therapy, 
although its similarity to biomedical areas such as immunology has attracted 
researchers interested primarily in the ultramolecular-placebo question. The 
trials by Reilly and colleagues for atopy, including hay fever and asthma, 
were designed and conducted for this purpose and produced their own 
highly positive meta-analysis, with 2 appearing in the highest-quality group 
(see Table 13.4) (Reilly & Taylor 1985; Reilly, McSharry, Taylor et al. 1986; 
Reilly, Taylor, Beattie et al. 1994). They are discussed further in 13.6.5.4. 
Table 13.4 Characteristics of 4 isopathy trials MQ :.::81 
First author, date Condition Control Vote MQ scores 
Cho Kleijnen Linde 
Papp 1998 Influenza p + 92 ni ni 
Reilly 1986 Allergic rhinitis p + 92 90 93 
Reilly 1994 Allergic asthma p + 89 ni 93 
Ferley 1989 Influenza p + 85 88 79 
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Two isopathic influenza trials in the top 40 used the ultramolecular nosode 
Oscillococcinum® C200, made from infected duck heart and liver (Perley, 
Zmirou, D' Adhemar et al. 1989; Papp, Schuback, Beck et al. 1998). Altogether 
there have been 4 (n = 1250, mean n = 312) randomized placebo-controlled 
postexposure treatment trials in widely different influenza epidemics 
(Casanova 1984; Casanova & Gerard 1992). Unlike nosodes and vaccines 
derived from specific influenza strains, Oscillococcinum® is derived from a 
rich mixture of pathogens and antigens, probably providing nonspecific 
immune enhancement. All 4 trials showed significant reductions in 
symptoms, and illness duration, and are discussed further in 13.6.5.3. 
Although prophylactic effects were claimed in a case-control study (Masciello 
& Felisi 1985) (MQ = 38%), a better-quality randomized trial (MQ = 62%) 
found no statistical difference from placebo (Attena, Toscano, Agozzino et al. 
1995). 
Isopathy seems to have been the most consistently successful homeopathic 
category reviewed here, and other isopathic trials investigated mostly similar 
conditions, with similar results. Different clinical areas included the 1941 
mustard gas trials reviewed in Ch. 9, and 2 good quality placebo-controlled 
trials of potentized human ovarian hormone for premenstrual syndrome. 
Lepaisant (1995) (MQ = 77%) gave Folliculinum CS to women showing marked 
premenstrual symptoms for more than 3 months. The apparent 20% attrition 
rate was due to the 1 month placebo run-in: 13/58 were not assigned because 
of positive responses- or natural remission-while on placebo. Masked 
evaluation of global success (including breast tension, pain, duration) 
favoured verum (p = 0.0159). In the other trial (Gillespie 1994) (MQ = 75%), 
patient-rated scores on validated scales showed ultramolecular Folliculinum 
C15 had been very much more effective than placebo (89% vs 7% of women 
recorded improvements), although significance tests were not given. 
13.3 Safety 
The search for evidence of adverse reactions found some authors claiming 
that homeopathy was risk free (e.g. Awdry 1996). A prior belief might of 
course make the search for evidence during a trial seem unnecessary. 
However, it would appear that homeopathy is not without side effects, 
although severe ones necessitating abandonment of therapy were hardly 
noticeable (see App. 3), since primary aggravations leading to 2 dropouts 
were found only in a single palliative trial for lung cancer (Hadjikostas 
1990?b ). A trial for primary female infertility reported transient skin 
symptoms in 10% of the homeopathically treated group, and explained these 
as a predictable and harmless eliminative response (Gerhard, Reimers, Keller 
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et al. 1993). One trialist included aggravations and returns of old symptoms as 
a predefined outcome (Schwab 1990)- according to miasmatic theory, chronic 
illness proceeds from the suppression of skin diseases in the patient's (or the 
community's) past, and healing is believed to allow suppressed symptoms to 
surface. Intriguingly though, many initial aggravations were found in some 
placebo groups as well (e.g. Reilly, McSharry, Taylor et al. 1986), suggesting 
that some ostensibly homeopathic aggravations might be psychological 
reactions to medication per se. Unfortunately, no information was given on 
whether patients were primed with expectations of adverse events - as part of 
informed consent, in trial information leaflets, for instance. 
Against the nocebo interpretation, the most convincing evidence of different 
unwanted reactions to verum and placebo was found in a large (n = 1573) 
influenza prevention trial (Attena, Toscano, Agozzino et al. 1995). Symptoms 
were reported by 10% of patients in the 24 hours after administration of the 
ultramolecular verum (Oscillococcinum® C200), and reactions such as myalgia, 
low grade fever and rhinorrhea predominated- as might be expected after 
conventional influenza vaccination (Govaert, Dinant, Aretz 1993). In contrast, 
only 2% of patients in the placebo group reported side-effects, and these were 
general symptoms such as dizziness, skin numbness and GI disturbance, as 
seen in other placebo groups in this review (see App. 3). Moreover, the 
incidence of responses to 3 subsequent doses of verum diminished over time, 
while placebo responses were more equally distributed. 
That such a large trial was needed to to produce a statistically reliable 
comparison between unsought post-verum and post-placebo symptoms 
indicates a major difficulty of trying to evaluate homeopathic safety from 
reports of small clinical trials which for the most part did not prespecify 
adverse reactions as endpoints. It probably has even more serious 
implications for the validity of contemporary pathogenetic drug tests, most of 
which have been extremely small, and rarely include placebo washouts as 
used in the latter half of the nineteenth century (see Ch. 8 and: Dantas & 
Fisher 1998). 
Notwithstanding the absence of reported adverse events in the trial set, there 
are a number of safety issues, directly and indirectly attributable to 
homeopathic treatment, that need to be addressed. 
Toxicity For the most part, serial dilution progressively removes directly 
toxic substances from the medicine. However, very low potencies may 
contain traces of the potentized substance. Low potency complex treatments 
under review appear to have been formulated knowledgeably and subject to 
prior safety testing, and were consequently well tolerated. This is not always 
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the case, and complexes containing traces of heavy metals and other 
contaminants are sold over the counter in India and elsewhere, and have 
sometimes been imported into Europe and the US (Hentschel, Kohnen, Hahn 
1998). Indian recommendations for the minimum safe potency for each 
substance have been published, although the extent to which such guidelines 
are currently observed is unknown (Varma & Indu 1992). 
Interactions In most cases, concurrent treatments were excluded from the 
protocols, preventing assessment of drug interaction. Homeopaths have 
traditionally conceptualized their medicines as acting non-materially, and 
certainly not according to orthodox mass action-receptor site theory. 
Accordingly, drug interactions are not seen by them as a problem. However, 
the tendency for patients to self-prescribe homeopathic medicines alongside 
orthodox drugs suggests this view may be complacent. Although the present 
review contained few trials for acute life-threatening conditions as grave as 
diphtheria, as seen in Ch. 9.4.4, combined serum plus homeopathy showed 
higher mortality than serum alone (Hess 1942). Disregarding possible 
allocation bias, the finding appeared to corroborate the homeopathic 
recommendation to halve serum doses when using it with homeopathy. This 
highlights an area of potential concern, that could be particularly relevant 
when prescribing tautopathic potencies of concurrently prescribed orthodox 
drugs. 
Withholding treatment An indirect effect of increasing patient reliance on 
private homeopathic treatment is the possibility that standard biomedical 
interventions may be foregone. This has been shown to be the case in the UK, 
where many non-doctor homeopaths advise parents against vaccinating their 
children, because of fears about vaccine safety and inutility (e.g. Moskowitz 
1992), and in the belief that homeopathic prophylaxis or treatment is 
sufficient in diseases such as chicken pox, measles, mumps, rubella and 
whooping cough (Pinto & Feldman 2000: 133). 
13.4 Holism, quality of life and economic evaluation 
The poor quality of evidence relating to homeopathy's global effects, and the 
dearth of evidence relating to quality of life and economic evaluation has 
been noted in Ch. 12. This was particularly puzzling since, when these 
elements were incorporated into trial evaluation, they tended to favour 
homeopathy. 
13.4.1 Comorbidity and wellbeing 
In an equivalence trial for primary female infertility (Gerhard, Reimers, Keller 
et al. 1993), (MQ = 57%) improvements in baseline comorbidity were found in 
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19% of those receiving classical homeopathy (including: loss of libido; chronic 
headaches; chronic conjunctivitis and lymphadenitis; hay fever and 
headaches). The control treatments included hormone replacement and in-
vitro fertilization, but no comparable improvements were noted, and 29% of 
patients in this group reported feeling worse than before the trial. 
A 1987 randomized trial of classical homeopathy for migraine seems to have 
been the earliest in the set to measure a global outcome (Brigo and Serpelloni 
1991). Patients were asked to rate their own general wellbeing (cenesthesia) 
on a 10-point visual analogue scale (VAS) on 3 occasions, and the verum 
group showed significant improvement, unlike placebo. 
A VAS was again used to let patients rate changes in their sense of wellbeing 
in a trial comparing classical homeopathy with orthodox treatment in irritable 
bowel syndrome (Owen 1990) (MQ = 73%). The homeopathy group did not 
report as much benefit on this measure as the conventional group, but 
significant improvements were found in both groups when patients were 
asked to record improvements in their own worst-rated symptom on another 
VAS. 
As mentioned in 13.2.1, mental-emotional and physical wellbeing, as rated by 
patients with many different presenting conditions, were the main outcomes 
in another classical trial also in the top 20% (Kuzeff 1998). 
13.4.2 Quality of life 
Unfortunately, only 1 trial used a validated QOL instrument (SF-36), and it 
may be significant that the trial was an equivalence study conducted by a 
specialist trial organization (Weiser, Strosser, Klein 1998). Patients treated for 
vertigo with the complex VertigoHeel or betahistine hydrochloride were 
tested 3 times, and no significant difference was found between the 
improvements recorded in both groups. The MRC will not fund clinical trials 
that do not measure QOL (unless its omission can be justified), and although 
there are some objections to this (The Lancet 1995), homeopaths in particular 
need not resist the requirement since it begins to quantify something they 
have used intuitively for 200 years as an index of the progress of treatment in 
chronic illness. The choice of QOL instrument needs consideration, however. 
The limitations and rigidities of off-the-shelf questionnaires have been 
recognized more generally, and the intuitively attractive idea of patient-
generated measures has come to seem the most appropriate (Gill & Feinstein 
1994; Ruta, Garratt, Leng et al. 1994). 
13.4.3 Economic evaluation 
The infertility trial mentioned in 13.4.1 above was the only one to include 
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cost-benefit analysis (Gerhard, Reimers, Keller et al. 1993). The clinic costs 
(treatment and therapist time) per successful birth ('take home baby') were 
335 DM for homeopathy vs 11 661.5 DM for orthodox treatment. Social costs 
were not included, but it was recorded that orthodox treatment required 
patients to attend hospital 6 times as often on average. It is particularly 
interesting that these figures should reflect so closely the cost comparisons 
made in pragmatic trials in the middle of the nineteenth century (Ch. 8). It 
would be unwise to extrapolate these results too far outside this immediate 
clinical situation however: orthodox infertility treatment is notoriously 
expensive at present, and NHS postcode rationing is common, while many 
orthodox drugs for many other conditions are comparatively cost-effective. 
Several authors state that one of the reasons for employing homeopathy is the 
low cost of treatment, and this was particularly mentioned in those trials 
concerned with diseases of poverty. This seems borne out in a European 
context by a survey of costs in 1988 obtained from the North-Wurttemberg 
Kassenarztliche Vereinigung (a health insurance union). General practitioners 
in this area at that time were compared to an equivalently sized group of GPs 
who also practised naturopathy or homeopathy, and differences between the 
2 groups were significant with respect to drug costs and sickness certificates, 
but not with respect to physician fees (Wiesenauer, Groh, Haussler 1992). 
However, in some clinical conditions, the increased cost of homeopathic 
practitioner time would undoubtedly offset the small savings on medication -
e.g. the irritable bowel trial which found that classical homeopathy with 
extended interviews was no more effective than orthodox treatment involving 
dicyclomine hydrochloride, fecal bulking agents and a diet advice sheet 
(Owen 1990). 
13.5 Methodological quality measurement 
The MQ scale used here provided good comparability with scales devised by 
Kleijnen et al. (1991) and Linde et al. (1997) for systematic reviews of 
homeopathy trials, and appeared well-suited for its purpose of discriminating 
finely between studies of widely different conduct and reporting quality. It 
showed the same approximately normal distribution as the 2 comparison 
scales, but the floor and ceiling effect seen in the other scales wre absent - the 
inclusion criteria used here meant no trial could score below 17%, and no trial 
scored more than 96%, almost certainly because of Questions 8 and 9 about 
random selection of patients from the target population. 
A post hoc validation and justification for the choice of scale emerged after 
quality scoring had been completed. A comparison of 25 quality scales was 
made by rating 17 trials of low-molecular-weight heparin (LMWH) or 
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standard heparin in prevention of deep vein thrombosis during surgery (Jiini, 
Witschi, Bloch et al. 1999). The sample of 17 trials was taken from an earlier 
meta-analysis which recommended standard heparin (Nurmohamed, 
Rosendaal, Buller 1992). The reviewers demonstrated a wide spread of 
estimates of effect, from scales which appeared to replicate the findings of 
Nurmohamed et al. to scales such as Linde et al. (1997) which showed greater 
benefit from LMWH, reversing the original meta-analysis. Because of this 
variation, the reviewers questioned the function and reliability of quality 
scales per se. However, the reversal of results appears to correlate more with 
the level of high-quality cut points in the individual scales than with the scale 
components themselves (Dean 2001). Linde et al.'s scale in particular had an 
exceptionally high cut point of 70% relative to the mean score of 60% obtained 
with it, scoring only 3 trials from 17 as high-quality. By comparison, Jadad et 
al.'s (1996) scale contains highly similar components - but the cut point of 
60% was identical with its mean, conferring high-quality status on 9 of 17 
trials. The heparin meta-analysis obtained from Cho & Bero' s MQ scale 
appeared among the least skewed in either direction in Jiini et al.'s review, 
along with Jadad et al.'s well-regarded but deliberately much less informative 
instrument. 
The scale used here has the additional advantage that designs excluded from 
this review - such as intrahomeopathic comparison studies without external 
controls, or even prospective case-series - could be included in the database 
at a later date and evaluated to a common standard. 
13.6 Clinical relevance 
The results of evaluation with the CR instrument correlated well with MQ 
scores. However, since CR scores contain a maximum of 14% of points for 
efficacy, it is possible for an unsuccessful treatment to achieve a higher CR 
score than an effective treatment, simply because it was better reported. It 
follows that the tool as it stands should probably only be used to measure 
clinical relevance of treatments known to be effective, and may need 
modification. The instrument could be described as measuring clinical fitness 
in situations where health professionals need to make decisions about 
whether to offer treatments where there may be little independently 
evaluated evidence available. 
In spite of the use here of a quantitative CR instrument, it must be 
acknowledged that the clinical relevance of homeopathy is a much more 
difficult problem to address than the placebo question. Put simply, at what 
point do the clinical, socioeconomic or psychological ad vantages of a novel 
treatment make its adoption desirable, inevitable or imperative? When the 
218 
competing therapy is as challenging to biomedical assumptions as 
homeopathy, some would argue that it can never be clinically relevant-even 
when superiority to placebo has been demonstrated (Langman 1997). Since 
this is the case, how can homeopathy be expected to demonstrate clinical 
relevance in the face of institutional scepticism and the consequent 
withholding of research funding? This important question is too large to be 
considered fully here, but implications for trial design and conduct can at 
least be considered on the basis of the clinical trials in this review. The 
discussion looks in turn at the operational and ethical questions posed by 
different sorts of comparative trial, the inclusion of patient preferences, and 
the evaluation of intrahomeopathic heterogeneity. 
13.6.1 Placebo problems 
In response to the difficulties found in the 3 classical migraine trials that failed 
to replicate the positive results of an earlier one (13.2.1), it has been suggested 
that the days of randomized placebo-controlled trials of homeopathy might 
be numbered, to be replaced by observational studies, audit and quality-of-
life assessment (Whitmarsh 2000). QOL assessment is not an alternative to 
trials, and has been discussed above (13.4.2). However, placebo controls 
themselves are problematic, to the extent that the validity of the construct 
faces serious challenge (Kaptchuk 1998b; Kienle & Kiene 1998). It is certainly 
arguable that placebos have been over-sold in clinical research, sometimes as 
a way of bringing new drugs to market that are less effective than those 
already available. It is also true that participants in randomized placebo-
controlled trials, both patients and therapists, may differ systematically from 
those who would not give consent. And placebos are simply unethical in 
many contexts. In protracted trials patients cannot be denied a different 
treatment known to be effective just to suit the interests of the researchers. 
Yet classical homeopaths have traditionally claimed they can successfully 
treat chronic disease when time is not a constraint, and there is good 
retrospective evidence to support this, e.g. in bronchial asthma (Eizayaga, 
Eizayaga, Eizayaga 1996). In the only prospective trial in this review to follow 
a severe debilitating relapsing chronic condition (ME/PVFS) for the sort of 
period homeopaths would normally recommend, it is reasonable to assume 
that patients only agreed to the possibility of being assigned to placebo over 
12 months because of the absence of plausible biomedical treatments (Awdry 
1996). 
Although observation and audit are frequently proposed as an answer to the 
confusing state of placebo research and the need for realistic treatment times, 
the nonexperimental approach brings its own uncertainties. An audit cycle 
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certainly allows therapists to find out what they are doing, and improve 
standards by feeding back the results of best practice. But what then? 
Observational studies, even of best practice, still have limited generalizabilty 
because of unknown biases (Sheldon 1995). And there are particular reasons 
why homeopathy may need to be cautious about a call for flexibility that 
originates from within biomedicine, and relates to competing but less 
controversial treatments (Black 1996). Because research into homeopathy's 
mechanisms has been so retarded, a retreat from experimental rigour - even 
in empirical outcomes research - would be seen as an admission of failure. 
13.6.2 Pragmatic trials 
However, the format of the clinical trial has evolved over the last 200 years to 
include not just placebos and double-blinding, but also randomization and 
statistical analysis (Lilienfeld 1982). There are good reasons for wanting to 
retain the advantages of the last two, and not throwing the baby out with the 
bathwater. Although some would dispense with randomization (Urbach 
1985) they have not convinced many that observational studies and historical 
comparisons are an adequate substitute. This is the point at which pragmatic 
and equivalence trials become relevant (Schwarz & Lellouch 1967). To show 
simultaneously the possible advantages of these over the observational and 
placebo-controlled models, a simple clinical situation that can easily be 
double-masked and controlled by a orthodox treatment and placebo is useful. 
The high-quality randomized three-armed trial (n = 156) mentioned in 13.2.2 
found Calendula ointment for second and third degree burns marginally 
significantly better than the vaseline excipient alone for rate of healing (p = 
0.05), and much better at pain relief (p = 0.002) (Lievre, Marichy, Baux et al. 
1992). Calendula promoted healing as well as a proprietary proteolytic 
ointment, Elase® (nsd). Elase® was significantly more likely to cause pain, 
however, being poorly tolerated in 41 of 52 patients (p = 0.002). Audit or 
observation of calendula treatment alone would have shown little. Suspicion 
of selection bias would prevent any attempt to publish the results outside the 
internal literature. Meaningful historical comparisons could not be made, 
because although Elase® was used in bums units throughout France it had 
not been subjected to satisfactory trials. A simple placebo-controlled trial of 
calendula might have been published, but would tend to be dismissed 
because the primary outcome (rate of healing) could be found once in every 
20 trials by chance. 
Clearly, the inclusion of the orthodox treatment raised the information value 
of the trial, and such findings are relevant whether the evaluation concerns 
homeopathy vs placebo, adverse reactions, QOL, or costs. This is now 
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realized more widely than was the case, and the high-quality trial of a 
complex versus betahistine hydrochloride for vertigo showed that it is no 
longer necessary to have a separate placebo arm to be published in 
mainstream journals (Weiser, Strasser, Klein 1998). There are occasions when 
orthodox treatments cannot be substituted for placebos (Tramer, Reynolds, 
Moore et al. 1998), but this argument rarely applies to homeopathy. 
13.6.3 Randomization and patient preferences 
To allow valid comparisons between treatments believed to be equivalent in 
some respects, it is necessary to recruit enough patients to meet the increased 
statistical power requirement Gones, Jarvis, Lewis et al. 1996), although the 
significantly lower levels of attrition in pragmatic trials found in this review 
(Table 12.9) might be indicative that placebo controls introduce other sorts of 
inefficiency. It also goes without saying that when treatment is given 
unblinded, independent masked assessment of outcomes is needed. 
However, the inclusion of classical homeopathy for chronic disease in a 
simple randomized comparison poses further problems. Similarly to 
therapists and patients who volunteer for double-blind placebo-controlled 
trials, patients who agree to be randomized to widely different open 
treatments may differ in important ways from the target population - an 
argument often put forward against randomization. This would be appear to 
be particularly true of treatments requiring a great deal of patient and 
therapist commitment, such as classical homeopathy. Also, patients informed 
of the risks and benefits found in previous trials might be expected in many 
situations to express a treatment preference at the outset. 
Nevertheless, ways of retaining the benefits of randomization and analysis 
have been proposed. Brewin and Bradley (1989)suggested that trial patients 
could be assigned to their preferred treatment (arms A and B) or randomized 
to either if they were equipoised (arms C and D). Such a design can provide 
even more information than a preference-only or randomized-only trial. An 
integrated pluralist health service may think it important to find out not only 
how groups A and B respond to their preferred treatments, but also how C 
and D feel about the acceptability of treatments after random assignment. 
One such trial of two methods of termination of pregnancy found A and B 
were equally satisfied, unlike C and D, where far more women in one group 
said they would not choose the same method again (Henshaw, Naji, Russell et 
al. 1993). A trial with a similar design reviewed here has shown that classical 
homeopathy is an acceptable alternative for women who reject conventional 
treatment for unexplained infertility, and convincingly demonstrated 
homeopathy's minimal drug costs and beneficial effects on unrelated 
comorbidity (Tarne, Runnebaum, Roebruck et al. 1998, later published as 
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Gerhard 1999). It also provided evidence of potential weaknesses in the 
Brewin-Bradley model: few with this condition were willing to be 
randomized; and sociodemographic analysis revealed that the homeopathy 
preference group was significantly better educated and had unsuccessfully 
tried significantly more therapies before the trial. One answer to the limited 
generalizability of results obtained from unbalanced preference groups is to 
ask patients their preference, but to retain it only as a prognostic variable for 
analysis rather than to determine assignment, which is randomized as usual 
(Torgerson, Klaber-Moffett, Russell 1996). 
13.6.4 lntrahomeopathic comparisons 
One of the advantages of pragmatic trials is that comparisons can be made 
between different homeopathic methods at the same time. Of the 4 migraine 
trials (13.2.1), 3 allowed single medicines only (Straumsheim, Borchgrevink, 
Mowinckel et al. 1997; Walach, Haeusler, Lowes et al. 1997; Whitmarsh, 
Coleston-Shields, Steiner 1997) while the fourth allowed 2 to be combined in 
any one prescription (Brigo & Serpelloni 1991). Although this trial took place 
before the IHS definitions were drawn up, the inclusion criteria suggest that 
the patients were not so different from the migraine and chronic headache 
patients of the other 3 that the successful result can be ignored. Trial quality is 
frequently a reason for suspecting positive results, but this review suggests all 
4 trials were strictly comparable, with MQ scores clustered in a range of 
86-91 %. Given such a fundamental treatment difference, it is questionable 
whether the 3 later trials can be regarded as replications of the earlier one, 
and reasonable to ask whether unicist or pluralist treatment was a significant 
variable. The 4 unicist trials for childhood diarrhea (see 13.2.1) were more 
closely related, the main difference being the use of C30 and C6 potencies. 
Answers are needed to many similar internal and traditionally divisive 
questions, and observational study followed by pragmatic trial (perhaps 
involving patient preferences for the type of homeopathy) can do this more 
quickly than separate placebo-controlled trials, which are often 
incommensurable because of differences in design, recruitment, ethos and so 
on. Preliminary outcomes research exists to suggest that some classical 
repertorization strategies may indeed be more widely applicable or effective 
than others (Frei 1999), but experimental testing is needed before valid 
conclusions can be drawn. In an interesting attempt to make just such an 
intrahomeopathic comparison (excluded from the review because it lacked 
external controls), a standardized complex preparation for primary female 
infertility was tested against classical homeopathy (Gerhard, Keller and 
Schmuck 1993). An innovative trial design allowed an optional crossover 
from complex to classical treatment for women who were dissatisfied with 
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treatment, but was unbalanced by the absence of opportunity for a reciprocal 
crossover from the classical arm. Conceptions after crossover were attributed 
to classical treatment when they might have been carryover effects of the 
complex. Nevertheless, the staffing difficulties encountered in the trial meant 
that many more women could be treated with the complex. 
It is evident from the general literature that clinical and complex homeopathy 
and isopathy are often dismissed by the proponents of exclusively classical 
methodologies on theoretical grounds, and these attitudes could be detected 
in this review even in the face of evidence of efficacy and possible clinical 
relevance (e.g. the editorial comments accompanying Basu 1980; 1981). 
However, if trials show that changes in prescribing styles are indicated, then 
homeopaths have to be willing to adopt them. At the same time, health 
services need much better content-specific intrahomeopathic information than 
has been available hitherto. For example, classical homeopathy has been 
commissioned for atopy because successful high-quality isopathic trials have 
been conducted, even though classical homeopaths are unlikely to offer the 
same treatment (Reilly 1996). 
13.6.5 Clinically relevant trial proposals 
To sum up this discussion of clinical relevance, in situations where orthodox 
treatment is cost-effective, the question whether or not homeopathy is 
relevant by virtue of its supposed global effects cannot be answered on the 
basis of the trials in this review, and does not seem to have been formally 
tested. Probably the only feasible method of exploring the question would 
involve tracking sizeable and strictly comparable cohorts of patients receiving 
homeopathic and orthodox treatment over a considerable number of years. 
However, a key question thrown up here is whether homeopathy should be 
actively considered in situations where biomedicine has current difficulties in 
understanding or targetting a condition or its etiology, or where treatments 
have not been developed because of differing research priorities and 
economic objectives, or where they create unacceptable side-effects, or are 
rationed because of costs. Evidence of homeopathic efficacy in each of these 
overlapping areas has been presented, as well as independent replication in 
some cases. Using these as clinical relevance criteria it is possible to envisage 
pragmatic trials comparing cost-effectiveness and patient acceptability of 
homeopathic and orthodox treatment within the UK health system in several 
conditions. 
13.6.5.1 Unexplained female infertility 
Standard treatments (including AI and IVF) for female infertility of unknown 
origin have only ~0% efficacy on average, and are frequently invasive and 
223 
expensive. Women trying to conceive for ;;?:2 years were treated with classical 
homeopathy or standard treatment in a trial where permission to randomize 
could not be obtained, but careful matching on 12 prognostic criteria was 
used (Gerhard, Reimers, Keller et al. 1993). The number of successful births in 
each group was equivalent, and the global and economic advantages of 
homeopathy found in this trial have been mentioned above (13.4.1, 13.4.3). An 
independent replication incorporating partial randomization and patient 
preferences again found equivalence in the primary outcome, as well as 
superiority of homeopathy's global effects and costs (Tame, Runnebaum, 
Roebruck et al. 1998). A study group looking at infertility treatment has 
created an evidence-based hierarchy for treatment recommendations 
(Royal College of Obstetricians and Gynaecologists 2001). Grade A requires at 
least one randomized trial as part of a body of literature of overall good 
quality and consistency addressing the specific recommendation; Grade B 
requires availability of well-conducted clinical studies in the absence of 
randomized trials on the topic of recommendation; and Grade C includes 
expert evidence and clinical experience of respected authorities. The classical 
homeopathy trials undertaken in Germany are part of a growing body of 
research and evidence that currently falls between Grades A and B. A 
replication in the UK comparing homeopathy with RCOG's recommended 
treatment for unexplained infertility (ovarian stimulation with intrauterine 
insemination), and using local inclusion criteria such as trying to conceive for 
~3 years, would seem to be justified. This is particularly relevant since RCOG 
stressed that the Department of Health's advice to NHS commissioners 
should provide evidence about cost-effectiveness as well as clinical efficacy. 
13.6.5.2 MEIPVFS 
Classical homeopathy showed significant benefits over placebo in patients 
meeting standard diagnostic criteria for this relapsing chronic condition 
(Awdry 1996), and a randomized placebo-controlled replication is under way. 
No somatic treatment has proved satisfactory, and treatment with 
antidepressants is common. However, a placebo-controlled trial of fluoxetine 
showed no difference from placebo after 8 weeks on any outcome measure 
including depression, and 15% of verum patients dropped out from side-
effects (Vercoulen, Swanink, Zitman et al. 1996). A second trial randomized 
patients to fluoxetine plus a graded exercise programme, fluoxetine and 
appointments only, graded exercise only, or placebo, and after 6 months still 
found no difference from placebo, as well as 13% dropouts from side-effects 
(Wearden, Morris, Mullis et al. 1998). It would appear that biomedicine has 
little to offer patients, despite ME/PVFS having a greater impact on personal, 
physical and emotional disability than angina, hypertension, arthritis or 
chronic bronchitis (Wessely, Chalder, Hirsch et al. 1997). A cognitive 
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behaviour therapy (CBT) package aimed to help patients cope better with the 
disease has shown significant benefits over ordinary medical care or 
relaxation therapy in 2 randomized trials (Sharpe, Hawton, Simkin et al. 
1996). Although classical homeopathy aims to do more than help patients 
cope better, it could usefully be compared with CBT, possibly using a similar 
design to the unsuccessful fluoxetine plus graded exercise trial. 
13.6.5.3 Influenza treatment 
Biomedicine has had little success in targetting viral infections, and influenza 
treatment has traditionally consisted of advice to rest, maintain fluid intake 
and use antipyrexics or analgesics as needed. The recently-licensed zanamivir 
(Relenza) is supported by evidence from RCTs of symptom relief and 
reduction in time to recovery of 0.5 days. The R&D costs were enormous, 
leading to high prices, and the drug was subsequently not approved for NHS 
use, on the grounds that the trials showed insufficient evidence of effects. 
Outcry from practitioners and the manufacturer's economic threat to 
withdraw altogether from UK drug research were followed by limited 
approval for NHS use in at-risk groups (NICE 2000). Oscillococcinum's 
superiority to placebo in treatment of influenza appears to have been 
established in the 4 trials reviewed here, and a systematic review showed a 
mean reduction in illness duration of 0.28 days (Vickers & Smith 2000). The 
clinical relevance of this reduction has been questioned (FACT 2001), but it is 
equally questionable whether this single outcome adequately summarized the 
evidence. Oscillococcinum also showed significant relief of influenza 
symptoms in each trial, but costs much less than zanamivir (and less still 
when sold as the generic Anas barbarae). Moreover, while zanamivir can only 
be dispensed on prescription, Oscillococcinum is available over the counter, 
with possible implications for reducing demand on health services. A 
randomized equivalence trial of these competing treatments would seem to 
be justified on economic grounds alone. 
13.6.5.4 Inhalant allergy 
Biomedical treatment of atopy, including hayfever and asthma, is principally 
confined to management, typically with corticosteroids. Hyposensitization 
with allergen extract vaccines has not proved effective in asthma. Vaccines 
have been more successful in allergic rhinitis when specific allergens are 
known but are little used because of the risks of anaphylactic shock. 
Homeopathic immunotherapy (HIT) with specific allergens in C30 potency 
proved safe and significantly superior to placebo on a range of outcome 
measures in the series of trials for hay fever and asthma mentioned in 13.2.4 
above (Reilly & Taylor 1985; Reilly, McSharry, Taylor et al. 1986; Reilly, 
Taylor, Beattie et al. 1994). Although the trials were planned to test the 
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ultramolecular-placebo hypothesis, and the authors said there were no 
implications for clinical practice, a recent independent multicentric replication 
studying the model in perennial allergic rhinitis showed an effect on nasal 
inspiratory peak flow comparable to that found with topical nasal steroids 
(Malmberg, Holopainen, Simola et al. 1991; Taylor, Reilly, Llewellyn-Jones et 
al. 2000). A pragmatic trial of HIT and steroidal treatment of atopy would 
now seem to be justified, and could make use of the results of a randomized 
placebo-controlled comparison of 2 different potencies in the same model 
(Kayne & Beattie 1996, interim report excluded from this review). 
13.7 Limitations of the present review 
Less space has been given to criticism of internal validity of trials than in most 
previous homeopathy reviews, and more consideration to homeopathic 
validity and generalizability. This could be seen as avoiding the placebo 
question which has driven earlier reviews. Single-reviewer evaluation is also 
problematic, and if more resources had been available, twin MQ and CR 
scoring with a test for inter-rater agreement might have been preferable. A 
validated MQ instrument was used, however, which showed good rank 
correlations with MQ scores from previous high-quality systematic reviews, 
and allowed discussion to be restricted to best evidence for the most part. 
Although an advance on dichotomized results, the use of a stratified vote 
count is an imprecise measure of effect size. It was adopted because of the 
need to display and compare results from trials with more than 1 clinically 
relevant outcome. The development of meta-analytic techniques that are not 
limited to single outcomes - or alternatively, more frequent use of global 
outcomes such as QUALYs - ought to enable greater precision without 
sacrificing global effects. 
13.8 Further recommendations 
Suggestions concerning homeopathic trial design and conduct have been 
made throughout this chapter. Reviewers in all fields of healthcare are 
expected to urge researchers to improve reporting standards of clinical trials, 
and more help is available than ever before (CONSORT 2001; Moher, Schulz, 
Altman et al. 2001). On the basis of the reports reviewed here, areas specific to 
homeopathy where reporting (and probably trial planning) could be greatly 
improved without exceeding space restrictions in biomedical journals include 
the descriptions or identifications of: 
• rationales for selection of test medicines, potencies and repetition in 
clinical and complex homeopathy and isopathy 
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• repertorization and prescribing strategies in classical homeopathy 
• names, potencies and repetition of trial medicines in classical homeopathy, 
along with a frequency table of at least the principal medicines 
• which pharmacopeia and laboratory were used to manufacture test 
medicines 
• placebo details where used, e.g. unmedicated blanks, plain or serially 
diluted diluent, succussed or unsuccussed. 
Space is less limited in homeopathic and complementary healthcare journals, 
and it has been suggested that classical trials could be reported in much 
greater detail there, in parallel with abbreviated but more prestigious reports 
of the same trials in the biomedical press (Linde & Melchart 1998). This advice 
should probably hold good for all types of homeopathy. 
Further development and maintenance of an evaluated international trial 
database searchable by many variables, as used in the preparation of this 
review, should be a priority. It will allow efficient online systematic searches 
and reviews of clinical evidence, currently hampered by the grey literature 
and language problems, and enable rapid identification of significant 
similarities and differences between designs, inclusion and exclusion criteria, 
demographics, treatments and outcomes. Incorporating experimental and 
quasiexperimental designs not included here will be feasible, since the MQ 
instrument used is designed to allow such designs to be evaluated to a 
common standard, and will make studies that merit analysis and rigorous 
replication more readily available than hitherto. 
If the database were to be further expanded to incorporate preregistration of 
homeopathy trials it would begin to address the problem of publication bias 
in homeopathy. If structured to correspond with the CONSORT 
recommendations for parallel group randomized trials, or similar 
recommendations for other designs, it could also benefit prospective 
researchers in homeopathy by demonstrating standards of trial design and 
reporting to aim at. For political reasons, such a database should probably not 
be held in an existing homeopathic or biomedical centre, but in an impartial 
evidence-based healthcare environment. 
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PART IV: CONCLUSION 
14 Retrospect and prospect 
228 
14 RETROSPECT AND PROSPECT 
I: Homeopathy's place in the history of therapeutics 
In spite of high ideals and eager observation, neither the French nor the 
German attempts to reconstitute medicine in the late eighteenth century had 
much to offer therapeutically. Inductive description of the processes and 
endstates of disease did not lead to relief for patients; and the basic sciences, 
which would later reveal 'causes' and the possibility of treatments aimed at 
them, did not yet exist to underpin the search for deductive principles. 
Within both schools, the vacuum created by the abandonment of the 
apothecaries' concoctions was filled by increased reliance on blood-letting 
and a handful of drugs as the sole treatments. Therapeutic nonsense was 
replaced by therapeutic nihilism. Calomel, still in use today as a pesticide, 
continued as a mainstay of internal medicine throughout the nineteenth 
century, and was used into the 1920s as a purgative in the management of 
pneumonia (Porter 1997: 674). Likewise, blood-letting did not die out quickly 
after its inefficacy was timidly demonstrated in a single condition by Louis 
(1835). The retired British prime minister Sir Robert Peel was bled while 
dying- from concussion, multiple fractures and internal hemorrhaging, after 
falling from his horse- in central London in 1850. Most doctors in that year 
before the Great Exhibition complained that he should have been bled much 
more intensively-20 leeches were just too few to save him (Youngson 1979: 
18). And blood-letting was still advocated in pneumonia in the twentieth 
century at the highest levels of medical education (e.g. Osler 1912: 99). 
Hahnemann's rejection of the therapeutic anarchy of the late eighteenth 
century came before his homeopathic research, and proceeded alongside the 
new therapy until the end of his career. He was a highly competent critic, and 
the accuracy and prescience of his rejection of blood-letting and rationalist 
medical theories, and his calls for reform of the abuses of the apothecaries and 
the treatment of the mentally ill, were subsequently confirmed historically 
and scientifically. His plea for humane treatment of suicides took longer to be 
heard (Hahnemann 1819b): they committed a criminal offence in the UK until 
1961. 
A century after his death, opponents were still trying to neutralize the 
critique, claiming that homeopathy was an involuntary reaction and medical 
reform really began with the French school (Osler 1941: 221). In spite of earlier 
reluctance to acknowledge him, medical historians have more recently given 
Hahnemann much of the credit for orthodoxy's gradual abandonment during 
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the nineteenth century of bleeding, purging, polypharmacy and massive 
doses, as well as the belated adoption of the precautionary principle that 
medicines should be tested on the healthy before administering them to the 
sick (Shryock 1948: 139; Ackerknecht 1982b: 143f; Porter 1997: 390f). If he had 
done nothing else, Hahnemann's revival and continued aggressive advocacy 
of the forgotten principle of primum non nocere (first do no harm), from 1790 
until his death in 1843, can still reasonably be said to have had as much 
practical influence on medicine as any other individual reformer's 
contribution. The author of the entry for homeopathy in the 10th edition of 
the Encyclopaedia Britannica remarked: 
Hahnemann undoubtedly deserves the credit of being the first to break 
decidedly with the old school of medical practice, in which, forgetful of 
the teachings of Hippocrates, nature was either overlooked or rudely 
opposed by wrong and ungentle methods. We can scarcely now 
estimate the force of character and of courage which was implied in his 
abandoning the common lines of medicine. (Helmuth 1911) 
Hahnemann's commitment to Enlightenment ideals is hard to fault, and 
attempts to explain his critique away as a product of his personal 
inadequacies seem to have little basis in fact. 
Turning to Hahnemann's therapeutics, in order to assess the validity of the 
arguments that it was merely invented, or derived from Paracelsus, the 
distinctive aspects of the Hahnemannian research programme must be 
described, and then placed in their historical context. It is possible to see that 
far from being unconnected to the acknowledged problems of eighteenth-
century medicine - e.g.: its lack of any rational connection between materia 
medica and diseases; its dangerous therapies - Hahnemannian homeopathy 
built on critical ideas, experiments and therapeutic procedures already 
conjectured or in existence - particularly those of von Storck, Plenciz and John 
Hunter. Homeopathy began as a rational Enlightenment enterprise designed 
to fulfill the Kantian dream of a scientific medicine to match the other 
sciences, but with the added irony that it purported to be an unKantian 
science centred on aggregated human qualities and perceptions rather than 
measureable physical quantities. Homeopathy could be rejected because it 
was claimed that it was opposed to all scientific advances in medicine per se. 
Yet therapeutics was Hahnemann's primary target, not science: 
Without disparaging the services which many physicians have 
rendered to the sciences auxiliary to medicine, to natural philosophy 
[physics] and chemistry, to natural history [biology] in its various 
branches, and to that of man in particular, to anthropology, physiology 
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and anatomy, etc., I shall occupy myself here with the practical part of 
medicine only, with therapeutics itself, in order to show how it is that 
diseases have hitherto been so imperfectly treated. (Hahnemann 1833c: 
Introduction) 
Looking beyond the incompatible aspects of Kantian and Hahnemannian 
medical assumptions, there are interesting similarities in Hahnemann's and 
Hegel's programmes that undoubtedly warrant further study. Post-Kantians 
with ambitions to transform their disciplines, they both believed they had 
transcended the rationalism or empiricism of their medical and philosophical 
predecessors and contemporaries. Both rejected mind-body dualism, and 
created integrated systems that were phenomenologically and semantically 
based - possibly under Herder's influence -while asserting their scientific 
validity. There are ironic similarities in their reception as well. Both have 
frequently been derided as charlatans, or 'too difficult to understand', by 
practitioners and historians of medicine and philosophy, who have too often 
felt free to abandon academic objectivity when writing about them (for 
Hegel's reception, see: Cottingham 1984: 91ff). Both are often confused with 
the Naturphilosophen, despite their having taken care to distance themselves 
from biological and philosophical Romanticism. Both had immense influence 
on the subsequent development of their disciplines, that has often gone 
unacknowledged. 
As scholars such as Pagel (1982a; 1982b) and Debus (1998) have pointed out in 
regard to their postpositivist reassessments of Paracelsus' and Van Belmont's 
significance, Hahnemann's synthesis ought really to be regarded as a sign of 
his great creativity and seminal importance. In view of Hahnemann's stature, 
during his life to some extent, and certainly after his death, homeopathy 
inevitably acquired many aspects of a personality cult. Attempts to prevent 
this were heard within homeopathy from the 1820s on- such as the German 
'critical' homeopaths like Wolf, and independent medical thinkers like Tessier 
in France, or Dudgeon and Hughes in Britain - but their voices were lost as 
homeopathy and an infant biomedicine became increasingly divergent and 
antagonistic, rather than learning from each other. 
External rejection and internal division have usually been presented as 
consequences of a one-sided failure of homeopathy to keep up with 'the 
progress of science' (Campbell 1978; Bellavite & Signorini 1995). Another 
view would construct the problem slightly differently, and say that the 
accelerating growth of mechanistic reductionism in the nineteenth century 
did not use postmortem lesions, laboratory parameters and germ theory to try 
to augment understanding of the patient's experience of illness, but as a 
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replacement for understanding. A version of science intent on removing the 
human observer from the universe succeeded in relegating the perception and 
description of human sensation and emotion - proper subjects for medicine, 
not just homeopathy- to the arts. One could say the deliberate exclusion of 
homeopathy from biomedicine forced both streams into narrower channels. 
In homeopathy's case, clinical research gave way to scriptural exegesis of the 
canonical works (e.g. Kent 1900), and acausal phenomenology was sometimes 
lost in neorationalist backwaters of speculation about constitution, occult 
etiology and spiritized posology. This seems to have been more responsible 
for the objections of the clinical homeopaths than any objection to semiology 
on their part, and their contribution really comprises a self-correcting 
tendency within homeopathy, not a root-and-branch replacement. The later 
developments and ramifications of homeopathy are not invariably signs of 
'confusion', but also point to an underlying reality: the belief in the biological 
activity and therapeutic efficacy of homeopathic serial agitated dilutions 
across wide domains of sickness. 
II: Homeopathy and the development of clinical evaluation 
An adaptation of the systematic review technique has allowed important 
historical questions about the reception of homeopathy by science and 
orthodox medicine, and the reciprocal relationship between homeopathy and 
allopathy in the development of clinical evaluation, to be posed and answered 
in terms of evidence from trials and clinical practice. This is in marked 
contrast to the debate about scientific rationality and the resistance to change 
within orthodox medicine (including the rejection of dissident or alien 
therapies such as mesmerism, homeopathy and acupuncture) in the first half 
of the nineteenth century- a debate that is as familiar as it is undecideable, 
when based mainly on theoretical considerations and epistemological 
hindsight. 
This approach also allows an entirely different biographical perspective to 
emerge in which the key players are not the fabled elders and theoreticians of 
traditional and recent homeopathic historiography, hagiography and 
education, such as Hahnemann, Hering, Bonninghausen, Kent et al., who 
form the subject of Part I. Instead, names such as Marenzeller, Tessier, Casper 
and Wurmb, Wesselhoeft Senior and Junior, Boyd and Paterson occupy the 
stage - characters whose absence from homeopathic awareness in the present 
day ought to be a matter for concern. 
It has been shown here that the very earliest external placebo-controlled trials 
of homeopathy to be discovered used placebos modelled on those already in 
use as part of Hahnemannian practice. Convinced of the fundamental 
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soundness of their therapy, homeopaths seem to have been uninterested in 
placebo-controlled therapeutic trials, and insisted on pragmatic trials of 
homeopathy versus allopathy. Although the 1854 cholera treatment 
evaluation in London has been recognized as a defining moment in the 
evolution of the clinical trial (Lilienfeld 1982), the suppression and 
subsequent publication of the superior homeopathic results appears to be 
unknown outside homeopathic historiography. Medical historiography which 
continues to ignore large well-conducted comparative trials by experienced 
homeopaths such as Tessier's in favour of invalid earlier trials such as 
Andral's can no longer be seen as an impartial account of homeopathy's 
development. The main lesson from this period of clinical evaluation is that 
the opportunity was missed to research the possibilities of homeopathy as a 
distinct and useful approach within medicine, despite the attempts of 
homeopaths, hospital administrators and government officials. Only a Nobel 
laureate with no career at stake could risk saying: 
If I were confronted with a hitherto incurable disease and could see no 
way to treat it other than with homeopathy, I can assure you I would 
not be deterred from following this course by dogmatic considerations. 
(Behring 1905: xxvif) 
Remarkably, there is no evidence that homeopaths used placebo before the 
twentieth century to disguise a lack of treatment possibilities (as allopathy 
traditionally did), but only ever as a control. Homeopathy clearly has a 
longstanding tradition of awareness of psychological factors that affect the 
way we react to treatment, and incorporated a sophisticated use of placebo 
very early on in order to minimize apparently veridical but actually 
misleading responses in everyday clinical practice. However, the adoption by 
homeopaths of an explanatory biomedical approach in the early part of the 
twentieth century performed a useful service in allowing traditional empirical 
treatments to be discarded. Once again homeopaths appear to have been 
quick to take advantage of methodological developments in clinical 
evaluation, in order to demonstrate the validity of their therapy. 
Ill: Is homeopathy clinically relevant? 
The most enthusiastic proponents of homeopathy have consistently claimed it 
is entirely safe and free from side effects, that it is designed to treat the person 
as well as disease narrowly defined, and that it is a complete medical system 
- i.e. to be used at any time, with any patient, and for almost any condition 
(even including many that would normally be regarded as requiring surgery). 
This point of view notwithstanding, common sense says that controlled trials 
are likely to show that some clinical areas and therapeutic avenues yield 
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stronger evidence of efficacy than others. The evidence that it was possible to 
uncover in the review of contemporary trials suggests that: 
• homeopathy appears mostly as safe as reputed, but far more rigorous data 
collection and evaluation is required; 
• non-holistic clinical, complex and isopathic variants of homeopathy are 
possible, but require careful problem and treatment modelling; 
• classical homeopathy does appear to be capable of influencing global 
outcomes such as wellbeing and comorbidity, but it is unlikely that all 
versions of classical homeopathy are equally valid; 
• economic benefits are noticeable in the treatment of some conditions and 
not others. 
It may be no accident that clinically relevant areas seem to have been 
uncovered in pragmatic comparisons with biomedical treatments as well as in 
explanatory placebo-controlled trials, particularly in cases where the efficacy 
or costs of orthodox treatment are problematic. This would seem to be an area 
that has been as overlooked in the current homeopathy-placebo debate as it 
was in the mid nineteenth century. It is worth recalling that the structure and 
extended format of individualized homeopathic treatment in chronic diseases 
such as migraine, bronchial asthma and ME/PVFS has much in common with 
complex interventions such as psychotherapy, multistage surgery, and social 
and educational programmes (Medical Research Council 2000). These are the 
disciplines where pragmatic trials were developed because of the obvious 
problems of applying the pharmacological gold standard. The similarity in 
appearance of homeopathic medicines and orthodox drugs may have blinded 
users and researchers to remarkable differences in the content and operation 
of the fundamental therapeutic model, when confronted by the need to 
evaluate the therapy to acceptable scientific standards. 
There are further reasons for emphasizing pragmatic rather than placebo 
trials. Sceptics demand evidence from high-quality randomized placebo-
controlled trials of homeopathy, only to reject it when it proves positive (e.g. 
Aulas, Bordelay, Royer 1991: 154ff; Sampson & London 1995; Meyer 1996: 99; 
Vandenbroucke 1997; 2000), even though large numbers of biomedical 
treatments have not been similarly validated (Bower 1998). Leaving aside a 
priorism, the question as always is: What is the question? If you want to know 
whether some or all homeopathic medicines are just sugar pills, then placebo 
trials may be appropriate. However, the fact that few patients would demand 
placebo rather than verum, given a choice, shows something may be wrong 
with making placebo controls the automatic research model outside the 
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laboratory. 
There are more urgent questions, though. Health services are desperately 
short of hard information on the comparative benefits of treatments. It is more 
useful for them to know if homeopathy - or which of its versions - can be 
appropriately offered to some or all patients, whether it makes sense to 
introduce it into primary, secondary or tertiary care, and what the costs and 
benefits of its processes and outcomes are. To answer this type of question, 
pragmatic trials are more informative, testing unblinded homeopathy against 
the best available biomedical or other complementary treatments. This shift in 
perspective also allows the need for larger trials - acutely problematic in 
homeopathy because of isolation and underfunding - to be reframed as an 
opportunity: pragmatic trials are by their very nature collaborative and 
orientated towards health services requirements, so funding and recruitment 
could prove less difficult than hitherto . 
• • • 
Philosophically, the late twentieth-century rediscovery of psychology's 
'double ontology' -that personhood coexists with but is not necessarily 
reduceable to Cartesian co-ordinates or molecular activity (e.g. Harre 1998) -
seems to have gone hand-in-hand with the realization that Hegel's 
'hermeneutic circle' could well be a more productive model for current 
developmental theory than the accepted Cartesian-Kantian one (e.g. Markova 
1982; Kelso 1995). Whether this reorientation will eventually encompass 
Hahnemann's medical personalism and what his expanded nondualistic 
notion of pharmacology might be able to tell us about ourselves remains to be 
seen. Certainly, the outlook for homeopathy will improve at all levels in 
proportion to the extent that it interests researchers in adjacent fields, such as 
immunology, toxicology, psychopharmacology and health psychology, so 
long as they do not feel intimidated by historic prejudice from entering a 
forbidden zone (e.g. Calabrese & Baldwin 1999). But as far as homeopathy's 
enigmatic biomedical status as an irrefutable but unassimilable therapy is 
concerned (Unschuld 1995), it cannot be denied that recent commitments to 
pragmatic evidence-based healthcare have allowed Hahnemann's rationelle 
Heilkunst to surface and be examined more impartially than at any time since 
its inception - not just for what it might 'be', but also for what value it might 
have to offer patients, therapists and society on its own terms. 
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Trials (n = 56) reporting adverse reactions in homeopathy or control 
groups 
Methodological quality (MQ) and clinical relevance (CR) scores of 
prospective controlled trials of homeopathy 
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App. 1 Details of excluded homeopathic trials (cont.) 
First author, year Condition Reason for exclusion 
Classical 
Barros Camargo 1988a Hypertension (essential) too small (n = 18) 
Barros Camargo 1988b Hypertension (essential) too small (n = 18) 
Bruseth 1992 Post-exercise muscle soreness nonclinical; subgroup analysis of Tveiten 1991 
Carne 1996 Autism interim report 
Chapman 1994 Premenstrual syndrome too small (n = 10) (incl. Linde) 
Gaucherl993 Cholera no quantitative results 
Gerhard, Keller 1993 Primary infertility intrahomeopathic comparison 
Jansen 1992 Proctocolitis too small (n = 18 in 3 groups) 
Lara-Marquez 1997 Chronic asthma too small (n = 19) 
Mohan 1996 Cervical spondylosis intrahomeopathic comparison 
Schreier 1997 I nferti I ity interim analysis 
Clinical 
Baillargeon 1993 Hemorrhage surrogate outcome only 
Balachandran 1977 Schizophrenia no control (intrahomeopathic comparison) 
Barrois 1988 None performance enhancement 
Bekkering 1993 Menopause too small (n = 4) (incl. Linde) 
Benzecri 1991 Drug detoxification homeopathic treatment not identified; results uninterpretable 
Berthier 1985 Post-extraction dental neuralgia all groups received verum and placebo 
Campbell 1976(ii) Bruising (experimental) single group crossover 
da Silva 1986 Hypertension (essential) too small (n = 5) 
Damien 1986 Radiation injury (chelation) too small (n = 10) 
Danner 1998 Premenstrual syndrome poster presentation 
Davies 1988 Alzheimer's disease (aluminium chelation) non-clinical; toxicological experiment (incl. Kleijnen; Linde) 
Delaunay 1985 Pregnancy non-clinical 
Dorfman 1985 Sports injuries and performance enhancement performance enhancement mixed with acute treatment 
Estragnin 1979(i) Painful breasts opaque reporting 
Garrett 1997 Ulceration of leg too small (n = 23 in 3 groups) 
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App. 1 Details of excluded homeopathic trials (cont.) 
Greenfield 1996 Cystitis interim report 
Guillemain 1983 None performance enhancemen~ no objective measures 
Heidi 1992 Chronic obstructive lung disease inappropriate homeopathic medicine (Formic-ac D6) given as placebo comparison only 
Hess 1942 Diphtheria insufficient data on method; results not tabulated; number of control patients missing 
Hildebrandt 1983a(i) Post-exercise muscle soreness (experimental) induced and nonclinical; intrahomeopathic comparison (incl. Kleijnen) 
Hildebrandt 1983a(ii) Post-exercise muscle soreness (experimental) induced and nonclinical; intrahomeopathic comparison (incl. Kleijnen) 
Hildebrandt 1983b(i) Post-exercise muscle soreness (experimental) induced and nonclinical (incl. Kleijnen) 
Hildebrandt 1983b(ii) Post-exercise muscle soreness (experimental) induced and nonclinical (incl. Kleijnen) 
Hildebrandt 1984; Reitzner 1987 Post-exercise muscle soreness (experimental) intrahomeopathic comparison; induced and nonclinical (incl. Kleijnen) 
Jackel1997 Ankylosing spondylitis ongoing trial 
Kienle 1973 Respiratory insufficiency too small (n = 16) 
Kurz 1993 Dysuria no control results given 
Manchanda 1997 Warts i. (placebo-controlled crossover) outcome definition missing; ii. (parallel) allocated n for each group missing 
Melchart 1995 lmmunomodulation nonclinical physiological experiment 
Massinger 1984(i) Cholecystopathy single-group crossover 
Massinger 1984(ii) Cholecystopathy too small (n = 14) 
Padamprakash 1979 Uri nary tract infection control outcomes not tabulated 
Rost 1986 Circulatory weakness results and statistical tests missing for double-blind placebo-controlled trial 
Schmidt 1996 Post-exercise muscle soreness nonclinical; intrahomeopathic comparison 
Skaliodas, Kivelou 1988 Mixed chronic diseases tissue salts 
Tveiten 1991 Post-exercise muscle soreness nonclinical; see also Bruseth 1992 
Tveiten 1998 Post-exercise muscle soreness nonclinical 
Vickers 1998 Post-exercise muscle soreness (experimental) nonclinical 
Vu Dinh 1983 None performance enhancement 
Wiesenauer 1986 Allergic rhinitis intrahomeopathic comparison 
Complex 
Bornoroni 1997 Upper respiratory infections (recurrent childhood) results given for verum only 
Geiger 1968 Post-fracture bruising and edema results given for homeopathy only 
Grau 1992 Gastrointestinal complaints no control 
Hill 1993 Mosquito bites (experimental) results not tabulated 
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App. 1 Details of excluded homeopathic trials (cont.) 
Jawara 1997 Post-exercise muscle soreness (experimental) nonclinical 
Kirchhoff 1989 Degenerative arthrosis intrahomeopathic comparison: control was complex less 4 ingredients 
Mastromattei 1995 Childbirth preliminary results only 
Matusiewicz 1997b Chronic asthma preliminary 6 mon report 
Mergen 1969 Posttraumatic swelling intrahomeopathic comparison: control was different dosage 
Ruff 1992 Pollinosis insufficient results data 
Vickers 1997 Post-exercise muscle soreness (experimental) nonclinical 
Wolf1992 Insomnia mixed homeo-phytotherapy 
lsopathy 
English 1987 Whooping cough nonexperimental: half cohort/ half historical controls 
Hardy 1984 House dust allergy results not quantified 
Kayne 1996 Allergy interim report 
Lewith 1989 Influenza antibodies surrogate outcome only 
Mitchell 1975 Influenza insufficient data on method 
Paterson 1941 Diphtheria antibodies surrogate outcome only 
Sudan 1993 Seborrheic dermatitis too small (n = I) 
Sudan 1997 Seborrheic dermatitis too small (n = 1) 
Unknown 
Barry 1995 Rheumatoid arthritis too small (n = 16) 
Brewitt 1996 HIV/Aids poster presentation 
Kubista 1986 Painful breasts report classes test drug as phytotherapy {incl. Linde) 
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App. 2.1 Overview of controlled trials of classical homeopathy 
First author(s), year Methods Patients Treatments Results Vote 
D: design C: condition M: methodology [ n homeopaths to agree prescription] • clinical outcomes MQ 
A:. assignment I: inclusion criteria H: homeopathic medicine/ potency 
M:masking E: exclusion criteria D: dosage, repetition 
F: follow-up period N: included/analysed(% attrition) C: control treatment 
S: setting D: demographics 
Cardiovascular 
Hitzenberger 1982 D: crossover C: Hypertension (essential) M: etiology, constitution, pathology [restricted to best • change mmHg in last 2 w of treatment: + 3.5 vs • < 
A: random I: categories I and II WHO definition; subjective fit from 8 predefined trial medicines] [l] 20.25 79 M: double complaints H: 8 (prevalence missing) ( + anti hypertensive • relief of subjective symptoms (vertigo, headache, 
F: 16w E: inability to attend weekly follow-ups placebo)/ C4-12 tinnitus, insomnia etc.): nsd 
S: 1 centre, Austria N: 10/10 (0%) D:daily 
D: 50% female, age mean 52.6 y C: OT: antihypertensives + homeopathic placebo 
Dermatology 
McDavid 1994 D: parallel C:Acne M: missing [but cf. Schultz 1994, and Tsolakis 1995] • n (%) appearance improvement (photographic + 
A-. random I: acne; live in Greater Durban [2] comparison): 9 (60.0) vs 5 (46.7) (intragroup p=0.006 71 M:double E: use of other treatments for study condition; H: 7 (with prevalence)/ C9, 15 vs nsd) 
F:4 mon 'sandpaper' acne D:daily • n (%) patient assessment as improved: 9 (60) vs 11 
S: 1 centre, S. Africa N: 30/30 (0%) C: placebo (73) (p=0.015 vs 0.001) 
D: ?% female, age adult • correlation of appearance/assessment: .85 vs .31 
Van't Riet 1985 D: parallel C: Eczema (constitutional) M: individualized [1] • n (%) better on assessment localization of eczema; = 
A:. nonrandom I: missing H: missing/? itching; morphological features; activity (scale): 12 53 M: none E: H: continued use of steroids D: free ( 46) vs 12 (63) 
F:? N: 45/45 (0%) C: OT: corticosteroids • % H 21 resistant cases only: better 8 (38), same 11 
S: 1 centre, Netherlands D: ?% female, age <2-> 12 y (52.4), worse 2 (10.5) 
Schwab 1991Xi) D: crossover C: Skin complaints M: match constitutional Sulphur symptomatology [l] • n aggravations: 4/5 vs 0 + 
A: random I: [mostly mixed skin complaints, but not disease H: Sulphur/ C30 • n better. 5/5 vs 0 79 M: double specific] match constitutional Sulphur D: d 1: 1 x 3 glob(= 1 dose); d 2-3: 2 doses/d; d 4: 3 • n better without subsequent relapse: 3/5 vs 0 
F:37d symptomatology doses; d 5: 5 doses; d 6: 10 doses • n return of suppressed old symptoms: VS vs 0 
S: 1 centre, Germany E: missing C: placebo • n appearance of novel proving symptoms: 1/5 vs 0 
N: 7 /6 (14.29%) • overall p=0.05 
D: ?% female, age 6-40 y 
------Schwab l991Xii) D: crossover C: Skin complaints M: match constitutional Sulphur symptomatology[?] • n aggravations: 6/7 vs 0 + 
A:. random I: mixed chronic skin complaints; match Sulphur H: Sulphur/ C30, 200, 1000 • n better. 6/7 vs 0 79 M: double constitutional symptomatology D: d 1: 1 dose C30; d 2: C200; d 3: ClOOO • n better without subsequent relapse: 4/6 vs 0 
F:29d E: missing C: placebo • n appearance of novel proving symptoms: 4/7 vs 0 
S: 1 centre, Germany N: 8/7 (12.5%) • overall p=0.01; combined with Schwab 1990(i) 
D: ?% female, age 10-63 y p<0.001 
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Kainz 1996 D: parallel C:Warts M: common constitutional and personality types • n (%) with ~50% area reduction: 9 (30) vs 7 (23.3) 0 
A:random I: 6-12 y; warts [match 1 of 10 predefined trial medicines][?] (ns p=0.56) 76 M: double E: no match with 1 of 10 constitutional medicines H: 10 (with prevalence)/ 012, 30 • n (%) total cure: 5 (16.67) vs 1 (3.3) (ns p=0.22) 
F:8w N: 67 /60 (10.45%) 0: 1 dose D12/d or 03012d for 8 w 
S: 1 centre, Austria D: ?% female, age 6-12 y C: placebo 
Khan 1976 D: parallel C:Warts M: symptomatic [restricted to best fit from 6 • n cured at 4 w: A 8; B 10 vs OM 6, NT 0 > 
A: nonrandom !:missing predefined trial medicines] [?] 40 M: none E: missing H: A. 6 externally (prevalence missing) (then 
F:lOw N: 40/40 (0%) Sulphur)/ 0, D2, 6, 12, C30, 200 
S: 1 centre, UK D: ?% female, age 8-14 y B. 6 externally+ internally (prevalence missing) 
(then Sulphur) 
D: applied in felt cavity pad for 8 w; orally for 1-2 w 
only 
C: A. OT: salicylic acid 40%, silver nitrate 95% 
B. no treatment: adhesive plaster 
Schultz 1994 D: parallel C:Warts M: miasmatic/constitutional + local treatment [2] • n (%) with planimetric area reduction: 11 (73) vs 4 (+) 
It random I: warts; live in Greater Durban H: 7 basic, 16 local (with prevalence)/ C7, 9, 15, 30 (26.67) (nsd) 71 M: double E: other treatment for study condition; homeopathic D: 1 dose constitutional/w + 1 dose local/d • n (%) patient assessment as improved: 9 (60) vs 6 
F: 6 mon treatment for warts in previous 6 mon; genital warts C: placebo (40) (nsd) 
S: 1 centre, S. Africa N: 30/30 (0%) • correlation reduction/assessment .825 vs .0025 
D: ?% female, age? y 
Gastroenterology 
Gaucher1994 D: parallel C: Cholera M: mixed styles: single and multiple medicines • weight after 4 and 12 h: nsd 0 
It random I: medium to severe cholera with dehydration [restricted to best fit from 8 predefined trial • degree of dehydration: nsd 58 M: double requiring parenteral treatment medicines] [1] • duration of hospitalization: nsd 
F:12h E: missing H: 8 ( + ORD (prevalence missing)/ [C7] • volume perfused per patient nsd 
S: 1 centre, Peru N: 80/44 (45%) D: 3 gran/5--10 min 
D: ?% female, age ? y C: placebo ( + ORT) 
Jacobs 1993 D: parallel C: Diarrhea (acute childhood) M: individualized [?] • diarrhea d: 2.4 vs 3 (ns p=0.28) (+) 
It random I: 6 mon-5 r, ~3 liquid stools in previous 24 h H: 21 (prevalence missing) ( + ORD/ C30 • d for those with +ve stool test 1.7 vs 3.4 (p=0.04) 84 M: double E: diarrhea > 10 d; anti diarrheal medicine in previous D: 2 x 1 tab/d for 3 d, or until <3 liquid stools for 1 d • n stools on d 3: 1.5 vs 5.6 (p=0.002) 
F:6d 24h C: placebo ( + ORT) 
S: 1 centre, Nicaragua N: 34/33 (2.94%) 
0: ?% female, age 0.5---5 y 
Jacobs 1994 D: parallel C: Diarrhea (acute childhood) M: computer repertorization (RADAR) of signs, • diarrhea mean d: 3 vs 3.8 (p=0.048) + 
It random I: 6 mon-5 r, ~ 3 liquid stools in previous 24 h symptoms, temperament [l] • mean d with +ve stool test 2.5 vs 4.1 (p=0.006) 91 M: double E: diarrhea > 7 d; > 1 dose antibiotic, anti parasitic or H: 18 (with prevalence) ( + ORn / C30 • diarrhea index score: 2 vs 2.4 (p=0.037) 
F:5d antidiarrheal in previous 48 h; type C dehydration D: 2 x 1 tab/d for 3 d, or until <3 liquid stools for 1 d •weight/height% gain: 4.6 vs 2.8 (p=0.30) 
S: 2 centres, Nicaragua (WHO) C: placebo ( + ORT) 
N: 87 /81 (6.9%) 
D: ?% female, age 0. 5---5 y 
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Jacobs 1997 
Villatoro Cadena 1991 
Owen 1990 
Hadjikostas 1988 
D: parallel 
A: random 
M: double 
F: 5d 
S: 1 centre, Nepal 
D: parallel 
A:. random 
M:double 
F:~ld 
S: 1 centre, Mexico 
D: parallel 
A: random 
M: none 
F: 12w 
S: 1 centre, UK 
D: parallel 
A:. matched pairs 
M: double 
F:30d 
S: 1 centre, Greece 
Gynecology and obstetrics 
Yakir 1994 D: parallel 
A:. random 
M: double 
F: 5mon 
Tsolakis 1995 
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S: 1 centre, Israel 
D: parallel 
A:. random 
M: double 
F:8 mon 
S: 1 centre, S. Africa 
C: Diarrhea (acute childhood) 
I: 6 mon-5 y; ~3 liquid stools in previous 24 h 
E: diarrhea >5 d; antidiarrheal medicine in previous 
48h 
N: 126/116(7.94%) 
D: ?% female, age 0.5-5 y 
C: Diarrhea (acute childhood) 
I: ~ 5 y; 3 liquid stools in previous 24 h; history of 
acute childhood diarrhea 
E: diarrhea> 10 d; other treatments including herbal 
N: 50/50 (0%) 
D: 44% female, age 1-5 y 
C: Irritable bowel syndrome 
I: female; IBS diagnosis 
E: previous gynecological disease or surgery; use of 
either treatment in previous month; unwillingness to 
follow either treatment programme 
N: 23/20 (13.04%) 
D: female, age 20--69 y 
C: Upper digestive tract hemorrhage 
l:male 
E: hematocrit <20% 
N: 78/78 (0%) 
D: male, age 30-50 y 
C: Premenstrual syndrome 
I: Moos Daily Questionnaire score; match 1 of 10 trial 
medicines 
E:missing 
N: 27/23 (14.81%) 
D: female, age adults y 
C: Primary dysmenorrhea 
I:~ 30 r, internal exam; confirmatory diagnosis of 
primary dysmenorrhea 
E: IUD for contraception; using other medication for 
study condition 
N: 30/30 (0%) 
D: female, age <30 y 
M: computer repertorization (RADAR) of signs, 
symptoms, temperament [1] 
H: 5 most prevalent (85% cases) (+ORT)/ C30 
D: 1 dose after every unformed stool for ~5 d 
C: placebo ( + ORT) 
M: totality of symptoms in order of preference: 1. 
subjective symptoms related by mother; 2. physical 
exam; 3. appearance of stool [1] 
H: 8 (with prevalence) ( + ORT)/ CG 
D: 5 glob dissolved in 1 teaspoon distilled water 
C: placebo + ORT 
M: totality, essence or keynotes; local rx as required 
[I] 
H: 15 (with prevalence)/ C30, 200, lOM 
D: single dose ( + C6 local rx n=4) 
C: OT: dicyclomine hydrochloride+ fecal bulking 
agents + diet advice sheets 
M: constitutional + associated tissue salt [?] 
H: 12 (with prevalence) ( + tissue salts)/? 
D: 0.5 ml solution per os daily until discharge (mean 
10 d) then 1 capsule/ct tissue salt for 20 d 
C: OT: cimetidine 
M: classical; individual [match 1 of 10 predefined 
trial medicines] [1] 
H: 10 (prevalence missing)/? 
D: single dose 
C: placebo 
M: chronic + local relief as required [2] 
H: 14 (with prevalence) / C5-30 
D: 1 dose constitutional/w + 1 dose local/d 
C: placebo 
• diarrhea mean d: 3.5 vs 4.2 (p=0.065) 
• mean n stools/d: 2.9 vs 3.6 {p=0.03) 
• days duration: 10 vs 12 
• n (%) with complications (still vomiting 3 h after 
ORT): 1 (4)vs 10(40) 
• reduction participant-selected worst symptom 
(VAS): 4.55 vs 4.32 (intragroup p<0.01 vs p<0.01) 
• reduction dysmenorrhea (VAS): 2.67 vs 2.1 (ns vs 
ns) 
• reduction dyspareunia (VAS): 4.8 vs 6.13 (p<0.05 vs 
p=0.01) 
• reduction feeling unwell (VAS): 1.44 vs 1.41 (ns vs 
p<0.05) 
• blood units required: 1.74 vs 3.15 (p<0.001) 
• % hematocrit increase: 32 vs 19.1 (p<0.001) 
• MDQ score(% reduction): 0.14 (70.4) vs 0.34 (10.5) 
(intragroup p=0.03 vs 0.35) 
• n (%) patient-rated as improved: 11 (73.33) vs 8 
(53) (intragroup p=0.06 vs 0.9) 
(+) 
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App. 2.1 Overview of controlled trials of classical homeopathy (cont.) 
Gerhard, Reimers 1993 D: parallel 
A: matched pairs 
M: none 
F: until pregnancy/birth 
S: 1 centre, Germany 
Tame 1998 D: parallel 
A: random preference 
M: none 
F:48w 
S: 1 centre, Germany 
Infections (miscellaneous) 
Kumta 1977 D: parallel 
A:. pseudorandom 
M: single 
F:6d 
S: ? centre/s, India 
Solanki 1995 D: parallel 
Kumar 1994 
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A:. random 
M: double 
F:7d (mean) 
S: 1 centre, India 
D: parallel 
A:. matched pairs 
M: single 
F:69m 
S: I centre, India 
C: Primary infertility 
I: inorganic infertility; fallopian tubes without 
blockage; normal or slightly reduced spermiogram; 
normal Kremer-in-vitro sperm penetration test; > 1 
mobile sperm at 400-magnification in Sims-Huhner 
postcoital test; trying for pregnancy for > 2 y 
E: pituitary tumour; hypo- or hyperthyroid; major 
hypothalamic-pituitary regulatory disturbance; 
premature ovarian insufficiency 
N: 42/42 (0%) 
D: female, age 25--40 y 
C: Primary infertility 
I: trying for pregnancy~ y 
E: missing 
N: 84/84 (0%) 
D: female, age? y 
C: Acute hemorrhagic conjunctivitis 
I: presentation with symptoms of study condition 
E: other treatments 
N: 150/150 (0%) 
D: ?% female, age ? y 
C: Amebiasis; giardiasis 
I: abnormal stool findings: blood; mucus; parasite; 
pus cells; RBC; cysts; ova of giardia; ameba or 
vegetative forms 
E: other diseases; use of homeopathy 
N: 34/34 (0%) 
D: female, age 1&--40 y 
C: Filariasis 
I: symptomatic or asymptomatic microfilariasis 
E: other treatments 
N: 383/280 (26.89%) 
D: ?% female, age ? y 
M: individualized repertorization [1] 
H: 8 (prevalence missing)/? 
D: missing 
C: OT: Al, HRT, IVF as required 
M: missing [simillimum?] [?] 
H: missing/? 
D: missing 
C:OT: HRT 
M: symptomatic [1] 
H: 4 (with prevalence)/ C30 
D: 3 x 1 pill/d 
C: placebo 
M: subjective and objective indications, individual 
characteristics and constitutional make-up [l] 
H: 6 most common constitutional and 3 most common 
acutes listed (with prevalence)/ C200-50 000 
D: 3 x C200/d, higher potencies 3 doses only 
C: placebo 
M: individualized simillimum given within 
standardized clinical schedule [2] 
H: Rhus-tox, Apis or Rhod then simillimum then 
Sulphur then Thuja then Microfilaria W. Bancroftii / 
C30-CM 
D: unique treatment schedules for symptomatic or 
asymptomatic carriers: higher potencies given less 
frequently 
C: placebo 
• baby-take-home n: 6 vs 2 
• pregnancies n: 6 vs 6 
• months to pregnancy: 4.8 vs 16.5 
•%hormonal normalization and reduction of myoma: 
50vs 14 
• clinic cost (treatment and therapist time) per baby: 
335 DM vs 11 661.5 DM 
• baby-take-home n (%): 12 (26.1) vs 10 (26.3) 
• time to pregnancy: na 
• normalization of hormone levels: na 
• costs: na 
• days till symptom-free: 3.19 vs 5.07 [corrected] 
• n (%) -ve stool tests: 11 (57.9) vs 2 (13.3) 
(p=0.0105) 
• filarial attacks rate/y (RR): 0.437 (0.81) vs 0.539 
(1.0) 
• microfilarial density reduction: nsd 
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App. 2.1 Overview of controlled trials of classical homeopathy (cont.) 
Rastogi 1998 D: parallel C:HIV M: computer repertorization (Hompath) [?] • Scheme 1 (asymptomatic HIV, n = 50) upward trend (+) 
A: random I: 18--65 y; CDC stage II and Ill; seropositive to HIV-1, H: missing/? in CD4+ T cell n: 10/22 vs 10/23 79 M: double HIV-2 or both; Western blot confirmed. D: ni • Scheme 2 (persistent generalized lymphadenopathy, 
F:6 mon E: past history of convulsions or cardiac disease C: placebo n = 50) upward trend in CD4+ T cell n: 18/23 vs 
S: 1 centre, India currently controlled by medication; use of Alf in 10/18 
preceding 4 w; pregnancy and lactation; 
noncompliance; use of any other therapy; life-
threatening illness; severe adverse trial drug effects 
N: 100/86 (14%) 
D: 33% female, age 18-65 y 
Van Erp 1996 D: parallel C: Malaria M: systematic repertorization (Kent) using 9-pt • n (%) improved on ~3 listed symptoms: 25 (83.3) ::;: 
A: random I: some of: fever >37.5°C, possibly remitting; chills; checklist of signs, symptoms and their modalities [1] vs 18 (72) (ns p=0.31) 79 M: double general headache; headache above the eyes; lumbar H: 10 (with prevalence)(+ chloroquine placebo)/ 
F:[lor3w] pain; bone pain; anemia; splenomegaly; other C200 
S: 1 centre, Ghana symptoms e.g .. abdominal pain, dizziness, D: single dose 
palpitations C: OT: 5 x chloroquine ( + homeopathic placebo) 
E: <10 'f, pregnancy 
N: 74/55 (25.68%) 
D: ?% female, age mean 36 y 
Awdry 1996 D: parallel C: Postviral fatigue syndrome M: mental and general modalities ranked above • n (%) improved at 1 y (change in fatigue, disability, + 
A: random I: viral illness immediately prior; other prodromal characteristic symptoms [1 J mood disturbance, sleep disturbance): 10 (33.3) vs 1 70 M: double illness; fatigue on trivial exertion; short-term memory H: missing/? (3.2) 
F:ly and concentration loss with other neurological D: missing • n (%) unchanged at 1 y-. 20 (66.7) vs 30 (96.8) 
S: 1 centre, UK symptoms; symptom fluctuation from mental or C: placebo 
physical exertion; major symptoms for~ mon, and 
continuing 
E: >65 r, any other chronic medical complaint; PVFS 
> 10 r, use of other medication in 3 mon before or 
during trial 
N: 64/61 (4.69%) 
D: 70% female, age mean 40 y 
Ledermann 1954 D: parallel C: Tuberculosis of bones and joints M: simillimum (pathological, general or mental • n (%) unexpected progress: 9/27 (33.3) vs 3/24 (+) 
A:. random I: confirmed diagnosis symptoms); excluding nosodes [1] (12.5) (p=0.08) 67 M: double E: missing H: 40 (with prevalence)(+ TAU)/ C30, 200, 1000 • general progress (5-pt scale): nsd 
F:~y N: 61/59 (3.28%) D: collective single dose 
S: 1 centre, UK D: 31% female, age any C: placebo ( + TAU) 
244 
App. 2.1 Overview of controlled trials of classical homeopathy (cont.) 
Metabolic disorders 
Skaliodas, Hatzicostas 
1988 
D: parallel 
A: matched pairs 
M: single 
F:9 mon 
S: 2 centres, Greece 
Musculoskeletal & rheumatology 
Fisher 1986 D: parallel 
A-.random 
M: double 
F: 3 mon 
fisher 1989 
Mesquita 1987 
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S: 1 centre, UK 
D: crossover 
A-. random 
M: double 
F:8w 
S: I centre, UK 
D: parallel 
A: nonrandom 
M: none 
F: ly 
S: I centre, Brazil 
C: Diabetes mellitus type II 
I: hyperglycemia > 1 y; no ketosis in previous 4 mon 
E: hemolytic anemias; hemoglobin disease; cirrhosis; 
alcoholism; chronic renal failure 
N: 78/78 (0%) 
D: ?% female, age ? y 
C: Fibrositis 
I: fibrositis, defined as: 1. muscular pain/discomfort 
2. well defined trigger spots; 3. sleep disturbance; 4. 
no objective evidence of RA 
E: missing 
N: 24/24 (0%) 
D: ?% female, age ? y 
C: Fibrositis 
I: fibrositis (Yu nus et al. criteria); match Rhus-tox 
symptomatology 
E: missing 
N: 30/30 (0%) 
D: 77% female, age 29-64 y 
C: Osteoarthropathy 
I: osteoarthropathy 
E: missing 
N: 160/160 (0%) 
D: ?% female, age ? y 
M: missing [simillimum?] [?] 
H: missing(+ glibenclamide) /? 
D: missing 
C: placebo ( + glibenclamide) 
M: local symptoms only [restricted to best fit from 3 
predefined trial medicines] [1] 
H: 3 (with prevalence)/ CG 
D: I dose x Vd for 3 mon 
C: placebo 
M: local symptoms only [match Rhus-tox 
symptomatology] [1] 
H: Rhus-tox / C6 
D: 2 tab x 3/d for I mon 
C: placebo 
M: clinical data; characteristic, individual and 
peculiar symptoms; modalities of presenting 
symptoms [1] 
H: 12 (with prevalence) ( + physiotherapy)/? 
D: missing 
C: OT: TAU+ physiotherapy 
• Reduction in: 
HbAl %: 6.1 vs 9.5 (intragroup p<0.001 vs nsd) 
• RBS mg/%: 99 VS 154.3 {p<0.001 VS nsd) 
•%diabetes controlled: 38 (97) vs 16 (41) 
•%reduction glibenclamide use: >75 vs 16.8 
• n (%) stop glibenclamide: 18 ( 46) vs 2 (5) 
• % hyperlipemic: 50 vs 80 
• pain improvement: p=0.046 when well indicated, 
otherwise nsd 
• sleep improvement: p=0.018 when well indicated, 
otherwise nsd 
• n (%) improved pain or sleep scores: 53 (88) vs 27 
( 45) (p=0.0052) 
• n (% reduction) of tender points: 10.6 (25) vs 14.l 
(0) (p<0.005) 
• n consultations: 2.7 vs 6.7 
• n (%) discharges: 74 (92.5) vs 16 (20) 
• n (%) returns in 1 r- 10 (12.5) vs 41 (51.2) 
• n adjunct treatments required: I vs 2-5 
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App. 2.1 Overview of controlled trials of classical homeopathy (cont.) 
Andrade 1991 
Gibson 1978 
Gibson 1980 
D: parallel 
A-.random 
M: double 
F:26w 
S: 1 centre, Brazil 
D: parallel 
A-. pseudorandom 
M: single 
F: 1 y 
S: 1 centre, UK 
D: parallel 
A: pseudorandom 
M: double 
F: 3 mon ( + 3 mon) 
S: 1 centre, UK 
Neurology & psychiatry 
Lamont 1997 
Master 1987b 
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D: parallel ( + crossover 
for placebo group) 
A: pseudorandom 
M: single 
F: 3 mon 
S: 1 centre, USA 
D: parallel 
A: nonrandom 
M: single 
f:4 mon 
S: I centre, India 
C: Rheumatoid arthritis 
I: definite or classical RA; at least 3 of: (a) Ritchie's 
articular index (RAI) >20, (b) morning stiffness >45 
minutes, (c) tenderness on >6 joints, (d) >3 swollen 
joints, {e) erythrocyte sedimentation rate >28 mm in 
1st h 
E: treatment with slow-acting drugs in prior 3 
months; disease onset ~16 y; other concomitant 
systemic disease; prednisone (or equivalent steroid) 
dosage> IO mg/d; Steinbrocker functional class IV 
N: 55/44 (20%) 
D: 89% female, age mean 49 y 
C: Rheumatoid arthritis 
I: ARA criteria for 'definite' or 'classical' RA; 
seropositive or x-ray evidence 
E: treatment with corticosteroids, gold, D-
penicillamine, azathiopine, cyclophosphamide, 
levamisole 
N: 144/95 (34.03%) 
D: 71% female, age? y 
C: Rheumatoid arthritis 
I: ARA criteria for 'definite' or 'classical' RA; 
seropositive or x-ray evidence 
E: treatment with corticosteroids, gold, D-
penicillamine, azathiopine, cyclophosphamide, 
levamisole 
N: 49/46 (6.12%) 
D: 67% female, age mean 53 y 
C: Attention deficit hyperactivity disorder 
I: 2".DSM IV criteria; anti-ADHD medication 2".6 w 
E: missing 
N: 43/40 (6.98%) 
D: 42% female, age mean IO y 
C: Broca's aphasia 
I: r. handed, I. sided post-stroke Broca's aphasia. 
E: head injury; brain tumour; speech therapy; anti-
coagulants; diuretics; drugs to reduce cerebral edema 
N: 36/36 {0%) 
D: 22% female, age 41-80 y 
M: constitutional and symptomatic local treatment 
alternated during the day [I] 
H: 21 most prevalent/ C5-30 
D: missing 
C: placebo (TAU allowed) 
M: individual symptomatology [2] 
H: 6 most prevalenVc. 200 +TAU/? 
D: missing 
C: A: aspirin 
B: placebo 
M: classical, individualized [l] 
H: 20 most prevalent ( + TAU)/? 
D: missing 
C: placebo ( + TAU) 
M: standard homeopathic procedures with computer 
analysis (RADAR) [1] 
H: 5 listed/8 (with prevalence for first 3) I C200 
D: I x 6 tab/d for 5 d or until notable change in 
condition 
C: placebo 
M: missing [clinical, symptomatic?] [1] 
H: 5 (with prevalence) (TAU allowed)/? 
D: missing 
C: placebo 
• reduction in seconds(%) 15 m walking time: 2.4 
(12) vs 0.2 (1) (p<0.05) 
• functional class reduction (%): 0.38 (16) vs 0.09 (5) 
(p<0.05) 
• n (%) improved at final global assessment by 
doctor: IO (59) vs 7 (44) (nsd) 
• morning stiffness, grip strength, prednisone dose, 
NSAID daily score: either nsd from baseline, or nsd 
between groups 
• n (%) showing improvement (pain, grip, stiffness, 
functional index; reduction in TAU): 23 (42.6) vs OT: 
6 (14.6); vs P: 0 
• n (%) with toxic effects: 0 vs OT: 16 (39); vs P: 0 
• n (%) patient assessment as slightly or greatly 
improved (pain, grip, stiffness, functional index, 
laboratory parameters): 19 (82.6) vs 5 (21.7) 
(p=0.001) 
• improvement (5-pt scale) after I medicine: 1.0 vs 
0.35 (p=0.05) 
• improvements in crossover group: 1.13 vs 0.35 
(p=0.02) 
• % continued improvement at 2 mon: 57 
• n (%) improved (blood pressure; neurological 
exam.; speech): 22 (91.7) vs 3 (25) 
0 
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App. 2.1 
Bakshi 1990 
Carlini 1987 
Brigo 1991 
Straumsheim 1997 
Walach 1997 
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Overview of controlled trials of classical homeopathy (cont.) 
D: parallel 
A: nonrandom 
M:double 
F: 1 mon 
S: 1 centre, India 
D: parallel 
A: random 
M:double 
F:45d 
S: 1 centre, Brazil 
D: parallel 
A: random 
M: double 
F:16w 
S: 1 centre, Italy 
D: parallel 
A: random 
M:double 
F:4 mon 
S: 1 centre, Norway 
D: parallel 
A: random 
M: double 
F: 18w 
S: 1 centre, Germany 
C: Drug detoxification 
I: heroin addiction 
E: missing 
N: 72/60 (16.67%) 
D: male, age <20-39 y 
C: Insomnia 
I: severe insomnia 
E: missing 
N: 44/26 (40.91%) 
D: ?% female, age ? y 
C: Migraine 
I: symptom match with migraine model; match 1-2 of 
8 predefined trial medicines 
E: head pain from other causes, or differing from 
migraine model 
N: 60/60 (0%) 
D: 83% female, age mean 37 y 
C: Migraine 
I: IHS criteria ~l y; 2-6 attacks monthly in previous 6 
mon 
E: pregnancy, lactation; use of orthodox antimigraine 
treatment; serious hypertension; p-pills, hormones, 
benzodiazapams; stimulant drugs; illness preventing 
participation 
N: 73/68 (6.85%) 
D: ?% female, age 18-65 y 
C: Migraine 
I: IHS criteria headaches ~l y, and currently ~1 per 
w; willing to accept diet changes; team agreement on 
patient match with medicine 
E: spinal trauma in last 4 y; life-threatening diseases 
or serious other conditions requiring treatment; 
alcohol or drug abuse; psychiatric history, pregnancy 
or wish to have children; forseeable extreme social 
pressure; continuing medication interfering with 
homeopathic treatment; oral contraceptives; 
contraindication to homeopathic treatment; unclear 
medicine picture 
N: 101/98 (2.97%) 
D: 66% female, age 24-65 y 
M: most indicated single medicine for location, 
sensations and modifications of withdrawal 
symptoms; reviewed twice daily [?] 
H: 14 most prevalent/ ? 
D: daily 
C: placebo 
M: agreed simillimum [2] 
H: 17 (prevalence missing)/ D12-60, C6--60 
D:daily 
C: placebo 
M: personal reactivity and compiled modalities 
[match 1-2 of 8 predefined trial medicines] [1] 
H: 8 available, with option to associate 2 in any 
subject (prevalence missing)/ C30 
D: 1 dose/14 d for 8 w 
C: placebo 
M: constitutional, total assessment of patient [1] 
H: 60 (prevalence missing)/ D30, 200, M 
D: missing 
C: placebo 
M: classical, single medicine [6] 
H: 25 (prevalence missing)/ ClOOO, 10 000; Ql, 3 
D: C potencies single dose, Q potencies daily 
C: placebo 
• d till disappearance of withdrawal symptoms: 3.3 vs 
7.1 
•%absconding: 5 vs 35 
• increase in hours of sleep: both groups sleeping 
normally at d 45: (nsd) 
• reduction in n (%} attacks: 8.2 (82) vs 2 (20.2) 
(intragroup p=<0.001 vs 0.04) 
• reduction in intensity (11-pt scale): 6.2 (62) vs 0.6 
(6) (intragroup p=<0.001 vs nsd) 
• change in general wellbeing (11-pt scale): + 1.3 vs 
+.3 (intragroup p=<0.001 vs nsd) 
• patient assessment of reduction in n attacks: (ns 
p=0.54) 
• neurologist's assessment% with fewer attacks: 60 
vs 42 (p=0.04) 
• patient assessment reduction in intensity: nsd 
• neurologist's assessment% reduction intensity: 54 
vs 42 (p=0.08) 
• reduction in headache days: 1 vs 1 (nsd) 
• reduction in headache duration hours: 0.04 vs 1.14 
(nsd) 
• reduction in headache intensity (VAS): 1.46 vs 4.68 
(nsd) 
+ 
42 
0 
71 
+ 
86 
(+) 
87 
(·) 
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App. 2.1 Overview of controlled trials of classical homeopathy (cont.) 
Whitmarsh 1997 D: parallel C: Migraine M: individualized [match 1 of 11 predefined trial • % reduction in attack frequency: 19 vs 16.5 (nsd) (+) 
A-. random I: IHS criteria; recognizable attacks~ y, and 2-8 medicines] [l] • % reduction in frequency of moderate: severe 87 M:double monthly in previous 3 mon; 1~ y, informed H: 11 (with prevalence)/ C30 attacks: 38.2: 20.0 vs 13.2: 13.2 (p=0.0001) 
F:4mon consent D: 2x2tab/w • verum attack frequency reduced consistently until 
S: 1 centre, UK E: no symptom match with 11 study medicines; other C: placebo trial end: (p=0.001) 
headaches 
N: 63/60 ( 4.76%) 
D: 92% female, age 19-59 y 
Chapman 1997 D: parallel C: Mild traumatic brain injury M: subjective symptoms [restricted to best fit from 18 • patient-rated functional assessment (5-pt scale) + 
A: random I: >3 mon since injury predefined trial medicines] (2) • frequency of commonest symptoms: (p=0.02) ni M:double E: missing H: 18 unlisted/ [C200) • difficulty functioning in 18 different situations: 
F: 4 mon N: ?/50(?%) D: missing (p<0.01) 
S: 1 centre, USA D: ?% female, age ? y C: placebo 
Tsiakopoulos 1988 D: parallel C: Vertigo (benign paroxysmal positional) M: totality of symptoms [?) • n (%) :s;5 crises weekly: 25 (75.7) vs 4 (10.8) > 
A: nonrandom I: history of frequent crises (8-14 per d) for 5 y H: 35 (prevalence missing)/ ? (p<0.001) 60 M:double (average) D: 1 dose/d + 3 x placebo/d for 60 d • % improved and maintained at 6 mon: 93 vs 0 
F: 6 mon E: benign or malignant tumour; ear symptoms; C: OT: dimenhydrinate 4 x 50 mg/d for 60 d • % improved during treatment but not carried over: 
S: 1 centre, Greece cervical trauma; neurological syndromes; use of Ovs 74 
medicines likely to cause vertigo; pregnancy 
N: 74/74 (0%) 
D: ?% female, age 30-60 y 
Kuzeff 1998 D: crossover C: Well-being M: constitutional, according to Sankaran • mental~motional VAS (-10 to+ 10): 2.5 vs 0.66 (ns (+) 
A: random I: any consultation for constitutional homeopathy [situational?] [I] p=0.28) 84 
M:double E: regular psychotropic drugs; malignancy; requiring H: missing/ >C30 • physical VAS: 2.15 vs -0.32 (p=0.002) 
F: 14d emergency treatment; homeopathically unclassifiable D: 1 x IO drops in water/d for 2-3 d (higher potencies • CD4: 0.01 vs O(ns p=0.841) 
S: 1 centre, Australia N: 36/36 (0%) less often) 
D: 83% female, age <2-70 y C: placebo 
Oncology 
Kivelou 1990 D: parallel C: Breast cancer M: similimum + tissue salt[?] • n (%) survivors stage II: 26/31 (83.9) vs 17 /29 + 
A: nonrandom I: histological diagnosis of stage II or Ill; <75 y; WBC H: 8 first rx (with prevalence) (+tissue salt)(+ TAU: (58.6) (p=0.05) 51 M: none >4000/ml; platelets> 13 000/ml; surgery+ chemotherapy)/? • n (%) survivors stage Ill: 22/33 (58.3) vs 3/30 
F:6y E: early death; noncompliance (antidotes to or D: missing (10.0) (p=0.05) 
S: 1 centre, Greece improper taking of medicine; cease homeopathic C: no treatment surgery + chemotherapy + • n (%) relapse of +ve nodes: 6/36 (34.4) vs 16/26 
treatment >2 mon) radiotherapy (61.0) 
N: 158/123 (22.15%) 
D: female, age <75 y 
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App. 2.1 Overview of controlled trials of classical homeopathy (cont.) 
Hadjikostas 1990?a 
Hadjikostas 1990?b 
Polychronopolou 1990 
D: parallel 
A: matched pairs 
M: none 
F:6y 
S: 1 centre, Greece 
D: parallel 
A: matched pairs 
M: none 
F: 5y 
S: 1 centre, Greece 
D: parallel 
A: nonrandom 
M: none 
F:2y 
S: 1 centre, Greece 
Respiratory infections & ENT 
Chakravarty 1977 D: parallel 
Friese, Kruse I 997 
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A: nonrandom 
M: none 
F: I y 
S: ? centre/s, India 
D: parallel 
A:. nonrandom 
M: none 
F: ly 
S: 5 centres, Germany 
C: Cancer of the large intestine 
I: surgical resection of large bowel carcinoma: 
A. Cl Astler-Coller n=24; 
B. C2 Astler-Coller n=32 
E: rectal carcinoma; radio- or chemotherapy 
N: 56/48 (14.29%) 
D: 41% female, age 53-72 y 
C: Lung cancer 
I: correct histological diagnosis (tumour, nodes, 
metastases); A. early stages n=24; B. terminal n=54 
E: missing 
N: 78/74 (5.13%) 
D: ?% female, age ? y 
C: Pancreatic cancer 
I: histological confirmation; surgery 
E: carcinoma of ampulla 
N:42/42(0%) 
D: 21% female, age? y 
C: Chronic tonsillitis 
I: erythema and edema of anterior pillar, tonsil, soft 
palate, uvula; yellowish white discrete spots/patches 
over the tonsil; tenderness on palpation over tonsil; 
enlarged tonsillar lymph nodes; discharge of pus 
from tonsillar crypts on pressure over anterior pillar; 
hemolyticus streptococcus +ve 
E: missing 
N: 289/239 (17.3%) 
D: 52% female, age 2->40 y 
C: Otitis media 
I:~ signs of acute otitis media 
E: severe immune deficiency; longterm steroids, other 
immunosuppressants, prophylactic antibiotics; 1st 
contact with emergency service; >30km from practice 
N: 131/127 (3.05%) 
D: ?% female, age 0.5-11 y 
M: whole of physical and psychomental state; 
idiosyncratic simillimum [team] 
H: 20 most prevalent ( + surgery)/? 
D: single doses 
C: no treatment TAU + surgery 
M: simillimum + corresponding tissue salt ( + 
clinical rx for effects of chemo- or radiotherapy) 
[team] 
H: 17 used for 1st rx (with prevalence); 37 listed for 
follow up; 15 listed for 1st aid; ( + surgery in early 
stages) I? 
D: single doses ( + 1 dose tissue salVd) 
C: surgery ( + chemo- + radiotherapy) 
M: similimum + tissue salt [?] 
H: 10 (prevalence missing)(+ TAU: chemotherapy 
and/or radiotherapy)/? 
D: missing 
C: no treatment chemotherapy and/or radiotherapy 
M: totality of symptoms; individualization on peculiar 
uncommon characteristic symptoms; intercurrent 
treatment as required for acute exacerbations, return 
of old symptoms, vaccinosis, miasmatic hindrances 
etc.[?] 
H: 31 (with prevalence)/? 
D: missing 
C: no treatment 
M: simple, symptomatic [restricted to best fit from 12 
predefined trial medicines][?] 
H: 12 (prevalence missing)/ D2-30, C30 
D: as required depending on acuteness: usually 1 
dose/2 h or 3 x 1 dose/d 
C: OT: antibiotics, secretolytics, antipyretics, nasal 
decongestants 
• 5-y survival n (%) 
• A: 9/11 (81.8) vs 2/10 (20) (p<0.05) 
• B: 6/14 (42.8) vs 2/13 (15.4) (nsd) 
• early stage 5 yr survival n (%): 9/12 (75) vs 4/12 
(33.3) [ns p=0.0995] 
• terminal 5 yr survival n (%): 3/16 (18) vs 1/18 
(5.5) vs 2/16 (12.5) (nsd) 
• overall 5 yr survival n (%): 12/28 ( 42.9) vs 5/30 
(16.7) [p=0.0285] 
• n (%) 2-y survivors: 10/21 (48) vs 1 ( <5) (p<0.01) 
• n (%) symptom-free (see entry criteria): 126 (93) 
vs25 (24) 
• n (%) disappearance of b-hemolyticus 
streptococcus: 47/53 (88.67) vs 0/16 
• median d with pain: 2 vs 3 (ns p=0.1186) 
• median d of therapy: 4 vs 10 (p=OJXXll) 
• recurrences after 1 y: 0.41 vs 0.70 (p=0.39) 
• % without recurrence: 70.7 vs 56.5 
+ 
61 
= 
65 
+ 
51 
+ 
43 
= 
71 
App. 2.1 Overview of controlled trials of classical homeopathy (cont.) 
Nusche 1998 
de Lange-de Klerk 1993 
Schilsky 1941 
Surgical trauma 
Lokken 1995 
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D: parallel 
A-. nonrandom 
M: none 
F: 14 d 
S: 9 centres, Germany 
D: parallel 
A: random 
M:double 
F: ly 
S: 1 centre, Netherlands 
D: parallel 
A: pseudorandom 
M: none 
F:60d 
S: 1 centre, Germany 
D: crossover 
A: random 
M: double 
F: 14d 
S: 1 centre, Norway 
C: Tonsillitis 
I: children 3-14 y; local catarrhal, follicular, lacunar 
or membrane tonsillitis; +ve beta-hemolyticus 
streptococcus A 
E: illness began >48 h previously; penicillin allergy; 
inability of parents to cooperate or to speak German 
well; use of certain medicines; other illness before or 
during study, including heart, kidney, rheumatic 
fever, bronchitis, pneumonia etc. 
N: 51/50 (1.96%) 
D: ?% female, age 3-14 y 
C: Upper respiratory infections (recurrent childhood) 
I:<!: 3 URTI in previous y, or 2 URTI + otitis media 
with effusion on entry;<!: 3 symptoms matching a 
homeopathic constitutional medicine 
E: adenoidectomy, tonsillectomy; constitutional 
homeopathic treatment in previous 6 m; regular 
medical care for any other chronic condition; 
untreated dental caries; congenital respiratory tract 
or heart malformation; mental handicap; neurological 
disorder; history of rheumatic fever, endocarditis, 
myocarditis, nephritis 
N: 175/170 (2.86%) 
D: 53% female, age 1.5-10 y 
C: Whooping cough 
I: Whooping cough: A.> 12 mon; B. 13 moll-£ y 
E: Inadequate details of disease pre-admission 
N: 178/170 (4.49%) 
D: ?% female, age :5:6 y 
C: Post-extraction dental neuralgia 
I: bilaterally impacted wisdom teeth requiring 2 
separate operations 
E: missing 
N: 24/24 (0%) 
D: 83% female, age 1~28 y 
M: simillimum [1] 
H: 7 (with prevalence)/ D4-200, C30, Q6, 10 
D: individual 
C: OT: penicillin V 1000001.E./kg/d for 10 d 
M: constitutional + acute for respiratory 
emergencies; sometimes organotropic for glue ear 
and adenoids [1] 
H: >70 (with prevalence)(+ dietary advice)(+ TAU 
as required)/ D3-1000 
D: missing 
C: placebo + dietary advice (TAU as required) 
M: missing [simillimum?] [1] 
H: 13 given, + 25 for comp I ications ( + physical 
therapies)/ [D4-15) 
D: missing 
C: no treatment physical therapies 
M: symptomatic [restricted to best fit from 6 
predefined trial medicines] [2] 
H: 6 (with prevalence) I C30 
D: d 1: 1 x 3 doses/IS min for 3 h then I dose/h; d 2: 
2 x 1 dose/3 h then 4 doses before bed; d 3-7: 3 x 1 
dose/d 
C: placebo 
• mean reduction (16-pt scale) in clinical symptoms 
(state of tonsils, lymph nodes, fever, pain, general 
state): ca 14 vs ca 6* (p=0.0006) 
• septic complications: 7 vs 2 
• n (%) posttrial recidivism at 60 d: 2 (7.4) vs 4 (19) 
• daily score: 2.21 vs 2.61 (nsd) 
• % not requiring antibiotics: 62 vs 49 
• % adenoidectomies: 16 vs 21; % tonsillectomies 5 
vs 5 
• overall respiratory score: 5.1 vs 6.4 (p = 0.03) 
• overall score (20-pt scale): 6.8 vs 8.2 (p = 0.06) 
• Duration of illness/d: A. 66.6 v 67.4; B. 54.8 v 52.8 
• Appearance of complications in hospital 
(pneumonia, dyspepsia, measles): A. 9 v 6; B. 9 v 12 
• pain scores, treatment preference, swelling: nsd 
• n with reduction in trismus: 11 vs 5 (p=0.05) 
• postop bleeding: nsd 
• side effects: nsd 
< 
67 
(+} 
87 
0 
51 
0 
87 
App. 2.2 Overview of controlled trials of clinical homeopathy 
First author(s), year Methods Patients Treatments Results Vote 
D: design C: condition H: homeopathic medicine/ potency • clinical outcomes 
A: assignment I: inclusion criteria D: dosage, repetition MQ 
M: masking [: exclusion criteria C: control treatment 
F: follow-up period N: number included/analysed(% attrition) 
S: setting D: demographics 
Asthma & allergy 
Wiesenauer 1983 D: parallel C: Allergic rhinitis H: Galphimia glauca I D4 •%ocular symptom-free or marked improvement at + 
A: random I: acute allergic pollinosis symptoms D: 3 or 4 x 20 drops/d 5 w (4-pt scale): 81 vs 57 (p<0.05) 81 M:double [: corticosteroid or antihistamine usage C: placebo 
F: mean 5.5w N: 121/86 (28.93%) 
S: 28 centres, Germany D: 51% female, age ally 
Wiesenauer 1985 D: parallel C: Allergic rhinitis H: Galphimia glauca / D6 •%ocular symptom-free at 5 w: 80 vs A. 66 vs B. 65 (+) 
A: random I: acute pollinosis D: doctor free to choose (p=0.07) 76 M: double [: corticosteroid or antihistamine usage C: A. simple ·6 dilution of verum • % nasal symptom-free at 5 w: 78 vs A. 51 vs B. 58 
F:5w N: 164/108 (34.15%) B. placebo (p=0.07) 
S: 35 primary care D: 62% female, age >15y 
centres, Germany 
Wiesenauer 1990 D: parallel C: Allergic rhinitis H: Galphimia glauca / C2 • % ocular symptom-free or marked improvement at + 
A-. random I: acute allergic pollinosis <l w duration; history of D: 4 x 5 drops/d, but doctor free to choose 5 w ( 4-pt scale): 77 vs 51 (p<0.01) 83 M: double pollinosis >2 y C: placebo •%nasal symptom-free or marked improvement at 5 
F: mean33 d E: corticosteroid or antihistamine usage w: 77 vs 46 (p<0.01) 
S: 54 centres, Germany N: 243/201 (17.28%) 
D: 62% female, age ally 
Wiesenauer 1995 D: parallel C: Allergic rhinitis H: Galphimia glauca / 04 • % ocular symptom-free or marked improvement at + 
A-. random I: history of pollinosis >2 y D: 4 x 1 dose/d 4 w: 84.7 VS 63.1 (p=Q.0168) 84 M:double E: corticosteroid or antihistamine usage C: placebo •%nasal symptom-free or marked improvement at 4 
F:5w N: 164/116 (29.27%) w: 80 vs 68.8 (p=0.1316) 
S: 27 centres, Germany D: 59% female, age ? y 
Freitas 1995 D: parallel C: Chronic asthma H: Blatta orientalis ( + TAU)/ CG • severity score (intensity, frequency, duration): 7.55 0 
A-. random I: 1-12 y-, ~3 bronchospasms (~ mon intervals) or D: 3 x 2 glob/d for 6 mon vs 9.02 (nsd) 80 M: double continued wheeze without crisis ~3 mon C: placebo ( + TAU) 
F:~mon E: multiple and concurrent disease, except rhinitis 
S: 1 centre, Brazil and eczema 
N: 86/69 (19.n%) 
D: 49% female, age 1-12 y 
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App. 2.2 Overview of controlled trials of clinical homeopathy (cont.) 
Cardiovascular 
Ochoa-Bernall995 D: parallel C: Hypertension (acute) H: Lachesis/ C200+ • n (%) mmHg reduced ~10% at 15 min: 25 (83.3) vs + 
A: random I: diastolic BP ~95 mmHg, or systolic> 155 mmHg; D: 2ml/15 min (plussed with 10 succussions) for up 2 (7.14) {p<0.001) 76 M: single > 15 y; with or without previous treatment to 4 repetitions 
F: 1 h E: threat to life or vital organs; pregnancy; diagnosed C: placebo 
S: 1 centre, Mexico secondary arterial hypertension 
N: 58/58 (0%) 
D: 60% female, age 25-84 y 
Bignamini 1987 D: parallel C: Hypertension (essential) H: Baryta-carb (+TAU)/ Cl5 • reduction in arterial BP: nsd 0 
A: random I: mean systolic arterial pressure > 160 mmHg, or D: 1 x 5 gran/d • reduction in arterial BP in 8 equally-distributed 82 M: double diastolic pressure >90 mmHg C: placebo ( + TAU) prescreened Baryta responders: 
F:6w E: symptomatic or malignant hypertension; other • diastolic mmHg change: -5.8 vs +2.8 
S: 1 centre, Italy serious concomitant disease • systolic mmHg change: -26.25 vs+ 1.75 
N: 34/32 (5.88%) 
D: ?% female, age mean 75 y 
Macchi 1984 D: parallel C: Hypertension (essential) H: Sulphur/ C30 • (placebo run in then H vs no treatment) diastolic + 
A:. nonrandom I: hypertension D: I dose/2 d for 63 d mmHg (% change): 84.6 (-15.7) vs 97.6(+1.3) 71 M: single E: evidence of arteriosclerosis (Doppler velocimetry) C: A. placebo (p=0.005) 
F:63d N: 40/40 (0%) B. no treatment • (labetolol run in then H vs placebo) diastolic 
S: 1 centre, Italy D: ?% female, age 67.5 y pressure mmHg (% change): 85.5 (-14.7) vs 97.9 
( +0.1) (p=0.005) 
Master 1987a D: parallel C: Hypertension (essential) H: Adrenalin; Eel serum; Baryta-mur / CG, 30, 200 • n (%) normalized at 130/90 mmHg: 24 (75) vs 4 + 
A: nonrandom I: antihypertensive use (6 mon-10 y) D: 2 x 1 dose/din water (40) 43 
M: none E: missing C: placebo+ diet+ exercise + relaxation 
F:9 mon N:4V42{0%) 
S: I centre, India D: 12% female, age 40-80 y 
Wiesenauer 1987 D: parallel C: Hypotension H: Haplopappus / D2 • diastolic mm Hg (graphs only): (ns p=0.83) = 
k random I: hypotension; weak circulation with associated D:3xl/d • pulse rate (graphs only): (ns p=0.85) 83 
M: double symptom picture C: etilefrin 5 mg tds • 9 subjective symptoms (graphs only): (ns p=0.17) 
F: 7.5wmean E: hypertension; thyrotoxemia trend for Haplopappus 
S: 15 centres, Germany N: 50/41 (18%) 
D: 78% female, age >6 y 
Dermatology 
Massinger 1980 D: parallel C:Boils H: Hepar-s ( + Hamamelis salve)/ 04 • days to closure: 3.54 vs 4.32 (nsd) (+) 
k random I: boils, abscess or pyoderm D: 1 tab/h 75 
M: double E: carbuncle C: placebo ( + Hamamelis salve) 
F: ~12d N: 144/46 (68.06%) 
S: > 18 centres, Germany D: ?% female, age? y 
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App. 2.2 Overview of controlled trials of clinical homeopathy (cont.) 
Leaman 1989 D: parallel C: Burns H: Cantharis ( + paracetamol)/ C200 • VAS pain score (area under curve): 5978 vs 6946 0 
A: random I: 15-60 y; burned ~6 h previously; safely treated with D: I dose/h for 6 h (nsd) 62 M:double dressing alone; <5% body area C: placebo ( + paracetamol) • % pain reduction at 6 h: 61 vs 66 
F:6h E: missing 
S: 1 centre, UK N: 34/34 (0%) 
D: ?% female, age 15-60 y 
Lievre 1992 D: parallel C: Burns H: Calendula (in vaseline excipient) / 0 • n (%) success: 37 (69.1) vs A 35 (66.03) (nsd); vs B > 
A: random I: 2nd, deep 2nd or 3rd degree burn; no clear D: 1 application/ct under closed dressing 27 (54.0) (p=0.05) 94 M: none indication for immediate surgical dressing C: A. OT: [lase® • n (%) with no adverse effects: 18 (34.6) vs A 5 (9.6) 
F:8-12d [: <18 y; life-threatening condition; current treatment B. placebo: vaseline (p=0.003); vs B 18 (36.0)(nsd) 
S: 4 centre, F ranee with corticosteroids or immunosuppressant agents; • n (%) with no pain due to treatment: 32 (60.37) vs A 
diabetes mellitus; perinea! burns; treatment initiated 11 (21.15) (p=0.002); vs B 23 ( 46.0) 
>72 h after time of burn 
N: 156/156 (0%) 
D: ?% female, age 18-87 y 
Khan, Potter 1996 D: parallel C:Callus H: A. Tagetes erecta + felt cavity pad/ 0 • callus width: t=ll.7586 (p<0.001) + 
A: random I: adults 20-70 y; callus ~ y without concomitant B. T agetes erecta • callus length: t=ll.7758 (p<0.001) 77 M: double treatment; lesions needing routine clinical treatment D: 4 x 1 tincture+ paste application/w then 2 x oil • pain (VAS): t=17.2653 {p<0.001) 
F:8w ~4-8 w; not fully operable because of pain applications/d reducing to none at w 8 
S: 1 centre, UK [: use of analgesics or tranquillizers; diabetes; C: placebo + felt cavity pad 
vascular impairment; psoriasis or active eczema; 
pregnancy 
N: 30/30 (0%) 
D: 77% female, age 20-70 y 
British Homoeopathic D: parallel C: Mustard gas burns H: 1 of: Cantharides; Kali-bich; Mustard gas; Opium; • n lesions superficial/medium/deep: 36/44/15vs + 
Society 1943(ii) A: random I: adult male volunteers; application to forearm of 2 Rhus-tox; Variolinum / C30 26/30/28 [p=0.0085] 69 M: double mm drop of 10% mustard gas in benzene D: 1 pill ~5 min after application then 14 h later then 
F:7d [: missing 3 x 1/d for 7 d from d 2 
S: 1 centre, UK N: ?/179 (?%) C: placebo 
D: male, age 20-70 y 
British Homoeopathic D: parallel C: Mustard gas burns H: Rhus-tox / C30 • n lesions superficial/medium/deep: 8/12/1 vs + 
Society 1943(iv) A: random I: adult male volunteers; application to forearm of 2 D: 1 pill ~5 min after application, 14 h later then 3 x 8/3/9 [p=0.0028] 69 M: double mm drop of 10% mustard gas in benzene 1/d for 7 d from d 2 
F:7d [: missing C: placebo 
S: 1 centre, UK N: ?/41 (?%) 
D: male, age 20-70 y 
Gastroenterology 
Bignamini 1991 D: parallel C: Anal fissures H: Nit-ac / C9 • globally assessed as healed n (%): 12 (75) vs 6 (40) + 
P.. random I: anal fissure D: 1 x 5 gran/d for 15 d (p<0.005) 72 
M: double E: local treatment C: placebo • burning absent n (%): 16 (100) vs 9 (60) (p<0.005) 
F: 15d N: 31/31 (0%) 
S: 1 centre, Italy D: 55% female, age mean 38 y 
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App. 2.2 Overview of controlled trials of clinical homeopathy (cont.) 
Mtissinger 1976a(iv) D: parallel C: Gastritis H: Nux-v / 04 • n (%) improved: 19 (70) vs 16 (61) (nsd) 0 
A-. nonrandom I: missing D: missing 43 M:double E.: missing C: placebo 
F: missing N: 53/53 (0%) 
S: 9 centre, Germany D: ?% female, age ? y 
Ritter 1966 D: parallel C: Gastritis H: Nux-v /D4 • n (%) improved: 43 (63)vs 27 (48)(ns p=0.25). (+) 
A: random I: chronic or acute gastritis; ulcerative gastritis; D: 3 x 5 drops/d 67 M: double hepatopathy; cholecystopathy C: placebo 
F:14d E: missing 
S: 1 centre, Germany N: 147/126(14.29%) 
D: ?% female, age ? y 
Hochstetter 1966 D: parallel C: Gingivitis gravidica H: Mere-sol / D12 • VAS (0-4)(% change) tendency to bleed: 0.12 + 
A: nonrandom I: gingivitis gravidica definitely established D: 1 tab/d for 1 mon (-93.6) vs 2.0 ( + 203.03) 41 M: none E: missing C: no treatment • similar slopes for colour, texture, shape, size, 
F:30d N:4V42(0%) consistency, position 
S: 1 centre, Chi le D: female, age ? y 
Chirila 1990 D: parallel C: Hepatitis H: Phosphorus / C7 • Type B median d till discharge: 8 vs 20 (+) 
A: nonrandom I: hospitalized for hepatitis A or B D: 1 dose/d for 2 d 45 M: single E: missing C: placebo 
F: 2:4 w N: 348/348 (0%) 
S: 1 centre, Romania D: ?% female, age 0-70 y 
Rahlfs 1976 D: parallel C: Irritable bowel syndrome H: A. Asafoetida / D3 • patient global assessment (3-pt scale): A. 0.90 vs B. (+) 
A: random I: condition> 14 d; abdominal pain; colon sensitive on B. Asafoetida + Nux-v 0.82 vs 0.65 ( ns p=0.093) 79 M: double palpation; match Asafoetida symptomatology (3/9 D: 6 x 5 drops/d 
F: 14d symptoms) C: placebo 
S: 10 centre, Germany E: diarrhea; kidney stones; receiving essential 
longterm medication; pregnancy; <20 or >60 y 
N: 7V63 (12.5%) 
D: 51% female, age 20-60 y 
Rahlfs 1978 D: parallel C: Irritable bowel syndrome H: Asafoetida / D3 • patient global assessment ( 4-pt scale, 1 =worse, 4= + 
A:random I: condition> 14 d; abdominal pain; colon sensitive on D: 6 x 5 drops/d sx free): 3.12 vs 2.49 (p=0.001) 90 M: double palpation; match Asafoetida symptomatology (3/9 C: placebo 
F:14d symptoms) 
S: 29 centre, Germany E: diarrhea; kidney stones; receiving essential 
longterm medication; pregnancy; <20 or >60 y; 
Gastarbeiter and foreigners 
N: 119/85(28.57%) 
D: 69% female, age 20-73 y 
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Gynecology and obstetrics 
Atmadjian 1988 D: parallel 
A: missing 
M: double 
F: 7 d 
S: 1 centre, France 
Deguillaume 1981 D: parallel 
A: random 
M: double 
Eid 1993 
Eid 1994 
Ventoskovsky 1990 
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F: until relief 
S: 1 centre, France 
D: case control 
A: nonrandom 
M: none 
F: till delivery 
S: 1 centre, Italy 
D: parallel 
A: random 
M:double 
F: till delivery 
S: I centre, Italy 
D: parallel 
A: pseudorandom 
M: none 
F: until delivery + 1 min 
S: I centre, Ukraine 
C: Childbirth 
I: missing 
E: missing 
N: 30/30 (0%) 
D: female, age ? y 
C: Childbirth 
I: painful contractions >2 h without dilatation; normal 
contractions, dilatation arrested at 40 mm 
E: missing 
N: 34/34 (0%) 
D: female, age mean 24.9 y 
C: Childbirth 
I: primaparas; spontaneous labour at term; valid 
painful contractions: ~/10 min lasting 2:45 s; 3 cm 
cervical dilatation; effacement; medical or surgical 
treatment after cervical dilatation 
E: diabetes mellitus; hypertension; previous uterine 
surgery; treatment with tocolytics ~ w prior to 
admission; premature amniotic rupture; medical or 
surgical treatment during cervical dilatation 
N: 56/51 (8.93%) 
D: female, age 23-37 y 
C: Childbirth 
I: primaparas; w 38-40; spontaneous delivery; 
cephalic presentation 
E: missing 
N: 40/32 (20%) 
D: female, age adult 
C: Childbirth 
I: high risk of uterine contractile dysfunction in labour 
or postnatally; <40 w gestation; prophylactically 
prepared >5 d before onset of labour 
E: feto-placental insufficiency; fetal development 
anomalies; multiple pregnancy; hydramnios; placenta 
previa; preeclampsia; critical extragenital pathology 
N: 206/206 (0%) 
D: female, age ? y 
H: Amica/ C7 
D: missing 
C: placebo 
H: Caulophyllum / CS 
D: 1 x 3 gran/15 min until relief or~ h (whichever 
sooner) 
C: placebo 
H: Caulophyllum / C7 
D: 5 gran/h :2:4 h 
C: no treatment 
H: Caulophyllum / C7 
D: 4 x Stab/h 
C: placebo 
H: Pulsatilla M then Secale C50 then Caulophyllum 
C50 then Actea-rac C200 then Arnica M 
D: 1 dose/30 min of each alternately 
C: A. OT: synestrol, galascorbine and glutamic acid; 
thiamine and pyridoxine; calcium chloride; linetol; 
glutathione 
B. no treatment case-control 
• minutes of labour: 47.8 vs 49.53 (nsd) 
• overall n (%) positive response: 13 (76.5) vs 2 
(11.7) (p<0.005) 
• n false labour stopped: 6/9 vs 0/11 
• n dystocia stopped: 7 /8 vs V6 
• cervical dilatation (min): 227 vs 314 (p<0.05) 
• minutes of labour: 210 vs 355 (p=0.0) 
• % with uterine inertia: 13.7 vs A. 16.8 (nsd); vs B. 
26.4 
• % ineffective 1st stage: 2.9 vs A. 8.7 (p<0.05); vs 
B. 7.3 
• % false labour: 4.9 vs A. 11.6 (p<0.05); vs B. 10.6 
• blood loss ml: 243.7 vs A. 265.3 (nsd); vs B. 300.7 
(p<0.001) 
•%healthy infants (Apgar 7 at I min): 59.6 vs A. 
58.9; vs B. 51 
0 
61 
+ 
80 
+ 
67 
+ 
85 
> 
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App. 2.2 Overview of controlled trials of clinical homeopathy (cont.) 
Gauthier 1983 D: parallel C:Menopausal syndrome H: Lachesis + clonidine placebo / C30 • n flushes(% reduction) at d 30: 5.75 (26.0) vs OM < 
A: random I: naturally or surgically menopausal or D: 1 x 3 gran/d 2.64 (64.3); vs P 7.35 (27.1) (p<0.02) 78 M: double premenopausal; 2 flushes/d ~15 d; premenopausal C: A. OT: clonidine 1x325µg/d + Lachesis placebo • patient assessment improved: 6/8 vs 7 n; vs 5/13 
F:45d with amenorrhea >6 mon-1 y 8. Lachesis placebo+ clonidine placebo • prescreened Lachesis responders self-assessment 
S: 6 centres, F ranee E: unable to attend monthly follow-up; treated or improved: 5/6 vs 4/4; vs 0/2 
untreated hypertension; use of estrogen or 
corticosteroids; unable to avoid menthol or camphor 
N: 34/28 (17 .65%) 
D: female, age mean 50.3 y 
Ustianowski 1974 D: parallel C: Postcoital cystitis H: Staphysagria / C30 • lost all symptoms: 90 vs 40 + 
A: random I: started or restarted regular intercourse in previous D: 1 powder/d • much better: 8 vs 10 59 M: single 3mon C: placebo • unchanged: 2 vs 50 
F: 1 mon E: missing 
S: 1 centre, UK N: 200/200 (0%) 
D: female, age 16-30 y 
Infections (misc) 
Mokkapatti 1992 D: parallel C: Acute hemorrhagic conjunctivitis (prevention) H: Euphrasia / C30 • n (%) incidence of ocular symptoms: 48 (9.69) vs 0 
A: random I: day scholars 4-15 y D: 5-6 tab/d x 3 43 (8.62) (nsd) 72 M: double E: missing C: placebo 
F: 10d N: 1306/994 (23.89%) 
S: 2 schools, India D: ?% female, age 4-15 y 
Rios Varela 1995 D: parallel C: Acute hemorrhagic conjunctivitis H: Pulsatilla / C6+ • n (%) cure at s3 d: 26 (44.8) vs 2 (4.0) (p<0.001) > 
A:. random I: diagnosed with acute hemorrhagic conjunctivitis D: 1 dose/2-3 h (plussed); increasing interval until 67 M: none E: unavailable for daily follow-up; use of other or improved, max. 72 h 
F:3d mixed treatments C: cold herbal fomentations, then steroids if not 
S: 1 centre, Cuba N: 138/108 (21.74%) improved 
D: 58% female, age <15->60 y 
Anonymous 1980 D: parallel C: Cystitis H: Cantharis / [C30) • n improved: 9/21 vs 5/23 (+) 
A: random I: acute onset of burning or scalding pain throughout D: missing ni M: double micturition, accompanied by frequency or urgency C: placebo 
F:3d E: missing 
S: multicentric, UK N: ?/44(?%) 
D: ?% female, age ? y 
Metabolic disorders 
Spitze 1995 D: parallel C: Cellulite H: Nat-sul (+twice-weekly massage) I C9 •%change body fat -2.14 vs +2.41 (nsd) 0 
A:. random I: females; body mass index 2~30 D: 2 x 5tab/d • BMI reduction: 0.5 vs 0.515 (ns p=0.969) 76 M: double E: pregnancy; excessive smoking or alcohol intake C: placebo (+twice-weekly massage) 
F:12w N: 29/20 (31.03%) 
S: 1 centre, S. Africa D: female, age adult 
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Zicari 1992 D: parallel C: Diabetic retinopathy (prevention) H: Amica/ C5 • metabolic change at 4 mon: nsd (+) 
A-. random I: 20-70 y; central vision with correction 6/10; D: missing • retinal functional response change at 6 mon: 80 M:double refractive defect <±60; diabetes mellitus diagnosed C: placebo intragroup p=0.025 vs p=0.856 
F: 6mon >5y • green/red coefficient% increase at 6 mon: 52 vs 15 
S: 1 centre, Italy E: amblyopia; endoocular hypertonia; established (intragroup p=0.0006 vs p=0.705) 
degenerative retinopathy; maculopathy; senile • green/red critical fusion % increase at 6 mon: 26 
cataract; degeneration of optic nerve vs 15 (nsd) 
N: 60/26 (56.67%) 
D: ?% female, age ? y 
Joseph 1994 D: parallel C: Hypercholesterolemia H: Chelidonium / D3 • mmol/1 (%) reduction in total cholesterol (TC): {+) 
A-. random I: raised age-specific total cholesterol (TC) level + D: 2 x 1 dose/d 0.321 ( 4.8) vs 0.106 (1.8) (intragroup p=0.023 vs 80 M:double raised low density lipoprotein level; no change in C: placebo nsd) 
F: 12w lifestyle (exercise, smoking, diet) during trial • HDLC: LDLC ratio(%) increase: 0.08 (13) vs 0.027 
S: 1 centre, S. Africa E: pregnancy; recent surgery; myocardial infarction in (8) (intragroup p=0.019 vs nsd) 
previous 1 mon; cholesterol-lowering medication; 
high risk TC + hypertension or smoker 
N: 30/30 (0%) 
D: ?% female, age adults y 
Werk 1994 D: parallel C: Obesity H: Helianthus-tub ( + diet plan)/ DI • BMI points reduction: 2.3 vs 1.5 (p=0.05) + 
A: random I: Body mass index (BMI) ~6; doctor's judgement D: 2 x 30 drops/d • n (%) reached BMI s25: 28 (47) vs 13 (28) 72 M:double requiring treatment for obesity because of C: placebo ( + diet plan) (p<0.05) 
F: 12w cardiovascular risk or illness • weight reduction kg: 7.1 vs 4.7 {p<0.005) 
S: 12 centres, Germany E: BMI >35; doctor's judgement requiring very strict 
low calorie diet + appetite suppressants to avoid or 
reduce problems from obesity or adiposity 
N: 166/102 (38.55%) 
D: male, age 23-72 y 
Musculoskeletal & rheumatology 
Massinger 1976a(i) D: parallel C: Cramps (prevention) H: Cuprum-met / D4 • n (%) improved: 15 (83) vs 12 (75) 0 
A-. nonrandom I: missing D: missing 42 M: double E: missing C: placebo 
F:? N: ?/34(?%) 
S: 3 centres, Germany D: ?% female, age ? y 
Massinger 1976a(ii) D: parallel C: Cramps (prevention) H: Cuprum-met / D30 • n (%) improved: 9 ( 45) vs 15 (55) 0 
A-. nonrandom I: missing D: missing 42 M: double E: missing C: placebo 
F:? N: ?/47 (?%) 
S: ? centre/s, Germany D: ?% female, age ? y 
Massinger 1976a(iii) D: parallel C: Cramps (prevention) H: Cuprum-acet / D200 • n (%) improved: 20 (87) vs 20 (80) 0 
A-. nonrandom I: missing D: missing 42 M: double E: missing C: placebo 
F:? N: ?/48 (?%) 
S: ? centre/s, Germany D: ?% female, age? y 
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Puterman 1994 D: parallel C: Gout H: Colchicum / [C9] • mmol/I reduction blood uric acid: 0.01 vs 0.07 (ns 0 
A: random I: live in Greater Durban; hyperuricemia, or D:3x5tab/dforl0w p=0.52) 76 M:double symptomatic diagnosis C: placebo • n patient assessment improved: 12 vs 10 (ns 
F: 10w E: use of gout medication in previous mon; use of p=0.23) 
S: 1 centre, S. Africa medication affecting uric acid levels; renal or hepatic 
disease 
N: 30/28 (6.67%) 
D: 7% female, age ? y 
Khan 1985 D: parallel (contralateral) C: Hallux valgus H: T agetes erecta sp. / e • mm reduction(%) of angular width of great toe + 
A: nonrandom I: hallux valgus ~5--20 y D: 3 applications/d reducing to 3/w over 12 w joint: 51 (26) vs 12 (6) 53 M:single E: open wounds, septic lesions C: placebo 
F: 12w N: 10/10 (0%) 
S: 1 centre, UK D: female, age 20-80 y 
Khan 1986 D: parallel (contralateral) C: Hallux valgus H: Tagetes erecta sp. / 0 •%reduction in length: 66.85 vs 19.65 (p<0.001) + 
A: nonrandom I: hallux valgus D: 3 applications/d reducing to 3/w over 43 w •%reduction in width: 38.8 vs 10.9 (p<0.001) 64 M:single E: adhesive plaster allergy C: placebo • angular reduction: 3.05 vs O (p<0.001) 
F:43w N: 100/20 (80%) 
S: 1 centre, UK D: female, age 20-80 y 
Khan 1996 D: parallel ( + C: Hallux valgus H: Tagetes patula / 0 •%reduction of width (photo): 34 vs O (p<0.001) + 
contra lateral) I: bilateral hallux valgus (n=20); unilateral hallux D: 4 x paste+ cavity pad/w then 3 x applications/d • % reduction of angle (x-ray): 30 vs O (p<0.001) 77 A-. random valgus (n=40) reducing to none at w 8 •%reduction of pain (10-pt scale): 100 vs 0 
M:double E: ulcerated condition; currently on medication; C: placebo (p<0.001) 
F:8w previous surgery for condition 
S: 1 centre, UK N: 60/60 (0%) 
D: 92% female, age 20-70 y 
Shipley 1983 D: crossover C: Osteoarthrosis H: Rhus-tox / D6 • pain (on movement, at rest, at night): nsd < 
A: random I: clinical and radiographic criteria for OA of ~1 hips D: 3 x 5 drops/d • paracetamol use: nsd 73 M:double or knees; match Rhus-tox symptomatology C: A. OT: fenuprofen 
F:2w E: Helsinki convention; previous use of trial B. placebo 
S: 2 centres, UK medicines 
N: 36/33 (8.33%) 
D: 67% female, age 37-82 y 
Neurology & psychiatry 
Alibeu 1990 D: parallel C: Agitation (postoperative childhood) H: Aconitum / D4 • amelioration n (%): 23 (95) vs 11 (50) + 
A-. random I: children matching Aconite symptomatology of D: single dose with option to repeat twice if no 69 M:double postoperative anxiety and agitation response after 15 min 
F: 15 min E: missing C: placebo 
S: 1 centre, France N: 50/46 (8%) 
D: 28% female, age 0.5--14 y 
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Singh 1994 D: parallel C: Emotional palmar hyperhidrosis H: Pilocarpus jaborandi / C9 • sweat: ns p=0.659 0 
A: random I: live in Greater Durban; emotional hyperhidrosis D: 1 x 5tab/d • n patients improved: 8 vs 7 75 M:double localized on palms C: placebo 
F:90d E: emotional hyperhidrosis localized elsewhere; 
S: 1 centre, S. Africa inability for simple mental arithmetic 
N: 30/30 (0%) 
D: ?% female, age > 10 y 
Savage 1977 D: parallel C: Stroke H: Amica/ C30 • 3-mon survival n (%): 9 (45) vs 8 (40) 0 
A: random I: inpatients s.7 d of stroke regardless of pathology D: 6 x 1 tab/2 h • survivors' assessment score (4-20) (% increase): 72 M:double E: missing C: placebo 17.0 (26.2) vs 19.5 (40.6) 
F: 3 mon N:40/40(0%) 
S: 1 centre, UK D: 50% female, age mean 79 y 
Savage 1978 D: parallel C: Stroke H: Amica / ClOOO • 3-mon survival n (%): 9 (45) vs 9 (45)(nsd) 0 
A-. random I: inpatients s.7 d of stroke regardless of pathology D: 6 x 1 powder/2 h • survivor assessment score (4-20) (% increase): 76 M: double E: missing C: placebo 18.6 (41.2) vs 17.7 (46.2) 
F:3 mon N: 40/40 (0%) 
S: 1 centre, UK D: 68% female, age mean 78 y 
Ophthalmology 
Basu 1980 D: parallel C: Simple myopia H: Physostigma / C30, 200, M, lOM • n (%) eyes much improved: 61 (67.8) vs 0 + 
A: nonrandom I: corrected or uncorrected simple myopia (diagnosed D: C301 drop/d dl-3; 2001 drop/d d40-42; M 1 • slightly improved: 25 (27.8) vs 0 61 M: single with retinoscopy, ophthalmoscopy, slit lamp); general drop/d d85--87; lOM 1 drop/d d130-132 • unchanged: 5 (5.6) vs 9 (22.5) 
F: 180d good health C: placebo • worse: 0 vs 31 (77.5) 
S: 1 centre, India E: ocular pathology 
N: 65/65 (0%) 
D: 44% female, age 0-35 y 
Basu 1981 D: parallel C: Progressive myopia H: Physostigma / C30, M, lOM • n (%) eyes much improved: 82 (74.5) vs 0 + 
A-. nonrandom I: corrected or uncorrected progressive myopia D: C301 drop/d dl-3; M 1 drop/d d 85--87; lOM 1 • slightly improved: 21 (19.1) vs 0 61 M: single (diagnosed with retinoscopy, ophthalmoscopy, slit drop/d d130-132 • unchanged: 7 (6.4) vs 5 (12.5) 
F: 180d lamp); general good health C: placebo • worse: 0 vs 35 (87.5) 
S: 1 centre, India E: ocular pathology 
N: 75175 (0%) 
D: 35% female, age 0-25 y 
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Respiratory infections & ENT 
Friese 1997 D: parallel 
A: random 
M:double 
F:12w+ 
Miissinger 1982 
Gassinger 1981 
Massinger 1985 
Mossinger 1973 
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S: 1 centre, Germany 
D: parallel 
It random 
M: double 
F:14d 
S: 38 centres, Germany 
D: parallel 
It random 
M: none 
F:lOd 
S: I centre, Germany 
D: parallel 
It random 
M: double 
F:? 
S: 13 centres, Germany 
D: parallel 
It random 
M: double 
F:? 
S: > 1 centre, Germany 
C: Adenoidal growths 
I: 4-10 y; adenoidal growths needing operation in 
parents' or doctors' opinion; snoring indicating acute 
infection; nasal breathing impossible; ~6 URTI yearly; 
hearing difficulty; late speech development; internal 
nares obstructed by adenoids; match all 4 study 
medicines 
E: allergic ENT; allergic rhinitis, asthma; bronchial 
asthma; well-defined tonsillar hyperplasia; extremely 
enlarged throat tonsils; urgent clinical need for 
operation; using immunosuppressants; 
multi morbidity; parent unable to understand or 
comply with study; participant in another clinical trial 
in previous 3 mon 
N: 97/82 (15.46%) 
D: 37% female, age 4-10 y 
C: Coryza 
I: ~ d with cold 
E: missing 
N: 106/104 (1.89%) 
D: ?% female, age ? y 
C: Influenza 
I: aching limbs+ 2:1 of: pyrexia, bronchitis, rhinitis, 
laryngitis, pharyngitis 
E: <20 or > 70 r, > IO% normal weight; flu >48 h; 
chronic bronchitis; suppurating tonsillitis; fever 
>39°C; longterm treatment begun <3 w; aspirin 
contraindicated 
N: 53/53 (0%) 
D: 55% female, age? y 
C: Otitis media 
I: treatment started ~1 d from onset 
E: other serious illness 
N: 44/38 (13.64%) 
D: ?% female, age ~16 y 
C: Pharyngitis 
I: pharyngitis with or without temperature 
E: missing 
N: 19Vl48 (22.92%) 
D: ?% female, age ? y 
H: Nux-vom D200 then Okoubaka D3 then 
Tuberculinum D200 then Baryta-iod D4 then Baryta-
iod D6 
D: 1 x 5 glob Nux-vom then Okoubaka for 4 w then 1 x 
5 glob Tuberculinum then 3 x 1 dose Baryta-iod/d for 
4 w then 3 x 1 dose Baryta-iod/d for 4 w 
C: placebo 
H: Euphorbium / D3 
D: missing 
C: placebo 
H: Eupatorium / D2 
D: 5 x 10 drops or 5 x 2 tab/d 
C: 3 x 1 acetylsalicylic acid/d 
H: Pulsatilla / D2 
D: 5 drops/h in water until improvement 
C: placebo 
H: Phytolacca / D2 
D: 5drops/h 
C: placebo 
• % assessed by doctor as still needing operation at 
12 w: 21.9 vs 29.3 (nsd) 
•%assessed by doctor as symptom free: 15.2 vs 2.2 
(p=0.062) 
• % assessed by parent as symptom free: 13 vs 4.3 
(p=0.284) 
• % feel much better by d7: 88.1 vs 77 .8 (ns 
p=0.126) 
• % soreness of nostrils and upper lip: nsd 
• % follow-on catarrh: 25.4 vs 26.6 (nsd) 
• patient assessment of symptoms (6-pt scale): nsd 
• temperature: nsd 
• erythrocyte and hemoglobin tests: nsd 
• % used other flu medication: 50 vs 71 
• rectal temp: nsd 
• doctors' final assessment of good response: 100 vs 
73.68 (p=0.05) 
• broken nights: nsd 
• duration of subjective complaint (entry on dl/2): 
3.57 vs 4.69 (p<0.05) 
• duration of temperature: too few to compare 
•%frequency of postpharyngitis complications: 
52/52 
• % doctor broke off trearnent early: 82 vs 23.7 
(p=<0.0125) 
0 
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App. 2.2 
Mossinger 1976b 
Wiesenauer 1989(i) 
Wiesenauer 1989(ii) 
Lewis 1984 
Surgical trauma 
Hofmeyr 1990 
Bourgois 1984 
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D: parallel 
A:random 
M: double 
F:~ld 
S: > 1 centre, Germany 
D: parallel (factorial) 
A: random 
M: double 
F: 30 d (median) 
S: 47 centres, Germany 
D: parallel (factorial) 
A: random 
M: double 
F: 30 d median . 
S: 47 centres, Germany 
D: crossover 
A: random 
M: double 
F:? 
S: 1 centre, UK 
D: parallel 
A:. random 
M: double 
F:4d 
S: 1 centre, S. Africa 
D: parallel 
A:. random 
M: double 
F: ca 14 d 
S: 1 centre, France 
C: Pharyngitis 
I: consult and treatment begun on d 1 or 2 
E: missing 
N: 118/82 (30.51 %) 
D: ?% female, age? y 
C: Sinusitis (acute) 
I: any nasal sinus illness plus chronic pansinusitis; 
sinusitis plus other respiratory disease; sinusitis plus 
other disease under treatment 
E: current treatment with glucocorticoids 
N: 83/83 (0%) 
D: 52% female, age? y 
C: Sinusitis (chronic) 
I: any nasal sinus illness plus chronic pansinusitis; 
sinusitis plus other respiratory disease; sinusitis plus 
other disease under treatment 
E: current treatment with glucocorticoids 
N: 69/69 {0%) 
D: 55% female, age? y 
C: Whooping cough 
I: > 1 y; paroxysmal cough ~5 d; coughing bouts 
ending with retching, vomiting or whoop 
E: lower respiratory infection; other complicating 
factors 
N: 35/29 (17.14%) 
D: 48% female, age 2-11 y 
C: Childbirth 
I: episiotomy; perinea! tearing needing suturing 
E: missing 
N: 17V171 (.58%) 
D: female, age mean 24 y 
C: Hematoma 
I: treatment for breast cancer, leading to any or allot 
pain from hematomas and injections; hematomas due 
to injections (infusions or blood tests); difficult 
venous access following chemotherapy; +ve response 
to Amica in previous open study 
E: pain from extravasation of antimitotic drugs into 
tissues; heamatoma from blood transfusion 
N: 29/27 {6.9%) 
D: female, age mean 54.4 y 
H: Phytolacca / 02 
D: missing 
C:placebo 
H: A. luff a operculata + Kali-bich + Cinnabaris / D3, 
4 
B. Kali bichromicum + Cinnabaris 
C. luffa operculata 
D: 5 x 1 tab/d then 3 x 1 on improvement 
C: placebo 
H: A. luffa-operc + Kali-bich D4 + Cinnabaris D3 / 
D3,4 
B. Kali bichromicum + Cinnabaris 
C. Luffa operculata 
D: 3 x 1 tab/d, but doctors free to change dose 
C: placebo 
H: Drosera / C30 
D: s6 x I dose with each coughing bout for 2 d; no 
treatment on d 3; if no change, repeat schedule with 
alternate container 
C: placebo 
H: A. Amica / D6 
B. Arnica / D30 
D: 3 tab/4 h for 2 d then 3 x 3 tab/d for 3 d 
C: placebo 
H: Amica/ C5 
D: 2 x 3 gran/d from 24 h before perfusion 
C: placebo 
• days to normal rectal temperature: 4 vs 5 (p = 
0.05) 
• days with main complaint: 2.67 vs 3.3 (nsd) 
•%sick >4d: 2 vs 16 (p=0.03) 
• Combined score from 6 symptoms: nsd in any group 
• Combined score from 6 symptoms: nsd in any group 
• parental global assessment as ~50% improved: 14 
vs 15 
• Drosera A responders crossing over to B: 2/7 
• n (%) perinea! pain moderate/severe: A. 8 (22), B. 
10 (26) vs 18 (21) (OR to placebo: 1.0, 1.3) 
• n (%) unhappy: A. 0, B. 5 (13) vs 2 (2.4) (OR to 
placebo: 014, 7.0) 
• n (%) treatment thought effective: A.16 (43), B. 9 
(23) vs 39 (46) (OR to placebo: 0.9, 0.39) 
•pain(% reduction) on 160 mm VAS: 13.1 (61.7) vs 
73.5 (151) {p=0.001) 
• hematomas (% reduction): 1.0 (64.5) vs 1.7 (32.0) 
(ns p=0.l) 
• venous accessibility on 10-pt scale(% reduction): 
1.5 (56.0) vs 2.0 (20.0) (p=0.005) 
+ 
65 
0 
73 
0 
73 
0 
66 
0 
86 
+ 
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App. 2.2 Overview of controlled trials of clinical homeopathy (cont.) 
Hariveau 1991 D: crossover C: Hemodialysis related muscle cramps H: Cuprum-met/ Cl5 • cramp stopped after 3 min: 12 vs 3 (p<0.01) + 
A:. random I: hemodialysis 3 x per w D: 1 dose sublingually, repeated after 3 min if cramp • cramp stopped after 6 min: 6 vs 4 (p=0.05) 75 M: double E: missing persists 
F: 12 d mean N: 20/20 (0%) C: placebo 
S: 1 centre, F ranee D: 45% female, age 35--77 y 
Saruggia 1992 D: crossover C: lntradialytic symptoms H: China/C9 • % change in occurrence during dialysis: + 
A:. random I: endstage renal failure; chronic dialysis 3 x weekly D: 2 x 3 gran/d for 14 d • headache: -16.7 vs -5.5 (p=0.02) 76 M:double E: missing C: placebo • lethargy: -20.8 vs + 10.6 (p=0.013) 
F:8w N: 35/35 (0%) • asthenia: -33.2 vs +2.2 (p<0.001) 
S: 1 centre, Italy D: 51% female, age l&-76 y • trends for nausea and vomiting (p=0.26 and 
p=0.37) 
Ludtke 1998(i) D: parallel C: Knee - arthroscopy H: Amica / D30 • effect ratio of change in knee circumference at d 1: (+) 
A: random I: indication for knee arthroscopy D: 1 tab x 5/d preop, 3 tab x 5/d for 1 d postop 0.11 (p=0.184) ni M: double E: swollen knees; severe organic or systemic disease C: placebo 
F:? N: 227 /227 (0%) 
S: 1 centre, Germany D: ?% female, age l&-75 y 
Ludtke 1998(ii) D: parallel C: Knee- artificial joint implantation H: Amica / D30 • effect ratio of change in knee circumference at d 2: {+) 
A:. random I: indication for knee replacement D: 1 tab x 5/d preop, 3 tab x 5/d for 2 d postop 0.48 {p=0.184) ni 
M: double E: free ot swollen knees; severe organic or systemic C: placebo 
F:2d disease 
S: 1 centre, Germany N: 35/35 {0%) 
D: ?% female, age l&-75 y 
Ludtke 1998(iii) D: parallel C: Knee - cruciate ligament surgery H: Amica/ D30 • effect ratio of change in knee circumference at d 2: + 
A:. random I: indication for cruciate ligament surgery D: 1 tab x 5/d preop, 3 tab x 5/d for 2 d postop 0.66 (p=0.019) ni 
M:double E: free of: swollen knees; severe organic or systemic C: placebo 
F:2d disease 
S: 1 centre, Germany N: 57 /57 (0%) 
D: ?% female, age l&-75 y 
Albertini 1985 D: parallel C: Post-extraction dental neuralgia H: Amica Cl then Hypericum Cl5 • % patient assessment of reasonable pain control at + 
A:. random I: dental neuralgia following extraction D: 1 dose alternately at 4 h intervals day 3 (10-pt scale): 76 vs 40 {p<0.01) 68 M:double E: antiinflammatory usage C: placebo 
F:3d N: 60/60 (0%) 
S: 1 centre, F ranee D: 55% female, age mean 39 y 
Bendre 1980 D: parallel C: Post-extraction dental neuralgia H: Amica then Hypericum / C200 • % patient assessment of +ve response at day 2 (5- + 
A:. nonrandom I: dental extraction D: 4 tab A then 4 tab Hafter 15 min {no repetition) pt scale): 93 vs 16 (p<0.001) 69 
M:single E: missing C: placebo 
F:2d N: 200/200 {0%) 
S: 1 centre, India D: ?% female, age 12-18 y 
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Kaziro 1984 D: parallel C: Post-extraction dental neuralgia (prevention) H: Amica ( + Codis) / C200 • pain (VAS) day 8: H worse than OM (p<0.001) and P < 
k. random I: impacted mandibular wisdom teeth extraction D: 2 x 1 dose/d for 8 d (p<0.05) 70 M:double E: missing C: A. OT: metronidazole • trismus (VAS) day 8: H nsd from OM (p>O.l) or P 
F: 8d N: 118/118 (0%) B. placebo • edema (VAS) day 8: H worse than OM (p<0.02) and 
S: 1 centre, UK D: ?% female, age ? y P(p<0.01) 
• wound healing (VAS) day 8: H worse than OM 
(p<0.01); nsd from P 
Pinsent 1986 D: parallel C: Post-extraction dental neuralgia (prevention) H: Amica/ C30 • pain score (3-pt scale): 0.74 vs 1.67 (p=0.031) + 
k. random I: extraction of a single tooth D: 1 tab 30 min preop then I asap postop; 1 x 3/15 • bleeding (2-pt scale): 1.04 vs 1.42 (p=0.104) 74 M: double E: use of other analgesics min then 1 x 6/2 h; 3 x 1/d • severity (sum of pain and bleeding): 1.78 vs 3.08 
F:7d N: 100/59 (41%) C: placebo (p=0.022) 
S: 1 centre, UK D: ?% female, age? y 
Kennedy 1971 D: parallel C: Postoperative complications (prevention) H: Amica/ C200 • n complications upper abdominal: 1/6 vs 0/1 0 
k. random I: upper or other abdominal, prostate or bladder, or D: 1 tab/d for 14 d • n (%) complications other abdominal: 1 (4.2) vs 1 73 M: double varicose vein surgery C: placebo (5.0) 
F:14d E: missing • n (%) complications prostate and bladder. 3 (13.6) 
S: 1 centre, UK N: 128/128 (0%) VS 1 (3.2) 
D: ?% female, age ? y • n (%) bruising varicose: 10 (58.8) vs 4 (57.1) 
Michaud 1981 D: parallel C: Postoperative edema (prevention) H: Amica/ C15 then Apis / C7 • n (%) edema absent: 20 (87) vs OM 9 (75) (nsd); vs = 
k. pseudorandom I: rhinoplasty; resetting nasal fracture D: 4 x 1 dose/ d alternately P: 11 (50) (p<0.05) 60 M: single E: missing C: A. OT: antibiotics + antinflammatories 
F:7d N: 57 /57 (0%) B. placebo 
S: 1 centre, France D: ?% female, age? y 
Marrey 1989 D: parallel C: Postoperative edema and hematoma (prevention) H: Amica / C7 • patient assessment of edema: chi square 13.49 + 
A: random[?] I: wisdom tooth extraction; nose fracture; D: 1 dose/24 h preop then 2 x 1 dose/d of op then 3 x (p<0.001) 75 
M: double septorhinoplasty; basocellular epithelioma; informed 1 dosek3d • patient assessment of hematoma: chi square 0.55 
F:4-5d consent C:placebo (nsd) 
S: 1 centre, F ranee E: spinocellular epithelioma; prior serious pathology; 
unable to follow protocol 
N: 36/36 (0%) 
D: 42% female, age adult 
Aulagnier 1985 D: parallel C: Postoperative ileus H: Opium then Raphanus then Arnica / C9 • d to 1st flatus: 2.47 vs 3.17 (p<0.001) + 
k. random I: surgical opening of abdominal or peritoneal cavity D: 5 tab/2 h of each alternately from op + 1 d • d to 1st stool: 4.0 vs 4.88 (p<0.001) 78 
M: double E: missing C: placebo • % patient global assessment as good: 66 vs 48 
F:>5d N: 200/200 (0%) (p=0.05) 
S: 1 centre, F ranee D: 26% female, age 33-80 y 
Castelain 1979 D:parallel C: Postoperative ileus H: A. Raphanus / CS • h to 1st stool (32 children): A. 67.9 vs B. 53.7 vs N. + 
k. nonrandom I: appendectomy, hernia or cholecystectomy without B. Opium/ Cl5 86.7 37 
M: none complications D: 4 x 3 gran/d for 2 d from 1st flatus • h to 1st stool (40 adults): A. 98.9 vs B. 83.7 vs N. 
F:s5d E: missing C: no treatment 110.8 
S: 1 centre, France N: 72172 (0%) 
D: ?% female, age ally 
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Chevrel 1984 D: parallel C: Postoperative ileus H: Opium/ C15 • h to 1st flatus: 42.65 vs 52 (p<0.035) + 
A: random I: abdominal surgery D: 4 x 3 tab/d for 48 h from regaining consciousness • h to 1st stool: 99.9 vs 78.2 (nsd) 70 M: double E: missing C: placebo 
F:48h N: 96/96 (0%) 
S: 1 centre, F ranee D: ?% female, age mean 51 y 
Estragnin 1979(ii) D: parallel C: Postoperative ileus H: Amica C7 + China C7 + Pyrogeninum CS • n (%) <2 d to 1st flatus: 36 (72.0) vs 33 (70.2) 0 
A: random I: laparotomy during gynecological surgery or D: Amica + China 2 x 5 gran/d, Pyrogeninum 1 (nsd) 64 M: double cesarian dose/d 
F: $;14 d E: missing C: placebo 
S: 1 centre, F ranee N: 97 /97 (0%) 
D: female, age adults y 
Grecho 1989 D: parallel C: Postoperative ileus H: A. Opium/ Cl5 • h to 1st stool: nsd 0 
A: random I: > 18 y; gastrectomy; cholecystectomy; resection of B. Opium C15 + Raphanus CS • h to 1st flatus: nsd 92 M:double intestine, colon or rectum D:3x4 tab/d 
F: till 1st stool or flatus E: abdominal-peritoneal amputation C: A. placebo 
S: 12 centres, F ranee N: 600/600 (0%) B. no treatment 
D: 63% female, age mean 54 y 
Valero 198l(i) D: parallel C: Postoperative ileus (prevention) H: Raphanus / C7, 15 • h until 1st flatus: 59.1 vs 78.4 + 
A: pseudorandom I: any surgical patient undergoing general anesthesia D: 1 dose 24 h preop 72 M:single E: preventive treatment for ileus; children; senile or C: placebo 
F: until 1st flatus psychiatric patients; hernia operations; lacking good 
S: 1 centre, F ranee spoken French 
N: 5V39 (25%) 
D: ?% female, age adults y 
Valero 198l(ii) D: parallel C: Postoperative ileus (prevention) H: Raphanus / C7 • h until 1st flatus: 53.3 vs 58.6 (p<0.5) + 
A:. random I: any surgical patient undergoing general anesthesia D: 1 dose 24 h pre- or postop 89 M: double E: children; senile or psychiatric patients; hernia C: placebo 
F: until 1st flatus operations; lacking good spoken French 
S: I centre, France N: IOV80 (21.57%) 
D: 50% female, age adults y 
Hart 1997 D: parallel C: Postoperative pain and infection (prevention) H: Amica/ C30 • pain score: nsd 0 
A:. random I: total abdominal hysterectomy D: 2 x I dose in 24 h preop; 3 x I dose for 5 d postop • infection (need for antibiotics): nsd 84 M: double E: missing C: placebo • time in hospital: nsd 
F: 5d then atl4 d N: 93/73 (21.51%) 
S: I centre, UK D: female, age 25-76 y 
Felisi 1994 D: parallel C: Radiodermatitis H: Belladonna/ C7 + X-ray/ Cl5 •%reduction in global score (edema, pain, (+) 
A:. random I: radiotherapy following surgery for breast cancer D: Bell 2 x I dose/d for 6 w; X-ray 3 x 1 dose once discoloration): 11.79 vs 7.68 (ns p=015) 71 M: single E: geographically inaccessible; serious concomitant C: placebo 
F:8w pathology 
S: I centre, Italy N: 67 /62 (7.46%) 
D: female, age 28-71 y 
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Kulkarni 1988 
Amodeo 1987 
Trauma 
Gibson 1991 
Campbell 1976(i) 
Bouchez 1988 
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Overview of controlled trials of clinical homeopathy (cont.) 
D: parallel 
ft.. random 
M: single 
F:6w 
S: 1 centre, India 
0: parallel 
A: missing 
M: double 
F:3w mean 
S: 1 centre, Italy 
D: parallel 
A: random 
M:double 
F: varied with patient 
S: 1 centre, UK 
D: crossover 
ft.. random 
M: double 
F:? 
S: 1 centre, UK 
D: parallel 
ft.. random 
M: single 
F:~7d 
S: 1 centre, France 
C: Radiotherapy adverse effects (prevention) 
I: receiving treatment in radiation oncology 
department 
E: missing 
N:8V82(0%) 
D: ?% female, age? y 
C: Venous pathology from protracted infusion 
(prevention) 
I: A. parenteral nutrition (n=21) 
B. protracted infusion >72 h (n=9) 
C. chemotherapy ( n=9) 
E: missing 
N: 39/39 (0%) 
D: 36% female, age 24-60 y 
C: Acute trauma 
I: less progress than others with similar conditions; in 
ward for 24 h; wounds dressed, fractures stabilized; 
informed consent 
E: steroid use 
N: 20/20 (0%) 
D: ?% female, age ? y 
C: Bruising (experimental) (prevention) 
I: missing 
E: missing 
N: 22/20 (9.09%) 
D: ?% female, age adult 
C: Neonatal traumatic edema 
I: neonatal traumatic edema, whatever the 
localization, symptoms, type of delivery 
E: nontraumatic edemas (metabolic, lymphatic etc); 
serious cases requiring Arnica 
N: 221/192 (13.12%) 
D: ?% female, age O y 
H: A. Causticum / C30 
B. Cobaltum 
0: 1 x3pills/dfor6w 
C: placebo 
H:Arnica/C5 
0: 4 x 3 gran/d for lw before, during and after 
treatment 
C: placebo 
H: Amica/ C30 
0: 3 or 4 doses only 
C: placebo 
H: Amica/ C30 
0: 1 tab before bruising, 1 after 4 h, 1 before bed; 2 
doses on d 2 
C: placebo 
H: Amica / C9 
D: 3 drops before each feed until cure 
C: placebo 
• 16 symptoms (4-pt Likert scale combined): A4.7, B 
5.4 vs 8.5 (significant) 
• A+B: hyperemia score (3-pt scale): 0.28 vs 1.67 
• A+B: edema score (3-pt scale): 0.09 vs 1.22 
• A+B: pain score (0--10 scale): 2.02 vs 8.05 
• A+B+C: hematoma n: 0/26 vs 8/13 
• objective (pulse rate, systolic and diastolic BP, 
respiratory rate): nsd individually (combined 
p=0.024) 
• subjective (stiffness, pain, anxiety): nsd individually 
(combined p=0.035) 
• overall trend (binomial test): p=0.0075 
• n with markedly smaller bruise: 1 vs 2 
• n expressing treatment preference: 3 vs 6 
• l/2 d with lesion: 415 vs 343 (ns p=026) 
+ 
55 
+ 
57 
(+) 
62 
0 
60 
(-) 
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App. 2.3 Overview of controlled trials of complex homeopathy 
First author(s), year 
Asthma & allergy 
Abelson 1996 
Matusiewicz 1997a 
Cardiovascular 
Ernst 1990 
Dermatology 
Hill 1995 
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Methods 
D: design 
A: assignment 
M: masking 
F: follow-up period 
S: setting 
D: parallel (contralateral) 
A: random 
M: double 
F: 14d 
S: 1 centre, USA 
D: parallel 
A-. random 
M: double 
F: 6mon 
S: 1 centre, Poland 
D: parallel 
A-. random 
M: double 
F:24d 
S: 1 centre, Austria 
D: parallel (intrasubject) 
A-. random 
M: double 
F: 3 h; 31 h 
S: 1 centre, UK 
Patients 
C: condition 
I: inclusion criteria 
E: exclusion criteria 
N: number included/analysed(% attrition) 
D: demographics 
C: Allergic conjunctivitis 
I: ocular health within normal limits; sensitive to 
short ragweed, cat dander or timothy grass 
E: > 1 + hyperemia; ocular itching; use of NSAIDS, 
antihistamines, steroids; contact lenses 
N: 66/66 (0%) 
D: ?% female, age ? y 
C: Chronic asthma 
I: FEY ~50%; PEFR ~80% normal afternoon value; 
using triamcinolone 4--8 mg/d ~ 5 y 
E: missing 
N: 40/40 (0%) 
D: 50% female, age 24-48 y 
C: Varicose veins 
I: clinical diagnosis+ physical signs (swelling, 
trophic changes)+ light reflection rheography 
E: post-traumatic or post-thrombotic chronic venous 
insufficiency; lymphedema; hereditary vascular 
abnormalities; venous compression syndromes; 
congestive heart disease; liver or kidney disorders; 
malignant or inflammatory disease; hematological 
abnormalities; peripheral arterial occlusive disease 
N: 61/61 (0%) 
D: 74% female, age mean 58.l y 
C: Mosquito bites (experimental) 
I: healthy adults > 18 y; history of pruritis and 
erythema from mosquito bites 
E: hypersensitive to stings of mosquitoes, bees and 
wasps; skin sensitive to citronella or eucalyptus oil; 
use of systemic antihistamines, corticosteroids or 
NSAIDS in previous month 
N: 68/65 (4.41%) 
D: 62% female, age 20-62 y 
Treatments 
H: homeopathic medicine/ potency 
D: dosage, repetition 
C: control treatment 
H: Similisan Eye Drops #2 /? 
D: 4 x 1-2 drops/din assigned eye for 14 d 
C: placebo 
H: Engystol N (+corticosteroid + methyloxanthine) / 
D4-30 
D: 1 ampoule subcutaneously/~? d 
C: placebo ( + corticosteroid + methyloxanthine) 
H: Poikiven I DI, 4 
D: 3 x 20 drops/d for 24 d 
C: placebo 
H: Prrrikweg® / 0, DI 
D: 90 mg applied at 0, 1, 3, 6, 26 and 31 h 
C: A. placebo 
B. no treatment 
Results 
• clinical outcomes 
• reduction hyperemia (5-pt scale): 1.14 vs 1.12 
(intragroup p=0.004 vs 0.009) 
• reduction itching (5-pt scale): 1.00 vs 0.97 
(intragroup p=0.(XX)l vs 0.(XX)2) 
•%change in PEFR: +65 vs -9.5 (p<0.01) 
•%change in FVC: +59.1 vs -4.34 (p<0_Ql) 
•%change in FEY: +41.18 vs -5.26 (p<0.01) 
• % change in corticosteroid usage: -50 vs +40 
• s change in venous filling time: +441 vs -18.4 
(p<0.001) 
• reduction in leg volume: -0.78 vs -0.75 (nsd) 
• % pain reduction: 83.9 vs 66.7 
• median total erythema mm2*h: 10.5 vs A. 12-9 
(p=0.13); vs B.13.3 (p=0_06) 
• itching: nsd 
Vote 
MQ 
+ 
82 
+ 
75 
+ 
82 
(+) 
84 
App. 2.3 Overview of controlled trials of complex homeopathy (cont.) 
Hill 1996 
Gastroenterology 
Martel 1985 
Oberbaum 1998 
D: parallel ( contralateral) 
A: random 
M: double 
F:48h 
S: 1 centre, UK 
D: parallel 
A: random 
M:double 
F:3w 
S: 1 centre, F ranee 
D: parallel 
A: random 
M: none 
F:? 
S: 1 centre, Israel 
Gynecology and obstetrics 
Lasserre 1986 D: parallel 
A: random 
M:double 
F: 1 mon 
Beer 1995 
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S: 1 centre, France 
D: parallel 
It random 
M: none 
F: 3 mon 
S: multicentric, Germany 
C: Mosquito bites (experimental) 
I: healthy adults; history of pruritis and erythema 
from mosquito bites 
E: negroid; hypersensitive to stings of mosquitoes, 
~sand wasps; skin sensitive to citronella or 
eucalyptus oil; use of systemic antihistamines, 
corticosteroids or NSAIDS in previous month 
N: 100/99 (1%) 
D: 51% female, age 21-63 y 
C: Gingivitis 
I: missing 
E: missing 
N: 58/58 (0%) 
D: 78% female, age ? y 
C:Stomatitis 
I: children receiving chemotherapy 
E: missing 
N: 27 /27 (0%) 
D: ?% female, age IH8 y 
C: Childbirth 
I: ~15 d treatment; informed consent 
E: previous obstetric problems (eg cesarian); serious 
illness in mon 1-8 (hypertension, diabetes); needing 
cesarian because of infection (herpes); 
fetal-maternal dysproportion 
N: 93/93 (0%) 
D: female, age ? y 
C: Menopausal syndrome 
I: menopausal women with typical menopausal 
symptoms 
E: missing 
N: ?/130 (?%) 
D: female, age mean 53 y 
H: Prrrikweg® / 0, 01 
D: 150 mg applied topically at 0, 0.5, 1, 26.5 and 48 h; 
self application allowed (see outcomes) 
C: placebo 
H: Homeodent /? 
D: 3 x 1 application/dafter meals 
C: placebo 
H: Traumeel Oral Liquid/ Dl, 2, 3, 6 
D: missing 
C: no treatment 
H: Actea-rac + Amica + Caulophyllum + Gelsemium 
+ Pulsatilla / C5 
D: 2 x 3 tab/d from mon 9, increased at start of 
contractions to 3 tab/15 min 
C: placebo 
H: Wechseljahrstropfen / D2, 3, 4, 6, 10 
D: 15 drops/d orally 
C: OT: estrogen replacement 
• n (%) patient preference regarding itching: 24 (48) 
vs 21 ( 42) (p=0.766) 
• n self application: 0.81 vs 0.91 (p=0.664) 
• erythema (baseline/treatment): 1.001 vs 0.836 
(p=0.098) 
• VAS (0-3) gingival index(% reduction): 0.4 (78.9) 
vs 0.9 (52.6) (p<0.01) 
• n (%) patient global assessment of good/very 
good: 14 (48.3) vs 1 (3.4) (p<0.001) 
• n (%) doctor global assessment of good/very good: 
18 (62.0) VS 3 (10.3) (p<0.001) 
• mean d symptom duration: 6 vs 13 (p=0.001) 
• h duration of labour: 5.1 vs 8.48 (p<0.001) 
• n (%) with dystocia: 6 (11.3) vs 16 (40) (p<0.001) 
• endometrial thickness (by ultrasound): nsd between 
groups (p=0.456) 
• reduction in FSH: favours OM (p=0.012) 
• reduction in estradiol: nsd (p=0.451) 
• 18 subjective parameters: equal improvement in 
most in both groups, except 
• headache favours homeopathy (p=0.045) 
• insomnia favours homeopathy {p=0.047) 
(+) 
85 
+ 
79 
+ 
55 
+ 
84 
= 
63 
App. 2.3 Overview of controlled trials of complex homeopathy (cont.) 
Musculoskeletal & rheumatology 
Wiesenauer 1991 
Thiel 1994 
Casanova 1981 
Nahler 1996 
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D: parallel 
A: random 
M: double 
F: 12w 
S: 6 centres, Germany 
D: parallel 
A:. random 
M:double 
F:36d 
S: 1 centre, Germany 
D: parallel 
A:. random 
M: single 
F:30d 
S: 1 centre, France 
D: parallel 
P-:.random 
M: none 
F:5w 
S: 12 centres, Austria, 
Germany 
C: Chronic polyarthritis 
I: certain diagnosis of chronic polyarthritis of~ mon 
standing; treatment for :2:3 mon; NSAID & analgesic 
treatment unchanged for :2:4 w; 5/8 ARA criteria 
[: systemic or local glucocorticoids or 
immunosuppressive treatment; other serious 
illnesses eg cancer, chronic inflammatory intestinal 
disease; pregnancy; breastfeeding; <18 or> 70 y; 
uncooperative or nonconsenting patients 
N: 111/106 (4.5%) 
D: 54% female, age 18-70 y 
C: Hemarthrosis 
I: posttraumatic irritation of knee joint with 
hemarthrosis; no neutral position of knee and hyper 
distention impossible 
E: pregnancy; bi- and unilateral joint injury; >72 h 
old; open wounds etc. 
N: 80/73 (8.75%} 
D: 34% female, age mean 36 y 
C: Myalgia 
I: sports people affiliated to clubs; myalgia or 
arthralgia from training or overwork 
E: inflammatory or neurological cause; psychafgia; 
hypo-uric, anti inflammatory or analgesic use 
N: 60/60 (0%) 
D: 52% female, age 18-50 y 
C: Osteoarthrosis 
I: 35-85 r. primary clinical osteoarthrosis ~3 mon; x-
ray; constant pain 
E: osteoarthrosis from previous deformity, injury; 
other similar coccarthrosis; varicosis; bone or muscle 
disease; RA; acute inflammation; stationary, 
bedridden; changing level of physical activity, 
surgical treatment; intraarticufar steroids in previous 
2 mon; low-level pain; allergic reaction from 
medication; serious liver or kidney disease; 
immunosuppressants in previous month; ongoing 
analgesic or anti inflammatory treatment 
N: 119/114 (41%) 
D: 80% female, age 37-84 y 
H: Rheumaselect / D4 
D: 3-4 x 10-20 drops/d suggested, but doctor free to 
change 
C: placebo 
H: Traumeel N (injection)/ 0, D1,3,4,6 
D: injection on d 1, 4 and 8 
C: placebo 
H: Urarthrone / 0, D1-4 
D: 2 x 2 tsp in water/d for 3 w 
C: placebo 
H: Zeef /? 
D: 2 x 2 ml intraarticular injections/w 
C: OT: hyafuronic acid 
• n (%) global success vs failure: 44 (78.6) vs 30 (60) 
(p<0.01) 
• % with pain score of Oat d 30: 64.9 vs 36.1 
• % painfree patients at 4 w: 86.5 vs 66.7 
• mean change (4-pt Likert scale) in myalgia, 
tendonopathy, joint pain: nsd 
• patient global assessment of success, failure, 
unsure: 19/7 /4 vs 9/16/5 (p<0.03) 
• pain intensity on exercise: nsd 
• global assessment of tolerance: nsd 
+ 
83 
+ 
65 
(+) 
58 
= 
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App. 2.3 Overview of controlled trials of complex homeopathy (cont.) 
Casper 1967 
Zell 1990 
Bohmerl992 
0: parallel 
A:. pseudorandom 
M: none 
F:20d 
S: 1 centre, Germany 
D: parallel 
A: random 
M:double 
F: 15d 
S: 1 centre, Germany 
D: parallel 
A:. random 
M:double 
F: 15d 
S: 1 centre, Germany 
Neurology & psychiatry 
Heulluy 1985 D: parallel 
A: random 
M: double 
F:30d 
McCutcheon 1996 
Dexpert 1987 
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S: 1 centre, France 
D: parallel 
A: random 
M: double 
F: 15d 
S: 1 centre, USA 
D: parallel 
A: nonrandom 
M: double 
F: missing 
S: 1 centre, France 
C: Posttraumatic swelling 
I: male inpatients; swelling with or without fracture 
E: missing 
N: 35/34 (2.86%) 
D: male, age 18-84 y 
C: Sprains 
I: upper or lower ankle sprain 
E: missing 
N: 73/69 (5.48%) 
0: 28% female, age 18-28 y 
C: Sprains and contusions 
I: 18-50 y; good general health; visible or palpable 
joint changes or injuries as result of distortion or 
contusion; outpatient; mild to medium severity of 
injury 
E: anti inflammatory or analgesic use; confirmed 
allergies; skin problem in region of injury; injury >4d 
old; injury already treated with other medication; 
multiple injuries; earlier injury in same extremity in 
previous 6 months; open wounds with risk of 
infection; none sports people 
N: 10V101 (.98%) 
D: 35% female, age 18-50 y 
C: Anxiety 
I: female; 20-ro r, depression, postmenopausal 
involution or thymo-effective dystonia 
E: use of neuroleptics, neurosedatives or 
antidepressants 
N: 60/60 (0%} 
D: female, age 20-60 y 
C:Anxiety 
I: informed consent; score 2:18 on pretest 
E: other treatments 
N: 77172 (6.49%) 
D: 65% female, age mean 36 y 
C: Motion sickness (prevention) 
I: missing 
E: missing 
N: 55/34 (38.18%) 
D: 21% female, age 9-47 y 
H: Traumeel® /? 
D: 3 x 15g/d orally+ 1 ampoule intramuscular 
C: no treatment 
H: Traumeel ointment (+electrotherapy)/ 0, 
01,3,4,6 
D: compression ointment bandage 
C: placebo ( + electrotherapy) 
H: A. Traumeel S / 0, 01,3,4,6 
B. Traumeel Sine (Traumeel S minus 6 
ingredients) 
D: 1 x 10 g on d 1 then 2 x 10 g/d until d 15 
C: placebo 
H: L72/ DI, 3,4 
D: missing 
C: OT: diazepam 2 
H: Anti-Anxiety (L72) / 01, 3, 4 
D: 3-4 x 20 drops in 3 oz water for 15 d 
C:placebo 
• d till swelling subsided: 10 vs 13 (nsd) 
• % with ~10% difference in contralateral joint 
movement at d 10: 51.5 vs 25.0 (p=0.03) 
• % with no pain on movement at dlO: 84.8 vs 36.1 
(p=0.015) 
•%reduction in swelling: A. 4.38, B. 4.68 vs 3.46 
(p=0.0067) 
• % reduction in temperature difference between 
injured and contralateral uninjured side: nsd 
• % recovery of muscle force: A. 92.3, B. 92.12 vs 
72.32 (p=0.0052) 
• % reduction in pain score: A. 61.67, B. 65.0 vs 51.67 
(p=0.0002) 
• d to resumption of training: A. 12.1, B. 12.2 vs 13.5 
(p=0.004) 
• % patient assessment of treatment as good or very 
good: 85.3, 94.0 vs 50.0 (p=0.0001) 
• patient assessment of reduction in thymo-effective 
parameters (Hamilton scale score)(%): 1.74 (74) vs 
1.5(65) 
• reduction in somatizations (Hamilton scale score) 
(%): 1.35 (59.7) vs 1.41 (63) 
• h (%) sleep gained: 1.48 (27) vs 2.0 (39) 
• reduction in pulse rate: 10 vs 10 
• reduction in state-anxiety score: 4.8 vs 6.3 (nsd) 
• reduction in trait-anxiety score: 4.9 vs 7.1 (nsd) 
• reduction in resting pulse rate: 1.5 vs 3.9 (nsd) 
• h (%) sleep gain: 1.31 (37.5) vs 0.54 (15.6) 
(p<0.05) 
H: Cocculine / C4 • n (%) good response: 9 (52.9) vs 4 (23.5) 
D: 1 dose before bed previous evening; I dose 10 min 
pretest 
C:placebo 
0 
45 
+ 
89 
+ 
96 
= 
73 
0 
83 
+ 
45 
App. 2.3 Overview of controlled trials of complex homeopathy (cont.) 
Hariveau 1992 
Ponti 1986 
Weiser 1998 
D: parallel 
A-. random 
M: double 
F:3d 
S: 1 centre, France 
D: parallel 
A-. random 
M: single 
F:2d 
S: 1 centre, 
Mediterranean Sea 
D: parallel 
A-. random 
M: double 
F:42d 
S: 15 centres, Germany 
Respiratory infections & ENT 
Schmidt 1987 D: parallel 
A-. random 
M: double 
F:4w 
S: 4 centres, Germany 
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C: Motion sickness (prevention) 
I: sailors; Beaufort scale >3 
E: missing 
N: 150/150 (0%) 
D: male, age mean 25 y 
C: Motion sickness (prevention) 
I: susceptibility to seasickness 
E: missing 
N: 93/93 (0%) 
D: 23% female, age mean 34 y 
C: Vertigo 
I: acute or chronic vertigo symptoms; ~3 vertigo 
attacks in week prior to study; vertigo intensity score 
2-4 on 5-pt scale 
E: chronic vertigo ;;:6 mon if treated in 4 w prior to 
study; vertigo from: psychovegetative disorders; 
tumour or coffee, tea, tobacco, alcohol or drug abuse; 
vertigo caused by inflammation from an underlying 
disease; myocardial infarction s6 mon prior to study; 
severe metabolic disease; gastroduodenal ulcer; 
pheochromocytoma; bronchial asthma; other vertigo 
or antiemetic medication; psychoactive drugs; 
vascular drugs during study (washout 7 d before 
study) 
N: 119/105 (11.76%) 
D: ?% female, age ? y 
C: Chronic bronchitis 
I: missing but design included 3 d washout of 
bronchospasmolytics 
E: allergic asthma; severe cardiac insufficiency; 
recent myocardial infarction; severe kidney or liver 
insufficiency; children; bedridden 
N: 32/32 (0%) 
D: 50% female, age 23-75 y 
H: Cocculine® / C4 
D: 3 x 2 doses for 3 d 
C: A. OT: dimenhydrinate 
B. placebo 
H: Cocculus + Nux-v + Tabacum / C2 
D: 2 doses on d 1 then free to repeat 
C: placebo 
H: Vertigoheel (+ betahistine hydrochloride placebo) 
I D3, 4, 6, 8 
D: 15 drops x 3/d of verum and placebo for 42 d 
C: OT: betahistine hydrochloride ( + H placebo) 
H: Asthmakhell / ? 
D: 3 x 15 drops/d 
C: OT: theophylline 
• nausea: H = OM; both better than P (p<0.05) 
• cold sweat H better than OM (p<0.05) 
• vertigo: H better than both (p<0.05) 
• drowsiness: H = P; better than OM (p<0.01) 
• visual disturbance: H = P; better than OM (p<0.01) 
• n (%) with nausea: 4 (8.6) vs 35 (74) (p<0.001) 
• n (%) with vomiting: 0 vs 9 (19.1) (p<0.001) 
• n (%) with headache: 0 vs 8 (17 .O}(p<0.001) 
• n (%) rating treatment as very good: 42 (91) vs 11 
(24) 
• n doses required on d2: 4.5 vs 7.0 (p<0.001) 
• n (%) using orthodox anti nausea treatment 
(metapimazine): 0 vs 7 (15) 
• mean % reduction in frequency of attacks: 84.1 vs 
82.5 (nsd) 
• duration (5-pt scale): 70.6 vs 66.7 (nsd) 
• intensity (5-pt scale): 73.1 vs 76.0 (nsd) 
• secondary outcomes 
1 (quality of life (SF36): equivalent improvement 
2 severity and impact (Neuro-Otologische 
Datenerfassung Claussen test): equivalent 
improvement 
• combined therapeutic effect nsd 
• % patient assessment of 'better': 75 vs 62 (nsd) 
• % increase in vital capacity: 2.9 vs 8.6 (intragroup 
p=0.3 vs 0.004) 
•%increase in FEV: 8.8 vs 12.9 (p=0.002 vs 0.001) 
• % with 'mild' rales: 75 vs 50 (p=0.39) 
• % cough better: 87 vs 50 (p=0.19) 
> 
70 
+ 
58 
= 
96 
= 
75 
App. 2.3 Overview of controlled trials of complex homeopathy (cont.) 
Demonceaux 1990 D: parallel C: Common cold H: Coryzalia /? • patient assessment of efficacy (YAS): nsd > 
A: random I: congestion or rhinopharyngeal irritation; shivering, D: 1 dose/hon d 1-> 1 dose/2 h for 4 d • % with asthenia: 47 vs 67 (p =<0.015) 49 M: none sneezing, lachrymation, weakness C: OT: I tablet norephedrine, phenyltoloxamine + • % complete recovery by d 8: 53 vs 10 (p =<0.05) 
F:8d E: missing paracetamol 4 hourly for 5 d • % dry mouth or drowsiness: <10 vs 50 (p 
S: 7 centres, France N: 60/60 (0%) =<0.001) 
D: 52% female, age 1&->65 y 
Bordes 1986 D: parallel C:Cough H: Drosetux / Cl, 3 • % reduction in cough score (total from n coughs in + 
k random I: recent or old cough D: 4 spoons/d (large or small depending on age) for 24 h, severity & pain (5-pt scale), frequency of 73 M: double E: <5 y-, organic pulmonary or pleural cause; 7d waking at night from cough): 22.7 vs 11.8 (p<0.001) 
F:8d productive cough requiring treatment of bronchial C: placebo • % patient assessment of good or very good 
S: 1 centre, F ranee secretion; antitussives in previous 2 w response: 20 (67) vs 8 (27) (p<0.01) 
N: 60/60 (0%) • % good or very good tolerance: 100 
D: 42% female, age >5 y 
Bordes 1988 D: parallel C:Cough H: Drosetux / Cl, 3 • % reduction in cough score (total from n coughs in = 
A: random I: both sexes, 6 mon--65 y-, dry cough s7 d, or older; D: 4 spoons/d (large or small depending on age) for 24 h, severity & pain score (5-pt scale), frequency of 69 M: none with or without other pathology 7d waking at night from cough): 70 vs 70 (nsd) 
F:8d E: organic pathology of heart, lungs or pleura; C: OT: reference cough syrup incl. oxomemazine and • n (%) patient global assessment of good or very 
S: 2 centres, France productive cough requiring expectorants; use of paracetamol good response: 29 (64.4) vs 30 (66.7) (nsd) 
antitussives in previous 7 d; concomitant treatments • % good or very good tolerance: 100 
affecting bronchial tubes 
N: 94/90(4.26%) 
D: ?% female, age 0.5-65 y 
Diefenbach 1997 D: parallel C: Inflammatory RT disease H: Bronchiselect I D3--6 • % patient assessment of efficacy good or very good: + 
krandom I: Acute inflammation of respiratory tract has to D: 3 x 30 drops/d 81 vs 67.8 (p =<0.02) 75 M:double include coughing with expectoration; diagnosis by C: placebo • % doctor assessment of efficacy good or very good: 
F:5.3 w mirror exam or stethoscope; condition 5.10 d 78 vs 60 (p =<0.03) 
S: 4 centres, Germany E: pneumonia, asthma, chronic bronchitis, life- • % symptom free at day 21: 91 vs 69 
threatening disease, tumours, children, pregnant • median duration in days: 9 vs 12 
women, psychiatric or neurological conditions, weak 
immune system, alcoholics, drug addicts, 
participation in any study in previous 4 w 
N: 258/238 (7.75%) 
D: 65% female, age> 16 y 
Lecocq 1985 D: parallel C: Influenza H:L52/Dl-6 • % patient preference: 93.3 vs 40 (p=<.001) + 
krandom I: missing D: 4-5 x 40 drops/d at first then 5-8 x 20 drops/d • % pain, cough, coryza, bronchial symptoms, 70 
M:double E: use of antipyretics or analgesics C: placebo antibiotic use: all significant for H (p=0.05---0.001) 
F: 10d N: 60/60 (0%) •%with temperature: 3.3 vs 10 (ns p=0.I) 
S: >I centres, France D: ?% female, age 5.40 y 
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App. 2.3 
Maiwald 1988 
Ferley 1987 
Heilmann 1994 
Torbicka 1998 
Weiser 1994 
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Overview of controlled trials of complex homeopathy (cont.) 
D: parallel 
A: random 
M:single 
F:lld 
S: 1 centre, Germany 
D: parallel 
A: random 
M: double 
F:4w 
S: 83 centres, France 
D: parallel 
A-. random 
M: double 
F:8w 
S: 1 centre, Germany 
D: parallel 
A-. random 
M: none 
F: 14 d 
S: 1 centre, Poland 
D: parallel 
A-. random 
M:double 
F: 5mon 
S: 11 centres, Germany 
C: Influenza 
I: axillary temperature >37°C + 2:3/8 subjective 
symptoms; 2: V4 pain symptoms; 2:1/4 clinical state 
E: chronic bronchitis; septic tonsillitis, >4 d from 
start of illness; recent medication; aspirin 
contraindicated; axillary temperature >39°C 
N: 170/115 (32.35%) 
D: male, age 17-49 y 
C: Influenza (prevention) 
I: Good French 
E: <5 y; immunostimulants or -depressants; antiviral; 
flu vaccination 
N: 1270/1182 (6.93%) 
D: 61 % female, age 5-95 y 
C: Influenza and common cold (prevention) 
I: healthy males 
E: missing 
N: 10V102 (0%) 
D: male, age 20-48 y 
C: Respiratory syncytial virus infection 
I: infant; confirmation of RS virus in first 2 din 
hospital 
E: missing 
N: 128/128 (0%) 
D: ?% female, age <l y 
C: Sinusitis (chronic) 
I: 2:18 r, established, chronically recurrent (not acute) 
rhinosinusitis; 2:3 episodes in previous 1 y, or 2:4 
episodes in previous 3 y, or current constant 
nasopharyngeal discharge; 2:1 subjective criterion: 
respiratory blockage, rhi norrhea, headache, sensation 
of pressure; > 1 ultrasound criterion: anterior wall 
echo, cysts, fluid 
E: tobacco users; nasoendoscopically confirmed 
polyposis; ethmoid opacity, unhealed apical 
granulomata; odontogenous sinusitis; infectious 
rhinitis; surgery in previous 6 mon; other sinusitis 
medication; medication affecting nasal mucosae; 
benzalkonium chloride allergy; in another clinical 
study in previous 4 w; females: pregnant nursing or 
insufficient contraception 
N: 104/104 (0%) 
D: 39% female, age 2:18 y 
H: Gripp-Heel / D3-12 
D: 3 x 3 tab/d for 10 d 
C: OT: acetylsalicylic acid 
H: L.52 / D1-6 
D: 3 x 25 drops/d for 4 w 
C: placebo 
H: Engystol N /? 
D: 6 injections in 3 w 
C: placebo 
H: Engystol N (+TAU)/ D4, 6, 10, 30 
D: 0.55 ml intramuscular injection/d for 7 d then /2d 
for 7 d 
C:OT:TAU 
H: Euphorbium compositum SI D2,4, 8, 10, 13 
D: 4 x 2 discharges in each nostril/d for 5 mon 
C:placebo 
• % recovered on d 4/5: 30 vs 20 (p=0.437) 
• % recovered on d 10/11: 70 vs 60 (p=0.39) 
• days off work: 11.72 vs 12.95 (nsd) 
• overall significance: p:o:;0.02 
•%incidence offlu: 6.46 vs 7.24 (nsd) 
• d duration: 6.8 vs 7 (nsd) 
• incidence of URI: nsd 
• d to 1st infection: 34 vs 19 
• d duration: 11 vs 16 
• improvement in temperature, pharyngitis, rhinitis, 
cough, dyspnea etc. on d 5, 10, 15 (5-pt Likert scale): 
favours H - d 5 (p=0.03); d 10, 15 (p=0.058) 
• 12 humoral and cellular immmunity values: nsd 
• % reduction in global symptom score (day/night 
anterior rhinoscopy and ultrasound): 21.1 vs 14.3 
(p=0.016) 
> 
86 
0 
84 
(+) 
55 
= 
60 
+ 
89 
App. 2.3 Overview of controlled trials of complex homeopathy (cont.) 
Stippig 1996 
Trapani 1994 
Surgical trauma 
Kirchhoff 1982 
Dorfman 1992 
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D: parallel 
A: random 
M:double 
F: 10d 
S: 1 centre, Germany 
0: parallel 
A: missing 
M: none 
F: 5 mon 
S: ? centres, Italy 
D: parallel 
A: nonrandom 
M: none 
F:5w 
S: I centre, Germany 
D: parallel 
A-.random 
M:double 
F:72h 
S: 1 centre, Italy 
C: Upper respiratory infections 
I: ~16 y; 1 of: rhinopharyngitis, rhinolaryngitis, 
retropharyngitis, rhinolaryngotracheitis, tracheitis, 
bronchitis, rhinobronchitis, pertussis 
E: asthma, spastic bronchitis, chronic obstructive 
bronchitis, bronchial tumour 
N: 80/80 (0%) 
0: 61% female, age ~16 y 
C: Upper respiratory infections (seasonal childhood) 
(prevention) 
I: rhinopharyngitis; pharyngotonsillitis; otitis; 
laryngitis; influenza; bronchitis 
E: missing 
N: 254/254 (0%) 
D: ?% female, age 1-13 y 
C: Lymphedema 
I: single or double mastectomy for breast cancer with 
lymph node or gland involvement; tumour class 
Tl-T3, NO-N2, MO 
E: tumour class T3 progressing to T4, N2 to N3, Ml; 
treatment-resistant hypo- and hyperkaliemia, serum 
K level >5.5 val/I; kidney problems; decompensatory 
cardiac insufficiency; medication affecting lymph 
build-up, e.g. diuretics 
N: 80/80 (0%) 
D: female, age 40-76 y 
C: Postoperative ileus (prevention) 
I: missing 
E: missing 
N: 80/80 (0%) 
D: 62% female, age 14-67 y 
H: Lomabronchin®-N-drops / 0, D4, 6 
D: ~2 y: 15 drops x 3/d; 2-6 'f. 25 drops x 3/d; ~6 'f. 
60 drops x 3/d, for 10 d or until better if sooner 
C: OT: Bromhexin hydrochloride 
H: Dolisobios 15 I C4-9 
D: 1 dose/w for 4 w then 1 dose/mon for 4 man 
C: no treatment 
H: A. Lymphomyosot / D3-6, 12 
B. Lymphomyosot ( + manual lymph drainage) 
D: 1 x 1 ml injection/d for 2 w then 3/w for 3 w 
C: OT: manual lymph drainage 
H: China CS+ Raphanus CS+ Arnica C9 
D: 2 x 20 drops/d from 1 d preop 
C:placebo 
•%cough free at d 10: 55 vs 47.5 (nsd) 
• reduction in cough intensity at d 10 (VAS): 73-> 16.5 
vs 69-> 13 (nsd) 
• % reduction infections compared with previous 
winter: 42.7 vs 22.3 
• % reduction duration of infections: 48.4 vs 16.l 
• % reduction antibiotic use: 66 vs 18 
• % global estimate 'good': 40 vs 23 (p<0.05) 
• n (%) good or very good reduction in numbness or 
burning sensation (4-pt scale): 44 (91.7) vs B. 9 (90) 
vs OM. 9(90) 
• n (%) good or very good reduction in pain: 58 (96.7) 
VS B. 10 (100); VS OM. 10 (100) 
• % very good response for all categories: 55 vs B. 
81; vs OM. 77 
• h to 1st flatus: 46.5 vs 62 (p<0.01) 
• % incidence of nausea/vomiting: 25 vs 43 
(p=0.01) 
• n incidence of medium or serious pain: 14 vs 34 
(p<0.001) 
= 
75 
+ 
40 
< 
49 
+ 
69 
App. 2.4 Overview of controlled trials of isopathy 
First author(s), year Methods Patients Treatments Results Vote 
D:design C: condition H: homeopathic medicine/ potency • clinical outcomes MQ k assignment I: inclusion criteria D: dosage, repetition 
M:masking E: exclusion criteria C: control treatment 
F: follow-up period N: number included/analysed(% attrition) 
S: setting D: demographics 
Asthma & allergy 
Reilly 1994 D: parallel C: Allergic asthma H: Individualized allergen/ C30 •%change overall symptom intensity (VAS): -7.2 vs + 
A: random I:> 16 y; asthma> 15% improvement in FEV with D: 3 x 1 dose in 24 h, once; option to represcribe at 4 +7.8 (p=0.003) 89 M: double bronchodilators; > 1 y history; atopic reactivity to w 
F: 8 w ( + 8 w optional) inhaled allergens and +ve skin test C: placebo 
S: 20+ centres, UK E: Deterioration during grass-pollen season; allergen 
avoidance in previous 6 w; previous homeopathic 
immunotherapy for asthma; respiratory infection; 
severe concomitant disease; pregnancy; 
antihistamines in past 4 w; parenteral steroids in past 
6mon 
N: 28/24 (14.29%) 
D: ?% female, age > 16 y 
Reilly 1985 D: parallel C: Allergic rhinitis H: Mixed grass pollens (12 spp.) / C30 • n (%) +ve response to treatment (patient + 
k random I: 2 y history of seasonal rhinitis; currently active D: 2 x 1 tab/d for 2 w assessment): 8/9 (88) vs 7 /14 (50) 78 M: double rhinitis with or without eye symptoms C: placebo • n (%) +ve response to treatment (doctor 
F:4w E: acute asthma or infection; pregnancy, lactation; assessment): 9/11 (82) vs 9/25 (36) 
S: 16 GPs centres, UK severe chronic illness; previous homeopathic pollen •%dropouts because of symptom severity: 9 vs 28 
or grass therapy; other homeopathic treatment 
N: 36/36 (0%) 
D: 39% female, age 12-45 y 
Reilly1986 D: parallel C: Allergic rhinitis H: Mixed grass pollens (12 spp.) / C30 •%reduction symptom intensity (VAS): 17.2 vs 2.6 + 
krandom I: >5 y; 2-y history of seasonal rhinitis+ current D: 2 x 1 tab/d for 2 w (p=0.02) 92 M:double symptoms; informed consent C: placebo •%reduction doctor assessment (VAS): 27.7 vs 12.2 
F:Sw E: eye symptom only; acute asthma or infection; (p=0.05) 
S: 2 hospital clinics+ 26 pregnancy, lactation, risk of pregnancy; serious • histamine use: 111 vs 19.7 (p=0.03) 
primary care centres, UK illness other than allergy; use of drugs other than trial 
medicine 
N: 158/144 (8.86%) 
D: ?% female, age ~Sy 
Boucinhas 1990 D: parallel C: Chronic asthma (prevention) H: Pneumo-histamine/ CS • n asthma crises(% decrease) during 2nd trimester: + 
A:. nonrandom I: missing D: 2 x 5 drops/d 0.38 (77.5) vs 1.54 (0.08) 51 M: none E: missing C: no treatment 
F:6mon N: 135/116 (14.07%) 
S: 1 centre, Brazil D: 53% female, age 2-9y 
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App. 2.4 Overview of controlled trials of isopathy (cont.) 
Dermatology 
British Homoeopathic 
Society 1943(i) 
British Homoeopathic 
Society 1943(iii) 
D: parallel 
A: random 
M: double 
F:7d 
S: 1 centre, UK 
D: parallel 
A: random 
M:double 
F: 7d 
S: 1 centre, UK 
Gynecology and obstetrics 
Kirtland 1994 D: parallel 
A: random 
M:double 
F: 6mon 
Lepaisant 1995 
Carey 1986 
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S: 1 centre, S. Africa 
D: parallel 
A: nonrandom 
M: double 
F:2mon 
S: 1 centre, Italy 
D: parallel (factorial) 
A: random 
M:double 
F:14d 
S: I centre, UK 
C: Mustard gas burns (prevention) 
I: adult male volunteers; application to forearm of a 2 
mm drop of 10% mustard gas in benzene 
E: missing 
N: 28/28 (0%) 
D: male, age 34-52 y 
C: Mustard gas burns (prevention) 
I: adult male volunteers; application to forearm of 2 
mm drop of 10% mustard gas in benzene 
E: missing 
N: ?/39(?%) 
D: male, age 20-70 y 
C: Premenstrual syndrome 
I: live in Greater Durban area; MMDQ score in 2 
successive mon 
E: other treatment for PMS 
N: 34/31 (8.82%) 
D: female, age adult 
C: Premenstrual syndrome (prevention) 
I: .?:18-g6 r, regular menstrual cycle with verified 
PMS .?:3 mon; symptom free "?:.7 d after menses; 
breast pain for .?:4 d during observational period 
E: previous serious cardiovascular, neurological, 
psychiatric, endocrine or gynecological disease; 
malign breast tumour; pregnant, lactating; ongoing 
medication; homeopathic or allopathic PMS treatment 
in previous 2 mon 
N: 45/36 (20%) 
D: female, age 18-46 y 
C: Vaginal discharge 
I: white vaginal discharge; no bacterial growth from 
high vaginal swab, or positive candida culture 
E: missing 
N: 40/40 (0%) 
D: female, age ? y 
H: Mustard gas/ C30 
D: 6 x 1 pill/2 hourly, starting immediately before 
application then 3 x 1/d for 7 d from d 2 
C: placebo 
H: Mustard gas I C30 
D: 3 x 1 dose 14 d before application 
C: placebo 
H: Folliculinum / Cl5 
D: 5 x 1 dose/d from d 14 of a 28-d or d 16 of a 31-d 
cycle until menstruation 
C: placebo 
H: Folliculinum / C9 
D: l dose on d 7, 12, 21 of menstrual cycle 
C: placebo 
H: A. Borax 
B. Candida 
C. Borax+ Candida/ C30 
D: 1 tab/d for 14 d (stopped if symptoms worse, or if 
all symptoms absent for 3 d) 
C: placebo 
• n intact skin: medium to deep lesion: 14: 2 vs 2: 14 
• n lesions superficial/medium/deep: 13/5/5 vs 
1/7 /8 (p=0.0055) 
• % patient self-assessment as improved (MMDQ, 
PAF, MC): 89 vs 7 
• n (%) doctor assessment global success (incl. 
breast tension, pain, duration): 21 (100) vs 10 (66.7) 
(p=0.0159) 
• diary record of discharge, pain, itching (3-pt scale) 
• n success: 2, 2, 4 vs 1 ( nsd) 
• success n (%) prescreened responders vs 
nonresponders: 7 /18 (39) vs V22 (9) 
+ 
62 
+ 
72 
+ 
75 
+ 
n 
(+) 
69 
App. 2.4 Overview of controlled trials of isopathy (cont.) 
Infections (misc) 
Jenaer 1990 
Castro 1975 
Metabolic disorders 
D: parallel 
A: nonrandom 
M: none 
F:2y 
S: 1 centre, Zaire 
D: cohort control 
k. nonexperimental 
M: none 
F: 6 mon 
S: > 1 centres, Brazil 
Gillespie 1994 D: parallel 
· A: random 
M: double 
F:12w 
S: 1 centre, S. Africa 
Respiratory infections & ENT 
Casanova 1984 D: parallel 
k. random 
M:double 
F:8d 
S:? centres, France 
Casanova 1988 D: parallel 
k. random 
M:double 
F:4d 
S: 27 centres, F ranee 
276 
C:HIV 
I: HIV +ve 
E: missing 
N: 39/39 (0%) 
D: 51 % female, age 2-65 y 
C: Meningitis (prevention) 
I: at risk children living in Guaratingueta, Sao Paulo 
E:na 
N:24364/24364(0%) 
D: ?% female, age :514 y 
C: Hypercholesterolemia 
I: Total cholesterol (TC) level = moderate/high risk 
for CHO; no change in lifestyle (exercise, smoking, 
diet) during trial 
E: pregnancy; surgery or myocardial infarction in 
previous 3 mon; cholesterol-lowering medication; 
high risk TC + hypertension or smoker 
N:3V32(0%) 
D: ?% female, age adults 
C: Influenza 
I: <48 h from first appearance of symptoms 
E: Use of antibiotics and antiinflammatories 
N: 100/100 (0%) 
D: 55% female, age mean 42 y 
C: Influenza 
I: missing 
E: missing 
N: 300/300 (0%) 
D: 61 % female, age > 18 y 
H: RNA, DNA, cyclosporin, anti-CD4 / C~9, 30 
D: 1 capsule/d for 90 d 
C: no treatment 
H: Meningococcinum / ClO 
D: 1 drop per os 
C: no treatment 
H: Cholesterolinum / C9 
D: 2 x 1 dose/d 
C: placebo 
H: Oscillococcinurn® / C200 (K) 
D: 4 x I dose/d for 2 d 
C: placebo 
H: Oscillococcinurn® / C200 (K) 
D: 2 x I dose for 3--4 d u nti I better 
C: placebo 
• frequency diarrhea lasting >2 mon (% total 
consultations): 7 vs 41 
• frequency fever: 8 vs 15 
• frequency infections: 24 vs 49 
• kg weight change: + 1 vs -14 
• % T4 lymphocyte increase: 186 vs 5 
• T4/T8 ratio% increase: 34 vs 28 
• n (%) notified incidence of meningitis: 7 (0.039) vs 
10 (0.157) [p=0.0021] 
• mmol/1 (%) reduction in total cholesterol (TC): 
0.377 (5.7) vs 0.118 (2) (intragroup p=0.004 vs nsd) 
• n with TC reduction: increase: 13:3 vs 11:5 
• increase in HDLC: LDLC ratio: nsd 
• n (%) global success (reduction in fever, cough 
etc): 40 (80) vs 19 (38) (p=<0.001) 
• temperature reduction: highly sig from d 2 
• shivering stopped on d 4 %: 55 vs 26.5 (p=<0.001) 
• myalgia stopped on d 4 %: 78 vs 48 (p=<0.001) 
+ 
53 
+ 
51 
(+) 
77 
+ 
66 
+ 
JI 
App. 2.4 Overview of controlled trials of isopathy (cont.) 
Ferley 1989 D: parallel C: Influenza H: Oscillococcinum® / C200 (K) •%recovery at48h: 17.l vs 10.3 (p=0.03) + 
A: random I: > 12 y, during epidemic: rectal temperature D: 2 x 1 dose/ d for 5 d • % use of OM for pain or fever: 40.7 vs 50.2 85 M:double >37 .5°C plus~ of: headache, stiffness, lumbar and C: placebo (p=0.04) 
F:7d articular pain, shivers • % patient preference: 61.2 vs 49.3 (p=0.02) 
S: multicentric, France E: immunodeficiency; local infection; flu vaccination; 
treatment with immunodepressants or -stimulants 
N: 478/ 462 (3.35%) 
D: ?% female, age > 12 y 
Papp 1998 D: parallel C: Influenza H: Oscillococcinum® / C200 (K) • n (%) symptom-free at 48 h: 32 (19.2) vs 25 (15.0) + 
A: random I: consult for influenza-like syndrome; infection $24 h D: 3 doses/d for 3 d (p=0.0028) 92 M: double before entry; rectal temperature ~38°C; muscle pain; C: placebo • n (%) clear improvement at 48 h: 73 ( 43.7) vs 56 
F:7d headache; ~1 of: shivering, thoracic, periarticular or (33.5) 
S: 15-20 centres, spinal pain, cough, irritated nasal mucosa, general • time to elimination of symptoms: p=0.023 
Germany feeling of illness 
E: <12 or >60 y; requiring preventive anti-flu 
treatment in 1st 48 h of study; immune system 
disorders; local infections; previous immunization 
against flu; additional immunosuppressant or 
immunostimulant therapy; use of antiinfluenzal 
medicines, analgesics or antibiotics in 1st 48 h of trial 
N: 37V334 (10.22%) 
D: 49% female, age mean 35 y 
Attena 1995 D: parallel C: Influenza (prevention) H: Oscillococcinum (not®)/ C200 (K) •Incidence%: 21.6 vs 23.5 (ns p = 0.38) (-) 
A: random I: missing D: 1 dose/w for 3 w; I dose 4 w later 62 M: double E: missing C: placebo 
F:>6w N: 1595/1573 (1.38%) 
S: multicentric, Italy D: 51% female, age? y 
Bungetzianu 1988 D: parallel C: Influenza (prevention) H: Influenza vaccine/ Cl5 • incidence of flu or CNSLD or bronchospasm: H vs = 
A:. missing I: missing D: missing OM nsd 31 M: none E: missing C: A. OT:lnfluenza vaccine • ORL reactivation: H+ vs OM-
F:? N: 52V522 (0%) 8. placebo • lgA, lgG % increase (95 H cases only): 42.1, 20.9 
S: ? centres, Romania D: ?% female, age? y • lg[, lgD % decrease (95 H cases only): 77.9 
Davies 1971 D: parallel C: Influenza (prevention) H: lnfluenzinum I C30 • incidence of flu: 6/16 vs 7 /13 (p=0.0554) (+) 
A:. random I: missing D: I dose/2 w for 6 w 60 M:double E: missing C: placebo 
F:3 mon N: 36/29 (19.44%) 
S: 1 centre, UK D: ?% female, age ? y 
Masciello 1985 D: historical control C: Influenza (prevention) H: Oscillococcinurn® I C200 (K) • n (%) with flu symptoms: 5 (10.86) vs 487 (36.75) + 
A:. random I: male; ~55 y-, good health D: I dose/w for 12 w [p<0.001] 38 M: none E: missing C: no treatment 
F:12w N: 1376/1371 (.36%) 
S: I centre, Iran D: male, age 2~55 y 
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App. 2.4 Overview of controlled trials of isopathy (cont.) 
Nollevaux 1991 D: parallel C: Influenza (prevention) H: Mucococcinum / C200 (K) • % incidence: 12.l vs 30.4 (p<0.005) + 
k. nonrandom I: missing D: 1 dose/2w 74 M: double E: flu vaccination; cortisone; immunosuppressants; C: placebo 
F:? tricyclic antidepressants; MAO inhibitors; AIDS; 
S: 1 centre, Netherlands lupus; severe collagen disease 
N: 200/191 (4.5%) 
D: 65% female, age > 18 y 
Rottey 1995 D: parallel C: Influenza (prevention) H: Mucococcinum / C200 (K) • n reported flu symptoms: 1.69 vs 2.04 (p=0.01) + 
A-. random I: missing D: 1 dose/w for 12 w • % reporting no fever, muscle pain or headache: 71 M:double E: flu vaccination C: placebo 90.93 vs 84.4 (p=0.05) 
F: 12 w? N: ? /501 (?%) • doctors' assessment (10-pt scale): 8.07 vs 7.01 
S: 40 centres, Belgium D: 56% female, age 1-88 y (p=0.001) 
Hunin 1991 D: parallel C: Rhinopharyngitis (recurrent childhood) H: Thymulin (+ TAU as required)/ C7, 9 • n rhinopharyngitis episodes, episodes with fever, = 
k. random (prevention) D: 1 dose/w for 4 w -> 1/2 w for 4 mon (C7 <2 y; complications: nsd 59 M: none I: 1-6 y; routine visit or recurrent ENT infection C9>2y) • duration of episodes and antibiotic use: trend in 
F: 6mon E: at risk; severe i II ness C: OT: reference immunostimulant containing favour of H 
S: 1 centre, F ranee N: ?/88(?%) glycoproteins with or without ribosomal fractions • % incidence of otitis media: 26 vs 35 
D: 42% female, age <6 y (usually Ribomunyl); TAU as required • % incidence of specialist ENT consultations: 18 vs 
31 
Hourst 1981 D: parallel C: Upper respiratory infections (prevention) H: MRV vaccine (stallergene Merieux) / Cl5; • illness score(%) reduction (6-pt scale): 0.84 ( 431) (+) 
A-. random I: 3 mon-1 y; attend creche ~3 d/w; remain at creche Pneumo-histamine/ C15; Thuja / C9 VS 0.77 (33.3) 74 M:double 3mon D: MRV 10 drops/w; P-h 10 drops/d for 15 d; T 10 
F: 1 mon E: continued absence ~15 d; previous use of drops/ct for 15 d 
S: 1 centre, France homeopathy C:placebo 
N: 41/41 (0%) 
D: ?% female, age 0.25--4 y 
Surgical trauma 
Valero 198l(iii) D: parallel C: Postoperative infection (prevention) H: Pyrogenium / Cl • n (%) infections: 15 (27.7) vs 20 (27.0) (nsd) 0 
A: random I: any surgical patient undergoing general anesthesia D: 1 dose 24 h preop 75 M:double E: preventive treatment for ileus; children; senile or C: placebo 
F: missing psychiatric patients; hernia operations; lacking good 
S: 1 centre, France spoken French 
N: 161/128 (20.5%) 
D: ?% female, age ? y 
Valero 1981(iv) D: parallel C: Postoperative infection (prevention) H: Pyrogenium / C7 • n (%) infections: 2 (10.5) vs 5 (21.7) (+) 
A: random I: any surgical patient undergoing general anesthesia D: 1 dose 24 h preop 65 M:double E: children; senile or psychiatric patients; hernia C: placebo 
F: missing operations; lacking good spoken French 
S: 1 centre, F ranee N: 49/42 (14.29%) 
D: ?% female, age ? y 
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App. 3 Trials (n = 56) reporting adverse reactions in homeopathy or control groups 
First author, year 
Andrade 1991 
Attena 1995 
Aulagnier 1985 
Beer 1995 
Bourgois 1984 
Bungetzianu 1988 
Casa nova 1984 
Chakravarty 1977 
Chapman 1997 
Davies 1971 
de Lange-de Klerk 1993 
Demonceaux 1990 
Diefenbach 1997 
Felisi 1994 
Ferley 1987 
Fisher 1986 
Friese 1997 
Friese, Kruse 1997 
Gerhard, Reimers 1993 
Gibson 1978 
Hadjikostas 1990?b 
Hariveau 1992 
Hart 1997 
Heulluy 1985 
Hofmeyr 1990 
Hunin 1991 
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Homeopathy Control treatment 
Classical Placebo (TAU allowed) 
lsopathy 
Clinical 
Complex 
Clinical 
lsopathy 
lsopathy 
Classical 
Classical 
lsopathy 
Classical 
Complex 
Complex 
Clinical 
Complex 
Classical 
Clinical 
Classical 
Classical 
Classical 
Classical 
Complex 
--
Clinical 
Complex 
Clinical 
lsopathy 
Placebo 
Placebo 
OT: estrogen replacement 
Placebo 
A. OT: Influenza vaccine; 
B. Placebo 
Placebo 
No treatment 
Placebo 
Placebo 
Placebo ( + dietary advice) (TAU as required) 
OT: I tablet norephedrine, phenyltoloxamine + paracetamol 4 hourly for 5 d 
Placebo 
Placebo 
Placebo 
Placebo 
Placebo 
OT: antibiotics, secretolytics, antipyretics, nasal decongestants 
OT: Al, HRT, IVF as required 
A. OT: aspirin; 
B. Placebo 
OT: surgery ( + chemo- + radiotherapy) 
A. OT: dimenhydrinate; 
B. Placebo 
Placebo 
OT: diazepam 2 
Placebo 
OT: reference immunostimulant containing glycoproteins with or without 
ribosomal fractions (usually Ribomunyl) + TAU as required 
Reported adverse reactions 
scarce and comparable in both groups, e.g. headache, anorexia, diuiness; mild and transient 
% side-effects within 12 h: 9.8 vs 2.1 (RR 4.6); H: myalgia, low grade fever, rhinorrhea etc vs P: diuiness, GI 
[pathogenesis?] 
H: 3 x digestive intolerance 
H: none found; OT: significant weight gain (p = 0.001) 
few, insignificant: skin eruptions (n = 2) 
H = P: none found; vaccine 3-3.5 times more [than none?] 
included in outcomes: aggravations looked for, but too few to analyse 
H: acute exacerbations, return of old symptoms in 40% 
few in either group 
Ix cold symptom after 1st dose 
H: 13.9% vs P: 15.5% 
included in outcomes:% dry mouth or drowsiness: H: <10 vs OT: 50 (p = <0.001) 
included in outcomes: n (%) poor tolerance: H 2 (1.6): P: 4 (3.5) 
H: I x aggravation of menopausal symptoms 
similar in both groups: 3.4% 
H: none found; P: disturbed sleep 
scarcely any in either group: mild stomach ache H x 1 vs P x 1 
no serious side-effects in either group; OT: diarrhea, stomach pain 
H: IO% with transient skin symptoms vs OT: 29% worse than before trial; many adverse effects 
included in outcomes: H: none found vs OT: 16 (39%) vs P: none found 
H: 5% dropout from aggravations 
included in outcomes: drowsiness: H = P; H better than OM (p<0.01) 
included in outcomes: H pain score higher on d 2 (nsd) [pathogenesis?] 
included in outcomes: drowsiness n H: I vs OT: 2 
included in outcomes: trend for worse results in 030 group; significantly worse for happiness and treatment 
satisfaction [pathogenesis?] 
H: higher incidence of URI at beginning of treatment 
App. 3 Trials (n = 56) reporting adverse reactions in homeopathy or control groups (cont.) 
Kaziro 1984 Clinical 
Kumar1994 Classical 
Lasserre 1986 Complex 
Lecocq 1985 Complex 
Lievre 1992 Clinical 
Lokken 1995 Classical 
Maiwald 1988 Complex 
Nahler 1996 Complex 
Nusche 1998 Classical 
Owen 1990 Classical 
Papp 1998 lsopathy 
Rahlfs 1978 Clinical 
Reilly 1985 lsopathy 
Reillyl986 lsopathy 
Reilly 1994 lsopathy 
Schmidt 1987 Complex 
Schwabl99<Xi) Classical 
Schwab 199(Xii) Classical 
Shipley 1983 Clinical 
Singh 1994 Clinical 
Straumsheim 1997 Classical 
Tsiakopoulos 1988 Classical 
Ventoskovsky 1990 Clinical 
Villatoro Cadena 1991 Classical 
Walach 1997 Classical 
Weiser1994 Complex 
Weiser 1998 Complex 
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A. OT: metronidazole; 
B. Placebo 
Placebo 
Placebo 
Placebo 
A.OT: Elase® 
B. Placebo: vaseline excipient 
Placebo 
OT: acetylsalicylic acid 
OT: hyaluronic acid 
OT: penicillin V 1000001.E./kg/d for 10 d 
OT: dicyclomine hydrochloride + fecal bulking agents + diet advice sheets 
Placebo 
Placebo 
Placebo 
Placebo 
Placebo 
OT: theophylline 
Placebo 
Placebo 
A. OT: fenuprofen; 
B. Placebo 
Placebo 
Placebo 
OT: dimenhydrinate 4 x 50 mg/d for 60 d 
OT: synestrol, galascorbine and glutamic acid; thiamine and pyridoxine; 
calcium chloride; linetol; glutathione; 
Placebo ( + ORT) 
Placebo 
Placebo 
OT: betahistine hydrochloride+ H: Placebo (double dummy) 
included in outcomes: H worse than P for pain (p<0.05) and edema (p<0.01) [pathogenesis?) 
ratio of episodes of filarial fever: H: 2 vs P: 1 [aggravation?) 
H: 1 x Gelsemium-type trembling and exhaustion [pathogenesis?] 
P: I x gastralgia (from aspirin) 
included in outcomes: n (%) with no pain due to treatment: H: 32 (60.37) vs OT: 11 (21.15) (p = 0.002) vs P: 
23 (46.0) 
included in outcomes: nsd 
H: 3% vs OT: 7% 
local inflammation, itching n: H: 6 vs P: 13 (p = 0.079) 
H: none found; OT: increased proteinuria (p = 0.034) 
H: 18% with transient aggravations 
5 x side-effects reported: doctors felt only 1 headache could be attributed to medication 
mild aggravations and return of old symptoms in both groups 
H: initial aggravation 
initial aggravations: H x 21 vs P x 11 (p<0.05) 
initial aggravations: H x 1 vs P x 2 
H: 1 x headache vs OT: 1 x mild agitation for 14 d; 1 x severe vomiting for 3 d then broke off treatment 
included in outcomes: n aggravations: H: 4/5 vs P: O; n return of suppressed old symptoms: H: V5 vs P: O; n 
appearance of novel proving symptoms: H: 1/5 vs P: 0 
included in outcomes: n aggravations: H: 6/7 vs P: O; n appearance of novel proving symptoms: H: 4/7 vs P: O 
H: 5 x aggravations of symptoms vs OT: GI disturbance 
H: none found; P: 2 x minor effects 
initial aggravations: H: 17 vs P: 20 
H: none found; OT: 7 x diarrhea; 13 x drowsiness 
H: none found; OM allergic reactions: 2 x synestrol; 4 x B vitamins; 3 x nausea and diarrhea from linetol 
% saccharine intolerance: H: 1 vs OT: 10 
H: aggravations (n = ?) 
H: 1 x local irritation, 1 x drowsiness and agitation vs P: 1 x herpes zoster 
% probably drug-caused: H: 3.4 vs OT: 1.7 
App. 3 Trials (n = 56) reporting adverse reactions in homeopathy or control groups (cont.) 
Whitmarsh 1997 Classical Placebo H:xlvsP:x3 
Wiesenauer 1983 Clinical Placebo H: none found; P: mild only 
Wiesenauer 1995 Clinical Placebo H: none found; P: 1 x nausea 
Key: H = homeopathy; P = placebo; OT= orthodox treatment; TAU= treatment as usual 
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App. 4 Methodological quality (MQ) and clinical relevance (CR) scores of prospective controlled trials of homeopathy 
First author(s), year 1 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 MQ% Kl Li Cl C2 C3 C4 CS CG C7 CR~ 
Abelson 1996 15 2 1 2 2 2 0 x 2 2 2 0 0 2 0 x 2 2 2 x 2 2 82 ni ni 2 2 2 2 2 0 2 86 
Albertini 1985 15 l 2 2 2 2 0 X 0 0 2 0 0 0 0 0 2 2 2 X 2 2 68 38 ni 2 2 2 2 0 0 2 71 
Alibeu 1990 15 2 1 1 2 2 0 X 0 2 2 0 X X 0 X O 0 2 2 2 1 69 23 57 2 2 2 2 0 2 79 
Amodeo 1987 12 2 1 2 2 0 X X 2 2 1 0 0 0 0 0 0 0 X 2 2 57 35 43 2 2 2 2 2 0 2 86 
Andrade 1991 15 2 2 2 2 2 0 X 2 2 2 0 0 0 0 0 2 2 1 2 1 73 ni 79 2 2 2 0 2 0 2 71 
Anonymous 1980 interim rep_ort 13 ni 
Atmadiian 1988 12 1 2 0 2 2 0 X X 2 2 0 0 0 0 0 2 2 0 X 2 2 61 ni ni 2 2 0 0 0 1 43 
Attena 1995 15 2 2 0 1 0 X 2 2 2 0 0 0 0 0 1 0 2 1 1 2 62 ni ni 2 2 0 2 0 1 57 
Aula_gnier 1985 15 2 2 1 2 2 0 X O 2 2 0 2 2 0 X 1 1 2 X 2 2 78 75 64 2 2 2 2 0 2 79 
Awd!J.1996 15 2 2 2 2 2 0 X 2 2 2 0 0 0 X 0 0 0 0 2 2 2 70 ni ni 2 2 2 2 0 1 2 79 
Bakshi1990 12 0 1 0 2 2 0 X O 2 2 0 0 0 0 0 0 0 0 2 0 0 42 ni ni 2 2 2 2 0 0 2 71 
Basu 1980 12 2 1 2 2 2 0 X X 0 0 1 2 2 0 X 0 0 0 X 2 2 61 35 ni 2 2 2 2 0 0 2 71 
Basu 1981 12 2 1 2 2 2 0 X X 0 0 1 2 2 0 X 0 0 0 X 2 2 61 ni ni 2 2 2 2 0 0 2 71 
Beer 1995 15 2 1 0 2 2 0 X O X X 0 0 0 0 X 2 2 2 0 2 63 ni ni 2 2 2 2 1 0 2 79 
Bendre 1980 12 2 2 1 2 2 2 2 X 0 0 2 0 0 0 0 X 2 2 2 X 2 69 ni ni 2 2 2 2 0 0 2 71 
Bi_g_namini 1987 15 2 2 2 2 2 0 X 2 2 2 2 2 2 0 0 1 0 2 2 2 82 58 ni 2 2 2 2 0 2 79 
Bi_g_namini 1991 15 2 2 0 2 2 0 X 0 2 2 2 0 0 0 0 2 2 2 X 2 72 ni 64 2 2 2 2 0 2 79 
Bohmer1992 15 2 2 2 2 2 0 X 2 2 2 2 2 2 X X 2 2 2 X 2 2 96 ni 100 2 2 2 2 2 1 2 93 
Bordes 1986 15 2 2 1 0 X 1 2 2 0 1 1 0 x 2 2 2 X 1 73 70 57 2 1 2 2 0 2 71 
Bordes 1988 15 2 2 2 2 2 0 X 0 X X 0 1 0 0 X 2 2 0 1 1 2 69 ni ni 2 2 2 2 2 0 2 86 
Bouchez 1988 15 1 2 2 2 0 X 1 1 1 0 2 2 1 0 2 2 2 2 2 2 78 ni ni 0 2 2 0 0 0 1 36 
Boucinhas 1990 12 2 1 1 1 0 X X 0 X 0 0 0 0 0 2 2 0 1 2 51 ni ni 2 1 1 2 0 0 1 50 
Bour_g_ois 1984 12 2 2 2 2 2 1 0 x 2 2 0 0 0 0 X 2 2 2 2 2 2 74 ni 36 2 2 2 2 2 1 2 93 
Bri_go 1991 15 2 2 2 2 2 0 X 2 2 2 0 2 2 0 X 2 2 X 2 2 86 68 79 2 2 2 2 0 0 2 71 
British Hom. Society 1943(i) 15 2 1 1 2 2 0 X 1 2 2 0 1 0 0 X 0 0 0 0 2 2 62 ni 64 2 2 2 2 0 1 2 79 
British Hom. Society 1943(ii) 15 2 1 1 2 2 0 X 2 2 2 0 0 0 0 0 2 2 0 2 2 69 ni 57 2 2 2 2 0 1 2 79 
British Hom. Society 1943(iii) 15 2 1 1 2 2 0 X 2 2 2 0 0 0 0 X 2 2 0 2 2 72 ni 57 2 2 2 2 0 1 2 79 
British Hom. Society 1943(iv) 15 2 1 1 2 2 0 X 2 2 2 0 0 0 0 0 1 2 2 0 2 2 69 ni 57 2 2 2 2 0 1 2 79 
Bun_g_etzianu 1988 12 0 0 0 1 1 0 X X 0 1 0 0 X 0 0 0 0 0 0 0 1 31 0 ni 0 0 2 1 0 0 29 
Campbell 1976(i) 15 2 1 0 2 2 0 X 0 2 2 0 I O 0 0 0 0 0 2 2 2 60 38 36 1 2 2 0 0 0 2 50 
Carey1986 15 1 1 2 2 2 0 X 2 2 2 0 X X 0 0 0 0 0 2 2 2 69 35 57 2 2 2 1 0 0 2 64 
Carlini 1987 15 2 1 2 2 0 X 2 2 2 0 0 0 0 0 2 2 2 2 1 71 45 ni 2 2 2 0 0 2 2 71 
Casanova 1981 15 1 1 2 2 2 0 X 0 0 1 0 1 0 0 0 1 2 2 X 1 0 58 45 29 1 1 2 0 0 2 50 
Casanova 1984 15 1 1 2 1 1 0 X 0 2 2 0 1 0 0 0 2 2 2 X 2 66 ni ni 1 1 2 2 0 2 64 
Casanova 1988 15 1 1 0 1 0 X 0 1 1 0 0 0 0 0 2 2 2 X 1 2 57 ni 57 1 1 2 0 0 1 43 
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App. 4 Methodological quality (MQ) and clinical relevance (CR) scores of prospective controlled trials of homeopathy (cont.) 
First author(s), year 1 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 MQ% Kl Li Cl C2 C3 C4 C5 CG C7 c~ 
Cas~r 1967 12 2 1 1 2 2 0 x x O O O O O O O O O O 1 2 1 45 28 ni 2 2 2 1 1 0 2 71 
Castelain 1979 12 2 1 1 1 1 0 X X 0 0 0 0 0 0 0 0 0 0 X 0 1 37 20 7 1 1 1 1 0 0 1 36 
Castro 1975 9 2 1 1 1 1 0 x X X X O O 1 0 X 1 2 2 X 1 1 51 13 ni 2 2 2 1 0 0 2 64 
Chakrava_r:!y 19TT 12 2 1 1 2 2 0 X X 0 X O O O O O O O O 1 0 1 43 38 ni 2 2 2 2 2 86 
Chap_man 1997 conference abstract ni ni 
Chevrel 1984 15 2 2 0 2 2 0 X 0 2 2 0 0 0 0 2 1 2 X 2 2 70 58 71 1 2 2 2 0 0 57 
Chirila 1990 12 2 1 0 2 2 0 X X 2 2 0 0 0 0 0 0 0 0 0 0 45 ni ni 2 2 2 0 0 2 64 
Davies 1971 15 0 1 0 1 1 0 X 0 2 2 0 0 0 0 0 2 2 2 2 2 60 35 29 0 1 0 2 43 
de lan_@_-de Klerk 1993 15 2 2 2 2 2 0 X 2 2 2 0 2 2 2 0 2 2 2 2 2 87 ni 100 2 2 2 1 2 2 2 93 
De~illaume 1981 15 2 2 I 2 2 0 X 2 2 2 0 0 0 1 X 2 2 2 X 2 2 80 45 64 2 2 2 2 0 1 2 79 
Demonceaux 1990 15 2 I 1 1 1 0 X 0 X X O 0 0 0 0 1 0 0 1 49 ni ni 2 1 2 2 0 2 71 
Dex~rt1987 12 1 1 0 1 1 0 X X 2 2 0 0 0 0 X 0 0 0 1 45 25 29 2 0 0 2 2 0 1 50 
Diefenbach 1997 15 2 1 2 1 1 0 X 1 2 2 1 1 2 0 0 2 2 2 2 75 ni ni 2 1 1 2 2 1 2 79 
Dorfman 1992 12 2 1 1 2 2 0 X X 2 2 0 2 0 Q X 2 2 2 X 0 2 69 ni 36 2 2 2 2 0 2 79 
Eid 1993 9 2 2 2 2 2 0 X 0 x O 1 1 0 x 2 2 2 2 2 2 67 ni ni 2 2 2 I 2 2 86 
Eid 1994 15 2 2 2 2 2 0 X 2 2 2 0 2 0 Q X 2 2 2 2 2 2 85 ni ni 2 2 2 2 0 0 2 71 
Ernst 1990 15 2 2 2 2 2 0 X 0 2 2 2 X X Q 0 2 2 2 X 1 2 82 ni 71 2 2 2 2 2 0 1 79 
Estragnin 1979(ii) 15 2 1 1 2 2 0 X 2 2 0 0 0 2 0 0 0 0 X 2 2 64 48 43 1 2 2 0 0 1 2 57 
Felisi 1994 15 2 I 2 2 2 0 X 0 0 2 0 1 1 0 0 2 2 2 2 2 1 71 ni ni 2 2 2 2 0 2 79 
Ferley 1987 15 2 2 2 2 2 0 X 2 2 2 0 1 0 2 1 2 2 1 2 2 2 84 68 79 2 2 0 2 0 2 64 
Ferleyl989 15 2 2 2 2 2 0 X 2 2 2 0 2 2 0 0 2 2 2 2 2 2 85 88 79 2 2 2 2 0 0 2 71 
Fisher 1986 15 2 1 1 2 2 0 X 0 2 2 0 0 0 X 0 2 2 2 2 0 1 68 38 ni 2 2 2 2 0 2 79 
Fisher 1989 15 2 2 1 2 2 0 X 2 2 2 0 1 Q X 2 2 2 X 1 1 78 45 71 2 2 2 2 0 0 2 71 
Freitas 1995 15 2 2 2 2 2 0 X 2 2 2 0 0 0 0 2 2 2 2 2 2 80 ni 79 2 2 2 0 0 0 2 57 
Friese 1997 15 2 2 2 2 2 0 X 2 2 2 0 0 2 2 2 2 2 2 84 ni ni 2 1 1 2 2 2 79 
Friese. Kruse 1997 12 2 1 2 2 2 0 X X 0 X O 2 0 0 X 2 2 2 2 2 2 71 ni ni 2 1 2 1 2 2 79 
Gassinger 1981 15 2 2 2 2 2 0 X 2 0 X 0 I 2 0 X 2 2 0 0 2 2 75 58 ni 1 2 0 2 2 64 
Gaucher 1994 15 2 1 1 1 1 0 X 0 2 2 0 0 0 0 0 2 1 0 2 58 ni ni 2 2 2 0 0 0 2 57 
Gauthier 1983 15 2 1 2 2 2 0 X 1 2 2 0 l O 0 2 2 2 2 2 2 78 53 50 2 2 2 1 2 79 
Gerhard, Reimers 1993 12 2 2 2 2 2 0 X X X X 0 1 0 0 0 0 0 0 X 2 2 57 ni ni 2 1 2 0 2 64 
Gibson 1978 12 2 1 2 2 2 0 X X 0 1 0 0 0 X 0 2 2 2 2 2 1 65 33 ni 2 2 2 2 0 71 
Gibson 1980 12 2 2 2 2 0 X X 2 2 0 0 0 0 X 2 2 2 2 2 2 73 40 64 2 2 2 2 2 0 2 86 
Gibson 1991 15 2 1 2 2 2 0 X 0 2 2 0 0 0 0 0 1 2 0 1 1 1 62 ni ni 2 1 1 0 2 2 64 
Gillesp_ie 1994 15 2 1 2 2 2 0 X 2 2 2 0 2 0 0 0 2 2 2 X 2 1 77 ni ni 2 2 2 1 0 1 2 71 
Grecho 1989 15 2 2 2 2 2 0 X 2 2 2 2 2 2 2 0 2 2 2 X 2 2 92 90 86 2 2 0 0 2 2 64 
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App. 4 Methodological quality (MQ) and clinical relevance (CR) scores of prospective controlled trials of homeopathy (cont.) 
Firstauthor(s), year 1 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 MQ% Kl Li Cl C2 C3 C4 C5 C6 C7 c~ 
Hadiikostas 1988 12 2 I 2 2 2 0 x x I 2 0 0 0 0 x I 2 1 x 1 1 61 ni ni 2 2 2 2 0 0 2 71 
Hadiikostas 1990?a 12 2 1 1 2 1 0 X X X X O 1 0 0 0 2 2 2 1 2 61 ni ni 2 2 2 2 0 0 1 64 
Hadiikostas 1990?b 12 2 1 2 2 2 0 X X X X O 2 2 0 0 0 0 2 2 2 65 ni ni 2 2 2 2 0 2 79 
Hariveau 1991 15 2 2 1 2 2 0 X 0 2 2 0 0 0 0 X 2 2 2 X 2 2 75 ni 43 2 2 2 2 0 0 1 64 
Hariveau 1992 15 2 2 1 2 2 0 X 0 2 2 Q X X 0 X O 0 2 X 2 70 ni ni 2 2 2 2 2 0 2 86 
Hart 1997 15 2 1 1 2 2 0 X 2 2 2 2 2 2 0 0 2 2 2 2 2 1 84 ni ni 2 2 2 0 2 0 2 71 
Heilmann 1994 15 2 1 0 1 1 0 X 0 2 2 0 1 X 0 0 0 0 0 X 2 1 55 ni 43 1 0 0 0 2 36 
Heulluy 1985 15 2 1 2 2 2 0 X 0 X X O 2 0 0 0 2 2 2 X 2 2 73 45 ni 2 2 2 2 2 0 2 86 
Hill 1995 15 2 1 2 1 1 0 X 2 2 2 2 2 2 0 0 2 2 2 2 2 2 84 ni ni 1 2 2 2 0 2 2 79 
Hill 1996 15 2 2 2 2 2 0 X 2 2 2 2 1 1 0 0 2 2 2 2 2 2 85 ni ni 1 2 2 2 2 2 86 
Hitzenberger 1982 15 2 1 2 2 2 0 X 2 2 2 0 1 1 0 0 2 2 2 X 2 2 79 48 ni 2 0 0 0 0 2 36 
Hochstetter 1966 12 2 1 0 1 1 0 X X O O O O O 0 X O 0 0 X 2 41 ni ni 2 2 1 2 2 0 2 79 
Hof me}! 1990 15 2 2 1 2 2 0 X 2 2 2 0 X X X 0 2 2 2 2 2 2 86 ni 100 2 2 2 0 2 2 2 86 
Hourst 1981 15 2 1 1 2 2 0 X 2 2 2 0 0 0 X X X X X X 1 2 74 28 71 2 2 2 2 2 2 93 
Hunin 1991 15 1 2 2 1 1 0 X 0 0 X O 1 0 0 X 2 2 0 0 1 2 59 ni ni 2 1 2 2 0 2 71 
Jacobs 1993 15 2 2 2 2 2 0 X 2 2 2 0 2 2 0 0 2 2 2 1 2 2 84 ni 64 2 2 2 2 0 0 2 71 
Jacobs 1994 15 2 2 2 2 2 0 X 2 2 2 0 2 2 2 X 2 2 2 1 2 2 91 ni 86 2 2 2 2 1 2 86 
Jacobs 1997 conference abstract ni ni 
Jenaer 1990 12 2 1 0 2 2 0 X X 0 0 0 0 0 X X 1 1 0 X 2 2 53 ni ni 2 2 2 2 0 71 
Josegh 1994 15 2 2 2 2 2 0 X 2 2 2 0 2 0 0 0 2 2 2 1 2 2 80 ni ni 2 2 2 2 2 86 
Kainzl996 15 2 1 2 2 2 0 X 2 2 2 0 0 0 0 0 2 2 2 2 2 2 76 ni ni 1 2 2 0 0 0 2 50 
Kaziro 1984 15 2 2 0 2 2 0 X 0 2 2 0 0 0 0 0 2 2 2 X 2 2 70 ni 50 2 2 2 0 2 0 2 71 
Kennedy 1971 15 2 2 0 2 2 0 X 2 2 2 0 2 2 X 0 0 0 0 X 2 2 73 ni 57 2 2 2 0 0 0 2 57 
Khan 1976 12 0 1 0 1 1 0 X X X X O X X O 0 0 0 0 X 0 2 40 0 ni 2 0 0 2 0 0 36 
Khan 1985 12 2 1 2 2 0 X X 0 2 0 0 0 X X 0 0 0 X 2 1 53 15 ni 2 2 2 2 0 2 79 
Khan 1986 12 2 1 2 2 2 0 X 0 0 2 2 0 0 0 X 1 2 2 0 2 2 64 ni ni 2 2 2 2 2 1 2 93 
Khan 1996 15 2 2 1 2 2 2 0 2 2 2 0 1 0 0 X 2 2 X 2 n ni ni 2 2 2 2 2 2 2 100 
Khan, Potter 1996 15 2 2 2 2 2 1 0 2 2 2 1 0 0 0 X I 2 2 X 2 n ni ni 2 2 2 2 0 0 2 71 
Kirchhoff 1982 12 2 1 2 2 2 0 X X 0 0 0 I 0 0 0 0 0 0 X 2 1 49 33 ni 2 0 2 0 2 57 
Kirtland 1994 15 2 2 2 2 2 0 X 2 2 2 0 0 0 0 0 2 2 1 2 2 75 ni ni 2 2 2 2 0 2 79 
Kivelou 1990 12 1 1 1 1 1 0 X X X X O 0 0 0 X 1 0 2 2 1 51 ni ni 2 1 1 2 0 0 50 
Kulkarni 1988 15 2 2 0 1 1 0 X 0 0 2 0 X X O X 0 0 0 X 2 55 ni ni 2 1 2 0 0 50 
Kumarl994 12 2 1 1 2 2 0 X X 0 1 0 1 1 0 0 1 1 0 1 1 53 38 ni 2 2 2 1 1 0 64 
Kumtal9n 12 1 1 1 2 1 0 X 0 0 2 0 0 0 0 0 0 0 0 0 1 40 ni ni 2 2 0 0 0 43 
Kuzeff 1998 15 2 2 2 2 2 0 X 2 2 2 2 0 1 0 0 2 2 2 2 2 2 84 ni ni 2 2 0 0 2 57 
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App. 4 Methodological quality (MQ) and clinical relevance (CR) scores of prospective controlled trials of homeopathy (cont.) 
First author(s), year 1 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 MQ% Kl Li Cl C2 C3 C4 CS CG C7 c~ 
Lamont 1997 12 2 1 1 2 2 0 x x O 2 1 1 1 0 0 2 2 2 2 2 2 70 ni ni 2 2 2 2 0 0 2 71 
Lasserre 1986 15 2 2 2 2 2 0 X 2 2 2 0 l 0 X 2 2 2 X 2 2 84 80 71 2 2 2 2 2 1 2 93 
Leaman 1989 15 2 1 1 2 2 0 X 0 2 2 0 0 0 0 0 2 2 0 X 1 1 62 38 50 2 2 2 0 0 0 2 57 
Lecoc_g_ 1985 15 2 1 1 1 1 0 X 1 2 2 0 1 0 0 0 2 2 2 X 2 2 70 50 50 2 2 2 2 0 2 79 
Ledermann 1954 15 2 1 0 2 2 0 X 0 2 2 0 0 0 0 0 2 2 1 2 2 2 67 ni ni 2 2 2 1 0 2 71 
Le~isant 1995 12 2 2 2 2 2 0 X X 2 2 2 2 0 0 0 2 2 2 2 1 2 77 ni 64 2 2 2 2 2 0 2 86 
Lewis 1984 15 2 1 2 2 2 0 X 2 2 2 0 0 X 0 0 0 0 0 2 1 2 66 49 ni 2 2 2 0 0 57 
Lievre 1992 15 2 2 2 2 2 Q X 2 X X 2 2 2 1 X 2 2 2 2 2 2 94 ni ni 2 2 2 2 2 0 2 86 
Lokken 1995 15 2 1 1 2 2 0 X 2 2 2 2 1 2 0 2 2 2 2 X 2 2 87 ni 86 2 2 2 0 2 2 2 86 
Ludtke 1998(i) conference abstract ni ni 
Ludtke 1998.®_ conference abstract ni ni 
Ludtke 1998.@)_ conference abstract ni ni 
Macchi 1984 12 1 2 2 2 2 0 X X 0 1 2 2 2 0 X 1 0 2 X 2 2 71 ni ni 2 2 2 2 0 0 2 71 
Maiwald 1988 15 2 2 2 2 2 0 X 2 2 X O 1 1 2 X 2 2 1 2 2 2 86 65 ni 1 1 2 2 0 2 64 
Marreyl989 15 2 2 2 2 0 X 1 2 2 0 1 0 0 0 2 2 2 X 2 2 75 ni ni 2 2 2 2 0 1 2 79 
Martel 1985 15 1 2 0 2 2 0 X 0 2 2 1 X X Q X 2 2 2 X 2 2 79 ni ni 2 2 2 2 0 0 2 71 
Masciello 1985 9 1 0 1 2 0 X X X O O O Q X 0 0 0 X 2 1 38 18 ni 2 1 2 0 0 2 57 
Master 1987a 12 1 0 1 2 2 0 X X 0 X 0 0 0 0 0 0 0 0 X 2 1 43 13 ni 2 2 2 0 0 2 64 
Master 1987b 15 2 1 2 2 2 0 X 0 0 2 0 X X 0 0 0 0 0 X 1 57 23 29 2 2 2 2 0 0 0 57 
Matusiewicz 1997a 15 2 2 2 2 0 X 2 2 2 1 1 0 Q X 0 0 2 X 2 2 75 ni ni 2 2 2 2 0 0 2 71 
Mccutcheon 1996 15 2 2 2 2 2 0 X 1 2 2 0 2 X 0 0 2 2 2 2 2 2 83 ni ni 2 2 2 1 0 0 2 64 
McDavid 1994 15 I 2 I 1 I 0 2 2 2 2 0 0 0 0 I 2 2 X 2 2 71 ni ni 2 0 0 2 50 
Mes_quita 1987 12 2 I 1 2 2 2 0 X X X 0 X X Q X 1 X 0 0 1 1 58 ni ni 2 2 2 2 0 0 2 71 
Michaud 1981 12 2 I I 2 2 0 X X I 0 0 0 0 0 2 2 2 2 I 60 35 14 2 2 2 2 0 0 2 71 
Mokka~tti 1992 15 2 1 2 2 0 X 0 2 2 0 0 0 Q X 2 2 2 1 2 2 72 ni 43 2 2 2 0 0 1 2 64 
Massinger 1973 15 2 1 0 1 1 0 X 1 2 2 0 0 0 0 0 2 2 2 2 2 2 67 35 ni 2 0 1 2 0 0 43 
Massinger 1976a(i) 12 1 0 1 1 Q X X 2 2 0 0 0 0 0 0 0 0 0 1 1 42 13 29 0 1 0 0 0 0 14 
Massinger 1976a(ii) 12 1 1 0 1 1 0 X X 2 2 0 0 0 0 0 0 0 0 0 1 1 42 13 29 1 0 1 0 0 0 0 14 
Massinger 1976a(iii) 12 1 0 1 I 0 X X 2 2 0 0 0 0 0 0 0 0 0 1 42 13 29 1 0 1 0 0 0 0 14 
Massinger 1976a(iv) 12 I 1 0 1 0 X X 2 2 0 0 0 1 0 0 0 0 0 1 1 43 23 29 1 0 1 0 0 0 21 
Massinger 197Gb 15 2 I I Q X 1 2 2 0 0 0 0 0 2 2 1 2 2 1 65 25 50 2 0 I 2 0 0 2 50 
Massinger 1980 15 2 2 2 2 0 X 1 2 2 0 1 1 0 2 I I 0 2 2 2 75 43 36 2 2 2 0 I 2 71 
Massinger 1982 15 2 0 0 1 1 0 X 0 2 2 0 0 0 0 2 2 2 1 2 1 2 64 35 43 1 0 1 0 2 43 
Massinger 1985 15 2 1 2 2 0 X 2 2 2 1 0 0 1 0 2 2 1 2 1 1 73 38 50 2 2 2 2 0 2 79 
Nahler 1996 15 2 1 2 2 2 0 X 0 X 2 0 2 2 2 X 2 2 2 1 2 2 84 ni ni 2 2 2 2 2 2 2 100 
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App. 4 Methodological quality (MQ) and clinical relevance (CR) scores of prospective controlled trials of homeopathy (cont.) 
Fi~tauthor(s), year 1 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 MQ% Kl Li Cl C2 C3 C4 C5 C6 C7 c~ 
Nollevaux 1991 12 2 1 1 1 1 0 x x 2 2 0 2 x 1 x 2 2 2 x 2 2 74 ni 43 1 1 1 2 0 0 2 50 
Nusche 1998 12 2 1 2 1 2 0 x x O x O 1 1 2 0 2 2 1 2 1 2 67 ni ni 2 2 2 1 1 X 2 71 
Oberbaum 1998 15 2 1 0 1 1 1 0 0 x x O 0 0 x x 2 2 0 x 0 1 55 ni ni 2 1 1 2 0 0 1 50 
Ochoa-Bernal 1995 15 2 2 2 2 2 0 x 0 O 1 1 1 1 0 x 2 2 2 x 2 2 76 ni ni 2 2 2 2 1 0 2 79 
Owen 1990 15 2 2 2 2 2 0 x 0 x x 0 0 0 0 x 2 2 2 1 2 2 73 35 ni 2 2 2 2 2 0 2 86 
Pa~ 1998 15 2 2 2 2 2 0 x 2 2 2 2 2 2 0 x 2 2 2 2 2 2 92 ni ni 1 2 2 2 2 0 2 79 
Pinsent 1986 15 2 1 2 2 2 0 x 2 2 2 0 0 0 x 0 1 2 2 2 1 1 74 45 ni 2 2 2 1 0 1 2 71 
Polychronopolou 1990 12 1 1 1 1 1 0 x x x x 0 0 0 0 x 1 0 2 x 2 1 51 ni ni 2 1 1 2 0 0 1 50 
Ponti 1986 15 1 2 0 1 1 0 x 0 O 0 0 1 0 0 x 2 2 2 0 2 2 58 40 50 2 0 0 2 0 0 2 43 
Puterman 1994 15 2 1 2 2 2 0 x 2 2 2 0 x x O O 1 2 2 2 2 0 76 ni ni 2 2 2 0 0 1 2 64 
Rahlfs 1976 15 2 1 2 2 2 0 x 2 2 2 0 2 x 2 0 1 1 1 2 1 2 79 35 79 1 1 1 1 0 1 2 50 
Rahlfs 1978 15 2 1 2 2 2 0 x 2 2 2 0 2 x 2 x 2 2 2 2 2 2 90 50 79 2 1 1 2 2 0 0 57 
Rastogi 1998 15 2 2 2 2 2 0 x 0 2 2 0 2 x 0 x x x x 2 x 1 79 ni ni 2 2 2 1 0 0 2 64 
Reilly 1985 15 2 1 2 2 2 0 x O 2 2 1 1 1 0 0 2 2 2 2 2 2 78 50 50 2 2 2 2 1 2 2 93 
Reilly 1986 15 2 2 2 2 2 0 x 2 2 2 0 2 2 2 x 2 2 2 2 2 2 92 90 93 2 2 2 2 2 2 2 100 
Reilly 1994 15 2 2 2 2 2 0 x 2 2 2 0 2 2 2 0 2 2 2 2 2 2 89 ni 93 2 2 2 2 2 2 2 100 
Rios Varela 1995 15 2 1 0 2 2 0 x O O x O O 1 0 x 2 2 2 2 1 2 67 ni ni 2 2 2 2 0 0 2 71 
Ritter 1966 15 1 1 0 1 1 0 x 2 2 2 0 0 1 0 0 2 2 2 1 2 2 67 58 50 1 1 1 1 0 0 0 29 
Rottey 1995 15 2 1 1 2 2 0 x 2 2 2 0 0 0 0 0 2 2 1 1 2 2 71 ni ni 2 1 1 2 1 0 2 64 
Saruggia 1992 15 2 2 1 2 2 0 x 0 2 2 0 x x 0 0 2 2 2 x 1 2 76 ni ni 2 2 2 2 0 0 2 71 
Savag_e 1977 15 2 2 I 2 2 0 x 2 2 2 0 2 2 0 0 0 0 0 x 2 2 72 55 64 2 2 2 0 0 0 2 57 
Savage 1978 15 2 2 1 2 2 0 x 2 2 2 0 2 2 0 x 1 0 0 x 2 2 76 53 79 2 2 2 0 0 0 2 57 
Schilsky 1941 12 1 1 1 2 2 0 x x O O O 1 1 0 0 0 0 0 2 2 2 51 ni ni 2 2 2 0 0 0 2 57 
Schmidt 1987 15 2 1 1 2 2 0 x 1 2 2 0 1 0 0 x 2 2 2 x 2 1 75 45 ni 2 1 1 2 2 0 2 71 
Schultz 1994 15 1 1 2 1 1 0 2 2 2 2 0 0 0 0 1 2 2 X 2 2 71 ni ni 2 1 1 1 0 2 57 
Schwab I~ 15 2 2 1 2 2 0 X 2 2 2 0 0 0 0 X 2 2 2 2 2 2 79 20 71 2 2 2 2 2 1 2 93 
Schwab I~ 15 2 2 2 2 0 X 2 2 2 0 0 0 0 X 2 2 2 2 2 2 79 20 71 2 2 2 2 2 1 2 93 
Shi~l983 15 2 1 2 2 2 0 X 0 2 2 0 0 0 0 0 2 2 2 2 2 2 73 50 71 2 2 0 0 2 0 1 50 
Singh 1994 15 2 1 2 2 2 0 X 2 2 2 0 0 0 0 0 2 2 2 X 2 2 75 ni ni 2 2 2 0 2 1 2 79 
Skaliodas, Hatzicostas 1988 12 2 2 2 2 2 0 X X 0 2 0 0 0 0 X 1 0 X 2 59 50 ni 2 2 2 2 0 1 2 79 
Solanki 1995 15 2 1 2 2 2 0 X 0 0 2 2 0 0 X X 2 2 2 X 1 2 76 ni ni 2 2 2 2 0 0 1 64 
Sp_itze 1995 15 2 1 2 2 2 0 X 2 2 2 0 0 0 0 0 2 2 2 2 2 2 76 ni ni 1 2 2 0 0 1 2 57 
Stip_Q!g_ 1996 15 2 2 2 2 2 0 X 0 2 2 0 2 2 0 0 2 2 0 X 1 2 75 ni ni 2 2 2 2 2 0 2 86 
Straumsheim 1997 15 2 1 2 2 2 0 X 2 2 2 2 2 1 2 0 2 2 2 2 1 2 87 ni ni 2 2 2 1 2 2 2 93 
Tarne 1998 conference abstract ni ni 
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App. 4 Methodological quality (MQ) and clinical relevance (CR) scores of prospective controlled trials of homeopathy (cont.) 
Fi~tauthor(s), year l 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 MQ% Kl Li Cl C2 C3 C4 C5 CG C7 CR~ 
Thiell994 15 2 l 2 2 2 0 x O 2 2 l 2 0 0 0 0 0 0 2 2 1 65 ni 79 2 2 2 2 0 0 1 64 
Torbicka 1998 15 2 1 0 l 1 0 x O x x O O O x O 2 2 1 x 1 2 60 ni ni 2 1 1 1 2 2 2 79 
Trap_ani 1994 12 1 1 1 1 1 0 x x O O O O O O O 1 1 0 0 1 1 40 ni ni 2 1 1 2 2 0 1 64 
Tsiako_QQ_ulos 1988 12 2 1 2 2 2 0 x x 2 2 0 0 0 0 0 2 2 1 0 1 1 60 35 ni 2 2 2 2 2 0 2 86 
Tsolakis 1995 15 2 2 2 2 2 1 0 1 2 2 0 0 0 0 0 1 2 2 X 2 2 73 ni ni 2 2 2 1 2 0 2 79 
Ustianowski 1974 15 2 1 1 2 2 0 X 1 0 2 0 X X 0 X 0 0 0 0 1 2 59 45 29 2 2 2 2 0 0 2 71 
Valero 1981.ill 12 2 1 2 2 2 0 X X 0 2 0 2 2 X X X X X 1 2 1 72 50 ni 1 2 2 1 0 2 64 
Valero 1981.®_ 15 2 2 2 2 2 0 X 0 2 2 0 2 2 2 X 2 2 2 2 2 2 89 70 64 1 2 2 2 0 1 2 71 
Valero 1981@)_ 15 2 2 2 2 2 0 X 0 2 2 0 2 2 2 0 0 0 0 2 2 2 75 50 57 2 2 2 0 0 2 64 
Valero 1981~ 12 1 1 2 2 0 X X 0 2 0 0 0 X 2 2 2 2 2 1 1 65 ni ni 2 2 2 1 0 2 71 
Van Erp_ 1996 15 2 2 2 2 2 0 X 0 2 2 0 1 0 0 X 2 2 2 2 2 2 79 ni ni 2 2 2 2 0 0 2 71 
Van't Riet 1985 9 2 1 1 2 1 0 X X X X O 1 X 0 1 0 0 2 2 2 53 ni ni 2 2 1 0 0 2 57 
Ventoskovs~ 1990 12 2 1 2 2 2 0 X X X X O 2 2 0 X 2 2 2 X 2 2 78 22 ni 2 2 2 2 2 0 2 86 
Villatoro Cadena 1991 15 2 2 2 2 2 0 X 2 2 2 0 2 2 X 0 0 1 0 X 1 2 76 ni ni 2 2 2 1 0 2 71 
Walach 1997 15 2 2 2 2 2 0 X 2 2 2 0 2 2 2 X X X X 2 2 2 91 ni ni 2 2 2 0 2 2 79 
Weiser 1994 15 2 2 2 2 2 0 X 2 2 2 1 2 1 2 0 2 2 2 2 2 2 89 ni 79 2 1 1 2 2 0 2 71 
Weiser 1998 15 2 2 2 2 2 0 X 2 2 2 2 2 2 2 X 2 2 2 2 2 2 96 ni ni 2 2 2 2 2 0 2 86 
Werk 1994 15 2 1 2 2 0 X 0 2 2 0 1 0 0 X 2 2 2 2 1 72 ni 57 2 1 2 2 0 2 71 
Whitmarsh 1997 15 2 2 1 2 2 0 X 2 2 2 0 2 2 2 0 2 2 2 2 2 2 87 ni ni 2 2 2 2 2 2 93 
Wiesenauer 1983 15 2 2 1 2 2 0 X 2 2 2 0 0 Q X 2 2 2 2 2 2 81 75 79 2 2 2 2 2 1 2 93 
Wiesenauer 1985 15 2 2 1 2 2 0 X 2 2 2 0 1 0 0 0 2 2 2 2 2 76 85 79 2 2 2 0 1 2 71 
Wiesenauer 1987 15 2 2 2 2 2 0 X 2 2 2 0 1 0 X 2 2 2 2 1 2 83 58 ni 1 2 2 1 2 1 2 79 
Wiesenauer 19~ 15 2 2 1 2 2 0 X 2 2 2 0 0 0 0 0 2 2 0 2 2 2 73 ni ni 2 1 0 1 1 2 57 
Wiesenauer 19~ 15 2 2 1 2 2 0 X 2 2 2 0 0 0 0 0 2 2 0 2 2 2 73 60 ni 2 1 1 0 1 1 2 57 
Wiesenauer 1990 15 2 2 2 2 2 0 X 2 2 2 0 2 0 0 X 2 2 2 1 2 2 83 ni 86 2 2 2 2 0 1 2 79 
Wiesenauer 1991 15 2 2 2 2 2 0 X 2 2 2 0 1 0 0 X 2 2 2 2 2 2 83 ni 79 2 2 2 2 2 0 2 86 
Wiesenauer 1995 15 2 2 2 2 2 0 x 2 2 2 0 2 0 0 2 2 2 2 2 2 84 ni ni 2 2 2 2 1 1 2 86 
Yakir 1994 conference abstract ni ni 
Zell 1990 15 2 2 2 2 2 0 X 2 2 2 0 2 0 2 X 2 2 2 2 2 2 89 80 100 2 2 2 2 0 1 2 79 
Zicari 1992 15 2 2 2 2 2 0 x 2 2 2 0 X X 0 0 2 2 2 2 0 2 80 ni ni 2 2 2 1 1 0 64 
KEY: Kl= Kleijnen et al. (1991); Li= Linde et al. (1997); ni = not include 
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GLOSSARY 
aggravation (initial) Temporary worsening of symptoms following 
treatment. 
anthroposophical medicine Treatment according to the medical ideas of the 
German theosophist Rudolf Steiner (1861-1925). Anthroposophical doctors 
prescribe quasi-homeopathic (i.e. serially diluted but unsuccussed) medicines, 
according to psychospiritual theories that owe more to Naturphilosophie and 
Paracelsus than Hahnemann. 
centesimal potency A serial dilution of 1 part in 100. Centesimal potencies are 
designated here by a number up to 200 preceded by the letter C, but in other 
systems the number may precede the letter. Thus C6 (or 6C or 6c) represents a 
1 in 100 dilution carried out serially 6 times, each with a burst of succussion. 
The next potency used above C200 is lM, where M = 1000. Therefore lM = 
Cl000, 10M = Cl0 000 etc. 
chronic miasms Three infectious miasms - 'itch' (including scabies), 
gonorrhea and syphilis - eventually believed by Hahnemann (1828) to be 
responsible for all chronic disease. Modified by post-Hahnemannians to mean 
diathesis or dyscrasia, i.e. acquired or hereditary general traits and 
(pre)dispositions to illness. 
classical homeopathy Treatment based on strict semiotic individualization of 
each case, including psychological symptoms, and usually using a single 
medicine in a single prescription. Associated with symptom complex and unicist 
homeopathy, qqv. 
clinical homeopathy Treatment based mainly on nosological categories or 
pathological indications, without individualization. 
complex homeopathy Treatment with a combination of two or more clinical 
homeopathic medicines incorporated into one dosage form. 
concomitants Symptoms linked concurrently with other symptoms, 
constituting a clinical unit in the materia medica and repertory, e.g. stool 
accompanied by coryza. 
constitution Originally a biomorphological category. More usually, essential 
characteristics of healthy individuals, rather than the same characteristics 
affected by illness or disease, in which case they form part of the symptom 
complex. Constitutional prescribing treats patients with medicines 
corresponding to their healthy constitutional state. 
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decimal potency A serial dilution in the proportion of 1 part in 10. Decimal 
potencies are designated here by a number with the letter D preceding it, but 
in other systems the number may precede the letter x. Thus D6 ( or 6x) 
represents a 1 in 10 dilution carried out serially 6 times, each with a burst of 
succussion. Decimal potencies range from Dl to D200. 
dynamization Release of therapeutic power of a substance by means of 
trituration, serial dilution and succussion. Also known as potentization, qv. 
genius epidemicus, epidemic remedy Medicine corresponding to, or that has 
proved curative in, a particular epidemic disease at the population level. 
isopathy Treatment of a disease with medicines derived from the causative 
agent or organism of the disease (cf. nosode). 
keynote symptom Symptom providing a leading indication for a particular 
medicine, e.g. worse for movement, Bryonia. 
materia medica In homeopathy, a systematic register of symptoms produced 
in drug provings. Frequently augmented with symptoms or conditions cured 
in clinical practice not seen in provings. 
miasm Traditionally a nonspecific noxious emanation, Hahnemann' s 
preferred term for specific infectious agents including microorganisms. Now 
usually referring to a chronic miasm. 
modality Of great importance in homeopathy, any factor modifying the 
quality of a symptom, or the patient as a whole. 
mother tincture The standardized liquid preparation (symbol: 0) derived 
from raw source materials before potentization. Different processes are used to 
make mother tinctures, depending on the nature of the source, e.g. expressed 
plant juices, fresh plant material, dried plant material, animal material, organ 
preparations, nosodes etc. 
nosode Medicine derived from diseased organ, disease product or causative 
organism of disease (cf. isopathy). 
pathological prescribing Clinical treatment based on the correspondence of 
the patient's lesional pathology with lesional toxicology described in the 
materia medica, with little reference to semiology or other individualizing 
characteristics. 
pluralist homeopathy Treatment with more than one medicine representing 
different aspects of the illness given in a single prescription. The adjective 
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'pluralist' may describe the practitioner or the method. The instructions 
usually require the different medicines to be taken at different times, as 
distinct from complex homeopathy which uses fixed mixtures in a single 
dosage form. 
plussing Further dilution of medicines with succussion before each dose or at 
intervals during regular repetition of the dose. 
potency Therapeutic power released or developed by dynamization. The 
scalar degree to which a medicine has been potentized. 
potency scale Scale denoting the potency degree. Three are in common use: 
centesimal (C), decimal (D) and quinquagintamillesimal (Q). 
potentization The process developed by Hahnemann after 1816 by which 
medicinal power is released or increased, involving initial trituration followed 
by serial dilution with succussion. 
proving Pathogenetic drug test (German Priifung) involving administration 
of substances (in material dose, mother tincture or potency) to healthy 
volunteers, to elicit effects from which the therapeutic sphere of influence of 
the substance may be derived according to the similia principle. 
Q (quinquagintamillesimal) potency A serial dilution of 1 part in 50 000. Q 
potencies are designated here by a number with the letter Q preceding it, 
although in other systems the number may be preceded by the Roman 
numerals LM. Thus Q6 (or LM6) represents a 1 in 50 000 dilution carried out 
serially 6 times, each with a burst of succussion. Q potencies range from Ql to 
Q30. 
radionics A twentieth-century development of medical dowsing or 
radiesthesia, involving remote transmission of therapeutic energies or 
information. Makes frequent use of conventional and simulated homeopathic 
medicines in diagnosis and treatment, but the principles underlying the 
therapy and the reasons for prescriptions are often entirely different. 
repertory Symptomatic index to the homeopathic materia medica. 
Repertorization is the process of case analysis used to identify the medicine 
that best matches the patient's symptom complex. 
serial dilution A component of the potentization process. The sequential 
addition of 1 part of the stock or of the previous dilution as a specified 
proportion of diluent: 1:9, 1:99 or 1:49 999 (see centesimal, decimal and Q 
potencies respectively). The number of dilutions defines the potency. The two 
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methods principally used are: Hahnemannian, using a fresh flask or bottle for 
each dilution; and the more economical Korsakov or single flask method in 
which the container is emptied after succussion and refilled with diluent. 
specific A homeopathic medicine specifically indicated for a particular 
clinical condition. 
similia principle From 'similia similibus curentur' (let like be cured by like) -
the treatment of disease with substances that have induced similar symptoms 
in a healthy subject in a proving. 
simillimum The most accurate match possible between the patient's symptom 
complex and the materia medica. 
succussion Vigorous jolting given at each stage of serial dilution during 
potency preparation. 
symptom complex The aggregate of the patient's symptoms considered as a 
meaningful whole or essence (German Symptomeninbegriff). Sometimes 
translated as 'totality of symptoms', although this misses Inbegriff s dual 
meaning of epitome. 
tautopathy Isopathic treatment with a potentized preparation of a chemical 
substance, especially a conventional drug, that has had or is having some 
adverse effect on the patient. 
trituration Initial preparation and potentization from solid and insoluble 
source material, and in some cases from fresh plants, by grinding 1 part 
together with 99 parts of lactose as a diluent. 
unicist homeopathy Treatment with one medicine, ideally representing the 
symptom complex in a single prescription. The adjective 'unicist' may describe 
the practitioner or the method. 
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ABBREVIATIONS AND SYMBOLS USED IN TABLES 
0 
C 
D 
K 
1M,10M 
Q 
OT 
p 
TAU 
mother tincture 
centesimal potency, range Cl-C200 
decimal potency, range Dl-D200 
Korsakov single-flask centesimal potency 
centesimal potency degrees corresponding to ClO00, ClO 000 
quinquagintamillesimal potency, range Ql-Q30 
orthodox (biomedical) treatment 
placebo 
(biomedical) treatment as usual 
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